

# **WORLD GLAUCOMA CONGRESS**

**Paris, June 29 - July 2, 2011**

## **FINAL PROGRAM**



**Sponsored by the Hippocrates Glaucoma Foundation**

**WORLD GLAUCOMA ASSOCIATION**  
**The Global Glaucoma Network**

for  
glaucoma

# taflotan<sup>®</sup>

tafluprost

The first and only  
preservative-free prostaglandin

- Effective IOP reduction
- No adverse reactions from preservatives
- Ideal option for glaucoma patients with dry/sensitive eyes



15 µg/ml tafluprost

## taflotan<sup>®</sup>

The preservative-free prostaglandin.

**Abbreviated Prescribing Information TAFLOTAN<sup>®</sup>** (tafluprost 0.0015% eye drops, solution, single-dose container). **Presentation:** Low-density polyethylene single-dose containers packed in foil pouch. Each single-dose container has a fill volume of 0.3 ml and there are 10 containers in each foil pouch. The following pack sizes are available: 30 x 0.3 ml and 90 x 0.3 ml. One ml of eye drops contains 15 micrograms of tafluprost. **Indication:** Reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension in patients who would benefit from preservative-free eye drops or who are insufficiently responsive or intolerant or contra-indicated to first line therapy, as monotherapy or as adjunctive therapy to beta-blockers. **Dosage and Administration:** The recommended dose is one drop of TAFLOTAN<sup>®</sup> in the conjunctival sac of the affected eye(s) once daily in the evening. Not recommended in children or adolescents (under the age of 18). In renal or hepatic impairment use with caution. **Contraindications:** Hypersensitivity to tafluprost or to any of the excipients. **Precautions:** Before treatment is initiated, patients should be informed of the possibility of eyelash growth, darkening of the eyelid skin and increased iris pigmentation. Some of these changes may be permanent, and may lead to differences in appearance between the eyes when only one eye is treated. Caution is recommended when using tafluprost in aphakic patients, pseudophakic patients with torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for cystoid macular oedema or iritis/uveitis. There is no experience in patients with severe asthma. Such patients should therefore be treated with caution. **Interactions:** Specific interaction studies with other medicinal products have not been performed with tafluprost. **Pregnancy:** Do not use in women of childbearing age/potential unless adequate contraceptive measures are in place. **Driving:** Tafluprost has no influence on the ability to drive. **Undesirable Effects:** The most frequently reported treatment-related adverse event was ocular hyperaemia. It occurred in approximately 13% of the patients participating in the clinical studies with tafluprost in Europe and the US. Other side effects include: Common (1% to 10%): eye pruritus, eye irritation, eye pain, changes in eyelashes, dry eye, eyelash discolouration, foreign body sensation in eyes, erythema of eye lid, blurred vision, increased lacrimation, blepharal pigmentation, eye discharge, reduced visual acuity, photophobia, eyelid oedema and increased iris pigmentation and headache. Uncommon (0.1% to <1%): superficial punctate keratitis (SPK), asthenopia, conjunctival oedema, blepharitis, ocular discomfort, anterior chamber flare, conjunctival follicles, allergic conjunctivitis, anterior chamber cell, conjunctival pigmentation and abnormal sensation in eye, hypertrichosis of eyelid. **Overdose:** If overdose occurs, treatment should be symptomatic. **Special Precautions for Storage:** Store in a refrigerator (2°C - 8°C). After opening the foil pouch keep the single-dose containers in the original foil pouch, do not store above 25°C, discard an opened single-dose container with any remaining solution immediately after use. **MA Holder:** Santen Oy, Niittyhaankatu 20, 33720 Tampere, Finland. **Date of Preparation:** January 2010.

**Santen**

# **WORLD GLAUCOMA CONGRESS**

## **FINAL PROGRAM**



## Useful telephone numbers

|                    |                  |
|--------------------|------------------|
| Faculty Desk       | +33 1 406 815 13 |
| Social Event Desk  | +33 1 406 815 12 |
| Hotel Desk         | +33 1 406 815 02 |
| Registration Desk  | +33 1 406 815 03 |
| OIC Desk           | +33 1 406 824 05 |
| WGC Office         | +33 1 406 869 48 |
| Speaker Ready Room | +33 1 406 865 56 |

## Disclaimer

The Hippocrates Glaucoma Foundation, based upon an agreement with the World Glaucoma Association, organizes the World Glaucoma Congress with the aim of providing education and scientific discourse in the field of glaucoma. The Hippocrates Glaucoma Foundation accepts no responsibility for any products, presentations, opinions, statements or positions expressed by speakers at the congress. Inclusion of material in the scientific program does not constitute an endorsement by The Hippocrates Glaucoma Foundation.



### NON-SMOKING POLICY

Please be informed that the World Glaucoma Congress is a non-smoking congress: the congress committee thanks all participants to refrain from smoking in the congress venue.



### MOBILE PHONES

We kindly request all participants to keep mobile phones turned off in the congress area and especially in the meeting rooms during the scientific sessions.

Produced for The Hippocrates Glaucoma Foundation by Kugler Publications,  
P.O. Box 20538, 1001 NM Amsterdam, The Netherlands.

Cover design: Cees van Rutten, The Hague, The Netherlands  
Typesetting: Palm Producties, Nieuwerkerk a/d IJssel, The Netherlands  
Printed by: Koninklijke Drukkerij C.C. Callenbach bv, Nijkerk, The Netherlands

© 2011 World Glaucoma Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying or otherwise, without the prior consent of the copyright owners.



# CONTENTS

|   |     |
|---|-----|
| Welcome by the President of the WGA .....   | IV  |
| Welcome by the Local Organizing Committee .....                                   | V   |
| Welcome by the Program Committee .....  | VI  |
| WGC-2011 Committees .....   | 1   |
| The World Glaucoma Congress .....   | 2   |
| General Meeting Information .....   | 3   |
| Social Program .....  | 8   |
| Excursion Program .....   | 9   |
| Map of Paris, Hotels .....  | 11  |
| Scientific Program per day .....  | 14  |
| - Wednesday June 29, 2011 .....   | 14  |
| - Thursday June 30, 2011 .....  | 25  |
| - Friday July 1, 2011 .....   | 37  |
| - Saturday July 2, 2011 .....   | 53  |
| Global Assembly of Glaucoma Societies .....                                       | 57  |
| Scientific Program – Highlights .....   | 58  |
| Film Festival Program .....   | 62  |
| Curricula Vitae Faculty .....   | 70  |
| CME Disclosure.....   | 116 |
| Presenters Index .....  | 130 |
| World Glaucoma Association .....  | 133 |
| WGA Committees .....  | 136 |
| WGA Research Awards .....   | 139 |
| International Glaucoma Review .....   | 141 |
| Sponsors and Exhibitors of the 4 <sup>th</sup> World Glaucoma Congress 2011 ..... | 143 |
| Technical Exhibition .....  | 144 |
| - List of Sponsors and Exhibitors .....   | 144 |
| - Exhibit Floor Plan .....  | 146 |
| - Company Profiles .....  | 150 |
| Program at a Glance .....   | 165 |
| Congress Venue Map  |     |

# Welcome by the President of the WGA

Dear Colleagues,

With great pleasure and excitement, and on behalf of the World Glaucoma Association and its Board of Governors, international member glaucoma societies and the Organizing Committee, I would like to welcome you to the 4<sup>th</sup> World Glaucoma Congress in Paris on June 29<sup>th</sup>-July 2<sup>nd</sup>, 2011. We are pleased to inform you that we have more than 2000 pre-registered attendees, and that the WGC in Paris will be the largest and most comprehensive glaucoma congress ever held in the world to date. All sessions, symposia, courses, posters and grand rounds have been carefully planned and selected by the Scientific Committee to cover a wide span of topics and also to include many of the most updated information in glaucoma. Vibrant and stimulating discussion is to be anticipated and is encouraged.

As a city of beauty, culture, and above all, with an outstanding host glaucoma society endorsed with a long history of medical academism, Paris has been chosen as the site of this meeting. With its many museums, historical architectures and famous boutiques, Paris has much to offer to those who visit the city. For instance, the Louvre Museum, which is a short walk from the venue site. A wonderful stay for everyone is promised in this magnificent city. We believe that this meeting will be one of the most exciting and enjoyable meetings both in the academic and the tourist aspect. We also hope that we can offer you plenty of knowledge enriching your skills across the spectrum of glaucoma care.

Thank you very much for joining us at the 4<sup>th</sup> World Glaucoma Congress in Paris!



Makoto Araie

Makoto Araie  
Tokyo, Japan

# Welcome by the Local Organizing Committee

Dear Colleagues,

Paris needs no introduction.

La Ville Lumière offers more than anyone can take from any standpoint.

The beauty of the city, its culture, entertainment and atmosphere are unmatched and all come with easy logistics and affordable, well-functioning public transport.

This year's scientific program is outstanding and the social events were carefully chosen to cater for a variety of needs and tastes.



Eric Sellem



Carlo Traverso

We trust you will be able to focus on the scientific program, successfully network with colleagues, and generally enjoy your stay against the backdrop of such an ideal setting.

On behalf of the Local Organizing Committee we welcome you to yet another chance of professional and personal enhancement.


Eric Sellem, President, French Glaucoma Society

Carlo Enrico Traverso, President, European Glaucoma Society


# Welcome by the Program Committee



Dennis Lam



Jeffrey Liebmann



Choka Melamed



Joel Schuman

Dear Colleagues and Friends,

The World Glaucoma Congress 2011 Program Committee welcomes you to Paris! Together with our colleagues of the World Glaucoma Association, the Program Committee has worked hard to develop an innovative and cutting-edge scientific program. The program contains a variety of educational events: didactic sessions on key issues in glaucoma management and research today, scientific free paper presentations selected by competition from over 800 submitted abstracts, Grand Rounds case management, Best Contributions to the field of Glaucoma, breakfast, lunchtime and afternoon Industry sponsored symposia, surgical video presentations, and various courses on important practical clinical issues given by our best experts. There will be a full day devoted to surgery – Glaucoma Surgery Day, and over 700 scientific posters presented.

For this meeting, our French colleagues have also organized unique sessions for our French speaking colleagues, and 13 regional and national glaucoma societies will have their separate satellite sessions for their members as well.

The fourth WGC is the largest glaucoma meeting ever held. We would like to thank all of our colleagues and friends who helped us along the way to make this meeting a huge success: the WGA Board of Governors, WGA President Makoto Araie, Executive Vice President Kuldev Singh, the French Glaucoma Society, Scientific Review Committees, collaborating societies, and most of all – our Faculty, speakers, colleagues, participants and audience.

We all wish you a very enjoyable and fruitful four days of learning and fun here in Paris.

Dennis Lam  
Jeffrey Liebmann  
Choka Melamed  
Joel Schuman

# WGC-2011 COMMITTEES

## **Board of Governors:**

M. Araie, J. Ge, I. Goldberg, F. Grehn,  
D.E. Grigera, R.A. Hitchings,  
Y. Kitazawa, T. Krupin, D. Lam,  
J.M. Liebmann, K. Martin, K. Singh,  
R. Susanna Jr, R. Thomas,  
R.N. Weinreb

## **Organizing Committee:**

M. Araie (Co-chair), I. Goldberg,  
R.A. Hitchings, D. Lam, J.M. Liebmann,  
K. Martin, S. Melamed, J.S. Schuman,  
K. Singh (Co-chair), R. Susanna,  
R.N. Weinreb

## **Program Committee:**


D. Lam (Co-chair), J.M. Liebmann (Co-chair),  
S. Melamed (Co-chair), J.S. Schuman  
(Co-chair), T. Aung, E.Z. Blumenthal,  
J.D. Brandt, G.C. De Moraes, F. El Sayyad,  
F.J. Goñi, P. Healey, L.W. Herndon, G. Holló,  
F.S. Lerner, K. Martin, S. Miglior,  
J.P. Nordmann, K.H. Park, L. Sakata,  
R. Sihota, A. Sit, L. Vijaya, N. Wang

## **Local Organizing Committee:**

C. Baudouin, A. Bron, P. Denis, Y. Lachkar,  
J.P. Nordmann, J.P. Renard, J.F. Rouland,  
T. Shaarawy, E. Sellem (Co-chair),  
C.E. Traverso (Co-chair), F. Valtot

## **Film Festival Surgical Committee:**

E.Z. Blumenthal, A.S. Crandall, F. Grehn,  
D. Lam (Chair), F. Lerner, S. Melamed,  
N. Pfeiffer, T. Shaarawy, R.N. Weinreb





# THE WORLD GLAUCOMA CONGRESS

## Objectives

- To present new developments in Diagnosis and Therapy of Glaucoma to both the glaucoma expert and the general ophthalmologist interested in glaucoma
- To enhance communication about glaucoma among ophthalmologists from all over the world
- To enhance exchange of knowledge between the general ophthalmologist and glaucoma experts
- To maintain high scientific and ethical standards

## Special Features

- Largest glaucoma congress
- Highly appreciated didactic program
- Top-quality glaucoma experts
- Extensive course program at all levels

- Basic and clinical science sessions
- Special topic discussion symposia
- Grants for economically underprivileged colleagues
- Grand rounds
- Surgical Day sessions
- Scientific free paper sessions
- Scientific poster presentations
- Film Festival

## The Social Part

- Paris is an outstanding destination and guarantees memorable experiences to all its guests
- The WGC Dinner will be held at the Pavillon d'Armenonville, a gorgeous 18<sup>th</sup>-century lodge, surrounded by century-old trees and lake views
- Welcome Reception at the Palais des Congrès

# GENERAL MEETING INFORMATION

In 2007, the organizers of the World Glaucoma Congress and the organizers of the International Glaucoma Symposium decided that it was in the interest of worldwide glaucoma to merge the two meetings into one large glaucoma meeting.

## Venue

Le Palais des Congrès de Paris  
2 Place de la Porte Maillot  
75017 Paris, France  
[www.palaisdescongres-paris.com](http://www.palaisdescongres-paris.com)

## WGA Executive Office

*Corresponding address:*  
Jan van Goyenkade 11  
NL-1075 HP Amsterdam, The Netherlands  
**T:** +31 20 679 3411  
**F:** +31 20 673 7306  
**E:** [info@worldglaucoma.org](mailto:info@worldglaucoma.org)  
**W:** [www.worldglaucoma.org](http://www.worldglaucoma.org)

## Organizing Secretariat

OIC Srl – Organizzazione Internazionale Congressi  
Viale G. Matteotti, 7  
50121 Florence, Italy  
**T:** +39 055 50351  
**F:** +39 055 5001912  
**E:** [wgc2011@oic.it](mailto:wgc2011@oic.it)  
**W:** [www.oic.it](http://www.oic.it)

## Registration Desk

The registration desk located on the ground floor and mezzanine of the congress venue will be open for registration and information according to the following time table:

|                    |                       |
|--------------------|-----------------------|
| Tuesday, June 28   | 2.00 p.m. – 6.00 p.m. |
| Wednesday, June 29 | 7.00 a.m. – 6.30 p.m. |
| Thursday, June 30  | 6.30 a.m. – 6.30 p.m. |
| Friday, July 1     | 6.30 a.m. – 6.30 p.m. |
| Saturday, July 2   | 7.00 a.m. – 1.00 p.m. |

## Congress Registration Fees (Vat Included)

|  | ON-SITE |
|--|---------|
| Participants                                   | € 650   |
| Students, Physicians & Scientists in Training* | € 120   |
| Accompanying Persons                           | € 100   |
| Congress Dinner                                | € 50    |

*\* Proof of status is required upon registration, otherwise the regular fee will be applied.*

## Registration Fee Includes:

- Attendance to all Scientific and Poster Sessions
- Opening Ceremony and Welcome Reception
- Access to Industrial Exhibition
- Congress Bag
- Abstract Book
- Certificate of Attendance

## Accompanying Persons Fee Includes:

- Opening Ceremony
  - Welcome Reception
  - One half day tour of Paris
- Please note that the Accompanying Persons Fee does not entitle anyone to attend the Scientific Sessions.

## Hotel Reservations

For any enquiries on hotel reservations, please approach OIC Way staff at the hotel reservation desk in the Registration Area.

## Cancellation and Refunds

We kindly remind you that cancellations of registrations, hotel reservations and social events were accepted only until March 31, 2011.

In case of cancellation within the above-

mentioned deadline, applied in writing to the Organizing Secretariat, the paid amount is refunded with a deduction for administrative charges for each cancellation, except booking fees. No refunds are processed for cancellations received after March 31, 2011. For more information, please apply to the Registration Desk. In the event of no-show without any written notice, OIC Way reserves the right to cancel the hotel reservation. No-shows cannot be refunded. Any authorized refund will be made only after the end of the congress.

### **Badges**

All participants and accompanying persons will receive a personal badge upon registration. You are kindly requested to wear your name badge when attending any scientific session or social gathering.

Only participants who are wearing their name badge will be admitted to the meeting rooms. You should also wear your badge in the Exhibition area.

Please note: accompanying persons and exhibitors will not be admitted to the scientific sessions. Accompanying persons do have free access to the exhibition.

Name badges have been color-coded as follows:

|              |                        |
|--------------|------------------------|
| Blue:        | WGA Board of Governors |
| Red:         | Faculty                |
| Transparent: | Delegates              |
| Green:       | Accompanying persons   |
| Yellow:      | Exhibitors             |
| Orange:      | Press                  |

The charge for replacement of lost badges will be Euro 25.

### **Certificate of Attendance**

The certificate of attendance is included in the congress kit.

### **Insurance, Liabilities**

Neither The Hippocrates Glaucoma Foundation, nor the Organizing Secretariat can be held responsible for any personal injury, loss, damage, accident to private property or additional expenses incurred as a result of delays or changes in air, rail, sea, road, or other services, strikes, sickness, weather, acts of terrorism and any other cause. All participants are encouraged to make their own arrangements for health and travel insurance.

### **Technical Exhibition**

An extensive exhibition of pharmaceutical, technical and research products, equipment, books, journals, services, etc. is organized in conjunction with the World Glaucoma Congress.

The scientific program will allow participants ample time to visit the exhibits.

The exhibition area, located on the third floor of the Palais des Congrès (Halls Bordeaux and Havane) will be open at the following hours:

|                     |                       |
|---------------------|-----------------------|
| Wednesday, June 29: | 8.00 a.m. – 7.00 p.m. |
| Thursday, June 30:  | 8.00 a.m. – 6.00 p.m. |
| Friday, July 1:     | 8.00 a.m. – 6.30 p.m. |
| Saturday, July 2:   | 8.00 a.m. – noon      |

### **Internet Access**

An Internet Point is available in the Exhibition Area on the third floor, near the Bar.

### **Catering Facilities**

Coffee stations and lunch will be provided to congress registrants, but lunches are included only for participants to industry satellite symposia held from Wednesday to Friday in the Grand Amphitheatre. A bar serving coffee and snacks (at your own expense) is available in the congress area. Various restaurants will also be operating at the congress center during lunch hours.

## Program Changes

Actual program changes will be indicated on the message boards located throughout the congress center. The organizers cannot assume liability for any changes in the program due to external or unforeseen circumstances.

## Lost and Found

A lost and found is located in the Registration Area on the ground floor of the congress venue.

## Cloakroom and Luggage

In the cloakroom you can leave your belongings.

Opening hours:

|                     |                       |
|---------------------|-----------------------|
| Tuesday, June 28:   | 9.00 a.m. – 6.30 p.m. |
| Wednesday, June 29: | 7.00 a.m. – 6.30 p.m. |
| Thursday, June 30:  | 6.30 a.m. – 6.30 p.m. |
| Friday, July 1:     | 6.30 a.m. – 6.30 p.m. |
| Saturday, July 2:   | 7.00 a.m. – 1.00 p.m. |

## Personal Data Scanning

Participants may be asked by staff from industries at exhibit booths to provide their personal contact data through bar-code scanning. This way, companies will obtain information about name, surname, country and e-mail address, on an individual, voluntary basis. Please do not allow scanning of your badge by industry representatives if you don't agree. Neither the WGA nor OIC will release your data to other individuals, companies, or institutions, but they will be used only for WGA communication and updates.

## HOW TO GET AROUND PARIS

### Car Parking

There is a parking lot in the basement of the Congress Venue, with various entrances from Place Maillot, and direct access to the Palais des Congrès. For further information about rates and access: [www.vincipark.com](http://www.vincipark.com).

### Currency and Banks

The Euro (€) is the official currency in France. Traditional Bank business hours are Monday to Friday, 9.00 a.m. – 4.30 p.m.

Banks are usually closed on Saturday and Sunday. All bank agencies have automatic exchange located outside to provide 24 hours service.

All major credit cards (VISA, American Express, Master Card) are accepted in most shops, hotels and restaurants in Paris. It is advisable to carry an identity card or some form of photo identification. We remind you that some cards require a personal code (PIN) to process the payment, please check with your credit card provider. There are several ATM's and money exchanges in the shopping area of the congress venue.

### Climate

Paris lies in the midst of the Île-de-France region, which has France's lowest rainfall; however, the city is known for its unexpected showers, which can occur at any time of the year. Summer temperatures are mild to warm, with occasional heat waves. The average low temperature in July is 15° Celsius and the average high temperature is 25° Celsius.

### Electricity

220V out of double, round pin wall sockets.

## Emergency Telephone Numbers

The following numbers can all be dialed toll-free from any phone in France (including payphones):

Medical Emergencies: Dial 15

Fire brigade: Dial 18

Police: Dial 17

## First Aid & Hospital Services

Visitors from the EU and Scandinavian countries can make use of the same health services as French citizens. To do so they must obtain a form E111 from their social security in their home country. Other visitors are strongly advised to see to their own travel insurance.

## Public Transport

Paris offers an efficient and modern public transport network (underground, trams and buses) as well as taxi services. The best and fastest way to get from place to place is the metro, administered by the State-owned company RATP. You can get a map in any metro station. With one single metro ticket you can go anywhere within Paris city limits as long as you don't go out of the station where you are connecting from one line to another. The ticket policy on the bus works according to sections. According to the length of your stay you could buy a 'Paris Visite card' which gives you unlimited trips within the chosen section areas and discounts in museums, shops and attractions.

For more information:

**Metro, RER, Bus, RATP**

Web: [www.ratp.fr](http://www.ratp.fr)

**Train SNCF**

Web: [www.sncf.fr](http://www.sncf.fr)

## Shopping

In Paris, the larger stores are open from mid-morning to about 8.00 p.m. without closing for lunch. Department stores may stay open as late as 10.00 p.m. on Wednesday or Thursday.

Smaller shops/stores and supermarkets are open from 8.00 a.m. to 8.00 p.m., but they close between 1.00 and 3.00 p.m. There is limited Sunday shopping, mostly in the Latin Quarter, Marais, Bastille or Île-de-la-Cité sections.

Shopping in Paris is an experience in itself; the extensive fashion stores and shopping malls offer the latest fashions trends at any time.

## Taxi Service

15,300 taxis operate in Paris, day and night. You can take a taxi by hailing one in the street (it is free if the sign on the roof is lit up), at a taxi rank, by calling one of the main taxi firms, or by calling the unique number for all the firms: **01 45 30 30 30**.

There is a taxi rank just outside the Palais des Congrès.

Please note that Paris taxis start the meter from the moment the taxi driver leaves to pick you up, so when the taxi arrives, the meter will already show more than the minimum charge. Fees vary according to time of day and your point of origin or departure in the city.

Additional charges include approximately 1€ per piece of luggage as well as an airport fee of approximately 1€. Many drivers will not accept more than three passengers, but if you find one that does, the taxi is authorized to charge an additional fee for the fourth passenger.

## Time

Standard time zone: UTC/GMT +1 hour

Daylight saving time: +1 hour

Paris is on CEST (Central European Summer Time).



### **Tipping**

In France, a 15% service charge is added automatically to bills in cafes and restaurants. Waiters and waitresses, however, do not customarily receive this service charge as extra wages. Adding an extra tip (around 10%) is recommended if the service is good, particularly in restaurants. In cafes and bars, leaving a small tip (pocket change, essentially) is considered acceptable.

Tipping in Paris taxis isn't obligatory, although most people (including Parisians) do tip a small amount. Tips in hotels are always welcome.

### **What to Wear**

Business casual attire is appropriate for the congress. Men generally wear slacks and dress shirts or polo shirts, often with a jacket. Women generally wear pantsuits, skirts or slacks and blouses/golf shirts. The dress code for the Welcome Reception is business casual. The dress code for the Congress Dinner at Pavillon d'Armenonville is formal attire (black tie optional).

## SOCIAL PROGRAM

### Wednesday evening

June 29, 2011 - 5.30 p.m.

#### Welcome Reception at the Palais des Congrès

The Welcome Reception will be held in the exhibition area of the Palais des Congrès (third floor). This gathering will enable you to meet with your colleagues in the field of glaucoma from all over the world, while you can enjoy some typical local food and drinks.

*Dress code:* business casual

*Included in the registration fee for participants and accompanying persons.*

### Thursday evening

June 30, 2011

#### Free for National Social Gatherings

After the courses and the sponsored afternoon symposia which will end at 7.00 p.m., the WGA has purposely not planned any specific World Glaucoma Congress events. Therefore this evening is for smaller groups of participants to enjoy the numerous restaurants and cultural events in Paris.

### Friday evening

July 1, 2011 - 8.00 p.m.

#### Congress Dinner at the Pavillon d'Armenonville

The Congress Dinner of the World Glaucoma Congress will feature a cocktail dinner in an outstanding location: **Pavillon d'Armenonville**. The Venue is an 18<sup>th</sup>-century lodge on a gorgeous location surrounded by century-old trees and lake views. Lovers of architecture will be spellbound by this center that boasts an amazing Belle Epoque architecture.

*Dress code:* formal attire (black tie optional)

*Admission:* confirmation of participation will be made to pre-registered participants by a coupon, to be found in the congress kit. **This coupon must be exchanged for an entrance ticket at the Social Events Desk, within the date and time indicated. Entry to the Pavillon d'Armenonville will not be permitted without this entrance ticket. For on-site registration, please contact the Social Events Desk in the Registration Area.**

---

## EXCURSION PROGRAM

All tours will be conducted in English. Pre-booked tickets will be included in the participant's personal envelope, which is handed over upon registration. Additional tickets may be purchased subject to availability on site at the Social Events Desk in the Registration Area. The meeting point for all tours will be in front of the Palais des Congrès.

### Versailles and Le Marais

#### *Full day tour*

**Thursday 30 June - 9.00 a.m. - 6.00 p.m.**

Guided tour. During the trip from Paris to Versailles you will be provided with information. Upon arrival, the guide will lead you through the gardens and explain l'Orangerie and the perspective. Then you will go back to the entrance of the Château for a guideless visit. Louis XIV's palace and vast formal gardens were laid out mostly between 1664 and 1715, the year of his death. Some of the greatest designers of the day were involved – among them the architect Louis Le Vau, the painter Charles Le Brun, and the gardener André Le Nôtre. What they gave him was the biggest and most sumptuous royal residence ever built, and it has been a model for many other royal fantasies ever since.

After lunch, the second half of the day will be dedicated to the Marais, one of Paris' oldest and most dazzling quarters. First developed in the twelfth century, the Marais – the word means 'swamp' and still refers to the time this area was one – passed from being a royal favorite under Henri IV and Louis XIII, to falling into ruin after the 1789 Revolution. Since its revival in the 1960's, it has shone

as a center of Parisian artistic and cultural life. Le Marais is one of the few areas that preserve the narrow streets and architectural styles of Medieval and Renaissance times. Most of Paris was overhauled in the mid-nineteenth century under the direction of Napoleon III and architect Baron Georges Eugene Haussmann.

**Price: € 140 per person (incl. bus, guide and lunch)**

### Boat Cruise and Panoramic tour of Paris

#### *Half day tour*

**Friday 1 July - 9.00 a.m. - 1.00 p.m.**

**(included in the accompanying persons fee)**

One-hour cruise, departing from the Eiffel Tower. The boats with their wide views, terrace at the stern and outside walkways are perfectly designed for exploring and admiring the architectural treasures of the capital. After the cruise there is a photo stop at the Trocadéro, then the tour continues with a panoramic tour via Champs-Élysées, Place de la Concorde, Madeleine, Opéra.

**Price: € 47 per person (incl. bus, boat trip and guide)**

### Champagne region and Reims

#### *Full day tour*

**Saturday 2 July - 9.00 a.m. - 6.00 p.m.**

The wine producers of Champagne are convinced guardians of their name. Only vineyards within the officially designated Champagne region, surrounding the city of Reims and located along the chalky banks and hills of the River Marne, may call their product

Champagne. Similar wines are produced all over the world, from Australia to California, but Champagne is the only sparkling white wine whose name is instantly recognized around the world as a symbol of festivity and celebration. You will also visit a famous Champagne cellar for a one-hour visit including one tasting. The tour goes on to Reims, where you will visit the famous Cathedral with

its statue of the Smiling Angel, in which all the Kings of France were crowned.

***Price: € 145 per person (incl. bus, guide and lunch)***

**The organizers reserve the right to cancel tours with less than 20 participants, or change the date and time of a tour for logistical reasons**





# MAP OF PARIS, HOTELS



- 1) Amaran Arc de Triomphe
- 2) Bassano
- 3) California Paris Champs Elysées
- 4) Chateau Frontenac
- 5) Concorde La Fayette
- 6) Concorde Opera
- 7) De Banville
- 8) Elysée Régencia
- 9) Le Meridien Etoile
- 10) Montfleuri
- 11) Regent's Garden
- 12) The Westin
- 13) Astrid
- 14) Magellan
- 15) Monceau Elysées
- 16) Star Champs Elysées
- 17) Tilsit Etoile
- 18) Elysées Etoile





---

## SCIENTIFIC PROGRAM

C = Courses  
S = Symposia  
FP = Free Papers  
GR = Grand Rounds  
GS = Glaucoma Society

For descriptions and outlines, we refer to the separate Abstracts book.

World Glaucoma Congress, June 29-July 2, 2011

## SCIENTIFIC PROGRAM OVERVIEW PER DAY

WEDNESDAY JUNE 29, 2011

### GLAUCOMA SOCIETY SYMPOSIA

**8.00-9.45 a.m. Room 351**

**American Glaucoma Society - Symposium**

**Best of the AGS**

*Chairs:* D.S. Greenfield (USA), A. Sit (USA)

- |           |   |
|-----------|---|
| 8.00-8.05 | <b>Introduction</b><br>D.S. Greenfield (USA), A. Sit (USA)  |
| 8.05-8.13 | <b>IOP telemetry in non-human primates: Initial characterization of continuous IOP at multiple time scales</b><br>C. Downs (USA)  |
| 8.13-8.21 | <b>Day and night differences in aqueous humor dynamics in patients with ocular hypertension (OHT) treated with latanoprost, dorzolamide and timolol</b><br>C.B. Toris (USA) |
| 8.21-8.29 | <b>Baseline optic nerve topography and retinal nerve fiber layer thickness predict visual-field progression in glaucoma-suspect and glaucomatous eyes</b><br>M. Sehi (USA)  |
| 8.29-8.37 | <b>Prediction of risk and rates of visual-field progression in patients with established, treated glaucoma</b><br>C.G. De Moraes (USA)                                      |
| 8.37-8.45 | <b>Four-year incidence of open-angle glaucoma (OAG) and ocular hypertension (OHT) in Latinos: The Los Angeles Latino Eye Study (LALES)</b><br>R. Varma (USA)                |
| 8.45-8.53 | <b>A comparison of visual function in patients with progressive stages of glaucoma assessed in the home and clinic</b><br>A. Bhorade (USA)                                  |
| 8.53-9.01 | <b>Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up</b><br>S.J. Gedde (USA)   |
| 9.01-9.09 | <b>Change in intraocular pressure after cataract extraction in the observation group of the Ocular Hypertension Treatment Study (OHTS)</b><br>S.L. Mansberger (USA)         |
| 9.09-9.17 | <b>A randomized trial of brimonidine versus timolol in preserving visual function: Results from the Low-pressure Glaucoma Treatment Study</b><br>T. Krupin (USA)            |
| 9.17-9.45 | <b>Discussion</b>   |

Organized by The Hippocrates Glaucoma Foundation

---

## WEDNESDAY JUNE 29, 2011

### 8.00-9.45 a.m. Room 352B

#### Australian and New Zealand Glaucoma Interest Group - Symposium What's hot down under?

**A wonderful outlook – The Australian and NZ glaucoma landscape**

I. Goldberg (AUSTRALIA)

**Hunting families – for case detection**

P. Healey (AUSTRALIA)

**What the mutiny on the bounty did for glaucoma?**

D. Mackey (AUSTRALIA)

**It's all about compliance: The optic-disc response to acute IOP spikes**

A. Wells (AUSTRALIA)

**Bad genes that stop you looking good....**

J. Craig (AUSTRALIA)

**Going, Going, GONE**

M. Coote (AUSTRALIA)

**Filling in the scotoma-fMRI findings**

S. Graham (AUSTRALIA)

**Hard knocks and soft nerves**

J.G. Crowston (AUSTRALIA)

**So now you have seen**

I. Goldberg (AUSTRALIA)

### 8.00-9.45 a.m. Room 341

#### Canadian Glaucoma Society - Symposium

8.10-8.20 **Interim results of the Express vs. trabeculectomy trial**

Y.M. Buys (CANADA)

8.20-8.40 **Glaucoma drainage device complications**

G.E. Trope (CANADA)

8.40-9.00 **Deep sclerectomy with gold implant: A new surgical technique**

P. Harasymowycz (CANADA)

9.00-9.20 **Optic Disc Phenotype Progression Study**

M. Nicolela (CANADA)

9.20-9.45 **Discussion on interprofessional collaboration**

All panel members

World Glaucoma Congress, June 29-July 2, 2011

---

## WEDNESDAY JUNE 29, 2011

### 8.30-9.35 a.m. Room 352A

#### Glaucoma Society of India - Symposium

#### Glaucoma in the Developing World and innovative strategies

*Chairs:* H. Kumar (INDIA), R. Sihota (INDIA), L. Vijaya (INDIA)

- |           |   |
|-----------|---|
| 8.30-8.35 | <b>Cost and cost efficacy of medical vs. surgical therapy for glaucoma</b><br>R. George (INDIA) |
| 8.35-8.40 | <b>Barriers to Compliance in the developing world</b><br>M. Ariga (INDIA)                       |
| 8.40-8.45 | <b>The problem of patient drop-out</b><br>V. Gupta (INDIA)                                      |
| 8.45-8.55 | <b>Managing glaucoma in the developing world</b><br>R. Sihota (INDIA)                           |
| 8.55-9.00 | <b>Quality of life of glaucoma patients in the developing world</b><br>M.R. Pillai (INDIA)      |
| 9.00-9.05 | <b>Cost of blindness in India</b><br>P. Vyas (INDIA)  |
|           | <b>Innovative strategies:</b>   |
| 9.05-9.10 | <b>Reaching out to glaucoma patients: A novel approach</b><br>G. Murthy (INDIA)                 |
| 9.10-9.15 | <b>Tele-ophthalmology in glaucoma</b><br>S. Parthsarathi (INDIA)                                |
| 9.15-9.25 | <b>Economic issues in glaucoma care</b><br>S. Kymes (USA)                                       |
| 9.25-9.35 | <b>Summary by the chairs</b>  |

### 8.00-9.45 a.m. Room 342A + 342B

#### Latin American Glaucoma Societies - Joint Symposium

*Chairs:* J.F. Lynch (ARGENTINA), I. Maynar Tavares (BRAZIL)

- |           |  |
|-----------|--|
| 8.00-8.08 | <b>Improving filtering surgeries: Techniques and post-op care</b><br>J. Acosta (ARGENTINA) |
| 8.08-8.16 | <b>Glaucoma drainage devices: Managing difficult cases</b><br>I. Maynar Tavares (BRAZIL)   |
| 8.16-8.24 | <b>Trabeculectomy Hyperfiltration Management</b><br>J.J. Mura (CHILE)                      |
| 8.24-8.32 | <b>How to deal with Ahmed implants complications</b><br>J.C. Parra (COLOMBIA)              |
| 8.32-8.40 | <b>Miscellaneous</b><br>C. Chacón (ECUADOR)  |
| 8.40-8.48 | <b>Ahmed Valve: Surgical cases</b><br>F. Gil Carrasco (MEXICO)                             |

---

Organized by The Hippocrates Glaucoma Foundation



---

## WEDNESDAY JUNE 29, 2011

- 8.48-8.56 **Surgical pearls in glaucoma implant devices**  
R. Susanna (PAN AMERICANA)
- 8.56-9.04 **Conjunctival expansion as a treatment of leaking bleb**  
R. Pérez Grossman (PERU)
- 9.04-9.12 **Unroofing of a glaucoma drainage device**  
C. Hartleben (SLAG)
- 9.12-9.20 **Surgical options in the treatment of CACG**  
J.C. Viera (VENEZUELA)

### 8.00-9.45 a.m. Room 353

#### Middle East African Glaucoma Society (MEAGS) and Egyptian Society for Glaucoma (ESG) - Joint Symposium

#### The Middle East, Egyptian and African Disparities and challenges

*Chairs:* A. Abou-el Enein (EGYPT), F. El Sayyad (EGYPT), A. Ouertani (TUNISIA) (GS1)

- 8.00-8.07 **Glaucoma management in Africa and the Middle East: An update**  
F. El Sayyad (EGYPT)
- 8.07-8.14 **Glaucoma in Africa: The difficult challenge**  
A. Ouertani (TUNISIA)
- 8.14-8.21 **Trabeculectomy in end-stage glaucoma**  
T.H. Mokbel (EGYPT)
- 8.21-8.28 **Glaucoma in heredo-familial collagen disorders**  
M. Yaqub (SUDAN)
- 8.28-8.35 **Assessment of macular anatomical and functional changes in glaucoma patients**  
A. Sedky (EGYPT)
- 8.35-8.42 **Decentralizing ophthalmic care in Egypt**  
T. Shaarawy (EGYPT)
- 8.42-8.49 **The incidence of glaucoma surgery failure in Egypt**  
T. El-Beltagi (EGYPT)
- 8.49-8.56 **Traumatic glaucoma as a significant cause of blindness in our region**  
B. Nourelddin (LEBANON)
- 8.56-9.03 **Ocular blood flow in young patients with optic disc suspicious of glaucoma**  
L. Hammouda (EGYPT) (GS2)
- 9.03-9.10 **Selective laser trabeculoplasty (with regional experience)**  
A. Jazzaf (KUWAIT)
- 9.10-9.17 **Use of amniotic membrane in trabeculectomy operations in Egypt**  
T. El-Emari (EGYPT)

World Glaucoma Congress, June 29-July 2, 2011

---

## WEDNESDAY JUNE 29, 2011

- 9.17-9.24 **OCT progression analysis**  
 L. Alaswad (SYRIA)
- 9.24-9.31 **Management of glaucoma in silicone-filled eyes**  
 A. Abou-el Enein (EGYPT)
- 9.31-9.38 **Role of glaucoma societies in developing countries**  
 M. Nassar (EGYPT)
- 9.38-9.45 **Discussion**

### 8.00-9.45 a.m. Room 326M + 327M

#### Bangladesh Glaucoma Society - Symposium

#### Glaucoma Diagnosis and Treatment Challenges in Bangladesh

*Chairs:* M.A. Matin (BANGLADESH), S. Uddin (BANGLADESH)

- 8.00-8.05 **Introduction of Speakers**  
*Chairs*
- 8.06-8.12 **Epidemiology of glaucoma in Bangladesh**  
 N. Khan (BANGLADESH)
- 8.13-8.21 **Trends of early diagnosis of glaucoma in Bangladesh**  
 Z. Karim (BANGLADESH)
- 8.22-8.30 **Diagnostic tools for PACG**  
 Kh. Ziaul Islam Md. Ali (BANGLADESH)
- 8.31-8.40 **RNFL analysis by OCT**  
 M. Hossain (BANGLADESH)
- 8.41-8.50 **Medical treatment of glaucoma: Bangladesh perspective**  
 Z.S. Shahid (BANGLADESH)
- 8.51-9.00 **Laser treatment for glaucoma**  
 M.A. Karim (BANGLADESH)
- 9.01-9.15 **Tripple E (Easy, Economic & Effective). Trabeculectomy for developing countries**  
 M.N. Islam (BANGLADESH)
- 9.16-9.30 **Awareness and prevention of glaucoma in Bangladesh**  
 Sk. M.A. Mannaf (BANGLADESH)
- 9.31-9.45 **Discussion**

### 8.00-9.45 a.m. Room 364

#### Bulgarian Glaucoma Society - Symposium

*Chairs:* N. Petkova (BULGARIA), M. Atanassov (BULGARIA), M. Konareva (BULGARIA)

#### Glaucoma: A diagnosis based on probability

M. Atanassov (BULGARIA) (GS3)

---

Organized by The Hippocrates Glaucoma Foundation

## WEDNESDAY JUNE 29, 2011

**OCT evaluation of optic nerve head in patients suspected for glaucoma**

**L. Mishev (BULGARIA) (GS4)**

**CCT in patients with advanced primary open-angle glaucoma**

**S. Ivanova (BULGARIA) (GS5)**

**Combined surgery in advanced primary congenital glaucoma**

**N. Petkova (BULGARIA) (GS6)**

**Efficacy of trabeculectomy with MMC in pseudoexfoliative glaucoma patients after minimum two years follow-up**

**M. Konareva (BULGARIA) (GS7)**

**Express Implant. Technique. First results**

**Pr. Guguchkova (BULGARIA) (GS8)**

**First results with Express implant in patients with glaucoma**

**A. Misheva (BULGARIA) (GS9)**

**Successful control of intraocular pressure in secondary glaucoma with implants**

**Y. Kirilova (BULGARIA) (GS10)**

**in the diagnosis and follow-up of glaucomas**

**T. Hergeldzhieva-Fileva, Y. Kirilova, P. Vassileva (BULGARIA) (GS11)**

**8.00-9.45 a.m. Room Havane**

**Symposium of CIS Glaucoma Societies**

**Glaucoma - «State» without borders**

*Chairs:* E. Egorov (RUSSIA), T. Botabekova (KAZAKHSTAN), A. Kasimov (AZERBAIJAN), L. Marchenko (BELARUS)

- |           |  |
|-----------|--|
| 8.00-8.15 | <b>Epidemiological features of glaucoma in CIS: results of the multi-center study</b><br><b>E. Egorov, A. Kuroyedov (RUSSIA)</b>                         |
| 8.15-8.27 | <b>The efficiency of glaucoma detection in various forms of screening</b><br><b>T. Botabekova, N. Aldasheva, S. Islamov, Y. Kramorenko (KAZAKHSTAN)</b>  |
| 8.27-8.39 | <b>Pathogenic mechanisms of ischemic and non-ischemic types of primary glaucoma</b><br><b>N. Zavgorodnyaya (UKRAINE)</b>                                 |
| 8.39-8.51 | <b>Glaucoma is a neurodegenerative disease, a new paradigm for an old problem</b><br><b>L. Marchenko, A. Fedulov, A. Dalidovich, Y. Rozhko (BELARUS)</b> |
| 8.51-9.03 | <b>Glaucoma: Who, when and how we operate?</b><br><b>V. Erichev (RUSSIA)</b>   |
| 9.03-9.15 | <b>Glaucoma management in the Russian region - Tatarstan</b><br><b>A. Amirov (RUSSIA)</b>  |
| 9.15-9.30 | <b>Q/A-Summary</b>   |

World Glaucoma Congress, June 29-July 2, 2011

---

## WEDNESDAY JUNE 29, 2011

**8.00-9.45 a.m. Room 361**

### **Greek Glaucoma Society - Symposium**

**New trends in early glaucoma diagnosis**

A. Diagourtas (GREECE)

**Thessaloniki Eye Study: From the research to the clinical practice**

E. Anastasopoulos (GREECE)

**Early detection-early progression: Where the truth lies!**

E. Karmiris (GREECE)

**24-hour IOP monitoring in glaucoma**

A.G.P Konstas (GREECE)

**8.00-9.45 a.m. Room 343**

### **Korean Glaucoma Society - Symposium**

#### **New findings in glaucoma**

*Chair:* C. Kee (KOREA)

8.00-8.10 **Perimacular inner retinal layer thickness in glaucoma**

C. Yun Kim (KOREA)

8.11-8.20 **Structure/function correlation in the macula**

M.S. Kook (KOREA)

8.21-8.30 **Retinal nerve fiber layer imaging in glaucoma management: Premises, promises and challenges**

C.K.S. Leung (HONG KONG)

8.31-8.40 **Disc hemorrhage: The incidence and significance**

K.H. Park (KOREA)

8.41-8.50 **New targets for SD-OCT imaging in glaucoma**

N. Strouthidis (UNITED KINGDOM)

8.51-9.00 **New algorithm to image the lamina cribrosa**

T.W. Kim (KOREA)

9.01-9.10 **Dynamic iris and anterior segment parameter changes in angle closure**

K. Sung (KOREA)

9.11-9.20 **Thinner retinal nerve fiber layer in normal-tension glaucoma**

C. Kee (KOREA)

9.21-9.30 **New candidates for neuroprotective therapy in glaucoma**

M. Aihara (JAPAN)

9.30-9.45 **Discussion**

---

Organized by The Hippocrates Glaucoma Foundation

---

## WEDNESDAY JUNE 29, 2011

### 8.00-9.45 a.m. Room 322M + 323M

#### Portuguese Society of Ophthalmology - Portuguese Glaucoma Group - Symposium

*Chairs:* A. Figueredo (PORTUGAL), M. Carvalho (PORTUGAL)

- 8.00-8.15      **Exfoliative glaucoma: Our approach**  
H. Spohr (PORTUGAL)
- 8.15-8.30      **Malignant glaucoma**  
C. Aguiar (PORTUGAL)
- 8.30-8.45      **UBM versus OCT Visante® in glaucoma surgery**  
A. Coelho (PORTUGAL)
- 8.45-9.00      **Long term surgical and visual outcomes of trabeculotomy in primary congenital glaucoma**  
S. Estrela Silva (PORTUGAL)
- 9.00-9.15      **Canaloplasty, pitfalls and pearls**  
M. da Luz Freitas (PORTUGAL)
- 9.15-9.40      **Discussion**

### 8.00-9.45 a.m. Room 362 + 363

#### Saudi Glaucoma Group - Symposium

#### Congenital Glaucoma in Saudi Arabia

*Chairs:* I. Aljadaan (SAUDI ARABIA), O. Badeeb (SAUDI ARABIA)

*Moderator:* S. Alobeidan (SAUDI ARABIA)

- 8.00-8.15      **Introduction to congenital glaucoma in Saudi Arabia**  
O. Badeeb (SAUDI ARABIA)
- 8.15-8.30      **Genetics of congenital glaucoma**  
K. Abu-Amero (SAUDI ARABIA)
- 8.30-8.50      **Surgical options in congenital glaucoma**  
S. Alobeidan (SAUDI ARABIA)
- 8.50-9.05      **Anti-glaucoma medications in pediatric age group**  
I. Aljadaan (SAUDI ARABIA)
- 9.05-9.20      **Visual fields testing in pediatric age group**  
J. Morales (SAUDI ARABIA)
- 9.20-9.35      **PKP in congenital glaucoma**  
A. Alrahji (SAUDI ARABIA)
- 9.35-9.45      **Discussion**

**9.45-10.00 a.m. BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION**

World Glaucoma Congress, June 29-July 2, 2011

---

## WEDNESDAY JUNE 29, 2011

### 10.00-10.50 a.m. **Grand Amphitheatre**

#### **French Glaucoma Society Symposium**

*Chairs:* A. Bron (FRANCE), F. Valtot (FRANCE)

- |             |  |
|-------------|--|
| 10.00-10.10 | <b>Ocular surface and glaucoma</b><br>C. Baudouin (FRANCE)   |
| 10.10-10.20 | <b>Glaucoma economics</b><br>J.P. Rouland (FRANCE)   |
| 10.20-10.30 | <b>Risks factors in glaucoma: A case control study</b><br>J.P. Renard (FRANCE)   |
| 10.30-10.40 | <b>Therapeutic alliance in glaucoma: Are patients and ophthalmologists on the same wavelength?</b><br>J.P. Nordmann (FRANCE) |
| 10.40-10.50 | <b>Current data on ultrasound glaucoma treatment</b><br>P. Denis (FRANCE)  |

### 10.55-11.45 a.m. **Grand Amphitheatre**

#### **European Glaucoma Society Symposium**

#### **Regional Initiatives in Glaucoma**

*Chairs:* R.A. Hitchings (UNITED KINGDOM), C.E. Traverso (ITALY)

- |             |   |
|-------------|---|
| 10.55-11.04 | <b>Where glaucoma sits within other health issues in Europe</b><br>A. Azuara Blanco (UNITED KINGDOM)            |
| 11.04-11.13 | <b>A regional perspective on genetic studies and biobanks-EGS GlaucoGene</b><br>A. Viswanathan (UNITED KINGDOM) |
| 11.13-11.22 | <b>EGS GlaucoCard project and online system for patients' data collection</b><br>M. Schargus (GERMANY)          |
| 11.22-11.31 | <b>Use of IOP-lowering medications: Past, present and future</b><br>H. Uusitalo (FINLAND)                       |
| 11.31-11.40 | <b>Development of cooperation with patients associations</b><br>J. Thygesen (DENMARK)                           |
| 11.40-11.45 | <b>Report from the EGS 2010 Madrid Congress</b><br>F. Grehn (GERMANY)   |

### 10.00 a.m.-1.45 p.m. **Room 362 + 363**

#### **WGC FILM FESTIVAL**

Please see page 62 for the list of videos to be shown.

---

Organized by The Hippocrates Glaucoma Foundation



---

## WEDNESDAY JUNE 29, 2011

### PLENARY LUNCH SYMPOSIUM

#### 12.00-1.00 p.m. **Grand Amphitheatre**

#### **The Pressures of Glaucoma**

*Chairs:* R.N. Weinreb (USA), R. Susanna (BRAZIL), K. Barton (UNITED KINGDOM)

**Intraocular Pressure: 24 hours and beyond**

R.N. Weinreb (USA)

**Blood pressure and perfusion pressure: Should they be treated?**

K. Singh (USA)

**Intracranial pressure: Is it the next risk factor?**

K. Martin (UNITED KINGDOM)

**Pressure Independence: Is glaucoma progression related to more than just intraocular pressure?**

J.M. Liebmann (USA)

Boxed lunches provided following the symposium

### 1.00-3.00 p.m. BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION

#### 2.00-3.00 p.m. **Room 342A + 342B**

#### **Global Assembly**

|           |  |
|-----------|--|
| 2.00-2.05 | <b>Opening &amp; Welcome</b>                                 |
|           | M. Araie (JAPAN)   |
| 2.05-2.10 | <b>Introduction of new Glaucoma Societies since WGC-2009</b> |
|           | T. Shaarawy (SWITZERLAND)                                    |
| 2.10-2.20 | <b>WGA Statutes</b>  |
|           | D.S. Greenfield (USA), P. Healey (AUSTRALIA)                 |
| 2.20-2.25 | <b>International Glaucoma Review</b>                         |
|           | R.N. Weinreb (USA)   |
| 2.25-2.30 | <b>World Glaucoma Week</b>                                   |
|           | I. Goldberg (AUSTRALIA), R. Ritch (USA)                      |
| 2.30-2.40 | <b>Consensus Update</b>                                      |
|           | R.N. Weinreb (USA)   |
| 2.40-2.45 | <b>Highlights of the WGA African Glaucoma Summit</b>         |
|           | S. Melamed (ISRAEL)  |
| 2.45-2.55 | <b>WGA Strategic Plan</b>                                    |
|           | A. Sit (USA)   |
| 2.55-3.00 | <b>Summary and Concluding Remarks</b>                        |
|           | K. Singh (USA)   |

World Glaucoma Congress, June 29-July 2, 2011

## WEDNESDAY JUNE 29, 2011

### 3.30-5.30 p.m. **Grand Amphitheatre** **Opening Session**

- |           |   |
|-----------|---|
| 3.30-3.36 | <b>Welcome and Introduction of the President</b><br>K. Singh (USA)  |
| 3.36-3.39 | <b>Welcome by the WGA President</b><br>M. Araie (JAPAN)   |
| 3.39-3.40 | <b>Introduction of the French Glaucoma Society President</b>  |
| 3.40-3.43 | <b>Welcome by the French Glaucoma Society President</b><br>E. Sellem (FRANCE)   |
| 3.43-3.44 | <b>Introduction of the European Glaucoma Society President</b>  |
| 3.44-3.47 | <b>Welcome by the European Glaucoma Society President</b><br>C.E. Traverso (ITALY)  |
| 3.47-3.48 | <b>Introduction of the Program Committee Chairs</b>   |
| 3.48-3.57 | <b>Welcome by the WGC Program Committee Chairs</b><br>D. Lam (HONG KONG), J.M. Liebmann (USA), S. Melamed (ISRAEL),<br>J.S. Schuman (USA) |
| 3.57-3.58 | <b>Introduction of the Board of Governors</b>   |
| 3.58-4.03 | <b>Welcome by the Board of Governors First President</b><br>R.A. Hitchings (UNITED KINGDOM)   |
| 4.03-4.04 | <b>Introduction of Consensus</b>  |
| 4.04-4.12 | <b>Consensus Update</b><br>R.N. Weinreb (USA)   |
| 4.12-4.13 | <b>Introduction of the World Glaucoma Week</b>  |
| 4.13-4.18 | <b>World Glaucoma Week</b><br>I. Goldberg (USA)   |
| 4.18-4.19 | <b>Introduction of the International Glaucoma Review</b>  |
| 4.19-4.24 | <b>International Glaucoma Review Update</b><br>R.N. Weinreb (USA)   |
| 4.24-4.25 | <b>Introduction of the WGA African Glaucoma Summit</b>  |
| 4.25-4.35 | <b>WGA African Glaucoma Summit</b><br>S. Melamed (ISRAEL), T. Shaarawy (SWITZERLAND)  |
| 4.35-4.36 | <b>Introduction of the WGA Research Awards</b>  |
| 4.36-4.56 | <b>WGA Research Awards</b><br>M. Araie (JAPAN), R.N. Weinreb (USA)  |
| 4.56-4.58 | <b>Introduction of Lecture</b>  |
| 4.58-5.18 | <b>Wine, Glaucoma and Life</b><br>A. Bron (FRANCE)  |
| 5.18-5.20 | <b>Summary and Concluding Comments</b><br>K. Singh (USA)  |

**5.30-7.00 p.m. WELCOME RECEPTION – EXHIBITION AREA (THIRD FLOOR)**

Organized by The Hippocrates Glaucoma Foundation

---

## THURSDAY JUNE 30, 2011

### 7.00-7.55 a.m. **Room Havane**

This symposium is sponsored by Pfizer

#### **New approaches in the care of pediatric glaucoma**

*Chair:* N. Pfeiffer (GERMANY)

##### **The epidemiology and pathogenesis of pediatric glaucoma**

J. Brookes (UNITED KINGDOM)

##### **Current approaches, new developments and challenges to pediatric glaucoma management**

J. Thygesen (DENMARK)

##### **From pediatric to adult glaucoma: Learning from the clinical evidence in adults**

N. Pfeiffer (GERMANY)

##### **Questions and answers**

N. Pfeiffer (GERMANY), J. Brookes (UNITED KINGDOM), J. Thygesen (DENMARK)

### 7.00-7.55 a.m. **Room 343**

This symposium is sponsored by Ziemer

#### **Dynamic Contour Tonometer: Clinical relevance**

*Chair:* R.L. Stamper (USA)

##### **The Dynamic Contour Tonometer: Studies and application**

R.L. Stamper (USA)

##### **Effect of latanoprost on applanation tonometry and Dynamic Contour Tonometry**

E.T. Detorakis (GREECE)

##### **The relative accuracy and precision of clinical tonometry**

D. Garway-Heath (UNITED KINGDOM)

##### **Myth or truth: The anti-glaucomatous cataract surgery**

A. Viestenz (GERMANY)

### 8.00-9.30 a.m. **Grand Amphitheatre**

#### **S21 Grand Rounds**

*Chairs:* C. Baudouin (FRANCE), D. Epstein (USA)

*Panel:* A. Bron (FRANCE), I. Goldberg (AUSTRALIA), T. Samuelson (USA), R. Susanna (BRAZIL)

8.00-8.06

##### **GR01 Concurrent Posner Schlossman syndrome and CMV retinitis during immunotherapy for common variable immunodeficiency**

A. Espino García (SPAIN)

8.06-8.12

##### **GR02 Grand Round: Puzzling asymmetry**

J. Vazirani (INDIA)

## THURSDAY JUNE 30, 2011

- 8.12-8.18 **GR03 Severe and refractory ocular hypertension after IOL and intravitreal injection of triamcinolone**  
Y. Liang (HONG KONG)
- 8.18-8.24 **GR04 Normal-tension glaucoma in a young adult patient or what?**  
N. Kasahara (BRAZIL)
- 8.24-8.30 **GR05 Progression of glaucoma in a patient with Boston keratoprosthesis**  
P.K.R. Beeram (INDIA)  
Panel discussion

### 8.00-9.30 a.m. Room Bordeaux

#### S01 Angle-closure glaucoma

*Chairs:* D. Friedman (USA), J. Ge (CHINA), R. Thomas (AUSTRALIA)

- 8.00-8.08 **Epidemiology update**  
G. Gazzard (UNITED KINGDOM)
- 8.08-8.16 **Mechanism of ACG including discussion of the role of the lens in ACG**  
M. He (CHINA)
- 8.16-8.24 **Genetics of ACG**  
T. Aung (SINGAPORE)
- 8.24-8.32 **Recent clinical trials in angle closure**  
C.C.Y. Tham (HONG KONG)
- 8.32-8.40 **Major unanswered questions about angle closure**  
H. Quigley (USA)
- 8.40-8.48 **Iridoplasty, what is the evidence?**  
A. Azuara Blanco (UNITED KINGDOM)
- 8.48-8.56 **Innovations in angle-closure diagnosis**  
R. George (INDIA)

### 8.00-8.45 a.m. Room Havane

#### S04 Epidemiology and screening of primary open-angle glaucoma

*Chairs:* N. Congdon (CHINA), M. He (CHINA), L.M. Rossetti (ITALY)

- 8.00-8.08 **Is it better to under- or over-diagnose glaucoma?**  
M.S. Kook (KOREA)
- 8.08-8.16 **Are sleep apnea or other sleep disorders risk factors for glaucoma?**  
S.L. Mansberger (USA)
- 8.16-8.24 **Should we be treating low-perfusion pressure?**  
F. Topouzis (GREECE)
- 8.24-8.32 **How will genetics help with the management of glaucoma?**  
J. Wiggs (USA)

---

## THURSDAY JUNE 30, 2011

- 8.32-8.40      **How much should the IOP be lowered to prevent glaucomatous visual field loss?**  
D.E. Grigera (ARGENTINA)

### 8.45-9.30 a.m. **Room Havane**

#### **S05 Risk factors for glaucoma onset and progression**

*Chairs:* B. Bengtsson (SWEDEN), D. Leung Yu-Lung (HONG KONG), T. Zeyen (BELGIUM)

- 8.45-8.53      **Confirmed and unconfirmed risk factors for glaucoma**  
P. Healey (AUSTRALIA)
- 8.53-9.01      **Are risk factors for onset and progression of glaucoma different?**  
C.G. De Moraes (USA)
- 9.01-9.09      **Lifestyle and risk for glaucoma**  
J.C. Tsai (USA)
- 9.09-9.17      **Are any risks except IOP treatable?**  
L. Schmetterer (AUSTRIA)

### 9.00 a.m.-4.45 p.m. **Room 362 + 363**

#### **WGC FILM FESTIVAL**

Please see page 64 for the list of videos to be shown

**9.30-10.15 a.m. BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION**

### 10.15-11.45 a.m. **Grand Amphitheatre**

#### **S03 Glaucoma progression**

*Chairs:* D.S. Greenfield (USA), D.E. Grigera (ARGENTINA), A. Heijl (SWEDEN)

- 10.15-10.23      **Detection of retinal nerve fiber layer progression**  
K. H. Park (KOREA)
- 10.23-10.31      **Detection of optic disc and HRT progression**  
M. Nicolela (CANADA)
- 10.31-10.39      **Detection of visual field progression**  
B. Bengtsson (SWEDEN)
- 10.39-10.47      **Using structure and function information in clinical practice**  
J.M. Liebmann (USA)
- 10.47-10.55      **Should clinical therapy be advanced following optic disc hemorrhage?**  
T. Yamamoto (JAPAN)
- 10.55-11.03      **Management of rapid glaucomatous progression**  
R. Carassa (ITALY)

## THURSDAY JUNE 30, 2011

### 10.15-11.45 a.m. Room Bordeaux

#### S28 Innovative approaches for protecting the retinal ganglion cells

*Chairs:* K. Martin (UNITED KINGDOM), H. Levkovitch-Verbin (ISRAEL), R.N. Weinreb (USA)

- |             |  |
|-------------|--|
| 10.15-10.23 | <b>Clues to neuroprotection from genetic studies</b><br>J. Wiggs (USA)                   |
| 10.23-10.31 | <b>Gene therapy for glaucoma</b><br>P.L. Kaufman (USA)                                   |
| 10.31-10.39 | <b>Axoprotection</b><br>L. Wheeler (USA)   |
| 10.39-10.47 | <b>Treating the brain</b><br>N. Gupta (CANADA)   |
| 10.47-10.55 | <b>Mitoprotection</b><br>J.G. Crowston (AUSTRALIA)                                       |
| 10.55-11.03 | <b>Obstacles for clinical trials of neuroprotection of glaucoma</b><br>F. Medeiros (USA) |
| 11.03-11.11 | <b>The artificial retina</b><br>J.A. Sahel (FRANCE)                                      |
| 11.11-11.19 | <b>Where to from here?</b><br>J.E. Morgan (UNITED KINGDOM)                               |

### 10.15-11.00 a.m. Room Havane

#### S23 Glaucoma and myopia

*Chairs:* J. Jonas (GERMANY), T. Aung (SINGAPORE), S. Lin (USA)

- |             |  |
|-------------|--|
| 10.15-10.23 | <b>Biomechanics of the optic-nerve head in eyes with myopic features</b><br>J. Jonas (GERMANY) |
| 10.23-10.31 | <b>Glaucomatous disease in young Chinese myopes</b><br>K. Singh (USA)                          |
| 10.31-10.39 | <b>Glaucoma diagnosis in highly-myopic eyes using SD-OCT</b><br>M. Hangai (JAPAN)              |
| 10.39-10.47 | <b>The retinal nerve fiber layer in myopia</b><br>D.L. Budenz (USA)                            |
| 10.47-10.55 | <b>Structural changes in the eye in Asians with myopia</b><br>B. Mani (SINGAPORE)              |



---

## THURSDAY JUNE 30, 2011

**11.00-11.45 a.m. Room Havane**

**S25 Update on Consensus reports**

*Chairs:* J.M. Liebmann (USA) M. Araie (JAPAN), S.F. Lerner (ARGENTINA)

|             |  |
|-------------|--|
| 11.00-11.03 | <b>Introduction</b><br>M. Araie (JAPAN)              |
| 11.03-11.11 | <b>Who should be treated?</b><br>F. Medeiros (USA)   |
| 11.11-11.19 | <b>Selection of drugs</b><br>S.F. Lerner (ARGENTINA) |
| 11.19-11.27 | <b>Neuroprotection</b><br>T. Wong (SINGAPORE)        |
| 11.27-11.35 | <b>Unmet needs</b><br>C.K.S. Leung (HONG KONG)       |
| 11.35-11.43 | <b>Summary</b><br>J.M. Liebmann (USA)                |

### PLENARY LUNCH SYMPOSIUM

**12.00-1.00 p.m. Grand Amphitheatre**

**Clinical considerations in Glaucoma treatment: A preservative-free option**

*Chair:* C.E. Traverso (ITALY)

**Welcome and introduction**

C.E. Traverso (ITALY)

**The glaucoma patient: Who to treat and how to treat**

J.P. Nordmann (FRANCE)

**Effects of preservatives on the ocular surface and trabecular meshwork**

M. Kahook (USA)

**Clinical profile of the first and only preservative-free prostaglandin**

N. Pfeiffer (GERMANY)

**Diurnal IOP measurement: What is new?**

T. Shaarawy (SWITZERLAND)

**Q&A/Panel Discussion**

**Final comments & closing**

C.E. Traverso (ITALY)

This symposium is sponsored by Merck Sharp & Dohme and Santen

Boxed lunches provided following the symposium

## THURSDAY JUNE 30, 2011

1.00-2.00 p.m. BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION

### 2.00-3.30 p.m. **Grand Amphitheatre**

#### **S17 Glaucoma debates: hot topics (has glaucoma management improved in the last ten years?)**

*Chairs:* K. Singh (USA), P. RojanaPongpun (THAILAND), M. Nardi (ITALY)

- |           |   |
|-----------|---|
| 2.00-2.07 | <b>What is the best glaucoma operation when the first trabeculectomy fails: Trab</b><br>R. Fechtner (USA)                             |
| 2.07-2.14 | <b>What is the best glaucoma operation when the first trabeculectomy fails: Tube</b><br>R.K. Parrish (USA)                            |
| 2.14-2.21 | <b>Should pre-perimetric glaucoma be treated with IOP-lowering therapy: Yes</b><br>D.S. Greenfield (USA)                              |
| 2.21-2.28 | <b>Should pre-perimetric glaucoma be treated with IOP-lowering therapy: No</b><br>A. Heijl (SWEDEN)                                   |
| 2.28-2.35 | <b>Will non-IOP-lowering neuroprotective therapy be available within the next decade: Yes</b><br>C.K.S. Leung (HONG KONG)             |
| 2.35-2.42 | <b>Will non-IOP-lowering neuroprotective therapy be available within the next decade: No</b><br>K. Martin (UNITED KINGDOM)            |
| 2.42-2.49 | <b>Will trabeculectomy be the most frequently performed stand-alone glaucoma operation in five years: Yes</b><br>R.L. Stamper (USA)   |
| 2.49-2.56 | <b>Will trabeculectomy be the most frequently performed stand-alone glaucoma operation in five years: No</b><br>N. Pfeiffer (GERMANY) |
| 2.56-3.03 | <b>Is laser trabeculoplasty preferred first-line glaucoma therapy: Yes</b><br>R.L. Fellman (USA)                                      |
| 3.03-3.10 | <b>Is laser trabeculoplasty preferred first-line glaucoma therapy: No</b><br>F. J. Goñi (SPAIN)                                       |
| 3.10-3.17 | <b>Is modern cataract surgery the best glaucoma operation: Yes</b><br>R. Brown (USA)  |
| 3.17-3.24 | <b>Is modern cataract surgery the best glaucoma operation: No</b><br>C.E. Traverso (ITALY)  |

---

## THURSDAY JUNE 30, 2011

### 2.00-3.30 p.m. Room Bordeaux

#### S24 Exfoliation syndrome and exfoliative glaucoma

*Chairs:* R. Ritch (USA), H. Tanihara (JAPAN)

- 2.00-2.10      **Structure and function of the lysyl oxidases**  
K. Csiszar (USA)
- 2.10-2.20      **Epidemiology and genetics of exfoliation syndrome**  
K. Barton (UNITED KINGDOM)
- 2.20-2.30      **Ocular manifestations of exfoliation syndrome**  
G. Holló (HUNGARY)
- 2.30-2.40      **Systemic manifestations of exfoliation syndrome**  
R. Ritch (USA)
- 2.40-2.50      **The role of LOXL1 in the pathophysiology of exfoliative glaucoma**  
U. Schlötzer-Schrehardt (GERMANY)
- 2.50-3.00      **Treatment of exfoliative glaucoma**  
A.G.P. Konstas (GREECE)
- 3.00-3.10      **Surgical approach to glaucoma and cataract**  
C. Tello (USA)

### 2.00-2.45 p.m. Room Havane

#### S09 Laser trabeculoplasty for open-angle glaucoma

*Chairs:* S. Melamed (ISRAEL), J. Alvarado (USA), J. Zhao (CHINA)

- 2.00-2.08      **SLT for OAG: Where are we?**  
M.A. Latina (USA)
- 2.08-2.16      **Role of laser trabeculoplasty (ALT, SLT) in our glaucoma clinic**  
M. Wand (USA)
- 2.16-2.24      **SLT in pseudoexfoliative glaucoma**  
O. Geyer (ISRAEL)
- 2.24-2.32      **Should LTP be first-line treatment**  
R. Noecker (USA)

### 2.45-3.30 p.m. Room Havane

#### S34 Regenerative medicine in the 21<sup>st</sup> century - Can we repair the glaucomatous eyes?

*Chairs:* J.D. Brandt (USA), R. Burk (GERMANY), Y. Kuwayama (JAPAN)

- 2.45-2.53      **Targets for regenerative medicine in the outflow system**  
D.J. Rhee (USA)
- 2.53-3.01      **Delivering genes to the trabecular meshwork**  
J.D. Lindsey (USA)

## THURSDAY JUNE 30, 2011

- 3.01-3.09      **Repairing the central nervous system**  
Y. Yücel (CANADA)
- 3.09-3.17      **Repairing the retinal ganglion cell**  
F. Cordeiro (UNITED KINGDOM)
- 3.17-3.25      **The prosthetic ocular surface-glaucoma challenges**  
J.D. Brandt (USA)

3.30-4.00 p.m. BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION

### 4.00-5.00 p.m. **Grand Amphitheatre**

#### **C17 Imaging 1: Basic technology and diagnosis**

*Chairs:* C.K.S. Leung (HONG KONG), J.S. Schuman (USA)

*Speakers:* M. Fingeret (USA), J.C. Fujimoto (USA), H.G. Lemij (THE NETHERLANDS), F. Medeiros (USA), G. Wollstein (USA), L. Zangwill (USA)

### 4.00-5.00 p.m. **Room Bordeaux**

#### **C12 Glaucoma drainage devices - part 1**

*Chairs:* J. Freedman (USA), A. Molteno (NEW ZEALAND)

*Speakers:* G. Baerveldt (USA), E. Dahan (ISRAEL), M. Sherwood (USA), G.E. Trope (CANADA)

### 4.00-5.00 p.m. **Room Havane**

#### **French Glaucoma Society Courses: Irido-corneal angle and optic nerve head simulator**

*Chairs:* J.P. Rouland (FRANCE), J. Romanet (FRANCE)

### 4.00-5.00 p.m. **Room 341**

#### **C01 Glaucoma epidemiology: Prevalence and diagnosis**

*Chairs:* F. Topouzis (GREECE), R. Varma (USA), W. Nolan (UNITED KINGDOM), R. Thomas (AUSTRALIA)

*Speakers:* T. Aung (SINGAPORE), W. J. Feuer (USA), D. Friedman (USA), M. He (CHINA), R. Wilson (USA)

### 4.00-5.00 p.m. **Room 342A**

#### **C03 Congenital and infantile glaucoma**

*Chairs:* A.K. Mandal (INDIA) M. Lynch (USA)

*Speaker:* A.K. Mandal (INDIA), P.A. Netland (USA), L. Solebo (UNITED KINGDOM)

---

## THURSDAY JUNE 30, 2011

### 4.00-5.00 p.m. Room 342B

#### **C04 Glaucoma management and education in the developing world**

*Chairs:* F. Gomez Goyeneche (COLOMBIA), L.W. Herndon (USA)

*Speakers:* K. Ben Amor (TUNISIA), G. Gazzard (UNITED KINGDOM), L. W. Herndon (USA), K.F. So (HONG KONG), C. Zhang (CHINA)

### 4.00-5.00 p.m. Room 343

#### **C08 Tonometry and corneal biomechanics**

*Chairs:* J.D. Brandt (USA), L.E. Pillunat (GERMANY)

*Speakers:* N. Congdon (CHINA), D. Garway-Heath (UNITED KINGDOM), J. Jonas (GERMANY), J.H.K. Liu (USA), D. Mackey (AUSTRALIA), A. Sit (USA), A.Wells (NEW ZEALAND)

### 4.00-5.00 p.m. Room 353

#### **C14 Glaucoma patient organizations (how to organize, interact with GPO)**

*Chair:* G.N. Lambrou (GREECE)

### 4.00-5.00 p.m. Room 352B

#### **C06 Trabeculectomy pearls and pitfalls**

*Chairs:* F. El Sayyad (EGYPT), R. Ramakrishnan (INDIA)

*Speakers:* L. Al Aswad (SYRIA), F. El Sayyad (EGYPT), N. Pfeiffer (GERMANY), R. Ramakrishnan (INDIA)

### 4.00-5.00 p.m. Room 352A

#### **C20 Principles of medical therapy in glaucoma practice**

*Chairs:* R. Fechtner (USA), J. Thygesen (DENMARK), A. Hommer (AUSTRIA)

*Speakers:* R. Fechtner (USA), A. Hommer (AUSTRIA), Y. Lachkar (FRANCE), L. Schmetterer (AUSTRIA), H. Tanihara (JAPAN), J. Thygesen (DENMARK)

### 4.00-5.00 p.m. Room 351

#### **C11 Trabeculectomy-optimizing outcomes**

*Chairs:* K. Barton (UNITED KINGDOM), C. Baudouin (FRANCE)

*Speakers:* K. Barton (UNITED KINGDOM), C. Baudouin (FRANCE), T. Eke (UNITED KINGDOM), C.L. Ho (SINGAPORE), E.U. Leuenberger (PHILIPPINES)

### 4.00-6.00 p.m. Room 361

**'GOING BLIND' - A film by Joe Lovett, followed by questions and answers with Joe Lovett**

**'QUILTING BY HAND' - A film about Diane Rose by Texas Country Reporter**

## THURSDAY JUNE 30, 2011

### 4.00-5.00 p.m. Room 364

#### **C41 Identification of genes responsible for ocular quantitative traits as risk factors for glaucoma**

*Chairs:* D. Mackey (AUSTRALIA), C. Pang (HONG KONG), J. Craig (AUSTRALIA)

*Speakers:* F. Jonasson (ICELAND), W. Ramdas (THE NETHERLANDS), P. Sanfilippo (AUSTRALIA),

### 5.00-6.00 p.m. Grand Amphitheatre

#### **C18 Imaging 2: Progression and management**

*Chairs:* C.K.S. Leung (HONG KONG), J.S. Schuman (USA)

*Speakers:* M. Fingeret (USA), M. Hangai (JAPAN), H.G. Lemij (THE NETHERLANDS), F. Medeiros (USA), G. Wollstein (USA)

### 5.00-6.00 p.m. Room Bordeaux

#### **C13 Glaucoma drainage devices-part 2**

*Chairs:* J. Freedman (USA), A. Molteno (NEW ZEALAND)

*Speaker:* J. Freedman (USA), S.J. Gedde, A. Molteno (USA)

### 5.00-6.00 p.m. Room Havane

#### **French Glaucoma Society Courses: Functional progression in glaucoma**

*Chairs:* F. Valtot (FRANCE), F. May (FRANCE)

### 5.00-6.00 p.m. Room 341

#### **C02 Electrophysiology and glaucoma diagnosis**

*Chair:* S. Graham (AUSTRALIA)

*Speakers:* C. Bowd (USA), B. Fortune (USA), S. Graham (AUSTRALIA)

### 5.00-6.00 p.m. Room 342A

#### **C05 Laser surgery for OAG**

*Chairs:* L.J. Katz (USA), M. Wand (USA)

*Speakers:* J. Alvarado (USA), L.J. Katz (USA), M.A. Latina (USA), J. McAllister (UNITED KINGDOM), G.D. McLaren (SOUTH AFRICA), J. Myers (USA), M. Wand (USA)

### 5.00-6.00 p.m. Room 342B

#### **C07 Clinical trials and evidence-based glaucoma**

*Chairs:* W.J. Feuer (USA), L. Sakata (BRAZIL)

*Speakers:* T. Aung (Singapore), D.L. Budenz (USA), C.G. De Moraes (USA), W.J. Feuer (USA), L. Sakata (BRAZIL)

Organized by The Hippocrates Glaucoma Foundation



---

## THURSDAY JUNE 30, 2011

### 5.00-6.00 p.m. Room 343

#### **C15 Glaucoma health economics**

*Chairs:* A. Tuulonen (FINLAND), S. Kymes (USA)

*Speakers:* J. Burr (UNITED KINGDOM), R. George (INDIA), S. Kymes (USA), A. Tuulonen (FINLAND)

### 5.00-6.00 p.m. Room 353

#### **C24 Experimental models in glaucoma**

*Chairs:* J.G. Crowston (AUSTRALIA), J.E. Morgan (UNITED KINGDOM)

*Speakers:* J.G. Crowston (AUSTRALIA), P.L. Kaufman (USA), K. Martin (UNITED KINGDOM), J.E. Morgan (UNITED KINGDOM), C. O'Brien (IRELAND), C.B. Toris (USA)

### 5.00-6.00 p.m. Room 352B

#### **C09 Clinical optic disc evaluation**

*Chairs:* J. Jonas (GERMANY), M. Nicolela (CANADA)

*Speakers:* A. Bron (FRANCE), D. Garway-Heath (UNITED KINGDOM), J. Jonas (GERMANY), F. Medeiros (USA), M. Nicolela (CANADA)

### 5.00-6.00 p.m. Room 352A

#### **C23 Glaucoma therapies and ocular surface disease**

*Chairs:* R. Noecker (USA), M. Kahook (USA), R. Bourne (UNITED KINGDOM)

*Speakers:* C. Baudouin (FRANCE), R. Fechtner (USA), M. Kahook (USA), R. Noecker (USA), M. Sherwood (USA)

### 5.00-6.00 p.m. Room 351

#### **C16 How to detect and confirm progression and use it to manage glaucoma**

*Chairs:* B. Chauhan (CANADA), A. Heijl (SWEDEN)

*Speakers:* B. Bengtsson (SWEDEN), D. Garway-Heath (UNITED KINGDOM), K. Kashiwagi (JAPAN), B.E. Prum (USA), G. Tomita (JAPAN), L. Zangwill (USA)

### 6.00-7.00 p.m. Room Bordeaux

*This symposium is sponsored by EyeTechCare*

#### **UC<sup>3</sup>: One giant step in glaucoma...**

*Chairs:* S. Melamed (ISRAEL), E. Sellem (FRANCE)

**HIFU: Technology that may change surgery**

**G. ter Haar (UNITED KINGDOM)**

## THURSDAY JUNE 30, 2011

**Glaucoma: From a patient's perspective**

D. Wright (UNITED KINGDOM)

**UC<sup>3</sup>: From theory to therapy**

F. Aptel (FRANCE)

**EyeOP1 device: First outcomes from human trials**

P. Denis (FRANCE)

**How technology can improve the standard of care in glaucoma surgery**

T. Shaarawy (SWITZERLAND)

**6.00-7.00 p.m. Hotel Concorde La Fayette (next to the Palais des Congrès)**

This symposium is sponsored by Alcon

**Advances in glaucoma surgery: New evidence in filtration surgery**

*Chair:* I. Goldberg (AUSTRALIA)

**What is the EX-PRESS® Glaucoma filtration device and how is it different than a traditional trabeculectomy?**

R. Fechtner (USA)

**Improving the efficacy and predictability of filtration surgery with the EX-PRESS® Glaucoma filtration device – New 5 year study results comparing EX-PRESS® vs. trabeculectomy**

L. de Jong (THE NETHERLANDS)

**Final report from a novel 30 months RCT comparing the EX-PRESS® glaucoma filtration device to trabeculectomy in fellow eyes of the same patient**

E. Dahan (ISRAEL)

**Improving patient visual recovery in filtration surgery: Results from a newly published study on the EX-PRESS® Glaucoma filtration device**

M. Kahook (USA)

**The tips and pearls of using the EX-PRESS® Glaucoma filtration device**

M. Moster (USA)

---

## FRIDAY JULY 1, 2011

### 7.00-7.55 a.m. **Room 341**

This symposium is sponsored by AEON ASTRON EUROPE B.V.

#### **Can MMC Be Replaced: Collagen Matrix for Eye Tissue Repair**

##### **Opening**

M. Lai (AEON ASTRON EUROPE B.V.)

##### **Introduction of ologen® Collagen Matrix**

J. Lin (AEON ASTRON EUROPE B.V.)

##### **Biodegradable collagen matrix implant vs. mitomycin-C as an adjuvant in trabeculectomy: A two-year randomized clinical trial**

S. Cillino (ITALY)

##### **Trabeculectomy with ologen® and MMC**

J. Lai (HONG KONG)

##### **Trab with ologen®: The practical tips for the better outcome and the Indian experience**

P. Sathyan (INDIA)

### 7.00-7.55 a.m. **Room 343**

This symposium is sponsored by Anteis

#### **Three years of various clinical experiences using a crosslinked sodium hyaluronate implant in filtering surgery**

*Chair:* A. Mermoud (SWITZERLAND)

##### **Effect of injectable cross-linked sodium hyaluronate in trabeculectomy**

N. Wang (CHINA)

##### **Healaflo in deep sclerectomy**

P. Bettin (ITALY)

##### **Healaflo in difficult cases**

A. Mermoud (SWITZERLAND)

##### **'Healaflo and Express' / Healaflo and choroidal detachment management**

E. Dahan (ISRAEL)

##### **Healaflo: Clinical results**

S. Roy (SWITZERLAND)

## FRIDAY JULY 1, 2011

### GLAUCOMA SURGERY DAY

**8.00 a.m.-6.30 p.m. Grand Amphitheatre**

*Chairs:* F. Grehn (GERMANY), R.N. Weinreb (USA)

8.00 - 9.00 **Decision-making and laser trabeculoplasty**

9.00 -10.30 **Trabeculectomy**

11.00 -12.00 **Tubes – glaucoma drainage devices**

2.00 - 3.30 **Surgery for open-angle glaucoma**

3.30 - 4.30 **Angle-closure glaucoma**

4.30 - 5.30 **Cataract and refractive surgery in eyes with glaucoma**

5.30 - 6.30 **Childhood glaucoma**

---

## FRIDAY JULY 1, 2011

### 8.00-9.00 a.m. **Grand Amphitheatre**

#### **WGA SURGERY DAY: Decision-making and laser trabeculoplasty**

*Chairs:* M. Araie (JAPAN), N. Pfeiffer (GERMANY), R. Thomas (AUSTRALIA)

- 8.00-8.06      **Prevalence of worldwide glaucoma surgery**  
K. Mansouri (USA)
- 8.06-8.12      **Indications for surgery**  
E.Z. Blumenthal (ISRAEL)
- 8.12-8.18      **Pre-operative evaluation**  
T. Dada (INDIA)
- 8.18-8.24      **Reporting of surgical trials**  
T. Shaarawy (SWITZERLAND)
- 8.24-8.30      **Long-term results and clinical implications**  
L.J. Katz (USA)
- 8.30-8.36      **Argon vs. selective: Efficacy and repeatability**  
A.D. Realini (USA)
- 8.36-8.42      **Should LTP be first-line therapy?**  
F. Topouzis (GREECE)

### 8.00-8.45 a.m. **Room Bordeaux**

#### **S26 Normal-tension glaucoma: Diagnosis and treatment**

*Chairs:* G. D'Mellow (AUSTRALIA), T. Yamamoto (JAPAN), T. Krupin (USA)

- 8.00-8.08      **Is NTG a different entity than POAG?**  
R. Wilson (USA)
- 8.08-8.16      **CSF pressure, perfusion pressure, and IOP across the Lamina cribrosa**  
J. Jonas (GERMANY)
- 8.16-8.24      **Is structural and functional rate of progression in NTG different from HTG?**  
F. Medeiros (USA)
- 8.24-8.32      **Should NTG be treated differently from HTG? PRO**  
T. Yamamoto (JAPAN)
- 8.32-8.40      **Should NTG be treated differently from HTG? CON**  
G. D'Mellow (AUSTRALIA)

## FRIDAY JULY 1, 2011

### 8.00-8.45 a.m. Room Havane

#### **S07 IOP measurements: Present and future**

*Chairs:* A. Sit (USA), D. Garway-Heath (UNITED KINGDOM), G. Spaeth (USA)

- 8.00-8.08      **The need for better IOP measurements**  
R. Pérez Grossman (PERU)
- 8.08-8.16      **Measurement of IOP in office-new developments**  
S. Asrani (USA)
- 8.16-8.24      **Ocular biomechanical properties and IOP**  
C.K.S. Leung (HONG KONG)
- 8.24-8.32      **Home tonometry**  
M. Fingeret (USA)
- 8.32-8.40      **Measurement of 24-hour IOP**  
J.H.K. Liu (USA)

### 8.45-9.30 a.m. Room Bordeaux

#### **S10 Ocular blood flow (perfusion and WGA consensus)**

*Chairs:* A. Harris (USA), M. Araie (JAPAN), J. Flammer (SWITZERLAND)

- 8.45-8.52      **WGA ocular blood flow consensus review**  
I. Januleviciene (LITHUANIA)
- 8.52-8.59      **Ocular blood flow measurements and technologies**  
G. Michelson (GERMANY)
- 8.59-9.06      **Ocular perfusion pressure and blood flow deficits in glaucoma**  
V.P. Costa (BRAZIL)
- 9.06-9.13      **Systemic vascular abnormalities and glaucoma**  
M. Araie (JAPAN)
- 9.13-9.20      **Structure and functional correlates to altered ocular blood flow and perfusion**  
R.N. Weinreb (USA)
- 9.20-9.27      **Can ocular blood flow be managed?**  
J. Piltz-Seymour (USA)

### 8.45-9.30 a.m. Room Havane

#### **S12 New ideas in medical treatment**

*Chairs:* A. Azuara Blanco (UNITED KINGDOM), M. Diestelhorst (GERMANY), H.G. Lemij (THE NETHERLANDS)

- 8.45-8.53      **Introduction**  
A. Azuara Blanco (UNITED KINGDOM)

---

## FRIDAY JULY 1, 2011

- 8.53-9.01 **Interventions to improve adherence**  
M. Sherwood (USA)
- 9.01-9.09 **New targets for glaucoma treatment**  
P.T. Khaw (UNITED KINGDOM)
- 9.09-9.17 **Novel delivery methods and devices**  
R. Varma (USA)
- 9.17-9.25 **The impact of 24-hour intraocular pressure measurements on glaucoma care**  
A. Sit (USA)

**9.00 a.m.-4.45 p.m. Room 362 + 363**

### **WGC FILM FESTIVAL**

Please see page 64 for the list of videos to be shown.

**9.30-10.15 a.m. BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION**

**9.00-10.30 a.m. Grand Amphitheatre**

### **WGA SURGERY DAY: Trabeculectomy**

*Chairs:* F. Grehn (GERMANY), N. Gupta (CANADA), Y. Lachkar (FRANCE)

- 9.00-9.03 **How I do it (3 min videos)**  
N. Pfeiffer (GERMANY)
- 9.03-9.06 **How I do it (3 min videos)**  
N. Loewen (USA)
- 9.06-9.14 **Long-term results and clinical implications**  
J.M. Liebmann (USA)
- 9.14-9.22 **Primary surgery: MMC vs. 5-FU**  
T. Wong (SINGAPORE)
- 9.22-9.30 **Fornix- vs. limbus-based flaps**  
C.E. Traverso (ITALY)
- 9.30-9.38 **Minimizing early hypotony**  
N. Pfeiffer (GERMANY)
- 9.38-9.46 **Late complications**  
S.F. Lerner (ARGENTINA)

**10.15-11.00 a.m. Room Bordeaux**

### **S30 The most exciting contributions to glaucoma in the last five years**

*Chairs:* S. Melamed (ISRAEL), P. Chew (SINGAPORE), J.S. Schuman (USA)

- 10.15-10.23 **High-resolution imaging for glaucoma**  
J.C. Fujimoto (USA)



## FRIDAY JULY 1, 2011

- 10.23-10.31 **Glaucoma affects both eye and brain**  
R.N. Weinreb (USA)
- 10.31-10.39 **The development of useful models of glaucoma**  
J. Danias (USA)
- 10.39-10.47 **The expanding use of glaucoma drainage devices**  
K. Barton (UNITED KINGDOM)
- 10.47-10.55 **In-vivo visualization of retinal ganglion cells**  
F. Cordeiro (UNITED KINGDOM)

### 10.15-11.00 a.m. Room Havane

#### S14 Genetics (research, clinical applications)

Chairs: J. Wiggs (USA), S. Chakrabarthi (INDIA), F. Jonasson (ICELAND)

- 10.15-10.23 **Genome-wide association studies for primary open-angle glaucoma**  
J. Craig (AUSTRALIA)
- 10.23-10.31 **Identification of genes responsible for ocular quantitative traits as risk factors for glaucoma**  
D. Mackey (AUSTRALIA)
- 10.31-10.39 **Gene-gene and gene-environment interactions in glaucoma**  
L.R. Pasquale (USA)
- 10.39-10.47 **Genome-wide association studies in congenital glaucoma**  
S. Chakrabarthi (INDIA)
- 10.47-11.00 **Panel discussion**  
J. Wiggs (USA)

### 11.00 a.m.-12.00 p.m. Grand Amphitheatre

#### WGA SURGERY DAY: Tubes - glaucoma drainage devices

Chairs: K. Barton (UNITED KINGDOM), K. Singh (USA) R. Susanna (BRAZIL)

- 11.00-11.08 **How I do it – GDD**  
J. Freedman (USA)
- 11.08-11.16 **Long-term results and clinical implications**  
S.J. Gedde (USA)
- 11.16-11.24 **Enhancing efficacy: plate size and anti-fibrosis therapy**  
A. Molteno (NEW ZEALAND)
- 11.24-11.32 **Minimizing early hypotony**  
R. Feldman (USA)
- 11.32-11.40 **Implant location: Superior vs. inferior and angle vs. sulcus vs. pars plana**  
K. Barton (UNITED KINGDOM)

---

## FRIDAY JULY 1, 2011

### 11.00-11.45 a.m. Room Bordeaux

#### S06 Myths and misconceptions in glaucoma

*Chairs:* R. Susanna (BRAZIL), R.A. Hitchings (UNITED KINGDOM), J.S. Schuman (USA)

- 11.00-11.08     **Myths and misconceptions in IOP evaluation**  
F. Medeiros (USA)
- 11.08-11.16     **Myths and misconceptions in visual-field progression**  
B. Chauhan (CANADA)
- 11.16-11.24     **Myths and misconception in glaucoma treatment**  
M. Kahook (USA)
- 11.24-11.32     **Myths and misconceptions about the risks of glaucoma surgery**  
E. Dahan (ISRAEL)
- 11.32-11.40     **Myths and misconceptions about glaucoma blindness**  
R.S. Parikh (INDIA)

### 11.00-11.45 a.m. Room Havane

#### S15 Free Papers

*Chairs:* A. Böhm (GERMANY), A. Anton Lopez (SPAIN), E. Sellem (FRANCE)

- 11.00-11.06     FP01     **The velocity of visual-field progression in eyes with optic-disc hemorrhages in the Ocular Hypertension Treatment Study**  
C.G. De Moraes (USA)
- 11.06-11.12     FP02     **Corneal sensitivity in patients treated for glaucoma or ocular hypertension**  
C. Van Went (FRANCE)
- 11.12-11.18     FP03     **Mitochondrial damage in the trabecular meshwork of glaucomatous patients**  
R. Micale (ITALY)
- 11.18-11.24     FP04     **Assessment of retinal and optic nerve head biomarkers for prediction of the circumpapillary retinal nerve fiber profile**  
I. Pereira (AUSTRIA)
- 11.24-11.30     FP05     **Non-invasive three dimensional (3D) spectral domain optical coherence tomography (SDOCT) casting of the aqueous outflow system**  
L. Kagemann (USA)
- 11.30-11.36     FP06     **Socio-demographic factors that impact on cost of care for incident open-angle glaucoma**  
D. Musch (USA)

## FRIDAY JULY 1, 2011

### PLENARY LUNCH SYMPOSIUM

**12.00-1.00 p.m. Grand Amphitheatre**

**Discover a PGA Fixed Combination without BAK**

*Chair:* I. Goldberg (Australia)

**PG Combinations: A good choice for treatment?**

**P. Denis (FRANCE)**

**Clinical results of DuoTrav fixed combination**

**N. Pfeiffer (GERMANY)**

**Benefits of topical IOP lowering medication without BAK**

**M. Kahook (USA)**

**What can an ophthalmoscopic evaluation of the optic disc tell you?**

**R. Susanna (BRAZIL)**

**Panel discussion**

*This symposium is sponsored by Alcon*

*Boxed lunches provided following the symposium*

### 1.00-2.00 p.m. BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION

**2.00-3.30 p.m. Grand Amphitheatre**

**WGA SURGERY DAY: Surgery for open-angle glaucoma**

*Chairs:* R.N. Weinreb (USA), S. Melamed (ISRAEL), N. Wang (CHINA)

**2.00-2.06 Endocyclophotocoagulation**

**S. Lin (USA)**

**2.06-2.12 Non-penetrating surgery**

**A. Mermoud (SWITZERLAND)**

**2.12-2.18 Canaloplasty**

**T. Klink (GERMANY)**

**2.18-2.24 Short tube implants**

**A. Tanna (USA)**

**2.24-2.30 Trabeculectomy**

**K. Singh (USA)**

**2.30-2.36 Trabecular bypass shunts**

**A. Sit (USA)**

---

## FRIDAY JULY 1, 2011

- 2.36-2.42      **Shunts to uveoscleral outflow pathway**  
C. Tello (USA)
- 2.42-2.48      **Trabectome**  
S.S. Mosaed (USA)
- 2.48-2.54      **C02 Laser-assisted sclerectomy**  
S. Melamed (ISRAEL)
- 2.54-3.00      **Ethical considerations for use of new surgical procedure**  
G. Spaeth (USA)

### 2.00-3.30 p.m. Room Bordeaux

#### **S20 Decision-making, improving patient outcomes in glaucoma**

*Chairs:* J.M. Liebmann (USA), N. Pfeiffer (GERMANY), H. Tanihara (JAPAN)

- 2.00-2.03      **Introduction**  
J.M. Liebmann (USA), N. Pfeiffer (GERMANY), H. Tanihara (JAPAN)
- 2.03-2.11      **Life-expectancy considerations in glaucoma diagnosis and management**  
A. Tuulonen (FINLAND)
- 2.11-2.19      **Does early diagnosis or early treatment improve patient outcomes?**  
A. Shrivastava (USA)
- 2.19-2.27      **Factors related to progression of established glaucoma**  
N. Radcliffe (USA)
- 2.27-2.35      **What is the best way to detect structural progression in clinical practice?**  
D. Garway-Heath (UNITED KINGDOM)
- 2.35-2.43      **What is the best way to detect functional progression in clinical practice?**  
A. Viswanathan (UNITED KINGDOM)
- 2.43-2.51      **What is the best way to choose the optimal treatment modality; medical, laser or surgical?**  
A. Wells (NEW ZEALAND)
- 2.51-2.59      **When does Glaucoma damage impact the quality of life?**  
P. Ramulu (USA)
- 2.59-3.24      **Discussion**
- 3.24-3.30      **Conclusion**  
J.M. Liebmann (USA), N. Pfeiffer (GERMANY), H. Tanihara (JAPAN)

## FRIDAY JULY 1, 2011

### 2.00-4.00 p.m. Room Havane

#### French Glaucoma Society Session: Glaucoma surgical treatments

*Chairs:* E. Sellem (FRANCE), J.P. Nordmann (FRANCE)

- 2.00-2.10      **Ocular hypertension and penetrating keratoplasty**  
C. Allouch (FRANCE)
- 2.10-2.20      **Lens and closed-angle glaucoma**  
J.P. Nordmann (FRANCE)
- 2.20-2.30      **How to manage cataract in your glaucomatous patients?**  
A. Bastelica (FRANCE)
- 2.30-2.40      **The filtration blebs imagery**  
A. Labbé (FRANCE)
- 2.40-2.50      **Glaucoma surgery anesthesia**  
C. Ubaud (FRANCE)
- 2.50-3.00      **Glaucoma surgery preoperative preparation**  
J. Laloum (FRANCE)
- 3.00-3.10      **Sutures in glaucoma surgery**  
D. Gruber (FRANCE)
- 3.10-3.20      **Complications of non penetrating deep sclerectomy**  
Y. Lachkar (FRANCE)
- 3.20-3.30      **Fifteen years follow-up after non-penetrating deep sclerectomy**  
F. Valtot (FRANCE)

### 2.00-2.45 p.m. Room 342A

#### S16 Conventional and unconventional outflow

*Chairs:* P.L. Kaufman (USA), M. Johnstone (USA)

- 2.00-2.07      **TM and CM outflow – setting the stage**  
P.L. Kaufman (USA)
- 2.07-2.14      **Lymphatics in the CM**  
N. Gupta (CANADA)
- 2.14-2.21      **Genetic manipulation of outflow, both pathways**  
P.L. Kaufman (USA)
- 2.21-2.28      **WNT signaling in the TM – a regulator and a therapeutic target?**  
A. Clark (USA)
- 2.28-2.35      **RK inhibitors – a crowded neighborhood?**  
D. Epstein (USA)
- 2.35-2.42      **Building a new TM**  
J. Tan (UNITED KINGDOM)

---

## FRIDAY JULY 1, 2011

### **2.45-3.30 p.m. Room 342A**

#### **S27 Glaucoma management in the developing world**

*Chairs:* L.W. Herndon (USA), R. Sihota (INDIA), K. Ben Amor (TUNISIA)

- 2.45-2.53      **Glaucoma education in developing countries**  
R. Sihota (INDIA)
- 2.53-3.01      **Screening modalities in developing countries**  
J.E. Standefer (USA)
- 3.01-3.09      **Best treatment choices in developing countries**  
L. Vijaya (INDIA)
- 3.09-3.17      **Enhancing public awareness of glaucoma in developing countries**  
E. Ancker (SOUTH AFRICA)

**3.30-4.00 p.m. BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION**

### **3.30-4.30 p.m. Grand Amphitheatre**

#### **WGA SURGERY DAY: Angle-closure glaucoma**

*Chairs:* D. Lam (HONG KONG), J. Thygesen (DENMARK), D. Kim (KOREA)

- 3.30-3.38      **Acute angle closure**  
M. He (CHINA)
- 3.38-3.46      **Cataract extraction as a viable primary surgical procedure**  
C.C.Y. Tham (HONG KONG)
- 3.46-3.54      **Role and techniques for goniosynechialysis**  
C. Teekhasaene (THAILAND)
- 3.54-4.02      **Special considerations for trabeculectomy and tubes**  
P. RojanaPongpun (THAILAND)

### **4.00-5.00 p.m. Room Bordeaux**

#### **C10 Primary angle closure: Diagnosis and treatment**

*Chair:* W. Nolan (UNITED KINGDOM)

*Speakers:* M. He (CHINA), G. Gazzard (UNITED KINGDOM), W. Nolan (UNITED KINGDOM), N. Wang (CHINA), H.T. Wong (SINGAPORE)

### **4.00-5.00 p.m. Room Havane**

#### **French Glaucoma Society Courses: Structural progression in glaucoma**

*Chairs:* H. Bressont Dumont (FRANCE), D. Sirbat (FRANCE)

## FRIDAY JULY 1, 2011

### 4.00-5.00 p.m. Room 341

#### **C26 Blood flow and aqueous flow in glaucoma**

*Chairs:* M. Araie (JAPAN), A. Harris (USA)

*Speakers:* M. Araie (JAPAN), A. Harris (USA), M. Honjo (JAPAN), M. Inatani (JAPAN), K. Sugiyama (JAPAN)

### 4.00-5.00 p.m. Room 342A

#### **C25 Gonioscopy and imaging for anterior chamber and angle evaluation**

*Chairs:* T. Dada (INDIA), D. Friedman (USA)

*Speakers:* T. Dada (INDIA), M. He (CHINA), D. Friedman (USA)

### 4.00-5.00 p.m. Room 342B

#### **C29 Cyclophotocoagulation: Why, when and how?**

*Chairs:* S. Lin (USA), P. Bloom (UNITED KINGDOM)

*Speaker:* P. Bloom (UNITED KINGDOM), M. Kahook (USA), S. Lin (USA)

### 4.00-5.00 p.m. Room 343

#### **C31 Understanding the genetic basis of glaucoma: its role in clinical practice**

*Chairs:* J. Wiggs (USA), D. Mackey (AUSTRALIA)

*Speakers:* S. Chakrabarti (INDIA), J. Craig (AUSTRALIA), D. Mackey (AUSTRALIA), C. Pang (HONG KONG), J. Wiggs (USA)

### 4.00-5.00 p.m. Room 353

#### **C37 Management of complex glaucomas**

*Chair:* R. Susanna (BRAZIL), I. Goldberg (AUSTRALIA)

*Speakers:* Z. Burgansky-Eliash (ISRAEL), S.K. Fang (MALAYSIA), T. Howden (SINGAPORE), D.E. Grigera (ARGENTINA), T. Shaarawy (SWITZERLAND)

### 4.00-5.00 p.m. Room 352B

#### **C32 Interpretation of visual fields: Detection (diagnosis and selective tests)**

*Chairs:* F.J. Goñi (SPAIN), C.A. Johnson (USA), R.S. Harwerth (USA)

*Speakers:* J. Flanagan (CANADA), R.S. Harwerth, C.A. Johnson (USA), R.L. Stamper (USA)



---

## FRIDAY JULY 1, 2011

### 4.00-5.00 p.m. Room 352A

#### C38 Free Papers

*Chairs:* S. Melamed (ISRAEL), C. Matsumoto (JAPAN), L. Sakata (BRAZIL)

- |           |      |  |
|-----------|------|--|
| 4.00-4.06 | FP07 | <b>Morphological changes of lateral geniculate nucleus in patients with primary open-angle glaucoma: a 3.0T magnetic resonance imaging study</b><br>Z. Chen (CHINA)  |
| 4.06-4.12 | FP08 | <b>Ocular surface changes in glaucoma patients treated with fixed combinations of prostaglandines / timolol 0.5%</b><br>H. Russ (BRAZIL)   |
| 4.12-4.18 | FP09 | <b>Measurement of TNF-alpha, Interleukin-6, FasL, Interleukin-1 alpha and Interleukin-1 beta in the aqueous humor of patients with open-angle glaucoma using multiplex bead analysis</b><br>G. Mossboeck (AUSTRIA) |
| 4.18-4.24 | FP10 | <b>Effectivity of the Baerveldt glaucoma implant in patients with secondary glaucoma due to uveitis</b><br>A. Tan (THE NETHERLANDS)  |
| 4.24-4.30 | FP11 | <b>Multi-center glaucoma screening in Israel during the 2010 World Glaucoma Day</b><br>R. Neshet (ISRAEL)  |
| 4.30-4.36 | FP12 | <b>Combining structural and functional measurements to improve detection of glaucoma progression using Bayesian hierarchical models</b><br>F. Medeiros (USA)   |

### 4.00-5.00 p.m. Room 351

#### C21 Emerging glaucoma surgery-1 (ab interno)

*Chair:* D.J. Rhee (USA)

*Speakers:* M. Berlin (USA), V.P. Costa (BRAZIL), E. Dahan (ISRAEL), R. George (INDIA), F. Grehn (GERMANY), S.Y. Jea (KOREA), C.K.S. Leung (HONG KONG), T. Samuelson (USA), T. Shaarawy (SWITZERLAND), S. Vold (USA)

### 4.00-5.00 p.m. Room 361

#### C34 Stereoscopic optic disc viewing: Top-ten pitfalls in identifying glaucoma damage and progression

*Chair:* A.H. Zalta (USA)

*Speakers:* K. Kashiwagi (JAPAN), G. Tomita (JAPAN), L. Wang (CHINA)

## FRIDAY JULY 1, 2011

### 4.30-5.30 p.m. **Grand Amphitheatre**

#### **WGA SURGERY DAY: Cataract and refractive surgery in eyes with glaucoma**

*Chairs:* A.S. Crandall (USA), J.P. Nordmann (FRANCE), I. Goldberg (AUSTRALIA)

- 4.30-4.36      **How I do it: Combined procedure**  
S.F. Lerner (ARGENTINA)
- 4.36-4.42      **How I do it: Combined procedure**  
M. Aihara (JAPAN)
- 4.42-4.48      **Indications for a combined procedure and which one**  
R.L. Fellman (USA)
- 4.48-4.54      **Small pupil techniques**  
A.S. Crandall (USA)
- 4.54-5.00      **Multifocal lenses? Toric lenses?**  
S. Vold (USA)
- 5.00-5.06      **IOL calculations in hyperopic eyes**  
W. Haigis (GERMANY)
- 5.06-5.12      **Management of astigmatism in eyes with glaucoma**  
T. Samuelson (USA)
- 5.12-5.18      **Surgical management of the loose lens**  
N. Loewen (USA)

### 5.00-6.00 p.m. **Room Bordeaux**

#### **C19 Secondary angle closure: Diagnosis and management**

*Chairs:* G. Gazzard (UNITED KINGDOM), L. Vijaya (INDIA), S. Asawaphureekorn (THAILAND)  
*Speakers:* S. Asawaphureekorn (THAILAND), G. Gazzard (UNITED KINGDOM), H. Sakai (JAPAN), L. Vijaya (INDIA)

### 5.00-6.00 p.m. **Room Havane**

#### **French Glaucoma Society Courses: Gonioscopy**

*Chairs:* Y. Lachkar (FRANCE), J. Laloum (FRANCE)

### 5.00-6.00 p.m. **Room 341**

#### **C27 Neuroprotection and apoptosis of retinal ganglion cells related to glaucoma**

*Chairs:* N. Gupta (CANADA), K. Martin (UNITED KINGDOM), H. Quigley (USA), T. Nakazawa (JAPAN)  
*Speakers:* F. Cordeiro (UNITED KINGDOM), D.S. Greenfield (USA), M. Schwartz (ISRAEL), J.C. Tsai (USA)

---

## FRIDAY JULY 1, 2011

### 5.00-6.00 p.m. Room 342A

#### C28 Decision-making after failed trabeculectomy

*Chairs:* R. Carassa (ITALY), S.J. Gedde (USA)

*Speakers:* K. Barton (UNITED KINGDOM), Y.M. Buys (CANADA), S.J. Gedde (USA), K. Ishida (JAPAN)

### 5.00-6.00 p.m. Room 342B

#### C30 Modulating wound healing in glaucoma surgery

*Chairs:* R.K. Parrish (USA), P.T. Khaw (UNITED KINGDOM), F. Grus (GERMANY)

*Speakers:* M. Kahook (USA), P.T. Khaw (UNITED KINGDOM), D. Lu (TAIWAN), P.A. Netland (USA), R.K. Parrish (USA), R. Pérez Grossman (PERU)

### 5.00-6.00 p.m. Room 343

#### C36 Managing cataract and glaucoma: Surgical management of co-existing cataract and glaucoma

*Chairs:* D. Lam (HONG KONG), A.S. Crandall (USA), R. Fechtner (USA)

*Speakers:* A. S. Crandall (USA), R. Fechtner (USA), D. Lam (HONG KONG), C.C.Y. Tham (HONG KONG)

### 5.00-6.00 p.m. Room 353

#### C40 Alternative glaucoma therapies

*Chair:* N. Radcliffe (USA)

*Speakers:* A. Shrivastava (USA), S. Fernando Sieminski (USA)

### 5.00-6.00 p.m. Room 352B

#### C33 Interpretation of visual fields: Progression (rates, event vs. trend)

*Chairs:* F.J. Goñi (SPAIN), A. Johnson (USA)

*Speakers:* M. Fingeret (USA), J. Flanagan (USA), A. Iwase (JAPAN), R.L. Stamper (USA)

### 5.00-6.00 p.m. Room 352A

#### C39 Free Papers

*Chairs:* S. Chakrabarthi (INDIA), R. Johnston (USA), J.S. Schuman (USA)

- |           |      |   |
|-----------|------|---|
| 5.00-5.06 | FP13 | <b>300° Selective laser trabeculoplasty in pseudoexfoliative and primary open-angle glaucoma: A prospective clinical trial</b><br><b>P. Pasi Pehkonen (FINLAND)</b> |
| 5.06-5.12 | FP14 | <b>Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin)</b><br><b>O. Geyer (ISRAEL)</b>  |

## FRIDAY JULY 1, 2011

- |           |      |  |
|-----------|------|--|
| 5.12-5.18 | FP15 | <b>The Trabectome-clinical results and glaucoma subgroup analysis</b><br>J. Jordan (GERMANY)   |
| 5.18-5.24 | FP16 | <b>The contribution of retinal vasculature to spectral domain optical coherence tomography retinal nerve fiber layer scans in normal and glaucoma eyes</b><br>N. Patel (USA) |
| 5.24-5.30 | FP17 | <b>The intraocular pressure-reducing effect of oral paracetamol – a pilot study</b><br>D. Meyer (NEW ZEALAND)  |
| 5.30-5.36 | FP18 | <b>Temporal relationships of clinical signs of glaucomatous neuropathy</b><br>R.S. Harwerth (USA)  |

### 5.00-6.00 p.m. Room 351

#### **C22 Emerging glaucoma surgery-2 (ab externo)**

*Chairs:* T. Shaarawy (SWITZERLAND)

*Speakers:* M. Nardi (ITALY), R. Noecker (USA), T. Shaarawy (SWITZERLAND), C. Tello (USA)

### 5.00-6.00 p.m. Room 361

#### **C35 Exfoliation syndrome and exfoliation glaucoma**

*Chairs:* A.G.P. Konstas (GREECE), G. Holló (HUNGARY)

### 5.30-6.30 p.m. Grand Amphitheatre

#### **WGA SURGERY DAY: Childhood glaucoma**

*Chairs:* P.T. Khaw (UNITED KINGDOM), J.D. Brandt (USA), A.K. Mandal (INDIA)

- |           |  |
|-----------|--|
| 5.30-5.36 | <b>Examination and medical treatment</b><br>E. Maul (CHILE)                    |
| 5.36-5.42 | <b>Primary surgical approach</b><br>T.C. Chen (USA)                            |
| 5.42-5.48 | <b>When initial surgery is unsuccessful</b><br>P.T. Khaw (UNITED KINGDOM)      |
| 5.48-5.54 | <b>Long-term results and visual outcome</b><br>A.K. Mandal (INDIA)             |
| 5.54-6.00 | <b>Secondary glaucoma after congenital cataract surgery</b><br>A.D. Beck (USA) |
| 6.00-6.06 | <b>Ongoing management</b><br>J.D. Brandt (USA)                                 |
| 6.25-6.30 | <b>Concluding comments</b><br>R.N. Weinreb (USA), F. Grehn (GERMANY)           |

**8.00 p.m. WGC CONGRESS DINNER AT THE PAVILLON D'ARMENONVILLE**

Organized by The Hippocrates Glaucoma Foundation

---

## SATURDAY JULY 2, 2011

**8.00- 11.45 a.m. Room 362 + 363**

### **WGC FILM FESTIVAL**

Please see page 67 for the list of videos to be shown

**8.00-9.30 a.m. Grand Amphitheatre**

### **S02 Advances in imaging technology and application (detection, progression, technology, risk assessment)**

*Chairs:* J.S. Schuman (USA), M. Hangai (JAPAN), F. Medeiros (USA)

- |           |   |
|-----------|---|
| 8.00-8.08 | <b>Imaging technologies for the assessment of structure and function in glaucoma</b><br>J.C. Fujimoto (USA) |
| 8.08-8.16 | <b>Is detecting disease different than measuring change?</b><br>A. Manassakorn (THAILAND)                   |
| 8.16-8.24 | <b>Predicting glaucoma development</b><br>L. Zangwill (USA)   |
| 8.24-8.32 | <b>Glaucoma detection using GCC thickness on SD-OCT</b><br>M. Vizzeri (USA)                                 |
| 8.32-8.40 | <b>Detecting progression</b><br>E.M. Hoffmann (GERMANY)   |
| 8.40-8.48 | <b>Going beyond the OCT scanning circle</b><br>K. Sung (KOREA)  |
| 8.48-8.56 | <b>Apoptotic RGC imaging</b><br>F. Cordeiro (UNITED KINGDOM)  |

**8.00-9.30 a.m. Room Bordeaux**

### **S35 Glaucoma and coexisting diseases (cornea-DSEK, PKP, keratoprosthesis, retina, ocular surface and inflammation)**

*Chairs:* E.Z. Blumenthal (ISRAEL), A. Iwase (JAPAN), J.C. Tsai (USA)

- |           |  |
|-----------|--|
| 8.00-8.08 | <b>Glaucoma and a previous corneal graft</b><br>D. Lu (TAIWAN)         |
| 8.08-8.16 | <b>Glaucoma and a coexisting keratoprosthesis</b><br>D.J. Rhee (USA)   |
| 8.16-8.24 | <b>Glaucoma and active uveitis</b><br>R. Mills (USA)                   |
| 8.24-8.32 | <b>Glaucoma and a silicone-oil filled eye</b><br>S. Best (NEW ZEALAND) |
| 8.32-8.40 | <b>Glaucoma and ocular surface disease</b><br>C. Baudouin (FRANCE)     |

## SATURDAY JULY 2, 2011

- 8.40-8.48      **Glaucoma s/p a retinal detachment (buckle/vitreotomy) in need of glaucoma surgery**  
C. Kee (KOREA)
- 8.48-8.56      **Glaucoma and no-light-perception (a blind painful eye)**  
M.B. Agulto (PHILIPPINES)
- 8.56-9.04      **Intractable glaucoma resulting from an intraocular/peri-ocular corticosteroid injection**  
Y.M. Buys (CANADA)

### 8.00-8.45 a.m. Room Havane

#### S40 Pediatric glaucoma

*Chairs:* A.D. Beck (USA), A.K. Mandal (INDIA)

- 8.00-8.08      **Genotype and phenotype correlations in congenital glaucoma**  
J. Alvarado (USA)
- 8.08-8.16      **Management of aphakic and pseudophakic glaucoma**  
A. D. Beck (USA)
- 8.16-8.24      **360 degree trabeculotomy**  
R.L. Fellman (USA)
- 8.24-8.32      **Combined trabeculotomy-trabeculectomy**  
A.K. Mandal (INDIA)
- 8.32-8.40      **Glaucoma drainage devices and cyclodeconstruction**  
J.D. Brandt (USA)

### 8.45-9.30 a.m. Room Havane

#### S19 Managing the failing glaucoma surgery (trabeculectomy, tubes)

*Chairs:* C.E. Traverso (ITALY), F. El Sayyad (EGYPT)

- 8.45-8.53      **Where to act in the wound healing process**  
F. Grehn (GERMANY)
- 8.53-9.01      **How to recognize failing surgery**  
D.E. Grigera (ARGENTINA)
- 9.01-9.09      **Trabeculectomy failure: What to do and when**  
R. Chang (USA)
- 9.09-9.17      **Tubes failure: What to do and when**  
T. Dada (INDIA)



---

## SATURDAY JULY 2, 2011

9.30-10.15 a.m. BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION

### 10.15-11.45 a.m. **Grand Amphitheatre**

#### **S13 Cataract and glaucoma surgeries**

*Chairs:* D. Lam (HONG KONG), R. Bellucci (ITALY), T. Samuelson (USA)

- 10.15-10.22     **Diagnosis and management of the cyclodialysis cleft**  
J.D. Brandt (USA)
- 10.22-10.29     **Slit-lamp procedures in the management of glaucoma**  
P. Palmberg (USA)
- 10.29-10.36     **Non-penetrating trabeculectomy: Tips and pearls**  
T. Shaarawy (SWITZERLAND)
- 10.36-10.43     **Results and perspectives of deep sclerectomy with implants after 15 years of practice**  
P. Sourdille (FRANCE)
- 10.43-10.50     **Argon laser peripheral iridoplasty**  
C. Tello (USA)
- 10.50-10.57     **Phaco-goniosynechialysis**  
N. Wang (CHINA)
- 10.57-11.04     **MICS in angle-closure glaucoma**  
R. Bellucci (ITALY)
- 11.04-11.11     **Surgery tips for phaco in cases with angle-closure glaucoma**  
D. Lam (HONG KONG)
- 11.11-11.18     **Weak zonules, small pupils, and other cataract challenges in glaucoma patients**  
A.S. Crandall (USA)
- 11.18-11.25     **Combined phacotrabeculectomy**  
K. Singh (USA)
- 11.25-11.32     **EXPRESS implantation in combined phaco and glaucoma**  
S. Morselli (ITALY)
- 11.32-11.39     **Ab interno canal stenting procedures**  
T. Samuelson (USA)
- 11.39-11.46     **Shunt surgery: Emerging new shunt devices and surgeries**  
R.L. Stamper (USA)

### 10.15-11.00 a.m. **Room Bordeaux**

#### **S08 Initial treatment for glaucoma: Medical vs. laser vs. surgery**

*Chairs:* N. Pfeiffer (GERMANY), G.D. McLaren (SOUTH AFRICA)

- 10.15-10.23     **Initial medical treatment is best!**  
S. Gandolfi (ITALY)
- 10.23-10.31     **Initial laser treatment is best!**  
H. Thieme (GERMANY)

## SATURDAY JULY 2, 2011

- 10.31-10.39 **Initial trabeculectomy is best!**  
F. Grehn (GERMANY)
- 10.39-10.47 **Initial non-penetrating surgery is best!**  
F. Valtot (FRANCE)
- 10.47-10.55 **Initial tube-surgery is best!**  
G. Baerveldt (USA)
- 10.55-11.00 **Revealing the truth: Panel discussion**

### 10.15-11.45 a.m. Room Havane

#### S11 Clinician Scientist Symposium

*Chairs:* P. Healey (AUSTRALIA), C.K.S. Leung (HONG KONG)

- 10.15-10.23 **Eyedrops....will they be a thing of the past? Sustained drug delivery for lowering IOP**  
T. Wong (SINGAPORE)
- 10.23-10.31 **Some novel methodologies for glaucoma studies and risk calculation**  
F. Medeiros (USA)
- 10.31-10.39 **RCT of glaucoma screening**  
J. Burr (UNITED KINGDOM)
- 10.39-10.47 **Lens extraction for angle closure: A public health perspective**  
C.C.Y. Tham (HONG KONG)
- 10.47-10.55 **Neuroprotective vaccines for glaucoma**  
M. Schwartz (ISRAEL)
- 10.55-11.03 **Deep optic nerve head imaging-implications for progression and biomechanics**  
N. Strouthidis (UNITED KINGDOM)

### 11.00-11.45 a.m. Room Bordeaux

#### S33 Glaucoma: The patient's angle (WGPA, patient perspective)

*Chairs:* I. Goldberg (AUSTRALIA), G.N. Lambrou (GREECE), E. Ancker (SOUTH AFRICA)

- 11.00-11.08 **Glaucoma as Dis-Ease**  
G. Spaeth (USA)
- 11.08-11.16 **Quality of life for glaucoma patients**  
P. Ramulu (USA)
- 11.16-11.24 **Adherence and perseverance challenges in glaucoma therapy**  
E. Ancker (SOUTH AFRICA)
- 11.24-11.32 **Patient Support Associations**  
G.N. Lambrou (GREECE)
- 11.30-11.40 **World Glaucoma Week: What you can do**  
I. Goldberg (AUSTRALIA)

---

# GLOBAL ASSEMBLY OF GLAUCOMA SOCIETIES

The WGA unites 76 Glaucoma Societies. The larger regions are represented by the regional Glaucoma Societies in the General Assembly (e.g., the European Glaucoma Society represents the national Glaucoma Societies in Europe). The Global Assembly of Glaucoma Societies is organized every two years at the occasion of the World Glaucoma Congress. Representatives of all national and regional Glaucoma Societies (see page 133) get together during this major event to discuss topics of interest at a global glaucoma level. The Global Assembly is a unique occasion for representatives of the world Glaucoma Societies to meet each other. Since 2009, three additional Glaucoma Societies/Groups/Sections have joined the WGA and four regional societies have merged.

## Highlights from the Global Assembly agenda

- Introduction of new Glaucoma Societies & mergers since WGC-2009
- The World Glaucoma Association in 2011
  - Revision of WGA Bylaws
  - Strategic Plan
- International Glaucoma Research
- Glaucoma Societies
- African Glaucoma Summit
- World Glaucoma Week
- Consensus & Promulgation

## SCIENTIFIC PROGRAM – HIGHLIGHTS

### **This meeting**

After the highly successful World Glaucoma Congress in Vienna, 2005 and Singapore 2007 and Boston 2009 some adaptations were made to the program, largely based on the request from the faculty and participants. The Scientific Program is based upon the following principles:

- Opening with excellent keynote speakers
- Didactic sessions by invited top speakers
- Consensus outcome updates
- New consensus outcomes on Medical Therapy and Glaucoma Progression
- Parallel basic clinical science sessions (new developments with discussion)
- Topics from didactic sessions to come back in courses where extensive discussion is possible (more courses, more basic examination and treatment courses)
- Original research to be presented in posters and free paper sessions. Most presentations will be in a poster format; oral presentations will be in those areas that agree with the major and quality topics of the congress
- Special and extensive attention to posters (recognitions, discussion at the posters)
- Glaucoma Society posters: developments in each country that are of interest to others
- Special attention to physicians in training
- Special attention to upcoming clinician scientists

- Excellent surgical sessions
- More video surgical activity
- Grand Rounds

### **Symposia on hot issues**

These sessions have been introduced to cover the need for representation of various viewpoints on these issues and to provide the audience with an idea what future developments can be expected. The parallel Symposia and Debates present a large choice of topics in order to satisfy the divergent needs and interest of the audience.

### **Guidance through the program**

The WGC participants will find a majority of parallel sessions and a few solo sessions. The solo sessions are:

- French Glaucoma Society Symposium
- European Glaucoma Society Symposium
- Opening
- Plenary Lunch Symposia

### **Opening Session**

The Opening Session will present the role of France and Europe in the glaucoma world, as well as an overview on the WGA activities and initiatives: Consensus, IGR, World Glaucoma Week, the African Glaucoma Summit and the Global WGA Research Awards. Keynote lecture will highlight the topic 'Wine, glaucoma and life'.

---

## Consensus updates

The WGA proudly presents the result of its Consensus Meetings. Seven topics have been published in books (by Kugler Publications, Amsterdam):

- 2003: Structure and Function
- 2005: Surgery Open-Angle Glaucoma
- 2006: Angle-Closure Glaucoma
- 2007: IOP
- 2008: Screening
- 2009: Blood Flow
- 2010: Medical Therapy

On Tuesday, June 28, the 8<sup>th</sup> Consensus Meeting on Glaucoma Progression was held. Updates of these Consensus Meetings will be presented at the WGC Opening Session.

## Plenary Lunch Symposia

The WGC Platinum sponsors of the World Glaucoma Congress have been given the opportunity to organize a plenary midday symposium. This symposium will be part of the Scientific Program and as such will fall under the full responsibility of the Program Committee.

## Symposia

The 31 Symposia on Thursday, Friday and Saturday were especially created for this meeting. Their aim is to provide in one hour the various viewpoints on hot issues. The participants should leave the Symposia and Debates with a fair impression of the dominant line of thought on these issues. As there will be a wide selection of topics, there will be something of interest for each participant. The symposia are planned for all participants.

## Courses

The Courses have the usual course format with ample possibilities for discussion. This will allow participants to attend four of the courses of their choice during the congress including several popular courses.

## Surgery Day

A full intensive day dedicated to glaucoma surgery, discussing different topics: decision making and laser trabeculoplasty, trabeculectomy, glaucoma drainage devices and special sessions organized by the French Glaucoma Society.

## Posters

Posters are an excellent and important way of providing scientific information. The WGA is making an effort to provide high visibility for the posters. The posters will be on from Wednesday, June 29, noon until Saturday, July 2, noon.

## Poster Mounting and Removing

Posters should be mounted on Wednesday, June 29, between 8.00 a.m. and noon. Assistance and material for mounting the posters will be available from 8.00 a.m. at the Poster desk in the Poster area. Posters should be removed after 1.00 p.m. and before 3.00 p.m. on Saturday, July 2. Posters that have not been taken down by the author(s) will be removed and destroyed by the Congress Secretariat.

## Poster Recognition

The Abstract & Review Committee will announce the three best posters which will receive the World Glaucoma Congress Poster Recognition.

### Glaucoma Society Posters

As in 2007 and 2009, all Glaucoma Societies were asked to present a poster about their society. This year, the Program Committee asked Glaucoma Societies to create a follow-up to the Glaucoma Society poster presentations during the WGC in 2009. These Glaucoma Society Posters describe the major achievements of the Glaucoma Society between July 2009 and July 2011 including meetings, best research, awards, publication, scientific interaction with other WGA member societies, activities for World Glaucoma Week and promulgation.

### Discussions and Interactive Questions

The WGC will have the following types of discussions:

- Panel discussions during Surgical Grand Rounds and Surgical Videos
- During courses
- During debates

In addition to the discussions there will be frequent interactive questions (IQA) during most of the sessions, in order to give the participants the opportunity to express their opinion on several issues discussed at the WGC.

### Official Language

The official language of the Congress is English, simultaneous translation into French will be provided for sessions held in the Grand Amphitheatre. French to English translation will be offered in the Grand Amphitheatre for presentations made in French and in the Havane Room for French courses and symposia.

### Audio Visual Support / Speaker Ready Room

The Speaker Ready Room is located on the third floor of the Palais des Congrès, near the exhibition area, and will be open on the following days and hours:

Tuesday, June 28: 2.00 p.m. – 6.00p.m.  
Wednesday, June 29: 7.00 a.m. – 6.00p.m.  
Thursday, June 30: 6.30 a.m. – 6.00p.m.  
Friday, July 1: 6.30 a.m. – 6.00p.m.  
Saturday, July 2: 7.00 a.m. – 12.00p.m.

Equipment to enable a final check to be made for your presentation is available in the Speaker Ready Room.

**Power Point presentations: we strongly advise you to bring your presentation to the Speaker Ready Room AT LEAST 3 HOURS BEFORE** the start of your lecture. Please note that there are no facilities to use laptops in the session rooms.

### Travel Grants

The WGA has provided close to 60 travel grants, which include waiving of the registration fee, to glaucoma clinician scientists under forty years of age who have demonstrated a special interest in glaucoma.

### Continuing Medical Education Meeting Evaluation

It is essential for assessing the quality of the WGC that participants take time to complete the evaluation forms. Every participant can have an impact on the planning for the next WGC. The WGA has purposely created this elaborate evaluation system in order to provide the participants with an even better congress in two years. Your input is highly appreciated.



---

### CME Designations

The World Glaucoma Congress has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide CME activity for medical specialists.

The EACCME is an institution of the European Union of Medical Specialists (UEMS), [www.uems.net](http://www.uems.net).

The number of credits will be available on the website after the Congress.

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognized by the

American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, please contact the AMA. Industry sponsored symposia are not eligible for CME credit at this meeting.

**Please note that the registration code, printed on your badge and on the CME instruction in your congress envelope, is necessary to access the CME questionnaire and printing of the certificate, available at the web site**

**([www.worldglaucoma.org](http://www.worldglaucoma.org)) from July 4 to July 22, 2011.**

## FILM FESTIVAL PROGRAM

### WEDNESDAY

| Start Time | Number      | Best of show | Title  | Length |
|------------|-------------|--------------|--|--------|
| 10.00 a.m  | <b>VS01</b> | *            | Trabeculectomy Revisited<br>( <i>M.B. Khamar</i> )   | 8 min  |
| 10.08 a.m. | <b>VS02</b> |              | Is trabeculectomy possible without antimetabolites? ( <i>M. Ariga</i> )  | 8 min  |
| 10.16 a.m. | <b>VS03</b> |              | The 'Pearl Necklace' Suture. Never lose a antimetabolite-soaked sponge during Trabeculectomy again<br>( <i>D. Lindfield</i> )                  | 5 min  |
| 10.21 a.m. | <b>VS04</b> |              | The 'Constrictor Knot' for Drainage Surgery ( <i>D. Lindfield</i> )  | 6 min  |
| 10.27 a.m. | <b>VS05</b> | *            | Management of Late Bleb Complications after Trabeculectomy<br>( <i>T. Dada</i> )   | 8 min  |
| 10.35 a.m. | <b>VS06</b> |              | Management of Failing Filtering Blebs<br>( <i>G. Chandrasekhar</i> )   | 7 min  |
| 10.42 a.m. | <b>VS07</b> |              | Surgical Management of Encapsulated Bleb and Histopathology ( <i>P. Bathia</i> )   | 7 min  |
| 10.49 a.m. | <b>VS08</b> | *            | Management of leaking bleb<br>( <i>G. Chandrasekhar</i> )  | 8 min  |
| 10.57 a.m. | <b>VS09</b> |              | Repair of late bleb leak with lamellar scleral flap ( <i>R. Gupta</i> )  | 5 min  |
| 11.02 a.m. | <b>VS10</b> |              | Suprachoroidal Effusions and Hemorrhage after Trabeculectomy: Recognition and Management<br>( <i>G.J. Murthy</i> )                             | 8 min  |
| 11.10 a.m. | <b>VS11</b> | *            | 3D Evaluation of the Lamina Cribrosa Using Enhanced Depth Imaging Spectral Domain Optical Coherence Tomography in Glaucoma ( <i>E.J. Lee</i> ) | 8 min  |

---

**WEDNESDAY - continued**

| Start Time | Number      | Best of show | Title   | Length |
|------------|-------------|--------------|---|--------|
| 11.18 a.m. | <b>VS12</b> |              | Management of Traumatic Glaucoma with Subluxated Lens Using Scleral Fixated IOL and Trabeculectomy with MMC ( <i>L. Vijaya</i> )          | 7 min  |
| 11.25 a.m. | <b>VS13</b> |              | Two site Phaco-trabeculectomy on complicated secondary angle closure glaucoma in single sitting surgeon ( <i>A.P. Gandasubrata</i> )      | 7 min  |
| 11.32 a.m. | <b>VS14</b> |              | Surgical Technique of combined trabeculectomy and manual small incision cataract surgery using a modified technique ( <i>A.A. Karim</i> ) | 5 min  |
| 11.40 a.m. | <b>VS15</b> |              | Phaco surgery in eyes with shallow anterior chambers in cases of angle-closed glaucoma ( <i>D.T. Mai</i> )                                | 8 min  |
| 11.48 a.m. | <b>VS16</b> | *            | CLASS - CO2 Laser-Assisted Sclerectomy Surgery ( <i>D. Cotlear</i> )  | 8 min  |
| 11.56 a.m. | <b>VS17</b> |              | CO2 Laser Assisted Deep Sclerectomy in Open Angle Glaucoma ( <i>S. Senthil</i> )  | 8 min  |
| 12.04 p.m. | <b>VS18</b> |              | Non-Penetrating Glaucoma Surgery Made Simple by CO2 Laser Assisted Deep Sclerectomy ( <i>R. Venkatesh</i> )                               | 8 min  |
| 12.12 p.m. | <b>VS19</b> |              | Endoscopic cyclophotocoagulation in the management difficult Glaucomas ( <i>G.J. Murthy</i> )   | 8 min  |
| 12.20 p.m. | <b>VS20</b> |              | Trabeculotome guided deep sclerectomy ( <i>K. Nassar</i> )  | 7 min  |
| 12.27 p.m. | <b>VS21</b> | *            | Management of Intraoperative and Postoperative Complications with Ahmed Valve Implant ( <i>S. Senthil</i> )                               | 8 min  |
| 12.35 p.m. | <b>VS22</b> | *            | Repositioning of an Ahmed Glaucoma Valve (AGV) tube touching the cornea ( <i>R. Gupta</i> )   | 5 min  |

### WEDNESDAY - continued

| Start Time | Number      | Best of show | Title  | Length |
|------------|-------------|--------------|--|--------|
| 12.40 p.m. | <b>VS23</b> | *            | Split-Thickness Hinged Scleral Flap in the Management of Exposed Tubing of a Glaucoma Drainage Device<br>( <i>C.Y. Kim</i> )   | 5 min  |
| 12.45 p.m. | <b>VS24</b> |              | Enabling rural general ophthalmologists to adopt comprehensive Glaucoma care- the 'Nayana' experience ( <i>G.J. Murthy</i> )   | 7 min  |
| 12.52 p.m. | <b>VS25</b> |              | Safe and Effective Technique to Tackle Lens Induced Glaucoma in Developing World ( <i>R. Venkatesh</i> )                       | 8 min  |
| 1.00 p.m.  | <b>VS26</b> | *            | Surgical outcome of early onset glaucoma in children with Axenfeld-Rieger Anomaly ( <i>P.K.R. Beeram</i> )                     | 8 min  |
| 1.08 p.m.  | <b>VS27</b> |              | Twenty years of comprehensive care for children with congenital glaucoma ( <i>A.K. Mandal</i> )                                | 8 min  |
| 1.16 p.m.  | <b>VS28</b> |              | Congenital Glaucoma- A learner's perspective ( <i>A. Rao</i> )   | 8 min  |
| 1.24 p.m.  | <b>VS29</b> |              | Refractory Congenital Glaucoma ( <i>S. Senthil</i> )   | 8 min  |
| 1.32 p.m.  | <b>VS30</b> | *            | The Differential Diagnosis of Descemet's Tears (Haab Striae) and Surgical Outcome of Infantile Glaucoma ( <i>A.K. Mandal</i> ) | 8 min  |

### THURSDAY AND FRIDAY

| Start Time          | Number      | Best of show | Title   | Length |
|---------------------|-------------|--------------|---|--------|
| 9.00 a.m. 1.00 p.m. | <b>VS01</b> | *            | Trabeculectomy Revisited<br>( <i>M.B. Khamar</i> )                      | 8 min  |
| 9.08 a.m. 1.08 p.m. | <b>VS02</b> |              | Is trabeculectomy possible without antimetabolites? ( <i>M. Ariga</i> ) | 8 min  |

## THURSDAY AND FRIDAY - continued

| Start Time |           | Number      | Best of show | Title  | Length |
|------------|-----------|-------------|--------------|--|--------|
| 9.13 a.m.  | 1.13 p.m. | <b>VS03</b> |              | The 'Pearl Necklace' Suture. Never lose a antimetabolite-soaked sponge during Trabeculectomy again ( <i>D. Lindfield</i> )                     | 5 min  |
| 9.19 a.m.  | 1.19 p.m. | <b>VS04</b> |              | The 'Constrictor Knot' for Drainage Surgery ( <i>D. Lindfield</i> )  | 6 min  |
| 9.27 a.m.  | 1.27 p.m. | <b>VS05</b> | *            | Management of Late Bleb Complications after Trabeculectomy ( <i>T. Dada</i> )  | 8 min  |
| 9.35 a.m.  | 1.35 p.m. | <b>VS06</b> |              | Management of Failing Filtering Blebs ( <i>G. Chandrasekhar</i> )  | 7 min  |
| 9.42 a.m.  | 1.42 p.m. | <b>VS07</b> |              | Surgical Management of Encapsulated Bleb and Histopathology ( <i>P. Bathia</i> )   | 7 min  |
| 9.49 a.m.  | 1.49 p.m. | <b>VS08</b> | *            | Management of leaking bleb ( <i>G. Chandrasekhar</i> )   | 8 min  |
| 9.57 a.m.  | 1.57 p.m. | <b>VS09</b> |              | Repair of late bleb leak with lamellar scleral flap ( <i>R. Gupta</i> )  | 5 min  |
| 10.05 a.m. | 2.05 p.m. | <b>VS10</b> |              | Suprachoroidal Effusions and Hemorrhage after Trabeculectomy: Recognition and Management ( <i>G.J. Murthy</i> )                                | 8 min  |
| 10.13 a.m. | 2.13 p.m. | <b>VS11</b> | *            | 3D Evaluation of the Lamina Cribrosa Using Enhanced Depth Imaging Spectral Domain Optical Coherence Tomography in Glaucoma ( <i>E.J. Lee</i> ) | 8 min  |
| 10.20 a.m. | 2.20 p.m. | <b>VS12</b> |              | Management of Traumatic Glaucoma with Subluxated Lens Using Scleral Fixated IOL and Trabeculectomy with MMC ( <i>L. Vijaya</i> )               | 7 min  |
| 10.27 a.m. | 2.27 p.m. | <b>VS13</b> |              | Two site Phaco-trabeculectomy on complicated secondary angle closure glaucoma in single sitting surgeon ( <i>A.P. Gandasubrata</i> )           | 7 min  |

**THURSDAY AND FRIDAY - continued**

| Start Time |           | Number      | Best of show | Title   | Length |
|------------|-----------|-------------|--------------|---|--------|
| 10.32 a.m. | 2.32 p.m. | <b>VS14</b> |              | Surgical Technique of combined trabeculectomy and manual small incision cataract surgery using a modified technique ( <i>A.A. Karim</i> ) | 5 min  |
| 10.40 a.m. | 2.40 p.m. | <b>VS15</b> |              | Phaco surgery in eyes with shallow anterior chambers in cases of angle-closed glaucoma ( <i>D.T. Mai</i> )                                | 8 min  |
| 10.48 a.m. | 2.48 p.m. | <b>VS16</b> | *            | CLASS - CO2 Laser-Assisted Sclerectomy Surgery ( <i>D. Cotlear</i> )  | 8 min  |
| 10.56 a.m. | 2.56 p.m. | <b>VS17</b> |              | CO2 Laser Assisted Deep Sclerectomy in Open Angle Glaucoma ( <i>S. Senthil</i> )  | 8 min  |
| 11.04 a.m. | 3.04 p.m. | <b>VS18</b> |              | Non-Penetrating Glaucoma Surgery Made Simple by CO2 Laser Assisted Deep Sclerectomy ( <i>R. Venkatesh</i> )                               | 8 min  |
| 11.12 a.m. | 3.12 p.m. | <b>VS19</b> |              | Endoscopic cyclophotocoagulation in the management difficult Glaucomas ( <i>G.J. Murthy</i> )   | 8 min  |
| 11.20 a.m. | 3.20 p.m. | <b>VS20</b> |              | Trabeculotome guided deep sclerectomy ( <i>K. Nassar</i> )  | 7 min  |
| 11.27 a.m. | 3.27 p.m. | <b>VS21</b> | *            | Management of Intraoperative and Postoperative Complications with Ahmed Valve Implant ( <i>S. Senthil</i> )                               | 8 min  |
| 11.35 a.m. | 3.35 p.m. | <b>VS22</b> | *            | Repositioning of an Ahmed Glaucoma Valve (AGV) tube touching the cornea ( <i>R. Gupta</i> )   | 5 min  |
| 11.40 a.m. | 3.40 p.m. | <b>VS23</b> | *            | Split-Thickness Hinged Scleral Flap in the Management of Exposed Tubing of a Glaucoma Drainage Device ( <i>C.Y. Kim</i> )                 | 5 min  |
| 11.45 a.m. | 3.45 p.m. | <b>VS24</b> |              | Enabling rural general ophthalmologists to adopt comprehensive Glaucoma care- the 'Nayana' experience ( <i>G.J. Murthy</i> )              | 7 min  |

---

## THURSDAY AND FRIDAY - continued

| Start Time |           | Number      | Best of show | Title  | Length |
|------------|-----------|-------------|--------------|--|--------|
| 11.52 a.m. | 3.52 p.m. | <b>VS25</b> |              | Safe and Effective Technique to Tackle Lens Induced Glaucoma in Developing World ( <i>R. Venkatesh</i> )                       | 8 min  |
| 12.00 p.m. | 4 p.m.    | <b>VS26</b> | *            | Surgical outcome of early onset glaucoma in children with Axenfeld-Rieger Anomaly ( <i>P.K.R. Beeram</i> )                     | 8 min  |
| 12.08 p.m. | 4.08 p.m. | <b>VS27</b> |              | Twenty years of comprehensive care for children with congenital glaucoma ( <i>A.K. Mandal</i> )                                | 8 min  |
| 12.16 p.m. | 4.16 p.m. | <b>VS28</b> |              | Congenital Glaucoma- A learner's perspective ( <i>A. Rao</i> )   | 8 min  |
| 12.24 p.m. | 4.24 p.m. | <b>VS29</b> |              | Refractory Congenital Glaucoma ( <i>S. Senthil</i> )   | 8 min  |
| 12.32 p.m. | 4.32 p.m. | <b>VS30</b> | *            | The Differential Diagnosis of Descemet's Tears (Haab Striae) and Surgical Outcome of Infantile Glaucoma ( <i>A.K. Mandal</i> ) | 8 min  |

## SATURDAY

| Start Time |  | Number      | Best of show | Title  | Length |
|------------|--|-------------|--------------|--|--------|
| 8.00 a.m.  |  | <b>VS01</b> | *            | Trabeculectomy Revisited ( <i>M.B. Khamar</i> )  | 8 min  |
| 8.08 a.m.  |  | <b>VS02</b> |              | Is trabeculectomy possible without antimetabolites? ( <i>M. Ariga</i> )  | 8 min  |
| 8.16 a.m.  |  | <b>VS03</b> |              | The 'Pearl Necklace' Suture. Never lose a antimetabolite-soaked sponge during Trabeculectomy again ( <i>D. Lindfield</i> ) | 5 min  |
| 8.21 a.m.  |  | <b>VS04</b> |              | The 'Constrictor Knot' for Drainage Surgery ( <i>D. Lindfield</i> )  | 6 min  |
| 8.27 a.m.  |  | <b>VS05</b> | *            | Management of Late Bleb Complications after Trabeculectomy ( <i>T. Dada</i> )  | 8 min  |
| 8.35 a.m.  |  | <b>VS06</b> |              | Management of Failing Filtering Blebs ( <i>G. Chandrasekhar</i> )  | 7 min  |

---



**SATURDAY - continued**

| Start Time | Number      | Best of show | Title  | Length |
|------------|-------------|--------------|--|--------|
| 8.42 a.m.  | <b>VS07</b> |              | Surgical Management of Encapsulated Bleb and Histopathology ( <i>P. Bathia</i> )   | 7 min  |
| 8.49 a.m.  | <b>VS08</b> | *            | Management of leaking bleb ( <i>G. Chandrasekhar</i> )   | 8 min  |
| 8.57 a.m.  | <b>VS09</b> |              | Repair of late bleb leak with lamellar scleral flap ( <i>R. Gupta</i> )  | 5 min  |
| 9.02 a.m.  | <b>VS10</b> |              | Suprachoroidal Effusions and Hemorrhage after Trabeculectomy: Recognition and Management ( <i>G.J. Murthy</i> )                                | 8 min  |
| 9.10 a.m.  | <b>VS11</b> | *            | 3D Evaluation of the Lamina Cribrosa Using Enhanced Depth Imaging Spectral Domain Optical Coherence Tomography in Glaucoma ( <i>E.J. Lee</i> ) | 8 min  |
| 9.18 a.m.  | <b>VS12</b> |              | Management of Traumatic Glaucoma with Subluxated Lens Using Scleral Fixated IOL and Trabeculectomy with MMC ( <i>L. Vijaya</i> )               | 7 min  |
| 9.25 a.m.  | <b>VS13</b> |              | Two site Phaco-trabeculectomy on complicated secondary angle closure glaucoma in single sitting surgeon ( <i>A.P. Gandasubrata</i> )           | 7 min  |
| 9.32 a.m.  | <b>VS14</b> |              | Surgical Technique of combined trabeculectomy and manual small incision cataract surgery using a modified technique ( <i>A.A. Karim</i> )      | 5 min  |
| 9.40 a.m.  | <b>VS15</b> |              | Phaco surgery in eyes with shallow anterior chambers in cases of angle-closed glaucoma ( <i>D.T. Mai</i> )                                     | 8 min  |
| 9.48 a.m.  | <b>VS16</b> | *            | CLASS - CO2 Laser-Assisted Sclerectomy Surgery ( <i>D. Cotlear</i> )   | 8 min  |
| 9.56 a.m.  | <b>VS17</b> |              | CO2 Laser Assisted Deep Sclerectomy in Open Angle Glaucoma ( <i>S. Senthil</i> )   | 8 min  |
| 10.04 a.m. | <b>VS18</b> |              | Non-Penetrating Glaucoma Surgery Made Simple by CO2 Laser Assisted Deep Sclerectomy ( <i>R. Venkatesh</i> )                                    | 8 min  |

---

**SATURDAY - continued**

| Start Time | Number      | Best of show | Title  | Length |
|------------|-------------|--------------|--|--------|
| 10.12 a.m. | <b>VS19</b> |              | Endoscopic cyclophotocoagulation in the management difficult Glaucomas ( <i>G.J. Murthy</i> )                                  | 8 min  |
| 10.20 a.m. | <b>VS20</b> |              | Trabeculotome guided deep sclerectomy ( <i>K. Nassar</i> )   | 7 min  |
| 10.27 a.m. | <b>VS21</b> | *            | Management of Intraoperative and Postoperative Complications with Ahmed Valve Implant ( <i>S. Senthil</i> )                    | 8 min  |
| 10.35 a.m. | <b>VS22</b> | *            | Repositioning of an Ahmed Glaucoma Valve (AGV) tube touching the cornea ( <i>R. Gupta</i> )                                    | 5 min  |
| 10.40 a.m. | <b>VS23</b> | *            | Split-Thickness Hinged Scleral Flap in the Management of Exposed Tubing of a Glaucoma Drainage Device ( <i>C.Y. Kim</i> )      | 5 min  |
| 10.45 a.m. | <b>VS24</b> |              | Enabling rural general ophthalmologists to adopt comprehensive Glaucoma care- the 'Nayana' experience ( <i>G.J. Murthy</i> )   | 7 min  |
| 10.52 a.m. | <b>VS25</b> |              | Safe and Effective Technique to Tackle Lens Induced Glaucoma in Developing World ( <i>R. Venkatesh</i> )                       | 8 min  |
| 11.00 a.m. | <b>VS26</b> | *            | Surgical outcome of early onset glaucoma in children with Axenfeld-Rieger Anomaly ( <i>P.K.R. Beeram</i> )                     | 8 min  |
| 11.08 a.m. | <b>VS27</b> |              | Twenty years of comprehensive care for children with congenital glaucoma ( <i>A.K. Mandal</i> )                                | 8 min  |
| 11.16 a.m. | <b>VS28</b> |              | Congenital Glaucoma- A learner's perspective ( <i>A. Rao</i> )   | 8 min  |
| 11.24 a.m. | <b>VS29</b> |              | Refractory Congenital Glaucoma ( <i>S. Senthil</i> )   | 8 min  |
| 11.32 a.m. | <b>VS30</b> | *            | The Differential Diagnosis of Descemet's Tears (Haab Striae) and Surgical Outcome of Infantile Glaucoma ( <i>A.K. Mandal</i> ) | 8 min  |

## CURRICULA VITAE – FACULTY

### **Manuel B. Agulto, MD**

*Affiliation:* Philippine General Hospital (PGH); Director, Institute of Ophthalmology, University of the Philippines, Manila, Philippines.

*Areas of Interest:* Glaucoma Diagnosis and Treatment; Anterior Segment Diseases; Cataract and Refractive Surgery.

*Leadership Positions:* Past president and board member (SEAGIG and PGS); Board member/country representative (SEAGIG, AOGS, AACGS); Director (IO NIH); Professor/Glaucoma Service chief (UPCM-PGH), Department of Ophthalmology and Visual Sciences, UP Manila; Past president and emeritus chairman, Glaucoma Research Foundation (ERC-GRF); Board member, Ethics Committee Chair (PBO, PAO).

*Special Honors:* Outstanding Ophthalmic Educator (PAO); Distinguished Service Award (APAO); Merit Award (PBO); Most Outstanding Citizen in Medicine (Pampanga, San Jose City, San Fernando City, Philippines).



### **Makoto Aihara, MD, PhD**

*Affiliation:* Assistant professor, Director of Glaucoma division, Department of Ophthalmology, University of Tokyo.

*Areas of Interest:* Glaucoma: pharmacology, animal model, glaucoma surgery, neuroprotection.

*Leadership Position:* Steering Committee member World Glaucoma Association; Board member, Program Committee member Japanese Ophthalmological Society; Board member Japanese Glaucoma Society; Board member Japanese Society of Ophthalmic Surgery; Board member Japanese Neuro-ophthalmological Society.

*Special Honor:* World Glaucoma Congress Best presentation 2007; World Glaucoma Association Science Award 'the Promise' 2008; 113<sup>th</sup> Japanese Ophthalmological Society Designated Lecture 2009.



### **Jorge A. Alvarado, MD**

*Affiliation:* Professor of Ophthalmology, University of California San Francisco

*Areas of Interest:* all aspects of glaucoma.

*Leadership Positions:* 1976-1998: Chief, Glaucoma Service, UCSF; 1977-present: Course Instructor, American Academy of Ophthalmology; 1980-present: Invited by various Ophthalmological societies in Latin America to lecture and to perform

glaucoma surgeries in patients including children and infants using novel surgical procedures.

*Special Honors:* 1997, 2006, 2009: Best Speaker of the Day, The Royal Hawaiian Meeting; 1999: AAO Senior Honor Award; 2000: 'Histology of the Human Eye', written by Dr. M.J. Hogan, Jorge Alvarado & Joan Esperson Weddell (published by WB Saunders) was selected among the top 100 publications in Ophthalmology published during the 20th century by a Committee of Scholars assembled by the Archives of Ophthalmology.



### **Alfonso Anton, MD, PhD**

*Affiliation:* chairman of the Glaucoma and the Research Departments at Institut Català de Retina and glaucoma consultant at Parc Salut Mar (Barcelona).

*Areas of Interest:* epidemiology, telemedicine, health economics, imaging devices and functional tests.

*Leadership Position:* published over 40 publications and is referee of several scientific journals. A member of several international scientific and editorial committees, including the International Members Committee of ARVO, European Glaucoma Society and the editorial board of the Journal of Glaucoma.



### **Makoto Araie, MD, PhD**

*Affiliation:* Director, Kanto Central Hospital, The Mutual Aid Association of Public School Teachers; Professor Emeritus, The University of Tokyo; Visiting Professor, Institute of Medical Science, Tokyo Medical University; Visiting Professor, Saitama Medical University.

*Area of Interest:* Ocular blood flow, Normal tension glaucoma, Pharmacokinetics, Population-based study.

*Leadership Positions:* Executive Committee Member of Glaucoma Research Society (2003-2008); President, Japanese Society for Ocular Pharmacology (2004-2006), Trustee, The Japanese Society of Ophthalmic Surgeons (2002-); President, Japan Glaucoma Society (2006-); President, Japanese



Ophthalmological Society (2007-2009); President, Asia-Pacific Glaucoma Society (2007-), Council, Asia-Pacific Academy of Ophthalmology (2003-); President, World Glaucoma Association (2009-); Editor-in-Chief, Folia Japonica de Ophthalmologica Clinica (2008-); Editorial Board, Japanese Journal of Ophthalmology (1996-); American Journal of Ophthalmology (2001-2004); Journal of Glaucoma (2006-).

*Special Honors:* The Japan Ophthalmological Society Council Award (1999). The Japan Ophthalmological Society Award (2010).

**Somkiat Asawaphureekorn, MD, MSc**

*Affiliation:* Associate Professor, Glaucoma Unit, Department of Ophthalmology, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002. Thailand.

*Area of Interest:* Diagnosis and treatment of angle closure glaucoma, gonioscopy, glaucoma imaging, evidence-based ophthalmology, critical appraisal of medical literature, statistics in medicine.



**Sanjay Asrani, MD**

*Affiliation:* Associate Professor of Ophthalmology at Duke University in Durham, NC, USA.

*Area of Interest:* research on pressure fluctuations, drug delivery and new imaging modalities for glaucoma.

*Leadership Positions:* over 50 peer reviewed publications; member of the editorial board of EyeNet.

*Special Honors:* recipient of numerous awards, including the Career Development Award from Research to Prevent Blindness, Inc and the Mid-Career Scientist Award from the American Glaucoma Society. He has also been honored among 'America's Top Ophthalmologists' and 'Best Doctors' in America.



**Tin Aung, MBBS, FRCS(Ed), FRCOphth, MMed (Ophth), FAM, PhD**

*Affiliation:* Senior Consultant and Head, Glaucoma Service, Singapore National Eye Centre Deputy Director, Singapore Eye Research Institute. Associate Professor, Department of Ophthalmology, National University of Singapore.

*Areas of Interest:* angle closure



glaucoma and the molecular genetics of eye diseases.

*Leadership Positions:* member of the Editorial Board of Ophthalmology, Eye, Journal of Glaucoma, and six other journals. Leader of the Glaucoma Research Group and the Ocular Genetics Group at the Singapore Eye Research Institute/SNEC; more than 220 publications.

*Honors:* Invited Lecturer to >70 International Conferences and received numerous awards including the Singapore NMRC Clinician Scientist Awards in 2005 and 2008, the Nakajima Award from the Asia Pacific Academy of Ophthalmology in 2006 and the Singapore President's Science Award in 2009.

**Augusto Azuara-Blanco, PhD, FRCS (Ed)**

*Affiliation:* Health Services Research Unit, University of Aberdeen, UK.

*Areas of Interest:* Academic career focused on improving patient care, evaluating the efficacy and effectiveness of new technologies, and models of eye care. Principal investigator of two ongoing projects: an international multicentre Randomised Controlled Trial (RCT) evaluating the role of early lens extraction for primary angle glaucoma (EAGLE), and a multicentre automated imaging diagnostic study for glaucoma (GATE).

*Leadership Position:* Professor and Clinical Chair, University of Aberdeen. Recipient of the 2008 American Academy of Ophthalmology achievement award. Member of the Editorial Board of six specialist journals. Member of the Scientific Committee of the Royal College of Ophthalmologists. Published over 120 peer-reviewed papers, 17 book chapters, and edited 3 books.



**George Baerveldt, MD**

*Affiliation:* Professor of Ophthalmology, The Gavin Herbert Eye Institute, University of California, Irvine.

*Areas of Interest:* glaucoma research and surgical innovations. He developed the 'Baerveldt™ Glaucoma Implant' and presently holds four patents related to this invention. He is the inventor of the Trabectome®, a minimally-invasive glaucoma surgical instrument for the treatment of adult and infantile open-angle glaucoma. These surgeries are now being performed worldwide.

*Leadership Positions:* Director of Glaucoma at the Cleveland Clinic Foundation (1994-1999). Director of Glaucoma, The Gavin Herbert Eye Institute, University of California, Irvine, CA: Principal Investigator on the RPB Challenge Grant from





July 1, 2004-June 30, 2008; founding member of the American Glaucoma Society, the Glaucoma Society of Southern California and the Glaucoma Society of Orange County. Participated in 44 clinical trials involving glaucoma drugs and laser surgery. He has published 84 peer-reviewed papers and 11 chapters in books.

*Special Honors:* Dr. Baerveldt received the American Academy of Ophthalmology's Senior Achievement Award in 2002 and honored in Woodward and Whites 'Best Doctors in America' from 1996 - present. His humanitarian endeavors have been recognized by the National Society to Prevent Blindness and he received the 'Teacher of the Year' award in 1981 from the University of Southern California, and 'Staff of the Year' award from the Cleveland Clinic Foundation, 1997/1998 and 1998/1999.

**Keith Barton, MD, FRCP, FRCS, FRCOphth**

*Affiliation:* Glaucoma Service Director, Consultant Ophthalmologist, Moorfields Eye Hospital, London, United Kingdom; Honorary Senior Lecturer (Associate Professor), Division of Epidemiology and Genetics, Institute of Ophthalmology, University College London.

*Areas of Interest:* Surgical management of glaucoma; pathogenesis and management of uveitic glaucoma.

For further information please see: [www.keithbarton.co.uk/about.htm](http://www.keithbarton.co.uk/about.htm)



**Dr. Antoine Bastelica MD**

*Affiliation:* Ophthalmologist and anterior segment surgeon, Clinique Pasteur, Toulouse, France.

*Areas of Interest:* Cataract and glaucoma management. Diagnosis, medical and surgical treatment in glaucoma.



**Christophe Baudouin, MD, PhD, FARVO**

*Affiliations:* Professor and Chairman, Department of Ophthalmology, Ambroise Paré Hospital (APHP), University of Versailles; department of Ophthalmology, Quinze-Vingts National Ophthalmology Hospital, Paris.

*Areas of Interest:* all aspects of glaucoma.

*Leadership Positions:* Since 1997, he coordinates a group of research involved in ocular surface immunology and glaucoma treatments. Since 2004 he is the Director of an INSERM-labelled research group, located in Vision Institute,

University of Paris 6, a research center dedicated to ophthalmology and recently labeled as Laboratory of Excellence (Labex from the French Government). Editor-in-chief of the French Journal of Ophthalmology; President of the Ophthalmological Society of Paris, vice-president of the French Glaucoma Society, elected member of the Board of the French Society of Ophthalmology, and member of eight international societies. Dr. Baudouin has published more than 200 papers in international peer-reviewed journals and has developed in his laboratory various original techniques and models, in particular flow cytometry or confocal microscopy in conjunctival imprints, as well as a large range.

*Special Honors:* Silver fellow of ARVO (2011).



**Allen D. Beck, MD**

*Affiliation:* Redmond Professor of Ophthalmology, Department of Ophthalmology, Emory University School Medicine, Atlanta, GA, USA.

*Areas of Interest:* Treatment of pediatric glaucoma.

*Leadership Positions:* Principal investigator (1999-2009) for the Ocular Hypertension Treatment Study (OHTS); co-investigator and principal investigator for the Interactive Study to Increase Glaucoma adherence to Treatment (I-SIGHT); currently acting as the medical monitor for the Infant Aphakia Treatment Study (IATS), which evaluates the outcomes of pediatric cataract surgery with and without intraocular lens implants. Published numerous peer-reviewed articles, organized symposiums and given lectures at national and international meetings on pediatric glaucoma topics, and authored book chapters on pediatric glaucoma and surgical techniques.

*Special Honors:* Clinical Teaching Award, Emory Ophthalmology Residents (1999,2002); American Academy of Ophthalmology Achievement Award (2002); Best Doctors in America/ Atlanta Magazine Top Doctors (2009,2010).




**Dr. Khaled Ben Amor, MD**

*Affiliation:* Head of Glaucoma Unit of the Tunis Ophthalmology Associates and Clinique Ophthalmologique de Tunis.

*Areas of Interest:* Glaucoma, cataract and refractive surgery. Total quality management and Health information systems.

*Leadership Positions:* Founder and former General Secretary of the African Society of Glaucoma



---

(2006); Founder and General Secretary of the African Society of Refractive Surgery; Founder member of Nadi Al Bassar (fighting blindness NGO, several cataract campaigns in Africa).

**Boel M. Bengtsson, PhD**

*Affiliation:* Department of Clinical Sciences in Malmö, Ophthalmology Lund University, Sweden.

*Areas of Interest:* Clinical glaucoma, particularly diagnostics and perimetry.

*Leadership Position:* Associate Professor, Senior lecturer in the division of glaucoma in Malmö, Sweden.



**Dr. Stephen Best**

*Affiliation:* Director of Auckland Eye, honorary senior clinical tutor at Auckland University, Auckland.

*Areas of Interest:* Glaucoma and neuro-ophthalmology. He has been involved in multi-centre trials, and maintains an interest in the management of patients with refractory glaucomas.



**Professor Philip Bloom, FRCS, FRCOphth**

*Affiliations:* Consultant Ophthalmic Surgeon, Western Eye & Hillingdon Hospitals; Honorary Professor of Ophthalmology, Middlesex University; Honorary Senior Lecturer, Imperial College School of Medicine.

*Research Interests:* Trans-scleral and endoscopic cyclophotocoagulation; Combined cataract and glaucoma surgery; Spectacle independence following cataract surgery (including multifocal lens implantation, toric IOLs and incisional refractive surgery).

*Leadership Positions / Special Honors:* Service Director and Lead Clinician, Western Eye Hospital; Chief of Glaucoma Services, Hillingdon Hospital; Course Leader, Post-Graduate Diploma in Ophthalmology (Middlesex University); Surgical Tutor & Microsurgical Skills Faculty Member, Royal College of Ophthalmologists; Continuing Professional Development (CPD) representative (North Thames), Royal College of Ophthalmologists; Immediate Past Vice President, Ophthalmology section, Royal Society of Medicine; Hillingdon Hospital



Post-graduate Clinical Tutor in Ophthalmology, Royal College of Ophthalmologists.

**Eytan Blumenthal MD**

*Affiliation:* Head of the glaucoma Service at Hadassah University Hospital in Jerusalem.

*Areas of Interest:* Medical devices, glaucoma surgery, imaging of the RNFL.



**Andreas G. Boehm**

*Affiliation:* Head of the Department of Ophthalmology, Elblandklinikum Dresden-Radebeul, Germany.

*Areas of Interest:* structure/function relation in glaucoma, tonometry and ocular circulation.

*Leadership Positions:* Head of the glaucoma service and the vice-chair of the Department of Ophthalmology of the University Dresden.

*Special Honors:* His work was rewarded with several prizes and has been published in numerous papers in international peer-reviewed journals.



**Rupert Bourne**

*Affiliation:* Consultant Ophthalmic Surgeon (Hinchingsbrooke/Moorfields/Addenbrookes Hospitals); Professor of Ophthalmology, Vision & Eye Research Unit, Post-graduate Medical Institute, Anglia Ruskin University, Cambridge, UK.

*Areas of Interest:* Epidemiology of eye disease, in particular glaucoma; Glaucoma imaging and modalities to detect progression; Primary Angle Closure and Angle Closure Glaucoma; Glaucoma care pathway and electronic patient record developments.

*Leadership positions, honors and publications:* Co-director of Vision & Eye Research Institute; Leading a clinical trials unit (Huntingdon Glaucoma Diagnostic & Research Centre); Coordinator for Global Burden of Disease project's Vision Loss Expert group.



**Christopher Bowd, PhD**

*Affiliation:* Associate Research Scientist, Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, USA.

*Areas of Interest:* Glaucoma, primarily in the field of optical imaging assessment. He has co-authored over 100 peer-reviewed manuscripts and several book chapters. Dr. Bowd received federal and private grants to investigate electrophysiological techniques for detecting glaucoma and to apply machine-learning analysis techniques to data generated from structural and functional tests.



**James D. Brandt, MD**

*Affiliation:* Professor of Ophthalmology & Vision Science and Director of the Glaucoma Service at the University of California, Davis.

*Areas of Interest:* Glaucoma, with a particular focus on infantile and pediatric glaucoma. Research in the material properties of the eye as they affect the measurement of intraocular pressure and in the physiology of outflow resistance; nanotechnology and biomedical engineering to develop new methods to measure outflow resistance in the living human eye.

*Leadership Positions:* Dr. Brandt has served as the Principal Investigator of numerous clinical trials, including the Ocular Hypertension Treatment Study (OHTS). As an OHTS principal investigator, he initiated the effort to measure corneal thickness as a potential risk factor for glaucoma.



**Hélène Bresson Dumont, MD**

*Affiliation:* Department of Glaucoma, Clinique Sourdille, Nantes, France.

*Areas of Interest:* Glaucoma.

*Leadership Position:* Member of the board French Glaucoma Society.



**Alain Bron, MD**

*Affiliation:* Professor of Ophthalmology at the University Hospital of Dijon, France.

*Areas of Interest:* Ocular infection and glaucoma. His basic research is conducted at the National Institute for Research on Agronomy (INRA), where he is studying the influence of nutrition and lipids on the retina and the optic nerve in animal models.

*Leadership Positions:* Consultant for several major ophthalmic companies and the French Ministry of Health. He has participated in many clinical studies (phase I to III) for the evaluation of new drugs and medical devices in glaucoma. He is a well-established author in his field and has published numerous papers in international peer-reviewed journals such as American Journal of Ophthalmology, British Journal of Ophthalmology, Experimental Eye Research, Graefe's Archive for Clinical and Experimental Ophthalmology, Investigative Ophthalmology and Visual Science and Ophthalmology.



**Reay H. Brown, MD**


*Affiliation:* Private practice in Atlanta since 1988.

*Areas of Interest:* Glaucoma, glaucoma surgery and cataract surgery.

*Leadership Positions:* Pamela Firman Professor of Ophthalmology at the Emory University until 1999; Director of the Glaucoma Service, Emory University 1988-1999; Founding Partner, Atlanta Ophthalmology Associates, 1999. Dr. Brown has published more than

80 peer-reviewed articles on glaucoma, cataract surgery, and other aspects of eye care. He has been awarded 10 patents for new instruments to improve glaucoma and cataract surgery and has five other patents pending. Dr. Brown and his wife, Dr. Mary Lynch, invented the Eyepass, a trabecular bypass device in 1999. They directed four FDA studies on Eyepass. Eyepass was approved for use in Europe in 2005. Chairman, ASCRS Glaucoma Clinical Committee, 2005-2010. Member, ASCRS Glaucoma Clinical Committee, 1997-date; EyeWorld, Associate Editor, 2011; Dr. Brown has given numerous named lectures including the 2011 ASCRS Glaucoma Day Obstbaum Lecture.

*Special Honors:* Honor Award and Senior Achievement Award from the American Academy of Ophthalmology. He has been selected by his peers to be listed each year in Best Doctors in America and has been featured in a separate peer survey in Atlanta Magazine as one of the best ophthalmologists in Atlanta.





---

**Donald L. Budenz, MD, MPH**

**Affiliation:** Professor of Ophthalmology, Epidemiology, and Public Health, Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, Florida, USA.

**Areas of Interest:** Glaucoma.

**Leadership Positions:** editorial reviewer for several medical journals, including Ophthalmology, Archives of Ophthalmology, American Journal of Ophthalmology, Investigative Ophthalmology and Visual Science, Retina, Eye, and Ophthalmic Surgery and Laser Therapy; editor of the Glaucoma issue of Current Opinion in Ophthalmology; editorial board of the Journal of Glaucoma. He has been the principal investigator in a number of clinical trials including the Ocular Hypertension Treatment Study. He has been published widely in the field of glaucoma; he has authored a textbook, contributed chapters to several other books, and written or coauthored over 125 peer-reviewed journal articles. He is senior instructor of a graduate course entitled Clinical Trials in the Department of Epidemiology and Public Health at the University of Miami, School of Medicine.

**Special Honors:** Dr. Budenz is the recipient of a Golden Apple Award for Best Resident Teacher (Department of Ophthalmology, University of Pennsylvania School of Medicine) and has received the teaching award for Best Course in the Department of Epidemiology and Public Health at the University of Miami, Miller School of Medicine. He has been a guest lecturer at numerous universities, hospitals, and medical societies worldwide.

**Dr. Zvia Burgansky-Eliash**

**Affiliation:** Glaucoma service at the Edith Wolfson Medical Center in Holon, Israel; Lecturer of Ophthalmology at the Tel-Aviv University School of Medicine.

**Areas of Interest:** novel imaging techniques.

**Reinhard Burk, MD, PhD**

**Affiliation:** Professor Dr. med. Dr. med. Habil, Department of Ophthalmology, Klinikum Bielefeld, Bielefeld, Germany. Teaching Position: Department of Ophthalmology, University of Heidelberg, Department of Ophthalmology, Klinikum Bielefeld, Department of Ophthalmology, University of Münster **Areas of Interest:** Glaucoma Diagnosis and Glaucoma Therapy including surgical procedures. Compliance and Adherence to treatment. Cost effectiveness of therapeutical

approaches. Development of three-dimensional optic nerve head structure analysis by Laser Scanning Tomography (HRT) and Spectral Domain OCT. Surgical modifications of deep sclerectomy and viscocanalostomy by irrigation trabeculotomy and ab externo laser trabeculotomy (US patent). **Leadership positions:** Leadership Positions: 1992-2001 Vice Director, Department of Ophthalmology, University of Heidelberg; since 2001 Director and Head, Department of Ophthalmology, Klinikum Bielefeld. **Special Honors:** Awards: 'Glaukompreis' of the Deutsche Ophthalmologische Gesellschaft DOG.

**Jennifer Burr**

**Affiliation:** Director of the Centre for Healthcare Randomised Trials (CHaRT); Senior Clinical Research Fellow in Health Services Research.

**Leadership Positions:** experienced trialist. She leads a programme of publicly funded research with a focus on health care evaluation in relation to eye disease particularly glaucoma, and more widely around the design, conduct and analysis of randomized controlled trials of complex interventions.

**Yvonne M. Buys MD, FRCS**

**Affiliation:** Professor, Department of Ophthalmology and Vision Sciences, University of Toronto, Co-Director, Glaucoma Unit, University Health Network.

**Research interests:** Glaucoma epidemiology. Health economics in ophthalmology and glaucoma. Surgical innovations in glaucoma and cataract. Optic nerve imaging. Sleep issues in glaucoma. Visual function. Ocular blood flow.

**Leadership positions:** Treasurer and Board Member of the Canadian Ophthalmological Society; Glaucoma section editor for the Canadian Journal of Ophthalmology; immediate Past-President of the Canadian Glaucoma Society; Past-President and founding member of the Toronto Area Glaucoma Society; noneconomic loss physician for the WSIB; past examiner for the Royal College of Physicians and Surgeons of Canada; member of the College of Physicians and Surgeons of Ontario, the Toronto Hospital Research Institute, among many others. Published over 75 peer-reviewed sci-



entific papers, 11 invited editorials and seven book chapters. *Special honors:* Toronto Hospital Anderson Award (1998); University of Toronto Clive Mortimer Postgraduate Teaching Award (1999).

**Roberto Carassa, MD**

*Affiliation:* Director of the Italian Centre for Glaucoma, Milan.

*Areas of Interest:* Ophthalmic diagnostics and the treatment of glaucoma.

*Leadership Positions:* Board of directors of the Italian Association for the Study of Glaucoma. He is the President of the no-profit organization 'Italian Association for Prevention of Glaucoma' that he founded in 2009. He is a member of important scientific associations, such as the Italian Society of Ophthalmology, the Association for Research in Vision and Ophthalmology, and the American Academy of Ophthalmology.

*Special Honors:* Received several national and international scientific awards and has been an invited lecturer at numerous prestigious international courses on glaucoma. Professor Carassa is a regular reviewer for journals such as Ophthalmology, Archives of Ophthalmology, Journal of Glaucoma and the British Journal of Ophthalmology.

**Subhabrata Chakrabarti, PhD**

*Affiliation:* Associate Director (Research), L.V. Prasad Eye Institute, Hyderabad, India.

*Areas of Interest:* Molecular genomics and proteomics of glaucoma.

*Leadership Positions:* Member, Publications Committee of ARVO (2011-); Editorial Board Member, Molecular Vision (2011-); Associate Director (Basic Research), LVPEI, Hyderabad, India (2011-); Coordinator, International postgraduate education program, UNSW, Sydney (2009-); Co-Chair, Associate Advisory Board, World Glaucoma Association (2009); Editorial Board Member, World Journal of Diabetes (2009); Editorial Board Member, Journal of Glaucoma (2009-); Editorial Board Member, IGR (2009-); Member, WGA Award and Promulgation Committee (2008-); Chairman, Scientific Committee, Institutional Review Board (IRB), LVPEI, India (2007-); Visiting Scientist, National Eye Institute, NIH, Bethesda, MD, USA (2006); Member, Ethics Committee, LVPEI, Hyderabad, India (2006-); Staff Scientist, LVPEI, Hyderabad, India (2006).

*Special Honors:* Young Scientist Award, Asia Pacific Glaucoma Society (2010); Mehra INACO Award, Indian Association

of Community Ophthalmology, India (2010); TWAS (Academy of Sciences for the Developing World) Young Affiliate (2009); AIGS Travel fellowship, Singapore (2007); Young Scientist Platinum Jubilee Award, National Academy of Sciences India (2007); Indian National Science Academy (INSA) Young Scientist Medal, New Delhi, India (2006); International Society for Eye Research (ISER) Travel fellowship, USA (2006); Bausch and Lomb Travel fellowship, Singapore (2005); ARVO Collaborative Research Grant Travel fellowship, India and USA (2005); Clinician Scientist Award, World Glaucoma Association (2005).

**Robert Chang, MD**

*Affiliation:* Assistant Professor of Ophthalmology, Glaucoma Specialist, Stanford University, Stanford, CA, USA.

*Areas of Interest:* Glaucoma imaging and surgical drainage devices. The relationship between myopia, glaucoma, and visual field defects. Optical coherence tomography and glaucoma.

**Balwantray Chauhan**

*Affiliation:* Department of Ophthalmology and Visual Science, Dalhousie University, Halifax, N.S., Canada.

*Areas of Interest:* Glaucoma.


*Leadership Position:* Professor, Research Director, Chair in Vision Research, Dalhousie University.

**Teresa C. Chen, MD**

*Affiliation:* Associate Professor at the Harvard Medical School and is on the full-time staff at the Massachusetts Eye and Ear Infirmary; Director of Clinical Affairs at the Glaucoma Service and as the Chief Quality Officer for the Ophthalmology Department.

*Areas of Interest:* Pediatric glaucoma and optical coherent tomography.

*Leadership Positions:* Vice-President of the Chandler Grant Glaucoma Society, the Massachusetts Eye and Ear Infirmary and Harvard Medical School glaucoma fellowship alumni society. Sole editor for a new book entitled, Glaucoma Surgery, which is accompanied by a video of every type of surgery described



in the book and which has been translated into several languages. She has published over 100 original articles, major reviews, and book chapters.

*Special Honors:* Achievement Award from the American Academy of Ophthalmology.

**Paul Chew, MBBS, MMed (Ophth), FRCSEd, FRCOphth**

*Affiliation:* Associate Professor at the National University of Singapore and Senior Consultant, Department of Ophthalmology, National University Hospital, Singapore.

*Areas of Interest:* Angle closure glaucoma, including laser and surgical treatment, Imaging, topical medications in the treatment of open and closed angle glaucoma.




**Abbot (Abe) Clark, PhD**

*Affiliation:* Director of the North Texas Eye Research Institute, Professor of Cell Biology & Anatomy, and Graduate Advisor for the Visual Sciences Program at the University of North Texas Health Science Center in Ft. Worth, Texas, USA.

*Areas of Interest:* major research focus is directed at understanding the molecular and cellular basis of ophthalmic diseases, especially glaucoma, and ocular injury.

*Leadership Positions:* Section Editor for Experimental Eye Research.

*Special Honors:* Fellow of ARVO, Recipient of the Rudin Prize and the World Glaucoma Association Science Award for his glaucoma research.



**Nathan Congdon, MD, MPA**

*Affiliation:* Professor of Preventive Ophthalmology at Zhongshan Ophthalmic Center.

*Areas of Interest:* Glaucoma; training of eye doctors in China; quality of blindness prevention programs.

*Leadership Positions:* His research has resulted in the publication of over 100 peer-reviewed articles, and has been supported by the NIH, World Bank, RPB and the governments of China and Hong Kong.

*Special Honors:* Wilmer Resident Teaching Award, the Outstanding Service Award; Holmes Lecture Award from the APAO; Thousand Man Prize by the Chinese government.



**M. Francesca Cordeiro, MD, PhD**

*Affiliation:* Head the Glaucoma and Retinal Neurodegeneration Research Group at the Institute of Ophthalmology, University College London; Honorary Glaucoma Consultant Ophthalmologist at the Western Eye Hospital, Imperial College Healthcare NHS Trust in London, Director of the Glaucoma Research Unit.

*Areas of Interest:* Neuroprotection in glaucoma and neurodegenerative diseases. Molecular mechanisms involved in either the treatment or pathogenesis of retinal neurodegenerative diseases, including glaucoma, Alzheimer's and diabetes. The aims of her group's work are to establish new methods of diagnosis of early disease to avoid disability, identify early markers of cell processes in neurodegenerative disease and investigate therapeutic approaches to their treatment.

*Leadership Positions:* She serves on a number of international committees including the European Glaucoma Society and ICER and currently chairs the EGS Neuroprotection SIG.

*Special Honors:* Allergan Glaucoma Achievement Award 2010, the Lewis Rudin Glaucoma Prize 2005 from the New York Academy of Medicine, the 2000 International Glaucoma Review Award, and many others.



**Vital P. Costa, MD**

*Affiliation:* Director Glaucoma, Dept. of Ophthalmology, University of Campinas, Glaucoma Service, University of Campinas, Brazil.

*Areas of Interest:* Glaucoma Surgery, genetics, visual fields, Ophthalmic imaging.

*Leadership Positions:* Associate professor, Dept. Ophthalmology, University of Sao Paulo (2001-2008); Vice-President, Brazilian Glaucoma Society (2009-2011);

Vice-President, Ibero-american Glaucoma Society (2007-); Editorial Board, Boletim Panamericano de Glaucoma (1998-); Editorial Board, Glaucoma Today (2002-); Editorial Board, Universo Visual (2004-); Associate Editor, British Journal of Ophthalmology (2007-).

*Special Honors:* Best Poster At The American Academy of Ophthalmology: Influence of Age, Central Corneal Thickness, And Quality Score on Dynamic Contour Tonometry(2007).



**Jamie Craig, MD, PhD**

*Affiliation:* Associate professor, Department of Ophthalmology, Glaucoma, Flinders University, South Australia.

*Areas of Interest:* genetic susceptibility to glaucoma blindness, pseudoexfoliation syndrome, diabetic retinopathy and cataract.



**Leadership Positions:** As an NHMRC Practitioner Fellow he divides his time between clinical care of glaucoma patients and running a research laboratory. He established the Australian and New Zealand Registry of Advanced Glaucoma in 2007, which has recruited a repository of over 1200 cases of glaucoma blindness, and 800 secondary glaucoma cases. His laboratory conducts Genome Wide Association Studies and gene discovery projects in monogenic traits.



**Alan S. Crandall, MD**

**Affiliation:** Professor and Senior Vice-Chair of Ophthalmology and Visual Sciences, Director of Glaucoma and Cataract at the Moran Eye Center, University of Utah in Salt Lake City, Utah.

**Leadership Positions:** Diplomat of the National Board of Medical Examiners; member of the American Board of Ophthalmology; member of the American Society of Cataract and Refractive Surgery, American Glaucoma Society, the European Society of Cataract and Refractive Surgeons and the International Intra-Ocular Implant Club.



**Jonathan G. Crowston, BSc, MBBS, FRCOphth, FRANZCO, PhD**

**Affiliation:** Ringland Anderson Professor of Ophthalmology and Managing Director of the Centre for Eye Research Australia (CERA).

**Areas of Interest:** ageing and neuroprotection of the optic nerve. In particular the role of mitochondrial dysfunction in optic nerve vulnerability to injury.

**Leadership Positions:** He has published over 90 peer-reviewed manuscripts and co-authored two books and is a Practitioner-Fellow with the National Health and Medical Research Council (Australia).

**Special Honors:** He has received a number of awards for his research and recently gained the RANZCO College of Ophthalmologists Excellence in Teaching Award.



**Katalin Csiszar, PhD**

**Affiliation:** Research Professor, John A. Burns School of Medicine and Cancer Research Center, University of Hawaii, Honolulu, HI.

**Areas of Interest:** The role of the extracellular matrix, cell-matrix interactions and signaling in the pathomechanisms of tumor cell invasion, fibrotic diseases and exfoliative glaucoma.

**Leadership Positions:** Member of the American Heart Association; Reviewer for the NIH National Institute for Arthritis and Musculoskeletal Disorders, the Heart, Blood and Lung Institute, the National Cancer Institute, the U.S. Department of Defense Congressionally Directed Breast Cancer Research Program, the United States-Israeli Science Foundation, the French National Research Agency, the Wellcome Trust, and the British Research Council.



**Tanuj Dada, MD**

**Affiliation:** Additional Professor at RP Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi.

**Special Interest:** anterior segment imaging, primary angle closure glaucoma.

**Leadership Positions:** Editor-in-Chief Journal of Current Glaucoma Practice, Global Editor Glaucoma for World Ophthalmology Report, Member ARVO International Committee, Executive Committee International Society Glaucoma Surgery, Associate Advisory Board World Glaucoma Association and Editorial Board IGR. Has 142 indexed publications and five textbooks on Glaucoma.

**Special Honors:** Organizing Chairperson International Congress on Glaucoma Surgery 2010, American Academy of Ophthalmology Achievement Award 2009, Indian Intraocular Implant and Refractive Surgery Society Gold Medal 2009, South Asian Academy Achievement Award 2008.



**Elie Dahan**

**Affiliation:** Senior Consultant in Glaucoma, Pediatric Ophthalmology and Anterior Segment Surgery at the Ein Tal Eye Hospital in Tel Aviv, Israel.

**Areas of Interest:** Surgical Glaucoma, Anterior Segment Surgery and Pediatric Ophthalmology.

**Leadership Positions:** Head, St John University Eye Hospital in Johannesburg; Senior Consultant/Lecturer in the Department of Ophthalmology of the University of the Witwatersrand; Honorary Senior Consultant for surgical



glaucoma and complicated anterior segment surgery in the University Hospitals of Israel. During the early 2000's he made a breakthrough with the Ex-PRESS Glaucoma Filtration Device (Alcon) that is presently the mostly used glaucoma shunt in the world. He is a scientific advisor for IOPtimate that develops a CO2 Laser system for NPGS and has performed the first human case of CO2 Laser NPGS in 2004. Author of many scientific articles and chapters in Ophthalmology books. He is a reviewer of many Scientific Ophthalmology Journals.

*Special Honors:* D J Wood Award in 2007 (the highest ophthalmology award in South Africa).

#### **Ioannis Danias**

*Affiliation:* Professor, Departments of Ophthalmology and Cell Biology, State University of New York, Downstate, Brooklyn NY, USA.

*Areas of Interest:* various aspects of ophthalmology e.g. glaucoma.

*Special Honors:* Lewis Rudin Glaucoma prize (2006).




#### **Carlos Gustavo De Moraes, MD**

*Affiliation:* Research Assistant Professor of Ophthalmology at New York University School of Medicine and Head of Glaucoma Research at the Einhorn Clinical Research Center at the New York Eye & Ear Infirmary (NYEEI).

*Areas of Interest:* risk factors for glaucomatous visual field progression, optic nerve and retinal imaging, tonometry, electrophysiology, and surgical innovations.

*Leadership Positions:* Glaucoma section editor for two ophthalmology journals; expert reviewer for seven peer-reviewed journals in ophthalmology. He has published over 40 articles since 2008; 35 citations in peer-reviewed journals; 5 book chapters; 65 presentations and visiting professor and guest lecturer.

*Special Honors:* Six US-nationally-recognized awards.



#### **Dr. Philippe Denis, MD, PhD**

*Affiliation:* Professor and chair of the Department of Ophthalmology of Croix-Rousse University Hospital and Head of the Department of Pediatric Ophthalmology of the HFME (Hôpital Mère-Enfant) of Lyon; Director of the Optometry School of Lyon.

*Areas of Interest:* Treatment of glaucoma.

*Leadership Positions:* Member of the Executive Board of the French Society of Glaucoma; Vice-General Secretary of the

French Society of Ophthalmology. He has been productive in research into the medical and surgical treatment of glaucoma with more than 100 international papers published in peer-reviewed publications, and several books and book chapters.

*Special Honors:* The Chibret International Award in Singapore (1990) for his research in the field of retinal adrenergic receptors. Recipient of the French Society of Ophthalmology Award and of the Paris University Thesis Award.



#### **Michael Diestelhorst, MD**

*Affiliation:* Prof. of Ophthalmology, University of Cologne

*Areas of Interest:* Ocular surgery, ocular pharmacology, drug delivery, health economy, glaucoma, fluorophotometry.

*Leadership Positions:* more than 80 papers in peer review journal, book chapters.



#### **Guy D'Mellow**

*Affiliation:* Private practice as well as appointments to The Mater Misericordiae Hospitals and the Repatriation Hospital Greenslopes.

*Leadership Positions:* Member of the Council of Glaucoma Australia and on the Executive of the Australian & New Zealand Glaucoma Interest Group. Chairman of the Therapeutics Committee Royal Australian & New Zealand College of Ophthalmologists. He has been

a past Examiner in basic sciences (Physiology) for the Royal Australian & New Zealand College of Ophthalmologists, Federal Counselor, State Branch chairman, Chair of Ophthalmology Department Greenslopes hospital, and served on several State & Federal Government Expert Committees.



**Fathi El Sayyad, FRCSEd, FRCOphth**

*Affiliation:* Professor of Ophthalmology, Misr University for Science and Technology, Consultant Ophthalmologist, El Sayyad Eye Center

*Areas of Interest:* Surgical management of Glaucoma

*Leadership Position:* President of the Middle East African Glaucoma Society (MEAGS)



**David L. Epstein, MD, MMM**

*Affiliation:* Joseph A.C. Wadsworth Clinical Professor of Ophthalmology, Chairman, Duke Eye Center, Duke University School of Medicine, Durham, NC

*Areas of Interest:* Clinical and laboratory research interests. Fostering MD clinician scientists' careers in ophthalmology and translating the best in science to the understanding and treatment of human ocular disease.

*Leadership Positions:* Director of the Glaucoma Consultation Service, Harvard Medical School (1982-1991); President of the Association for Research in Vision and Ophthalmology (ARVO) from 1992-1993; President of the Chandler-Grant Glaucoma Society (2004-2005); President of the Association of University Professors of Ophthalmology (AUPO) in 2011. He has over 220 refereed scientific publications and has received numerous awards. He has served on many national Scientific Advisory Boards, often as Chairman.

*Special Honors:* The John R. Lynn Lecture (2009), the Jose S. Pulido Endowed Lecture (2009), Pittsburgh Ophthalmology Society's Thorpe Lecture (2010) and the Kerrison Lecture at the Medical University of South Carolina (2010).



**Seng Kheong Fang, MBBS (Mal), MS Ophthal (UKM)**

*Affiliation:* Senior Consultant Ophthalmologist and Glaucoma specialist at the International Specialist Eye Centre, Kuala Lumpur, Malaysia.

*Leadership Positions:* Organizing secretary of the 3rd South East Asia Glaucoma Interest Group (SEAGIG) scientific meeting in Kuala Lumpur in 2004 and the Honorary Treasurer for the Asia Pacific Academy of Ophthalmology (APAO) 20th Congress in Kuala Lumpur in 2005. Chairperson of the Organizing committee of the 7th Asian Angle



Closure Glaucoma Club (AACGC) meeting in Kuala Lumpur December 2009. Presently Honorary Secretary of SEAGIG since 2002, Regional representative for the AOGS since 2005, Regional representative of the AACGC since 2005, Society editor for the International Glaucoma Review of the WGA, Honorary Treasurer of Malaysian Society of Ophthalmology, Chairperson for Malaysian Glaucoma Interest Circle and Committee Member of Malaysian Small Incision Surgery. Received Distinguished Service Award from APAO in 2007 and the AACGC in 2009.

**Robert D. Fechtner, MD**

*Affiliation:* Professor, Director, Glaucoma Division, Institute of Ophthalmology and Visual Science, Chair, Institutional Review Board, New Jersey Medical School, UMDNJ, Newark, NJ

Dr. Fechtner is an active member of numerous scientific and medical organizations including the New Jersey Glaucoma Society, the American Glaucoma Society, the World Glaucoma Association, the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology, and the American Society of Cataract and Refractive Surgeons. He has served on the editorial boards of American Journal of Ophthalmology, Journal of Glaucoma, Review of Ophthalmology, and Video Journal of Ophthalmology. He has published over 100 articles, book chapters and monographs and is the associate editor of the Textbook of Ocular Pharmacology.



**Ronald L. Fellman MD**

*Affiliation:* Glaucoma Associates of Texas, Dallas, TX

*Areas of Interest:* Glaucoma, Ophthalmology

*Leadership Positions:* He is past Chair of the Patient Care Committee of the AGS and prior AGS councilor to the AAO. He has co-authored over 40 published papers and 15 book chapters on the medical and surgical management of glaucoma and helped create the Medicare Glaucoma Detection Benefit.

*Special Honors:* Recipient of the first Presidents' Award from the American Glaucoma Society, the first AGS surgical video award and Secretariat and Senior Honor Awards from the American Academy of Ophthalmology.



**William J. Feuer, PhD**

*Affiliation:* Scientist, Biostatistics Division, Department of Ophthalmology, Miller School of Medicine, University of Miami, Miami, FL, USA.

*Areas of Interest:* Ophthalmology, biostatistics.



**Leadership Positions:** Principal investigator of the Ahmed vs Baerveldt Comparison clinical trial and am responsible for statistical analyses for the Tube vs Trabeculectomy clinical trial. Reviewer Ophthalmology (1993-); Reviewer American Journal of Ophthalmology (1996-); Safety and Data Monitoring Committee, Tube vs Trabeculectomy Study (1999-); Safety and Data Monitoring Committee, Ahmed vs Baerveldt Comparison Study (2005-); Safety and Data Monitoring Committee, Pilot Feasibility Trial of Automated adjustment of inspired Oxygen Concentration in Neonates (2007-); Editorial Board Member, Journal of Current Glaucoma Practice with DVD (2007-); Faculty, World Glaucoma Congress (2007, 2009).



**Special Honors:** American Academy of Ophthalmology Achievement Award (2002).

#### **Murray Fingeret, OD, FFAO**

**Affiliation:** Chief of the Optometry Section, Brooklyn/St. Albans Campus, Department of Veterans Administration New York Harbor Health Care System. Clinical Professor at the State University of New York, College of Optometry. **Leadership Positions:** Fellow of the American Academy of Optometry; the National Academies of Practice; American Glaucoma Society; Board of Directors of the Glaucoma Foundation. Member of the medical eye care committee, American Optometric Association. Founding member and past-president of the Optometric Glaucoma Society, and currently its executive vice-president. Dr. Fingeret is chair of the Glaucoma Diplomate committee of the American Academy of Optometry. Editorial board for the Journal of Glaucoma, International Glaucoma Review, Glaucoma Today, Primary Care Optometry News, Optometry Times and Review of Optometry.



**Special Honors:** Recipient of the 2008 Distinguished Service Award Optometric Glaucoma Society; 2005 Carel C. Koch Memorial Medal from the American Academy of Optometry; 1999 AMSUS Federal Service Optometrist of the Year award.

#### **Josef Flammer**

**Affiliation:** Head and Professor, University Hospital Basel, Department of Ophthalmology, Basel, Switzerland

**Areas of Interest:** glaucoma

**Leadership Positions:** Guest Lecturer German Ophthalmology Society (2007); Guest Lecturer Samsung Medical Center/ National University / Catholic University (2007); Guest Lecturer South East Asia Glaucoma Interest Group / Asian Angle Closure Glaucoma Club (2007); Invited Professor, University of Brescia (2010).

**Special Honors:** Gold Medal, Saudi Ophth. Society, Riyadh (2006); Guest Lecturer of the South African Ophthalmology Society (2006); Guest Lecturer of the Japanese Glaucoma Society (2006).



#### **John Flanagan PhD, MCOptom**

**Affiliation:** Professor at both the Department of Ophthalmology and Vision Sciences, University of Toronto and the School of Optometry, University of Waterloo. Director of the Glaucoma Research Unit, Toronto Western Research Institute, Senior Scientist at the Toronto Western Hospital, University Health Network.

**Areas of Interest:** Basic mechanisms of human glaucoma (glial cell activation, proteomics, neuroprotection), ocular imaging, clinical psychophysics, 24-hour IOP, ocular blood flow and studies of vascular reactivity.

**Leadership Positions:** Founding member of the Optometric Glaucoma Society, was the Program Chair from 2002 to 2007, and is currently the OGS President. In 2008 he was appointed Chair of the Clinical Research Ethics Committee at the University of Waterloo. He has supervised 30 graduate students and has authored over 130 peer reviewed. He was a founding member of the Optometric Glaucoma Society, was the Program Chair from 2002 to 2007, and is currently the OGS President. In 2008 he was appointed Chair of the Clinical Research Ethics Committee at the University of Waterloo. Author of 10 book chapters and three books.

**Special Honors:** Awards include Certificate of Merit for Research Excellence, Glaucoma Research Society of Canada; Claire Bobier Lecture, University of Waterloo; Springer Lecture, University of Alabama; Glenn A. Fry Award from the American Academy of Optometry; Outstanding Performance Award, University of Waterloo; and most recently the Mel Silverman Mentorship Award from the Institute of Medical Sciences, University of Toronto.



#### **Brad Fortune, OD, PhD**

**Affiliation:** Associate Scientist and Director, Clinical Electrophysiology Service, Devers Eye Institute, Legacy Health Systems, Portland, OR; Clinical Instructor, Dept. of Ophthalmology, School of Medicine, Oregon Health Sciences University, Portland, OR.

**Areas of Interest:** Visual Function and Retinal Nerve Fiber Layer Structure.



*Special Honors:* Founding Member, Optometric Glaucoma Society (2002); Irvin and Beatrice Borish Award, American Academy of Optometry (2004); Junior Investigator Award.



**Jeffrey Freedman, MB Bch, PhD, FRCSE, FCS(SA)**

*Affiliation:* Professor of Clinical Ophthalmology Department of Ophthalmology SUNY, Brooklyn, New York.

*Areas of Interest:* Glaucoma Implants (introduced Molteno implants into the USA 1975). Immunology; Reported relationship between cytokines TGFb, and prostaglandins, to pressure levels in glaucoma implant blebs. Glaucoma surgery: Introduced concept of covering implant tubes with a scleral patch 1985, and management of the hypertensive phase by tapping the blebs. Developed concept of supra-Tenons placement of glaucoma implant.

*Leadership Positions:* Diplomat, American Board of Ophthalmology; Senior editor for American Academy of Ophthalmology 'Editors choice reviews' for the ONE academy program, since 2006 to present. Publications: 71 in peer reviewed journals; various chapters in books.

*Special Honors:* Chairperson for Symposium on Glaucoma implants. For the IGS (International Glaucoma Society) for the past 6 meetings held every two years in various locations worldwide. Invited 2008 to Chair Symposium on 'Glaucoma Implants' World Congress of Ophthalmology Hong Kong. Honor Award 1990 and Senior Honor Award 2007, American Academy Ophthalmology.

**David S. Friedman, MD, MPH, PhD**

*Affiliation:* Alfred Sommer Professor of Ophthalmology at the Wilmer Eye Institute of Johns Hopkins University.

Dr. Friedman is an epidemiologist and a glaucoma specialist with extensive research experience. He has participated in clinical trials in the past and is leading the glaucoma outcomes assessment of the MUST study. He is also the



Senior Ophthalmologist for Helen Keller International, a large non-profit organization dedicated to alleviating blindness worldwide.

**James G. Fujimoto**

*Affiliation:* Professor of Electrical Engineering and Computer Science, Department of Electrical Engineering and Computer Science and Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, MA, USA

*Leadership Positions and Honors:* Fellow of the OSA, APS, and IEEE. He was co-recipient of the Rank Prize in Optoelectronics in 2002. Dr. Fujimoto is in the National Academy of Engineering, the American Academy of Arts and Sciences and the National Academy of Sciences. He was co-founder of Advanced Ophthalmic Devices, the company that transferred OCT technology to Carl Zeiss for ophthalmic imaging and co-founder of LightLabs Imaging, a joint venture with Carl Zeiss in cardiovascular imaging that was recently acquired by St. Jude Medical in 2010.



**Stefano A. Gandolfi, MD**

*Affiliation:* Full Professor and Chairman at the University Eye Clinic of Parma.

*Areas of Interest:* various aspects of Glaucoma.

*Special Honors:* 2000 and 2004 1st Award from the European Glaucoma Society; since 2003 he acts as delegate of the EGS at the World Glaucoma Association (formerly AIGS); since February 2008, member elected of the Glaucoma Research Society; since 2009, member of the Scientific Committee of the EGS; Co-editor of the 3rd edition of the European Glaucoma Society Guidelines (Dec. 2008).



**David (Ted) Garway-Heath, MD, FRCOphth**

*Affiliation:* IGA Professor of Ophthalmology for Glaucoma and Allied Studies, NIHR Biomedical Research Centre for Ophthalmology; UCL Institute of Ophthalmology and Moorfields Eye Hospital, London, UK

*Areas of Interest:* The development of new tools that allow for an early detection of glaucoma. Research in imaging techniques for the detection and monitoring of



abnormalities in the optic nerve head (ONH). The inventor of the structure–function correlation map ('Garway-Heath Map'), which is being used widely in research aiming at establishing the correlation between visual field and ONH changes.

**Leadership Positions:** Principal Investigator of the UK Glaucoma Treatment Study; one of the six UK National Institute for Health Research Senior Investigators in Ophthalmology. Vice-President of the Imaging and Perimetry Society (IPS); Executive Member of the Glaucoma Research Society (GRS); Secretary of the Imaging Morphometry Association for Glaucoma in Europe (IMAGE). He is past Chairman of the ARVO Glaucoma Section Program Committee, past Chairman of the UK & Eire Glaucoma Society; and is Funder Member of the Scientific Committee of the European Glaucoma Society (EGS). He is on the editorial board of several international peer-reviewed journals and has authored numerous peer-reviewed papers.

**Gus Gazzard, MD, MA,  
MBBChir, FRCOphth**

**Affiliation:** Consultant in the Glaucoma and Cataract Services at Moorfields Eye Hospital, London; Honorary Senior Lecturer at the Institute of Ophthalmology, London.

**Areas of Interest:** angle closure glaucoma, selective laser trabeculoplasty, randomised controlled trials in glaucoma, anterior segment imaging and the epidemiology of myopia

**Leadership Positions:** Member of the EAGLE Study Group, an international multi-centre randomised controlled trial of early lens extraction in angle-closure, co-founded the European Glaucoma Society Special Interest Group in Angle Closure and is co-Clinical Lead for Moorfields at St George's teaching hospital.



**Steven J. Gedde, MD**

**Affiliation:** Professor of Ophthalmology and Residency Program Director at the University of Miami Miller School of Medicine/Bascom Palmer Eye Institute.

**Areas of Interest:** Medical education and glaucoma surgery.

**Leadership Positions:** Associate Editor of Curbside Consultation in Glaucoma: 49 Clinical Questions, and he has served on the Editorial Boards for the Journal of Academic Ophthalmology, EyeNet, Ocular Surgery News and EyeWorld. He is listed among Best Doctors in America since 2005. He has lectured nationally and internationally. He has published several book chapters and more than 200 articles and abstracts.

**Special Honors:** American Academy of Ophthalmology



Achievement Award in 2006. Selected as the Excellence in Health Care Educator of the Year in 2009. Study chairman for the Tube Versus Trabeculectomy (TVT) Study and Primary Tube Versus Trabeculectomy (PTVT) Study, multi-center randomized clinical trials comparing tube shunt surgery with trabeculectomy.

**Ronnie George, MD**

**Affiliations:** Senior Consultant in the glaucoma department at Sankara Nethralaya, Director, Research for Vision Research Foundation and Professor, Elite School of Optometry, Chennai.

**Areas of Interest:** Angle closure glaucoma, diagnostics, Glaucoma Epidemiology.

**Leadership Positions:** Associate Advisory Board member for the World Glaucoma Association (AIGS) and is past Secretary of the Glaucoma Society of India (2008-10); Published 57 papers in peer reviewed indexed National and International journals. Investigator for The Chennai Glaucoma Study 'Chennai Eye Disease Incidence Study'. In addition to being involved with residency and fellowship training in ophthalmology he is a faculty for BS, MPhil and PhD programs in optometry under Elite School of Optometry, Chennai and BITS, Pilani distance education programs.

**Special Honors:** The Thiru CK.Kumaraswamy Gold Medal by the Dr MGR Medical University for MS Ophthalmology; Thomas Gold Medal for the best outgoing resident in ophthalmology by the Christian Medical College Vellore (2001). The Pfizer best paper award at the XIIIth Annual Glaucoma Society of India meeting in 2003 and two AIOS IJO silver awards for best paper in 2009.



**Orna Geyer MD**

**Affiliation:** Associate Professor of Ophthalmology, Technion- Israel Institute of Technology Chair Department of Ophthalmology Carmel Medical Center, Haifa, Israel.



**Ivan Goldberg, AM, MB, BS (Syd), FRANZCO, FRACS**

**Affiliation:** Director of Eye Associates, Head of the Glaucoma Unit at the Sydney Eye Hospital and Clinical Associate Professor at the University of Sydney Discipline of Ophthalmology.

**Areas of Interest:** Glaucoma. Patient care, clinical research projects and educational strategies.

**Leadership Positions:** Co-founder and Vice President of Glaucoma Australia; President of the Australian and New Zealand Glaucoma Interest Group; Past President of the World Glaucoma Association; the Royal Australian and New Zealand College of Ophthalmologists and the South East Asia Glaucoma Interest Group (SEAGIG). Author or co-author of over 120 peer-reviewed publications, 20 Editorials, 18 book chapters; Reviewer for and a member of the Editorial Boards of a dozen international glaucoma and ophthalmology Journals. When President of RANZCO, he hosted the World Ophthalmology Congress in Sydney (2002), which attracted over 4000 ophthalmologists and other eye care workers. Earlier this year (2011) he was President of the Asia Pacific Academy of Ophthalmology meeting in the Darling Harbour Exhibition and Convention Centre, which had 4700 registrants, the majority from developing nations.

**Special Honors:** In recognition of his work promoting national and international glaucoma societies and patient support associations, this year Ivan was made a Member of the Order of Australia.



**Francisco Javier Goñi, MD, PhD**

**Affiliation:** Head of the Integrated Ophthalmology Department at Hospital de Granollers, Hospital de Mollet and Hospital de Sant Celoni (SIOVO, Vallès Oriental, Barcelona).

**Areas of Interest:** Diagnosis and medical treatment of glaucoma.

**Leadership Positions:** Member of the E.C. of the European Glaucoma Society since 2008.



**Stuart L. Graham, MBBS, PhD, MS, FRANZCO**

**Affiliation:** Professor and Head of Dept, Ophthalmology and Visual Science. ASAM, Macquarie University, Sydney, Australia, and Visiting Professor, Sydney University/Save Sight Institute

**Areas of Interest:** Glaucoma subspecialist ophthalmologist with background in electrophysiology and clinical research in glaucoma and optic neuritis. Has worked extensively on developing objective perimetry using the multifocal VEP.



**H. Fernando Gomez Goyeneche, MD**

**Affiliation:** Senior Consultant and Head, Glaucoma Service, Hospital Militar Central, Bogota, Colombia; Associate professor and chair of the glaucoma fellowship program at the Department of Ophthalmology, Universidad Militar Nueva Granada.

**Areas of Interest:** Glaucoma diagnosis. Angle closure glaucoma. Surgical treatment. Prevention of blindness.

**Leadership Position and Special Honors:** President of the Colombian Society of Ophthalmology 2010 -2012; Past President Colombian Glaucoma Society 2008 – 2010; Invited speaker in numerous national and international meetings, special recognition for various investigational projects.



**David S. Greenfield, MD**

**Affiliation:** Professor of Ophthalmology and Director of the Glaucoma Fellowship Program at the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Palm Beach Gardens, FL, USA.

**Areas of Interest:** Optic disc and retinal nerve fiber imaging, reflectance properties of the retinal nerve fiber layer, normal-tension glaucoma, bleb-related ocular infection, and complex glaucoma filtration surgery.

**Leadership Positions:** Associate Editor of Ophthalmic Surgery Lasers and Imaging; member of the editorial boards of American Journal of Ophthalmology, Journal of Glaucoma, and International Glaucoma Review; Co-founder of The International Society for Imaging in the Eye (ISIE); Secretary-Treasurer (2002-2007); President and co-founder of The Florida Glaucoma Society; Chair of the American Glaucoma Society Scientific Program Committee and chair of the World Glaucoma Association Bylaws Committee; past Chair of the AGS Bylaws and Strategic Planning Committee; member of the AAO Glaucoma Subspecialty Day Committee, Technology Assessment Committee, and EyeCare America Glaucoma Education Committee. Co-Chairman of the Glaucoma





Subspecialty Day of the American Academy of Ophthalmology (2003-4). Numerous guest lectures and named lectures nationally and internationally; Published over 225 original scientific papers, abstracts and book chapters. He has trained numerous clinical and research Fellows, many of whom hold distinguished academic positions worldwide. *Special Honors:* American Academy of Ophthalmology Achievement Award (2003); AGS Clinician-Scientist Lectureship (2010); Recipient of a National Eye Institute consortium grant studying advanced imaging technology in glaucoma, and has received funding from the NIH since 1999.

#### **Franz Grehn, MD**

*Affiliation:* Chairman of the Department of Ophthalmology, University of Würzburg.

*Areas of Interest:* Basic and clinical research in glaucoma; Glaucoma surgery; Childhood glaucoma and childhood cataract; Laboratory for cell biology in glaucoma research; Prospective Randomized Clinical Studies.

*Leadership Positions:* Member of the Board of Governors of the World Glaucoma Association (2007-) Honorary Member of the Union of Bulgarian Ophthalmologists (2009); President elect of the Glaucoma Research Society (2010); Honorary member of the Italian Glaucoma Society (2011); Member of the publishing advisory board and scientific advisory board of following journals: *Der Ophthalmologe* (Section Editor) and Vice Chief Editor; *Journal of Glaucoma*; *Zeitschrift Prakt. Augenheilkunde*; *Ophthalmochirurgie*; *Graefe's Archives of Clinical and Experimental Ophthalmology*; *Klinische Monatsblätter für Augenheilkunde*; 186 original publications, editor and publisher of 13 books.



#### **Daniel Grigera MD**

*Affiliation:* Head, Glaucoma Unit, Santa Lucia Eye Hospital (Hospital Oftalmologico Santa Lucia), Buenos Aires, Argentina; Assistant Professor of Ophthalmology, Faculty of Medicine, Universidad del Salvador, Buenos Aires.

*Leadership Positions:* Founding member and first President of the Argentine Glaucoma Society (2001-2002); President of the Pan American Glaucoma Society (PAGS) (2005-2007); President of the Latin American Glaucoma Society (LAGS); Pan American Glaucoma Society (2008-2012); Published more than 30 international papers on Glaucoma.



#### **Neeru Gupta, MD, PhD, FRCS, DABO**

*Affiliation:* Professor and Dorothy Pitts Chair of Ophthalmology and Vision Sciences and Professor of Laboratory Medicine and Pathobiology, University of Toronto; Director, Glaucoma and Nerve Protection Unit, Keenan Research Centre at the Li KaShing Knowledge Institute of St. Michael's Hospital.

*Areas of Interest:* Glaucoma neural degeneration in the central visual system; ocular lymphatics; basic and clinical research to understand and prevent vision loss in glaucoma.

*Leadership Positions:* President, Canadian Glaucoma Society; Advisory Council Member to International Council of Ophthalmology; Chair of the Glaucoma Section of the Association for Research in Vision and Ophthalmology; Chair, Glaucoma Residency Curriculum, International Council of Ophthalmology; Glaucoma Basic Science and Clinical Course Committee of the American Academy of Ophthalmology; Board of Directors and Vice Chair, Program Committee of the American Glaucoma Society; Board of Directors and Vice-Chair of the Scientific Advisory Committee, Glaucoma Research Society of Canada; Scientific Advisory Board Member of the Glaucoma Foundation; Editor, Vision Science Section, Canadian Journal of Ophthalmology; Executive Committee of the Institute of Medical Science, University of Toronto.

*Special Honors:* Nominated for the Colin-Woolf Education Award, University of Toronto (2011); New York Academy of Medicine Lewis Rudin Award (2010); Award of Excellence, Glaucoma Research Society of Canada (2009).



#### **Wolfgang Haigis, PhD**

*Affiliation:* Assistant Professor of Ophthalmic Biometry, Faculty of Medicine, University of Würzburg.

*Areas of Interest:* Ophthalmic biometry; IOL power calculation; Quality control in ophthalmic ultrasound; Computer/Internet applications in Ophthalmology.

*Leadership Positions:* Moderator and staff at various national and international educational courses, expert witness in various cases, reviewer for numerous peer-reviewed journals. Haigis formula for IOL calculation. Haigis-L formula for eyes after myopic and hyperopic laser refractive surgery. Participation in the development of PCI and its adaptation to ophthalmic biometry and ultrasonic standards (calibration curves and correction factors for Zeiss IOLMaster, Zeiss ACMaster). Introduction of online IOL calculation (1996), ongoing service henceforth. Founder of the User Group for Laser Interference Biometry (ULIB) (1999).



*Special Honors:* Several 'Best Paper of Session' Awards of the American Society of Cataract and Refractive Surgery (ASCRS); Science Award 2009 of the 'Deutschsprachige Gesellschaft für Intraokularlinsen-Implantation, interventionelle und refraktive Chirurgie (DGII)'.

**Masanori Hangai, MD, PhD**

*Affiliation:* Associate Professor, Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.

*Areas of Interest:* glaucoma imaging, and surgeries.



**Alon Harris, MS, PhD, FARVO**

*Affiliation:* Lois Letzter Endowed Chair in Ophthalmology, Professor of Ophthalmology, Professor of Cellular and Integrative Physiology, Director of Clinical Research, Eugene and Marilyn Glick Eye Institute, Director, Glaucoma Research and Diagnostic Center, Director, Ocular Vascular Reading Center; Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA.

*Areas of Interest:* To determine mechanisms involved in the etiology and pathophysiology of diseases of the eye such as glaucoma, age-related macular degeneration, and diabetic retinopathy; specifically to determine the role of ischemia in the development and pathogenesis of these diseases by applying appropriate technology. To discover therapeutic agents for addressing ocular ischemia. Population based studies. Drug Delivery studies. Imaging of Retina and Optic Nerve structure. Imaging of Metabolism and Blood Flow.

*Leadership Positions:* Director, Clinical Research, Eugene and Marilyn Glick Eye Institute; Director, Glaucoma Research and Diagnostic Center; Director, Ocular Vascular Reading Center, Indiana University School of Medicine; Governing Board Member, International Society for Imaging in the Eye; Executive Committee Member, International Glaucoma Society; Associate Editor, Acta Ophthalmologica; Editorial Board Member, International Glaucoma Review, Journal of Current Glaucoma Practice, Journal of Ophthalmology; Co-Chairman, World Glaucoma Congress Consensus on Ocular Blood Flow.

*Special Honors/Awards:* Lois Letzter Chair of Ophthalmology, Indiana University School of Medicine, July 1999- present; Alliance of Distinguished and Titled Professors, Indiana University, 2000-present; American Academy of Ophthalmology



Achievement Award (2001); Inaugural Pharmacia Ophthalmology Resident Study Award. May 2002; Glenn W. Irwin, Jr. MD Experience Excellence Recognition Award, winner, 2002; Silver Fellow Association for Research in Vision and Ophthalmology (ARVO) Fellows Class of 2010; National Review Board: Neuroscience and Mental Health Board (t-NMHB) Research Proposal Reviewer July 2010. Author of more than 240 peer-reviewed journal articles, 15 books and 39 book chapters.

*Patents:* 1. Novel Treatment of Macular Edema. U.S. Patent; 2. Method to Increase Retinal and Optic Nerve Head Blood Flow. U.S. Patent.

**Ronald S. Harwerth, OD, PhD**

*Affiliation:* John and Rebecca Moores Professor of Optometry, College of Optometry, University of Houston, Houston, TX.

*Areas of Interest:* Structure-function relationships in experimental and clinical glaucoma, perimetry, retinal nerve fiber layer, clinical psychophysics.

*Leadership Positions:* Chair of the Department of Vision Sciences, College of Optometry

*Special Honors:* Best Scientific Poster Presentation, World Glaucoma Congress (2005); Charles F. Prentice Medal, American Academy of Optometry (2006); Esther Farfel Award, University of Houston (2011).



**Mingguang He, MD, PhD**

*Affiliation:* Deputy Director and professor in Zhongshan Ophthalmic Center, Sun Yat-sen University in Guangzhou.

*Areas of Interest:* Clinical and epidemiological research, randomized trial, twin study and imaging technology.

*Leadership Positions:* Associate Advisory Board Member of World Glaucoma Association. Member of the Editorial board of Ophthalmology, Molecular Vision and International Glaucoma Review.



**Paul Healey, BmedSc (Cell Biology), MBBS (Hons), Mmed (Clin. Epi.), FRANZCO**

*Affiliation:* Director Glaucoma Services, Western Sydney Eye Hospital, Director of Glaucoma Research at the Westmead Millennium Institute (Department of Ophthalmology, University of Sydney), Chief glaucoma investigator for the Blue Mountains Eye Study, and Clinical Associate Professor at the University of Sydney and Honorary Medical Officer at Sydney Eye Hospital.

*Areas of Interest:* Glaucoma, Ophthalmic Epidemiology and Public Health, Cell Biology, Diagnostic Test and Screening

Evaluation and Genetic Epidemiology.

**Leadership Positions:** A number of regional and worldwide positions including board member and treasurer of South East Asia Glaucoma Interest Group, Australian representative for the Asia-Oceanic Glaucoma Society, and Chair of the Associate Advisory Board and the World Glaucoma Day Committee of the World Glaucoma Association. He has made over 180 scientific presentations at meetings throughout the world. Editorial board member of number of journals and has published over 100 articles based on original research.

**Special Honors:** International Young Clinician-Scientist Award from the Association of International Glaucoma Societies (2005).




**Leon W. Herndon, Jr., MD**

**Affiliation:** Associate Professor of Ophthalmology, Duke University Medical Center Durham, NC.

**Areas of Interest:** Studying novel treatment approaches in the diagnosis and management of glaucoma. He has ongoing research projects evaluating the high prevalence of primary open angle glaucoma in Ghana, West Africa.

**Leadership Positions:** Medical Director of the Duke University Eye Center; Faculty Advisor to the Duke chapters of Unite For Sight and Student Sight Savers Program; Editorial board of Glaucoma Today; Associate Examiner for the American Board of Ophthalmology; involved in the Leadership Development Program of the AAO.



**Roger A. Hitchings, FRCS, FRCOphth**

**Affiliation:** Honorary Consultant Ophthalmologist at Moorfields Eye Hospital, London and Professor Emeritus in Glaucoma and Allied studies at the University of London. He was Director of R+D at Moorfields Eye Hospital.

**Areas of Interest:** As a glaucoma specialist he has a special interest in optic nerve imaging, visual field progression, glaucoma surgery and normal tension glaucoma.

**Leadership Positions:** Roger Hitchings developed the glaucoma department at Moorfields Eye Hospital into the largest in the UK and one of the largest in the world. It now functions

with ophthalmologists and scientists representing all aspects of sub-specialization in glaucoma. He has also carried out research into the effect of topically applied medications on the conjunctiva and the success of glaucoma surgery. He has authored and edited four books, 15 book chapters and over 200 peer-reviewed papers on glaucoma. Currently past president of the European Glaucoma Society, and Founder Member of the World Glaucoma Association (AIGS).

As Director of R+D he had responsibility for establishing the Clinical Trials Unit and the associated Reading Centre. The latter has become one of the key centers for the evaluation of ophthalmic clinical trials in the UK. He was responsible for developing the Royal College of Ophthalmologists' 5 year Strategic Plan for Eye research which set out research goals in the specialty.

**Ho Ching Lin, MBBS, M.Med (Ophth), M.Med (Paed), FRCS (Edin)**

**Affiliation:** Head and Senior Consultant, Glaucoma Service, Singapore National Eye Centre. Senior Consultant, Singapore National Eye Centre Eye Associates, Gleneagles Hospital. Visiting Consultant, National University Hospital, Changi General Hospital, Kerdang Kerbau Women's and Children's Hospital. Clinical Lecturer, National University of Singapore.

Adjunct Clinical Investigator, Singapore Eye Research Institute.

**Areas of Interest:** Pediatric glaucoma, glaucoma surgery techniques and devices, tube shunts, lasers in glaucoma including SLT, angle closure glaucoma and angle imaging.

**Leadership Positions:** Board member, South East Asian Glaucoma Interest Group (SEAGIG). Secretary, Glaucoma Surgeons of Singapore. Board member, Lions SaveSight Centre. Invited speaker, chairperson and teaching faculty at many regional and international meetings, courses and workshops. Workgroup member of Asia Pacific Clinical Practice guidelines on Glaucoma and Singapore Glaucoma Clinical Practice Guidelines workgroup. Guidelines workgroup for Pediatric Glaucoma at the World Glaucoma Congress 2007. Examiner for FRCSE, MMed(Ophth) examinations. Reviewer for several peer-reviewed journals. Associate Councilor, North West Community Development Council(NWCDC). Vice Chairman, Youth Standing Committee, NWCDC.

**Special Honors:** Holmes Lecture Award 2010; Asia Pacific Academy of Ophthalmology (APAO) Prevention of Blindness award; APAO Distinguished Service Award; Wong Hock Boon Gold Medal for Pediatrics; Beecham Prize for Biochemistry; Spring Singapore Excellent Service Star and Silver awards; Singapore Health Quality Service Silver award; Parmigiani Fleurier Woman of Exception award for career achievements in the Science Category, Singapore.





**Esther M. Hoffmann, MD**

*Affiliation:* Consultant ophthalmologist at the University Medical Center, Dept. of Ophthalmology in Mainz, Germany.

*Areas of Interest:* Optic nerve head and RNFL imaging, evaluation of different tonometry devices, and glaucoma surgery.

*Leadership Positions:* Leads the glaucoma diagnostic section and is responsible for the eye diagnostic center.

*Special Honors:* Dagmar Eißner Award (2007); Award from the university Mainz for excellent scientific work of young female researchers.



**Megumi Honjo, MD, PhD**

*Affiliation:* Assistant Director, Dept. of Ophthalmology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan.

*Areas of Interest:* various aspects of glaucoma.



**Gábor Holló, MD, PhD, DSci**

*Affiliation:* Professor and Director of the Glaucoma Service and Perimetry Unit in the Department of Ophthalmology at Semmelweis University in Budapest, Hungary.

*Areas of Interest:* Pathogenesis, early diagnosis and medical, laser, and surgical treatment of glaucoma.

*Leadership Positions:* former Executive Committee member of the EGS; President of the Glaucoma Section of the Hungarian Ophthalmology Society; Reviewer for several international ophthalmology journals and member of the editorial board of several scientific journals. He has edited several books and book chapters, and authored or co-authored numerous scientific peer-reviewed publications.

*Special Honors:* Széchenyi Professional Award (2000-2004); European Glaucoma Society's (EGS) Special Recognition Award (2003).



**Masaru Inatani, MD, PhD**

*Affiliation:* Lecturer at the Department of Ophthalmology and Visual Science, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.

*Areas of Interest:* Surgical outcome of glaucoma surgery, molecular mechanism for glaucoma optic neuropathy, developmental molecular mechanism for the anterior chamber angle.

*Leadership Positions:* Trustee of Japan Glaucoma Society.

*Special Honors:* Award of Japan National Society for the Prevention of Blindness (2004); Imai Memorial Award (2004); Mishima Memorial Award (2006); Rohto Award (2008); Nakajima Award (2009); Suda Memorial Award (2009); Trustee Award of Japanese Ophthalmological Society (2009); Medical Research Award of the Japan Medical Association (2009).



**Kyoko Ishida, MD, PhD**

*Affiliation:* Assistant Professor, Gifu University Graduate School of Medicine; Assistant Department Manager, Gifu General Medical Center, Gifu, Japan; Clinical Associate Professor, Gifu University Graduate School of Medicine.

*Areas of Interest:* Glaucoma surgery, Normal-tension glaucoma, Imaging

*Leadership Position:* Councilor of Japan Glaucoma Society



**Anton Hommer, MD**

*Affiliation:* Senior Ophthalmologist and Head of the Glaucoma Unit at the Department of Ophthalmology at Hera Hospital, Vienna.

*Areas of Interest:* Glaucoma, clinical trials, compliance and medical therapy.

*Leadership Positions:* President of the 'Viennese Ophthalmological Society' ('Ophthalmologische Gesellschaft in Wien') in 2004/2005; member of the Executive Board of the European Glaucoma Society since 2008; He has given more than 400 lectures both nationally and internationally; also a reviewer for several peer reviewed journals.



**Aiko Iwase, MD**

*Affiliation:* Director, Tajimi Iwase Eye Clinic; Visiting Professor, Ophthalmology, Tokai University, Kanagawa, Japan; Adjunct Asst. Professor, Ophthalmology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan; Adjunct Asst. Professor, Ophthalmology, Gifu University Graduate School of Medicine, Gifu, Japan; Administrator, Health Center, Department of Health and Welfare of Tajimi City office.

*Leadership Positions:* Board Member, Imaging Perimetric



Society (IPS); Vice-President IPS 2002-2006; Board Member of Japan Glaucoma Society (JGS); Council Member of Japanese Ophthalmological Society.

*Special Honors:* AIGS Award (2004) on behalf of the Tajimi Study group of the Japan Glaucoma Society; Japan Glaucoma Society Special Recognition Award for Contribution to the Tajimi Study (2003); Japan Ophthalmologists Association President Award (2006).



**Ingrida Januleviciene, MD, PhD**

*Affiliation:* Head of Outpatient department, Eye Clinic of Lithuanian University of Health Sciences Hospital; Associate Clinical Professor, Eye Clinic of Lithuanian University of Health Sciences.

*Areas of Interest:* Diagnosis and management of glaucoma. To determine the mechanisms involved in the etiology and pathogenesis of glaucoma and age-related ocular changes; to investigate structural and functional changes consistent with glaucoma progression and hemodynamic parameters as possible predictors for glaucoma progression, to evaluate the effects of treatment on IOP and ocular circulation.

*Leadership Positions:* President of Lithuanian Glaucoma Society. Leader and pursue in ophthalmology of the EU program in Lithuania of human resource development in scientific research and innovation 'Realization of higher studies in medical physics and nanophotonics'. Member of World Health Organization Ophthalmology Topic Advisory Group contributing to the revision of the International Classification of Diseases 11th edition. Board member of European Ophthalmological Society. Editorial board of International Journal of Biomedical Science; Lithuanian Ophthalmology. World Glaucoma Association Consensus on Ocular Blood Flow in glaucoma section leader and co-chair. Author of 75 publications, four book chapters.

*Special Honors:* American Academy of Ophthalmology International Ophthalmologist Education Award; Recipient; Lithuanian University of Health Sciences Leader Award.



**Seung Youn Jea**

*Affiliation:* Glaucoma service, Goodmorning St. Mary's Eye Clinic, Busan, Korea.



**Chris A. Johnson, PhD**

*Affiliation:* Professor of Ophthalmology, University of Iowa School of Medicine, IA

*Areas of Interest:* Perimetry and Visual Field Testing; Vision and Driving; Structure-Function relationships in glaucoma Diagnostic Test Development; Progression in glaucoma and other ocular and neurologic diseases

*Leadership Positions:* Editorial Board Member, Journal of Glaucoma (1995-present); Editorial Board Member, Glaucoma Today (2005-present); Topical Editor, Optometry and Vision Science 1996-2003, 2009-present); Scientific Advisory Board, The Glaucoma Foundation (1997-present); Member, Ocular Hypertension Treatment Study Executive and Steering Committee (1992 to present); Glaucoma Advisory Committee, Prevent Blindness America (1985-present); President, International Perimetric Society (2009-present); Co-Founder and Co-Chair, North American Perimetric Society (1995-present).

*Special Honors:* Invited Speaker, Japanese Ophthalmological Society (Tokyo) (2004); Honorary Doctor of Science, State University of New York (2005); Senior Achievement Award, American Academy of Ophthalmology (2005); Levitt Visiting Professorship, University of Iowa School of Medicine (2006-2008); ARVO Fellow (Silver) (2009).



**Murray Johnstone MD**

*Affiliation:* Clinical Professor, Eye Institute, Department of Ophthalmology, Seattle, WA, USA.

*Area of Interest:* Aqueous Outflow System Morphology and Dynamics in Glaucoma.



**Jost B. Jonas, MD**

*Affiliation:* Professor and Chairman of the Department of Ophthalmology of the Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg in Germany.

*Areas of Interest:* Intravitreal application of medication as treatment of intraocular edematous, proliferative and neovascular diseases; the intravitreal cell-based drug therapy; the homologous intravitreal bone-marrow transplantation; the femtosecond laser assisted surgery of the cornea; the contact lens associated ophthalmodynamometry for measurement of the retinal arterial and venous blood pressure; the morphologic diagnosis of optic nerve diseases including the glaucomas; population-based studies (Beijing Eye Study; Central India Eye and Medical Study); and in Nanomedicine.

*Leadership Positions:* member of Editorial Board of several European ophthalmic journals; published 590 articles in peer-reviewed journals.

*Special Honors:* Glaucoma Award of the German Ophthalmologic Society; the Junior and Senior Award of the American Academy of Ophthalmology; International Gold Awards of the Chinese Ophthalmologic Society; Fellow of the Association of Research in Vision and Ophthalmology ARVO.



**Fridbert Jonasson, MD**

*Affiliation:* Professor of Ophthalmology, Faculty of Medicine and Consultant Ophthalmic Surgeon, Department of Ophthalmology, University of Iceland.

*Areas of Interest:* Epidemiology and Genetics of Age-related Eye Disease, in particular Glaucoma and AMD.

*Leadership Positions:* Board member, European Society of Ophthalmology (SOE) (1996-); Board member of Acta Ophthalmologica (2001-); Member of the Scientific Committee of European Society of Ophthalmology (SOE) (2005-); Treasurer, European Society of Ophthalmology (SOE) (2008-); European Society of Ophthalmology (SOE) Executive Committee (2008-); Authored about 100 articles, more than 200 scientific abstracts and several book chapters.

*Special Honors:* World Glaucoma Association Research Award (2007); Acta / EVER medal (2008); EVER certificate of excellence / the EVER-Acta lecture (2008).




**Malik Kahook, MD**

*Affiliation:* Associate Professor and Director of the Glaucoma Service in the Department of Ophthalmology at the University of Colorado; Faculty member in the Department of Bioengineering at the University of Colorado.

*Areas of Interest:* Medical and surgical care of glaucoma and cataracts. Novel surgeries to treat glaucoma, imaging of the eye and both clinical and basic science pharmacology studies.

*Leadership Positions:* He is involved in research, funded by government, industry and foundations. He has authored more than 120 peer-reviewed manuscripts, abstracts and book chapters.

*Special Honors:* AGS Clinician-Scientist Fellowship Award (2007); AGS Compliance Grant (2006); named New Inventor of the Year for the University of Colorado in 2009 and 2010.



**Kenji Kashiwagi, MD, PhD**

*Affiliation:* Assistant Professor, Department of Ophthalmology, University of Yamanashi, Faculty of Medicine.

*Areas of Interest:* Clinical investigations: Screening system for angle closure, WEB supporting system, Telemedicine for glaucoma, Medical treatment. Basic science: Neuro-protection, Drug delivery system for anti-glaucoma compounds.

*Leadership Position:* Counselor of Japanese Glaucoma Society and Japanese Society for Ocular Pharmacology. Director of Japanese Telemedicine and telecare association

*Special Honors:* Suda Award (Japan Glaucoma Society), Photo Award (Rohto pharmaceutical company).



**L. Jay Katz MD, FACS**

*Affiliation:* Professor, Jefferson Medical College, Attending Surgeon and Director, Glaucoma Service, Wills Eye Institute, Philadelphia, PA.

*Leadership Positions:* Dr. Katz has published more than 120 articles in such journals as Archives of Ophthalmology, the American Journal of Ophthalmology, Ophthalmology, and the Journal of Glaucoma. He is an Editorial Board member for Journal of Glaucoma, Survey of Ophthalmology, Clinical Therapeutics and Graefe's Archives of Clinical and Experimental Ophthalmology. He has authored, coauthored, or edited more than 30 books and book chapters.

*Special Honors:* Recipient of various awards, including the American Academy of Ophthalmology (AAO) Senior Achievement Award in 2002 and the Joint Commission on Allied



Health Personnel in Ophthalmology's Faculty Award in 2003. He was named Distinguished Alumnus of the Yale University Eye Center in 2003 and became a Honored Life Member of the Philadelphia Ophthalmic Club in 2007.

#### **Paul L. Kaufman, MD**

*Affiliation:* Peters A. Duehr Professor and Chairman, Dept. of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison, WI

*Areas of Interest:* Glaucoma, Mechanisms of aqueous humor formation and drainage, age-related loss of near vision (presbyopia).

*Leadership Positions:* Editor-in-Chief, Invest. Ophthalmol. Vis. Sci (2007-2012); Sci Adv Board, Proneuron Biotechnology Inc. (1997-); Sci Adv Comm, Alcon Res. Institute (1998-); Honorary doctorate from Uppsala University (2004-).

*Special Honors:* Helen Keller Fndn/Pfizer Ophthalmics Res Award in Glaucoma (Liu PI) (2006); ISER Bárány prize (2006); ARVO Distinguished Service Award (2007); Honoree, Am Glau Society (2009); The Glaucoma Foundation Robert Ritch Award for Excellence and Innovation in Glaucoma (2009).

*Patents:* Cytoskeletal Active Agents for Glaucoma Therapy; US Patent #s 5,798,380, 6,110,912, 6,586,425; 8/25/1998, 8/29/2000, 7/1/2003 (Expires 2/21/2016); Inventors: Paul L. Kaufman, Benjamin Geiger. Method for Treating Glaucoma (Caldesmon); Patent # PCT/US2005/005428; 2/18/2005 (Expires 2/18/2025); Inventors PL Kaufman, B Geiger, T Borrás, A.D. Bershadsky. Method for Treating Glaucoma (C3); Patent # PCT/US2005/005427; 2/18/2005 (Expires 2/18/2025); US Patent # 7,083,783; 08/01/2006; Inventors PL Kaufman, X. Liu.



#### **Changwon Kee, MD, PhD**

*Affiliation:* Professor and Chairman of the Department of Ophthalmology, Samsung Medical Center, School of Medicine, Syungkyunkwan University.

*Areas of Interest:* Glaucoma surgery, Gene therapy in glaucoma, Pathogenesis of NTG

*Leadership Positions:* President of the Korean Glaucoma Society.



#### **Peng T. Khaw PhD FRCP FRCS FRCOphth CBiol FSB FRCPATH FMedSci**

*Affiliation:* Professor of Glaucoma and Ocular Healing and Consultant Ophthalmic Surgeon; Director, National Institute for Health Research Specialist Biomedical Research Centre in Ophthalmology at Moorfields Eye Hospital and UCL Insti-

tute of Ophthalmology; Director, Research and Development, Moorfields Eye Hospital; Programme Director Eyes & Vision, UCL Partners Academic Health Science Centre.

*Areas of Interest:* Developing new therapies particularly for scarring and regeneration. He has developed surgical techniques which markedly improve the safety and outcome of glaucoma surgery, and developed new anti-scarring regimens based on laboratory

research leading to large international clinical trials and use. *Leadership Positions:* He is Director of the National Institute for Health Research Biomedical Research Centre in Ophthalmology to fast track new discoveries to clinical use. As part of the Centre, they have just completed one of the world's largest eye research facilities and also pediatric research units. The Centre developed the world's first human retinal gene therapy, has several innovative new stem cell therapies, and novel slow release therapies in development

*Special Honors:* He has been awarded many prizes including the first international ARVO/Pfizer Ophthalmic Translational Research Award. He has published over 350 papers, chapters and books, and helped raise over £50million for clinical and research facilities.



#### **Dong Myung Kim, MD**

*Affiliation:* Professor, Department of Ophthalmology and Human Genome Research Institute, College of Medicine, Seoul National University; Professor, Department of Ophthalmology, Seoul National University Hospital.

*Area of Interest:* Normal-tension glaucoma, imaging, genetics.



#### **Thomas Klink, MD**

*Affiliation:* Associate Professor in Ophthalmology at the Julius-Maximilians University, Würzburg.

*Areas of Interest:* Intensified post-operative care after trabeculectomy; Complication management after trabeculectomy; Canaloplasty; Pediatric Glaucoma surgery and postoperative care; Modifications in trabeculectomy; Penetrating keratoplasty; Descemet Stripping Automated Endothelial Keratoplasty (DSAEK).





**Anastasios-Georgios P. Konstas, MD, PhD**

*Affiliation:* Associate Professor of Ophthalmology and Head of the Glaucoma Unit in the 1st University Department of Ophthalmology at AHEPA Hospital in Thessaloniki, Greece.

*Areas of Interest:* 24-hour IOP monitoring, medical therapy in glaucoma, exfoliative glaucoma, the most common identifiable cause of open-angle glaucoma worldwide.

*Leadership Positions:* Authored or co-authored 123 publications in peer-reviewed journals and is an active participant and presenter at many international meetings. Vice President of the Panhellenic Ophthalmological Society (2003) and currently serves on the editorial boards of Ophthalmologia and European Journal of Ophthalmology. He is a scientific reviewer for 15 different journals.



**Michael S. Kook, MD**

*Affiliation:* Professor of Ophthalmology, University of Ulsan, College of Medicine, Seoul, Korea.

*Areas of Interest:* Normal-tension glaucoma, Blood flow and ocular perfusion in Glaucoma, Imaging studies in glaucoma, Pharmacotherapy in glaucoma, Wound healing in glaucoma surgery.

*Leadership Positions:* Chief ophthalmology consultant for US Army Hospital in Seoul, Korea; Executive director of Korean-American Ophthalmology Association. Reviewer of the journals: Investigative Ophthalmology and Visual Science, American Journal of Ophthalmology, Archive of Ophthalmology, Ophthalmology, British Journal of Ophthalmology, Journal of Glaucoma, Acta Ophthalmologica, Graefes Archives of Clinical and Experimental Ophthalmology, Eye, Japanese Journal of Ophthalmology.

*Special Honors:* Achievement Award by American Academy of Ophthalmology, Best publication awards at the International Glaucoma Symposium (IGS), Yeonam Glaucoma Publication Award- the Korean Glaucoma Society, Awarded International scientist of the Year (IBC, England).



**Yasuaki Kuwayama, MD, PhD**

*Affiliation:* Director, Fukushima Eye Clinic, Japan; Clinical Professor of Ophthalmology, Osaka University Medical School, Japan; Visiting Clinical Professor of Ophthalmology, Ehime University Medical School, Japan; Visiting Clinical Professor of Ophthalmology, Hokkaido University Medical School, Japan.

*Areas of Interest:* Circadian regulation of IOP, surgical outcomes.

*Leadership Positions:* Executive Director, Japan Glaucoma Society; Councilor, Japanese Ophthalmological Society; Councilor, Japanese Society for Ocular Pharmacology; Active Member, International Glaucoma Society.

*Special Honors:* Suda Memorial Award, Japanese Glaucoma Society.



**Steven Kymes, PhD, MHA**

*Affiliation:* Research Associate Professor in the Department of Ophthalmology and Visual Sciences, with a joint appointment in the Division of Biostatistics, Senior Fellow in the Washington University Center for Health Policy, Institute Scholar in the Washington University Institute of Public Health.

*Areas of Interest:* Methods of economic evaluation including micro-simulation and assessment of preference based measures of quality of life. Development of economic models for the progression of glaucoma, assessment of the impact of glaucoma progression on cost of care and quality of life; the development of economic models for evaluation of treatment of retina disease; evaluation of the cost-effectiveness of methods of stem cell mobilization in people with non-Hodgkins lymphoma; and economic evaluation of methods to avoid diagnostic error.

*Leadership Positions:* Author or co-author of over 30 peer reviewed publications and has served as principal investigator of more than ten NIH and industry funded grants. Served on several NIH and CDC review panels and as a member of Data and Safety Monitoring Committees for three National Eye Institute funded studies.



**Antoine Labbé, MD, PhD**

*Affiliation:* Assistant Professor in the Department of Ophthalmology, Quinze-Vingts National Ophthalmology Hospital in Paris.

*Areas of Interest:* Ocular surface immunology and glaucoma treatments. Toxic side effects induced by topical treatments and their preservatives in glaucoma.

*Leadership Positions:* Published several papers in international peer-reviewed journal on ocular surface



---

**Yves Lachkar, MD**

*Affiliation:* Head of department of Ophthalmology at the Saint-Joseph Foundation Hospital and the director of the Institute of Glaucoma in Paris; Professor at the College of Medicine of Paris Hospitals.

*Areas of Interest:* Non penetrating surgery and wound healing.

*Leadership Positions:* member of the Executive committee and the Scientific committee of the European Glaucoma Society (EGS), co author of the EGS Guidelines 1998, 2003 and 2007.

**Jacques Laloum MD**

*Affiliation:* Senior Glaucomatologist at the Rothschild Ophthalmology Foundation, Board member of the French Glaucoma Society.

**Shun-chiu, Dennis Lam, MD, FRCOphth**

*Affiliation:* Chairman of the Department of Ophthalmology & Visual Sciences, Chinese University of Hong Kong.

*Areas of Interest:* Some of his breakthrough researches include using anterior chamber paracentesis and argon laser iridoplasty to treat acute attack of angle-closure, early phaco to prevent CACG, and discovering 4-Phenylbutyrate as a potential new glaucoma drug to prevent and treat steroid-induced glaucoma.

*Leadership Positions:* Member of the board of governors of the World Glaucoma Association and one of the four programs directors of the World Glaucoma Congresses (2009 in Boston and 2011 in Paris), Secretary-General of Asia-Pacific Academy of Ophthalmology, International Adviser to the American Academy of Ophthalmology (AAO), Founding President of the Asia-Pacific Society of Eye Genetics and President of College of Ophthalmologists of Hong Kong (2003-5). He has also organized the World Ophthalmology Congress in Hong Kong in 2008 with over 13,000 delegates. He published more than 700 SCI journal articles published.

*Special Honors:* A number of awards including Highest Academic Achievements Award in Asia-Pacific, Best Clinical



Teacher in Ophthalmology in Asia-Pacific, Hundred Global Leader for Tomorrow, Ten Outstanding Young Persons of the World, and Hong Kong Humanity Award.

**Mark A. Latina, MD**

*Affiliation:* Surgeon in Ophthalmology at the Massachusetts Eye and Ear Infirmary and Associate Clinical Professor of Ophthalmology at Tufts New England Medical Center.

*Areas of Interest:* Laser applications in ophthalmology.

*Leadership Positions:* Author of numerous publications and holders of several patents. Most notably, he is the inventor of Selective Laser Trabeculoplasty, a new treatment for glaucoma.

*Special Honors:* Recipient of a Heed Foundation Award; the American Academy of Ophthalmology Honor Award; National Eye Institute Clinician-Scientist Award.

**Hans Lemij, MD, PhD**

*Affiliation:* Rotterdam Eye Hospital, Rotterdam, The Netherlands.

*Areas of Interest:* Glaucoma imaging, perimetry, glaucoma surgery and glaucoma genetics. In addition, he is committed to glaucoma education.

**S. Fabian Lerner, MD**

*Affiliation:* Consultant at the glaucoma service of the Hospital Oftalmológico Nuestra Señora de la Medalla Milagrosa, Buenos Aires; Director of the glaucoma section at the Postgraduate Department, University of Favaloro School of Medicine, in Buenos Aires, Argentina.

*Areas of Interest:* All aspects of glaucoma.

*Leadership Positions:* President-Elect of the Pan-American Glaucoma Society; Member of the Latin-American Glaucoma Society; President of the Argentina Glaucoma Association (2005-2007); Vice-President of the Argentine Society of Ophthalmology; Founder and president of the Fundación para el Estudio del Glaucoma, a non-profit organization devoted to glaucoma. He co-authored or was a contributor in 13 books.



He has authored or co-authored papers and abstracts, published in local or international peer-review journals. Reviewer for the journals *Ophthalmology*, *British Journal of Ophthalmology*, *Journal of Glaucoma* and *American Journal of Ophthalmology*; Medical editor of *Ocular Surgery News Latin American Edition*; Member of the Board of Editors in 'International Glaucoma Review', the journal of the World Glaucoma Association.

**Special Honors:** Several awards including the 'Achievement Award' by the American Academy of Ophthalmology; 2008 Allergan Latin American Glaucoma Research Award. He delivered the Inaugural Honorary Conference of the Argentine Society of Ophthalmology Meeting (2010).

**Edgar U. Leuenberger, MD**

**Affiliation:** Director of the Oscar M. Lopez Glaucoma Fellowship Program of the Asian Eye Institute, Philippines, Assistant Professor in Ophthalmology and is Chief of the Glaucoma Service at the University of the East Ramon Magsaysay Memorial Medical Center (UERMMMC).

**Areas of Interest:** Improvement and development of glaucoma diagnostic and surgical procedures.

**Leadership Positions:** Board Examiner of the Philippine Board of Ophthalmology; Reviewer of the Asian Journal of Ophthalmology. Published journal articles, book chapters, teaching materials, and lectures nationally and internationally.



**Christopher Leung, MD, MB, ChB**

**Affiliation:** Associate Professor of the Department of Ophthalmology & Visual Sciences, the Chinese University of Hong Kong (CUHK).

**Areas of Interest:** Ocular and molecular imaging and glaucoma management.

**Leadership Positions:** Associate Advisory Board of the World Glaucoma Association (WGA) and co-chair in the Clinician Scientists Committee.

**Special Honors:** Hong Kong Medical Association Prize; National Best Paper on Prevention of Blindness in the World Ophthalmology Congress (2006); Schanzlin Research Award; World Glaucoma Association Science Award – the Promise; AAO Achievement Award; ARVO/Alcon Clinician-Scientist Research Award; APAO Nakajima Award.



**Dexter Leung, MD**

**Affiliation:** Clinical Assistant Professor, Dept. of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Hong Kong.

**Research interest:** Normal-Tension Glaucoma and Angle-Closure Glaucoma.

**Leadership positions:** Member of the Scientific Program Committee, World Ophthalmology Congress (2008); APAO Congress 2010 at Beijing; 5th International Congress on Glaucoma Surgery at New Delhi and APAO Congress 2011 at Sydney; APAO Congress 2012 at Busan; World Ophthalmology Congress (2012) at Abu Dhabi; Charter Member and Executive Director (2008-) of von Graefe Society; Associate Editor, *Journal of Current Glaucoma Practice* (2008-); Editorial Board Member, *Society for Clinical Ophthalmology (UK)* (2009 -); Chairman of organizing committee for World Glaucoma Day Hong Kong Chapter (2008-2010); Council of Hong Kong Ophthalmological Society (2004-); Secretary of Hong Kong Ophthalmological Society (2009 -); Treasurer of Federation of Societies for Prevention of Blindness HK (2005-2008); and Member of Board of Trustees of Shaw College of the Chinese University of Hong Kong 2009-2012).

**Special honors:** Ho Hung-chiu Medical Foundation Fellowship (2006); SEAGIG Travel Grant Award (2006); Action for Vision Foundation Exemplary Eye Specialist Award (2007); the Best Paper Award in Glaucoma, American Academy of Ophthalmology annual meeting (2007); International Ophthalmologist Education Award, American Academy of Ophthalmology (2008); Outstanding Service Provider Award, Hong Kong Eye Hospital (2008); Asia-Pacific Academy of Ophthalmology (APAO) Travel Grant Award (2009, 2010); Action for Vision Foundation Best Researcher Award (2009); Outstanding Award (Oral Paper), Kowloon Central Cluster Convention, Hospital Authority of Hong Kong (2010); APAO Achievement Award (2010); the Ten Outstanding Persons of the Year 2010 Hong Kong Award.



**Special honors:** Ho Hung-chiu Medical Foundation Fellowship (2006); SEAGIG Travel Grant Award (2006); Action for Vision Foundation Exemplary Eye Specialist Award (2007); the Best Paper Award in Glaucoma, American Academy of Ophthalmology annual meeting (2007); International Ophthalmologist Education Award, American Academy of Ophthalmology (2008); Outstanding Service Provider Award, Hong Kong Eye Hospital (2008); Asia-Pacific Academy of Ophthalmology (APAO) Travel Grant Award (2009, 2010); Action for Vision Foundation Best Researcher Award (2009); Outstanding Award (Oral Paper), Kowloon Central Cluster Convention, Hospital Authority of Hong Kong (2010); APAO Achievement Award (2010); the Ten Outstanding Persons of the Year 2010 Hong Kong Award.

**Hani Levkovitch-Verbin, MD, MPA**

**Affiliation:** Head, Ophthalmology Field, Maccabi Health Services, Israel; Director, the Sam Rothberg Molecular Biology lab, Sheba Medical Center, Israel.

**Areas of Interest:** Pathogenesis of retinal ganglion cells death in glaucoma and optic nerve injury including regulation of cell death and survival, signal transduction pathways and axonal flow in the injured nerve. Developing novel approaches for neuroprotection and optic nerve regeneration





including stem cells and gene therapy. Genetics of glaucoma. Epidemiology of glaucoma.


*Special Honors:* Sheba Research day, Best Lecture Award, Tel-Hashomer, Israel (2006); MSD research award, Israel (2006); Stein Award for research in Ophthalmology, Tel-Aviv University (2011).

#### **Jeffrey M. Liebmann, MD**

*Affiliation:* Clinical Professor of Ophthalmology, New York University School of Medicine; Director, Glaucoma Services, Manhattan Eye, Ear and Throat Hospital and New York University Medical Center, New York, NY; Adjunct Professor of Clinical Ophthalmology at New York Medical College, Valhalla, New York.

*Areas of Interest:* investigations into the causes of glaucoma, glaucoma progression, glaucoma surgery, ocular imaging, and neuroprotection.

*Leadership Positions:* President of the American Glaucoma Society, program chair for the World Glaucoma Congress; Secretary-Treasurer of the New York Glaucoma Society; Member of the Board of Governors of the World Glaucoma Association; Member of the Board of Directors of The Glaucoma Foundation; Past-President of the New York Society for Clinical Ophthalmology and co-founder of the New York Glaucoma Research Institute; the Principal Investigator of two National Eye Institute Clinical Trials sponsored by the National Institutes of Health. Author and/or co-author of over 425 medical and scientific papers, book chapters, and abstracts. In addition, he has lectured widely in the United States and abroad on glaucoma diagnosis and management.



#### **Shan C. Lin, MD**

*Affiliation:* Professor of Clinical Ophthalmology, Department of Ophthalmology, University of California, San Francisco School of Medicine; Director of Glaucoma Service, San Francisco General Hospital, San Francisco, CA, USA.

*Areas of Interest:* Endoscopic cyclophotocoagulation; Angle closure glaucoma; Trabecular meshwork.

*Special Honors:* The Glaucoma Foundation Clinician-Scientist Award (2005); Kimura Resident Teaching Excellence Award, UCSF (2005); American Academy of Ophthalmology Achievement Award (2005).



#### **John H.K. Liu, PhD**

*Affiliation:* Professor, Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego. Faculty member, Graduate Program in Neurosciences, Sam and Rose Stein Institute for Research on Aging, Institute of Engineering in Medicine, and Clinical and Translational Research Institute, UC San Diego.

*Areas of Interest:* Regulation of intraocular pressure and ocular blood flow, aqueous humor dynamics, ocular pharmacology, circadian rhythm, and continuous monitoring of intraocular pressure.

*Leadership Positions:* Vice President of the Association for Ocular Pharmacology and Therapeutics (2004-2007).

*Special Honors:* ARVO Fellow.



#### **Nils Loewen**

*Affiliation:* Assistant Professor of Ophthalmology and Visual Science, the Director of the Glaucoma Section, Yale University School of Medicine.

*Areas of Interest:* Providing new, minimally invasive glaucoma procedures that are bleb-free: trabectome, suprachoroidal shunt implantation and canaloplasty in addition to small incision trabeculectomy. He performs complex cataract procedures and anterior segment reconstruction. Special interest in low pressure glaucoma. Offers patients diagnosed with this challenging disease opportunities to actively contribute to research by participating in observational studies.

*Leadership Positions:* Authored more than 70 abstracts, articles, book chapters and patents and serves as a reviewer for several scientific journals in ophthalmology and gene therapy.



#### **David A Mackey, MBBS, MD, FRANZCO, FRACS**

*Affiliation:* Professor of Ophthalmology, Centre for Ophthalmology and Visual Science, University of Western Australia; Managing Director Lions Eye Institute, Perth Western Australia.

*Leadership Positions:* Professor David Mackey has spent 20 years studying the genetics of the optic nerve. In 1993 he initiated the Glaucoma Inheritance Study in Tasmania, thereby creating one of





the largest glaucoma biobanks in the world, with over 5,000 DNA samples and clinical material from familial and sporadic cases of glaucoma. This study has resulted in over 50 papers, including co-authorship on the discovery of the myocilin gene and its association with glaucoma. His group has also examined the impact of providing DNA testing and results to glaucoma families and is currently working on models of cascade family screening for glaucoma. In 2000 he started the Twins Eye Study in Tasmania and Brisbane to investigate the genetic and environmental factors contributing to the ocular biometry related to glaucoma and myopia. He also leads the Norfolk Island Eye Study, examining 800 descendant of the Bounty Mutineers, and in Western Australia runs the Raine Eye Health Study of 2,000 20-year olds from a birth cohort. *Special Honors:* Asia-Pacific Academy of Ophthalmology Distinguished Service Award (2011); Alcon Research Institute Award (2010); Pfizer Australia Senior Research Fellow (2005 – 2009).

**Anita Manassakorn, MD**

*Affiliation:* Assistant Professor, Glaucoma Unit, Department of Ophthalmology, Chulalongkorn University, Bangkok, Thailand.

*Area of Interests:* Ocular imaging, Glaucoma diagnosis, Neuroprotection, Modulation of wound healing.



**Anil K. Mandal, MD**

*Affiliation:* Head of Jasti V Ramanamma Children's Eye Care Centre at the L V Prasad Eye Institute, Hyderabad, India.

*Areas of Interest:* Clinical and Genetic Aspects of Adult and Pediatric Glaucoma. Surgical Management of Cataract and Glaucoma.

*Leadership Positions:* He has published over 100 articles in National and International journals and published a book on pediatric glaucoma. In 2009 he has been elected as fellow of the National Academy of Medical Sciences for his contribution to science and ophthalmology.

*Special Honors:* Recipient of the Achievement Award of AAO in 2000; 'Shanti Swarup Bhatnagar Award for Medical Science' (2003), the highest National Award for Science and Technology (He is the first ophthalmologist to receive this award); Apollo Award of Medical Excellence (2004-05); He has been received the Senior Achievement Award in the year 2008 by the American Academy of Ophthalmology for his contribution to American Academy and Ophthalmology and also winner of best poster award in the scientific session in the same meeting.



**Baskaran Mani, DO, DNB**

*Affiliation:* Senior Clinical Research fellow in Singapore Eye Research Institute pursuing his PhD in Ophthalmology with National University of Singapore in epidemiology of glaucoma. Adjunct Assistant Professor in Duke-NUS Graduate Medical School, Singapore.

*Areas of Interest:* epidemiology of angle closure glaucoma, IOP and correction factors and imaging devices in glaucoma.

*Leadership Positions:* Participated in the consensus forums of World Glaucoma Association. Authored over 60 publications in international peer-reviewed journals and eight chapters in textbooks. Reviewer for more than 10 international journals. Member of the Editorial Board for ISRN Ophthalmology. He has three co-patents in software programs for diagnosis and detection of angle closure and optic disc analysis in glaucoma.



**Steven L. Mansberger, MD, MPH**

*Affiliation:* Associate Scientist and Director of Glaucoma Services and Ophthalmic Clinical Trials for the Devers Eye Institute in Portland, Oregon. Clinical Associate Professor of Ophthalmology and Public Health and Preventive Medicine at Oregon Health Science University (OHSU).

*Leadership Positions:* Dr. Mansberger has research grant support from the National Eye Institute and the Center for Disease Control and Prevention. He has won numerous awards including 'Best Doctors in America', Heed Fellowship, The Robert Watske Ophthalmology Instructor of the Year, American Glaucoma Society Clinician-Scientist award, among others. He participates on the Editorial Boards of Journal of Glaucoma and American Journal of Ophthalmology. He is an invited reviewer for Archives of Ophthalmology, British Journal of Ophthalmology, Ophthalmology, Investigative Ophthalmology and Visual Science, Survey of Ophthalmology, as well as four other journals. He has authored over 100 journal articles, book chapters, and abstracts.



**Kaweh Mansouri, MD, MPH**

*Affiliation:* Senior Clinical and Research Fellow, Hamilton Glaucoma Center, University of California, San Diego.

*Areas of Interest:* continuous IOP-monitoring; innovations in glaucoma surgical methods; characterization of the relationship between structure and function; and epidemiology of glaucoma.



---

**Keith R Martin, MD FRCOphth**

*Affiliation:* Professor of Ophthalmology, University of Cambridge; Clinical Director for Ophthalmology and Head of the Glaucoma Service at the Cambridge University Hospitals NHS Foundation Trust.

*Areas of Interest:* Medical and surgical management of complex glaucoma in adults and children.

*Leadership Positions:* Basic Science Section Co-Editor of the Journal of Glaucoma; Treasurer of the World Glaucoma Association. He established the Glaucoma Research Laboratory at the University of Cambridge in 2005, aiming to develop new treatments for eye disease using stem cells, gene therapy and other techniques.

*Special Honors:* In 2010, Professor Martin was presented with the ARVO Foundation for Eye Research/Carl Camras Translational Research Award. This International Award is given to a researcher from any country under the age of 50 years whose research is judged to have the potential to lead to major breakthroughs in the treatment of eye disease.

**Chota Matsumoto, MD, PhD**

*Affiliation:* Professor, Department of Ophthalmology, Kinki University Faculty of Medicine.

*Leadership Positions:* Vice-President, Imaging and Perimetry Society (IPS); President, Japanese Perimetric Society (JPS) President.

**Eugenio Maul MD**

*Affiliation:* Professor and Chairman, Department of Ophthalmology, Universidad Catolica Medical School, Santiago, Chile.

*Areas of Interest:* Developmental Glaucomas, Secondary Glaucomas, Optic disc and Visual Field Correlations.

*Leadership Positions:* Founder and Honorary President Chilean Society of Glaucoma, Past-President Chilean Society of Ophthalmology, Past-President Pan American Glaucoma Society, Past-Member Advisory Group for the Prevention of Blindness WHO. Past Technical Advisor SightFirst Program in 17 Countries of Latin America. Member



Glaucoma COMPASS panel American Academy of Ophthalmology.

*Special Honors:* Visiting Professor Dept. Ophthalmology and Visual Sciences, Yale University. American Journal of Ophthalmology Lecture, XX Pan American Congress of Ophthalmology 1995. Harry Gradle Lecture, XXV Pan American Congress of Ophthalmology 2005. Achievement Award American Academy of Ophthalmology 2008.

**James McAllister FRCS  
FRCoph FAAO**

*Affiliation:* Consultant Ophthalmic Surgeon, Prince Charles Eye Unit, King Edward VII Hospital, Windsor; Practising at Princess Margaret Hospital Windsor, UK

*Areas of Interest:* Particular interest in laser techniques.

**Shlomo Melamed MD, PhD**

*Affiliation:* Full Professor of Ophthalmology, Tel Aviv University Medical School, Tel Aviv; Director, The Sam Rothberg Glaucoma Center Sheba Medical Center, Tel Hashomer; Incumbent The Zukersussman Chair for Glaucoma Research, Tel Aviv University Medical School, Israel

*Areas of Interest:* various topics in Glaucoma

*Leadership Positions:* Founder and Co-President, the International Glaucoma Symposia (IGS), from 1991 till 2008. Program Committee member of the World Glaucoma Congress (WGC) Boston, 2009 and Paris, 2011. Chair, the World Glaucoma Projects Committee under WGA, planning education and on-site surgical support in developing world countries. Organizer and Director of Out-Reach Surgical Programs focusing on Glaucoma and Anterior Segment Surgery in Developing World countries. Organized and participated in expeditions in places like Papua New Guinea (2001), Micronesia (2003, 2005), Bolivia (2006), India (2007), Togo and Benin in West Africa (from 2000-2008), Burkina Faso (2008), India (2009) and Nigeria (2010).

**André Mermoud**

*Affiliation:* Glaucoma Center, Montchoisi Clinic, Lausanne

*Areas of Interest:* Development of new glaucoma surgery. Dr. Mermoud has been involved in the development of deep sclerectomy with collagen implant, the T-flux, the Healaflo as well as the EXPRESS-tube. He shows also great interest in the development of new devices to monitor the IOP; he has been working on the Tonopen, the Icare and the con-

tinuous measurements with the Triggerfish system. Authored 120 publications in peer reviewed papers, two books and 21 chapters in books.



**George Michelson, MD**

*Affiliation:* Associate Professor of Ophthalmology, Head of the Out-patient Dept., Dept. of Ophthalmology; Founder, Director of Interdisciplinary Center of Ophthalmic Preventive Medicine and Imaging, University Erlangen-Nürnberg, Germany

*Areas of Interest:* Automated Glaucoma screening; Ocular circulation in glaucoma; Telemedical assessment of retinal images; Tele-education in Ophthalmology.

*Leadership Positions:* President of International Society of ocular Circulation and Oxymetry (ISOCO) (2006-2009).

*Special Honors:* Price 'Medicine-Technique-Health' of the town Erlangen (2006); Innovation-Price of Stiftung Familie Klee, Frankfurt (2007); eHealth-Price University Bayreuth, Germany (2008).



**Richard Mills, MD, MPH**

*Affiliation:* Private practice, Seattle, WA, USA.

*Areas of Interest:* Visual fields, Optic disk imaging, Angle surgery, Compliance.

*Leadership Positions:* He has served the American Academy of Ophthalmology in numerous positions, including chair of the Public Information Committee, Secretary for Public and Professional Information, President (1995), Delegate to the AMA, Bylaws Committee Chair, and currently as Chief Medical Editor, EyeNet magazine, and Director of EyeCare America. He has chaired an Academy skills transfer course on Glaucoma Drainage Devices for 20 years. He was a Director of the American Board of Ophthalmology, delegate to the ABMS, and Vice-Chair of the Residency Review Committee. He has served the AGS as Director at Large, Quality of Care Subcommittee member, and Secretary (2006-9). He has been an editorial board member of the Journal of Glaucoma since its inception.



He has served as Secretary and Treasurer of the International Perimetric Society, and is an invited member of the international Glaucoma Research Society. He is a current member of the governing Council of the American Ophthalmological Society. He has authored over 120 peer reviewed articles, 27 book chapters, 90 editorials, 5 edited books, and has been a center PI in three NEI funded collaborative clinical trials.


**Anthony Molteno**

*Affiliation:* Professor and Head of Ophthalmology, University of Otago Dunedin School of Medicine, and Consultant Ophthalmologist, Dunedin Hospital, Dunedin, New Zealand.

*Areas of Interest:* Glaucoma drainage surgery and the development of drainage implants.

*Leadership Positions:* P.I. of the Otago Glaucoma Surgery Outcome Study; past President of the Ophthalmological Society of New Zealand (OSNZ); former Trustee of the Glaucoma Trust of the OSNZ.

*Special Honors:* Invited to become an Emeritus Member of the Glaucoma Research Society (2011); Distinguished Service Award by the Royal Australian and New Zealand College of Ophthalmologists (2009), made an Officer of the New Zealand Order of Merit (2006); received the Goldmann Medal from the International Glaucoma Association (1994).



**Sameh Mosaed, MD**

*Affiliation:* Associate Professor, Cataract and Glaucoma Surgery, Ophthalmology, School of Medicine, University of California, Irvine; Director of Glaucoma Fellowship Training Program, Department of Ophthalmology, University of California, Irvine, CA; Director of Glaucoma Services at the Long Beach Veteran's Hospital.

*Areas of Interest:* Glaucoma; treatment and management of complicated glaucoma.

*Leadership Positions:* Certified member of the American Board of Ophthalmology; Examiner for the American Academy of Ophthalmology's national board examination; Member of the editorial board for the International Glaucoma Review.

*Special Honors:* Phi Sigma Honor Society (1993-); Teacher of the Year Award, Department of Ophthalmology, University of California, Irvine (2006); Rising Stars – Ophthalmology, Lecturer. ISOV Meeting, Las Vegas (2006); Elected to 'America's Top Ophthalmologists', by the Consumers Research Council of America (2007); Best Doctor in America Award (2009-2010); Associate Examiner for the American Board of Ophthalmology (2008).





---

**Toru Nakazawa, MD, PhD**

*Affiliation:* Associated Professor at Department of Ophthalmology and Visual Science, Tohoku University Graduate School of Medicine, Miyagi, Japan.

*Research Interests:* Basic research for pathogenesis of glaucoma; Neuroprotective treatment of glaucoma; Translational research.

*Leadership Positions:* Trustee of Japan Ophthalmology Society and Glaucoma Society.

*Special Honors:* Suda Glaucoma Memorial Award (2007); Uehara Memorial Award (2008); Rohto Award (2008); Imai Glaucoma Memorial Award (2008); Research Award from Japan ophthalmology society (2009); Glaucoma Young Investigator Awards (2009); Takeda Research Memorial Award (2009).

**Marco Nardi, MD**

*Affiliation:* Full Professor of Diseases of the Visual Apparatus in the University of Pisa; Director of the Postgraduate School of Ophthalmology in Pisa; Coordinator of the Corneal Transplant Program for the Tuscany Region; Director of the postgraduate biennial Master on Glaucoma of the University of Pisa.

*Areas of Interest:* Glaucoma, cataract and cornea.

*Leadership Positions:* Vice President of the Italian Society of Glaucoma (2007-); Vice President of University Ophthalmological Society (2008-); Vice President of the Italian Ophthalmological Society (2010-); Italian Delegate for the UEMS Ophthalmology Section. Authored more than 260 scientific papers. He gave many lectures in international and national Congress and organized Congresses and Continuing Education Courses on bulbar surgery, including wet-lab activities.

**Winifred Nolan, FRCOphth MD**

*Affiliation:* Consultant Ophthalmologist on the Glaucoma service at Moorfields Eye Hospital London.

*Areas of Interest:* Angle closure glaucoma, epidemiology of glaucoma and anterior segment imaging.

She has published peer review papers, editorials and book chapters. She completed an MD thesis at the Institute of Ophthalmology, London, composed of research



into early detection and treatment of angle closure in Mongolia and has been an investigator on glaucoma studies in Asia and Africa.

**Jean-Philippe Nordmann, MD, PhD**

*Affiliation:* Professor of Ophthalmology, University of Paris V; Chairman of the Glaucoma Department, Hôpital des Quinze-Vingts, Paris.

*Areas of Interest:* Pharmacology, non penetrating surgery and visual function.

*Leadership Positions:* General Secretary of the French Glaucoma Society and past President. He is the author or co-author of around 80 publications, in international and French journals.

**Paul Palmberg, MD, PhD**

*Affiliation:* Professor of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL

*Area of Interest:* Glaucoma clinical trials, glaucoma surgery, slit lamp procedures in glaucoma management

*Leadership Positions:* Past President of the Pan-American Glaucoma Society, and Past President of the Medical Staff of the Anne Bates Leach Eye Hospital, Past President of the Miami Ophthalmology Society.

*Honors:* AIGS Glaucoma Award 2000 for the Advanced Glaucoma Intervention Study Banting and Best Award of the American Diabetes Association for the Diabetes Control and Complications Trial Best Doctors in America Shaffer Lecturer, American Academy of Ophthalmology.

**Professor Calvin Chi Pui Pang, BSc (Lond), DPhil (OXON)**

*Affiliation:* S. H. Ho Professor of Visual Sciences, Professor of Ophthalmology and Visual Sciences, Head, Graduate Division of Ophthalmology and Visual Sciences, Medical Panel, Faculty of Medicine, Professor (by courtesy), School of Biomedical Sciences, The Chinese University of Hong Kong; Deputy Director, Shantou University / Chinese University of Hong Kong Joint Shantou International Eye Center; Eastern Scholar and Chair Professor, Shanghai Municipal Education Committee; Laboratory Director, Shenyang Eye Research Institute; Director, Visual Sci-



ence Research Laboratories, School of Ophthalmology, Capital University of Medical Sciences, Tongren Hospital, Beijing; Academic specialist, Ningxia Hui Autonomous Region Peoples' Government.

**Areas of Research:** Genomic studies and gene mapping on glaucoma, age-related macular degeneration, high myopia, and congenital cataracts; Molecular genetics, mechanisms, and epi-genetics of retinoblastoma, Bietti crystalline dystrophy, Graves' ophthalmopathy, retinitis pigmentosa, uveitis, and cornea dystrophies; Biology of ocular stem cells; Biological effects of herbal chemicals.

**Leadership Positions:** Supervisor of 13 post-doctoral researchers and more than 50 PhD/Masters students. External examiner for PhD candidates of the University of Hong Kong and National University of Singapore. Honorary or visiting professor of 12 universities or research institutions. Reviewer for more than 20 international journals, including IOVS and Ophthalmology. Reviewer for 10 national and international research grant bodies, including Wellcome Trust UK, National Science Foundation China, and National Medical Research Council, Singapore. 268 papers in international peer reviewed SCI journals and 11 book chapters.

### **Rajul S. Parikh**

**Affiliation:** Director, Shreeji Eye Clinic and Palak's Glaucoma Care Centre, Andheri, Mumbai; Consultant and Head, Department of Glaucoma and Department of Clinical Research, Bombay City Eye Institute and Research Centre.

**Areas of Interest:** Clinical epidemiology, diagnosis and management of glaucoma and its antecedent problems. Optic disc examination using various newer imaging modalities. Management of angle closure of glaucoma.

**Leadership Positions:** Associate Advisory Board of World Glaucoma Association (WGA); Member of WGA Committee on Glaucoma Society Organization. Elected section editor for glaucoma for Indian Journal of Ophthalmology.



### **Ki Ho Park, MD, PhD**

**Affiliation:** Associate Dean for Planning, Professor of Ophthalmology, Seoul National University College of Medicine; Director of International Affairs of Korean Ophthalmological Society (KOS)

**Areas of Interest:** Normal Tension Glaucoma, Angle Closure Glaucoma, Neuroprotection, Early Detection of Structural Damage, Disc Hemorrhage and Peripapillary Atrophy.

**Leadership Positions:** Steering Committee Member of WGA; Consensus and Guidelines



Committee Member of WGA; WGC-2011 Scientific Program and Abstract Review Committee; General Secretary of 2008 SEAGIG Organizing Committee; Board Member of SEAGIG; Editorial Board of Asian Journal of Ophthalmology; Secretary General of Asian Angle-Closure Glaucoma Club (AACGC); Associate Editor of AACGC Textbook; Director of International Affairs of Korean Ophthalmological Society; Editorial Board of Korean Journal of Ophthalmology; Past Director of Scientific Program of Korean Glaucoma Society

**Special Honors:** Invited Lectures and Speakers of Courses in Asia Pacific Academy of Ophthalmology (APAO), WGC, WOC, SEAGIG, AACGC, and AOGS. Topcon Ophthalmology Award, Jules Stein Eye Institute Laboratory Research Award, Yonahm Academy Award from Korean Glaucoma Society, Taejoon Service Award from KOS, Distinguished Service Award from APAO.

### **Richard Kenneth Parrish II, MD**

**Affiliation:** Professor, Bascom Palmer Eye Institute, Department of Ophthalmology; Associate Dean for Graduate Medical Education, University of Miami Miller School of Medicine, Miami, FL

**Areas of Interest:** Glaucoma filtering surgery.

**Leadership Positions:** Editor, Transactions of the American Ophthalmological Society; Associate editor of the American Journal of Ophthalmology; Editor of the Ophthalmology Monograph Series. He published or presented more than 200 scientific papers and abstracts.



### **Louis R. Pasquale, MD**

**Affiliation:** Associate Professor of Ophthalmology at Harvard Medical School, Cambridge, MA; Director, Glaucoma Service at Mass Eye and Ear Infirmary; Director, Glaucoma Fellowship Program, the MEEI Teleretinal Program (2008 to present); Co-director, Harvard's Glaucoma Center of Excellence; Associate Epidemiologist, Channing Laboratory; Assistant Scientist, Schepens Eye Research Institute, Boston, MA.

**Areas of Interest:** Discovery of primary prevention strategies in the open-angle glaucomas.

**Leadership Positions:** NIH Principal Investigator with continuous support since 2006. In 2011, he was appointed as Distinguished Scholar in Ophthalmology.

**Special Honors:** Heed ophthalmic fellow; ARVO silver fellow; Recipient of the AAO's Achievement Award and Secretariat Award; Recipient of Research to Prevent Blindness' Physician Scientist Award. He has published well over 65 peer-



---

reviewed articles in scientific journals, 41 reviews/book chapters/editorials, and has given numerous talks/courses around the world.

**Rodolfo A. Pérez Grossmann, MD**

*Affiliation:* Chairman of the Instituto de Glaucoma y Catarata, Lima.

*Areas of Interest:* Molecular genetics of open angle glaucoma, clinical and surgery of glaucoma.

*Leadership Positions:* Past President of the Peruvian Glaucoma Society. Editor of the Latin American Glaucoma Society. Member of the Panamerican Glaucoma Society and the American Glaucoma Society.

*Special Honors:* Award for the research in Peruvian Ophthalmology.



**Norbert Pfeiffer, MD, PhD**

*Affiliation:* Chairman and Director of the Department of Ophthalmology, The University Hospital Mainz, Mainz.

*Areas of Interest:* Diagnosis and treatment of glaucoma.

*Leadership Positions:* CEO of Mainz University Hospital (1999-2002 and 2008-2010). Member of the Executive Committee of the European Glaucoma Society.

*Special Honors:* He was awarded several scientific prizes including the prestigious Galenus von Pergamon Prize for the introduction of innovative medical therapies.



**Jody Piltz-Seymour, MD**

*Affiliation:* Director of the Glaucoma Care Center, University of Pennsylvania, Philadelphia, PA.

*Areas of Interest:* Clinical research in glaucoma.

*Leadership Positions:* She has served on numerous academic committees for the American Glaucoma Society including the executive committee, program committee, membership committee, research committee and ethics committee. She has also served on the program committee for the glaucoma section of the American Academy Annual Meeting. Authored more than 100 articles and book chapters on glaucoma.

*Special Honors:* Recipient of a Senior Achievement Award from the American Academy of Ophthalmology for her years



of dedicated service. Philadelphia Magazine has selected Dr. Piltz-Seymour as a 'Top Doc' and 'Top Doc for Seniors', and she has been chosen for 'Best Doctors in America'.

**Dr. Bruce E. Prum**

*Affiliation:* Associate Professor with Tenure, Department of Ophthalmology, University of Virginia.

*Area of Interest:* Management of glaucoma after corneal transplant; Surgical management of glaucoma comparing argon laser trabeculoplasty to trabeculectomy (AGIS); Surgical management of glaucoma comparing trabeculectomy with mitomycin C to glaucoma implant (TVT and PTVT studies); Combined cataract and glaucoma surgery; Normal tension glaucoma; Cataract surgery in eyes with narrow angles and angle-closure glaucoma; Pars plana glaucoma implants for complicated glaucomas; Management of chronic choroidal detachments after trabeculectomy; Drug studies of latanoprost, latanoprost-timolol, travoprost, brimonidine (numerous).

*Leadership Positions:* American Academy of Ophthalmology Preferred Practice Pattern Committee for Glaucoma, Member (2003-2008), Chairman (2008-2013); American Board of Ophthalmology, Associate Examiner (2001-2005), Special Associate Examiner (2005-Present); American Academy of Ophthalmology Compass Panel for Glaucoma, 2007-2010, Vice Chairman; Primary Tube vs. Trabeculectomy Study, 2008-2013, Primary Investigator, Steering Committee, Tube vs. Trabeculectomy Study, 2000-Present; Primary Investigator, Steering Committee, Advanced Glaucoma Intervention Study, 1992-2005, Primary Investigator, Steering Committee.

*Special Honors:* American Academy of Ophthalmology Achievement Award (2008); University of Virginia Outstanding Attending Teaching Award (2004).



**Harry A. Quigley, MD**

*Affiliation:* Director Glaucoma, Director Dana Center for Preventive Ophthalmology, Wilmer Institute, Johns Hopkins University, Baltimore, MD.

*Areas of Interest:* His research has improved the early diagnosis of glaucoma and has developed instruments and techniques to identify glaucoma damage better. His investigations demonstrated the degree of glaucoma damage that precedes present detection methods. He was the first to report on long-term success with laser iridotomy. His suturing technique for trabeculectomy has been widely adopted.

*Leadership Positions:* Founding member of the American Glaucoma Society, serving eight years as its Secretary. He





was Chief executive officer of the Association for Research in Vision and Ophthalmology (ARVO) and Editor-in-Chief of Investigative Ophthalmology and Visual Science. He has over 300 peer-reviewed publications, and his articles were judged the most cited in the ophthalmic literature over the last 30 years (Archives of Ophthalmology, 2007).

**Special Honors:** Friedenwald Award by ARVO, the Doyne Medal by the Oxford Ophthalmological Congress, and by research awards from Research to Prevent Blindness, the Alcon Research Award (twice), the European Society of Ophthalmology (Prix Jules Francois), the Chicago Ophthalmological Society (best teacher), Ophthalmological Society of Scotland (Mackenzie Medal), Australian Society of Ophthalmology (Gregg Medal), Irish Ophthalmological Society (Mooney Medal), and the New York Academy of Sciences (Lewis Rudin Prize). He is a Gold Fellow of ARVO, a recipient of the Secretariat Award of the American Academy of Ophthalmology. He has given 30 named lectures, including the 66th Edward Jackson Lecture (American Academy of Ophthalmology).


### **Nathan M. Radcliffe, MD**

**Affiliation:** Director of Glaucoma Service, Assistant Professor of Ophthalmology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY.

**Areas of Interest:** Disc hemorrhage and parapapillary atrophy in glaucoma, use of optic nerve imaging (optical coherence tomography and flicker chronoscopy) in the evaluation of glaucoma and corneal properties in glaucoma.

Dr. Radcliffe is a dedicated teacher and researcher who is involved in numerous research projects related to the care of glaucoma patients. His research efforts have earned him research grants from The American Society of Cataract and Refractive Surgery and the American Glaucoma Society including the Mentoring for Advancement of Physician-Scientists (MAPS) Award Program in 2009.

**Special Honors:** Member of multimedia and bi-laws committees of the American Glaucoma Society.



### **Pradeep Y. Ramulu MD, MHS, PhD**

**Affiliation:** Assistant Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD

**Areas of Interest:** to evaluate how routine treatments (i.e. cataract surgery) and rehabilitative treatments improve functionality in individuals with compromised vision.

**Leadership Positions:** ANSI Z80



Glaucoma Devices Standards Committee; Standing Committee Member (2008-Present).

**Special Honors:** Dennis W. Jahnigen Scholar, American Geriatrics Society (2009); Career Development Scholarship Award, American Glaucoma Society (2008); Secretariat Award, American Academy of Ophthalmology (2008); Recipient, Johns Hopkins/Wilmer K12 Career Development Award (2007); Heed Fellowship in Ophthalmology (2006); Outstanding Senior Resident, Wilmer Eye Institute/Greater Baltimore Medical Center (2006).

### **Tony Realini, MD, MPH**

**Affiliation:** Associate professor of ophthalmology and clinical research director for the Department of Ophthalmology, West Virginia University, Morgantown, WV.

He is active in eye research, has received numerous research grants (including two from the National Eye Institute), and has published widely in the ophthalmic medical journals.



### **Jean-Paul G. Renard**

**Affiliation:** Professor, Chairman of the Department of Ophthalmology, Clinique Ophtalmologique, Hôpital du Val-de-Grâce, Paris.

**Research interest:** visual function, visual field, analyze and imaging of Optic Nerve Head.

**Leadership Positions:** Consultant in Clinical Research for the Ministry of Research since 1995; Consultant for the French Ministry of Health for glaucoma drugs since 1995; Consultant for the French Ministry of Justice since 2005; Member of the board of the French Society of Ophthalmology (2002-2009); Member of the jury of the European Board of Ophthalmology, since 2007; President of the Continuing Medical Education for the French Society of Ophthalmology since 2008; Vice President of the French Society of Glaucoma since 2009; Scientific Director of the Encyclopédie Médico-Chirurgicale EMC d'Ophtalmologie (Elsevier Masson) since 2010; Member of the Organizing Committee of the World Glaucoma Congress, 2011, Paris. Author of more than 400 publications in both French and English.

**Special Honors:** Gold Medal of the Société Algérienne d'Ophtalmologie (2003); Gold Medal of the Société Marocaine d'Ophtalmologie (2004).



### **Douglas J. Rhee, MD**

**Affiliation:** Associate Chief at the Massachusetts Eye and Ear Infirmary and Associate Professor of Harvard Medical School, Cambridge, MA



**Areas of Interest:** Matricellular proteins and matrix metalloproteinases and their coordinated activities in the trabecular meshwork and ciliary body to modulate IOP.

**Leadership Positions:** Vice President of the Massachusetts Society of Eye Physicians and Surgeons. Member of curriculum and/or program committees for the American Academy of Ophthalmology, American Glaucoma Society, and American Society of Cataract and Refractive Surgery. He has served as an examiner for the American Board of Ophthalmology. Dr. Rhee has been invited to give more than 130 lectures throughout the United States and internationally.



### **Robert Ritch, MD**

**Affiliation:** Shelley and Steven Einhorn Distinguished Chair in Ophthalmology; Surgeon Director and Chief of Glaucoma Services at the New York Eye and Ear Infirmary, New York City; Professor of Ophthalmology at The New York Medical College, Valhalla, NY.

**Areas of Interest:** The understanding of the nature of glaucoma and innovation in the medical, laser, and surgical treatment of glaucoma.

**Leadership Positions:** Diplomat of the American Board of Ophthalmology; Fellow of the American Academy of Ophthalmology, the American College of Surgeons, the International College of Surgeons, the Royal College of Ophthalmology, the Association for Research in Vision and Ophthalmology, and the New York Academy of Medicine. President of the Ophthalmic Laser Surgical Society, the New York Glaucoma Society, the Section on Ophthalmology of the New York Academy of Medicine, and the New York Society for Clinical Ophthalmology. He serves on numerous medical and scientific advisory and editorial boards and is a member of the Glaucoma Research Society, the Steering Committee of the World Glaucoma Association, the Advisory Board of Helen Keller International, and the Board of Governors of the International Society for Imaging in the Eye. He has co-authored or edited nine textbooks and over 1500 medical and scientific papers, book chapters, articles and abstracts. He has presented nearly 700 lectures worldwide, including 31 named lectures. In 1985, he founded the Glaucoma Foundation. Dr. Ritch has trained over 130 clinical and research fellows, many of whom occupy academic positions worldwide. The international training program that he established at the New York Eye and Ear Infirmary has hosted 30 International Council of Ophthalmology fellows and over 80 observers from over 40 countries. He has worked and lec-



tured extensively at the international level and has organized many symposia and conferences both in the United States and abroad. He has organized meetings, established teaching programs and helped to modernize ophthalmology in Thailand, Malaysia, the Philippines, Laos, Myanmar and other countries in Asia.

**Special Honors:** Awards since 2006 include the Albion O. Bernstein, MD Award of the Medical Society of the State of New York for outstanding contributions to medicine, the American Academy of Ophthalmology Lifetime Achievement Honor Award, the Leadership in Education in Ophthalmology (LEO) Award, the Dean's Distinguished Research Award from the New York Medical College, The Glaucoma Foundation Award for Innovation and Excellence in Glaucoma, the TKC Liu Memorial Award for Leadership in Ophthalmology, the Dominick Purpura Distinguished Alumnus Annual Award from Albert Einstein College of Medicine, the ARVO Distinguished Service Award, ARVO Gold Fellowship, the HRH Prince Abdulaziz Al-Saud Prevention of Blindness Award (2010) and the Jose Rizal International Medal (2011).

### **Luca Rossetti, MD**

**Affiliation:** Director Eye Clinic University of Milan San Paolo Hospital, Associate Professor of Ophthalmology, University of Milan, Milano.

**Research interest:** Clinical research in glaucoma.

**Leadership Positions:** Responsible for the Glaucoma Unit at the San Paolo Hospital since 2000. Author of more than 100 articles for peer-reviewed journals, mainly in the field of glaucoma. Investigator in more than 20 clinical trials, mainly in the field of glaucoma. Member of the European Vision Institute.



### **José-Alain Sahel**

**Affiliation:** Director of The Vision Institute, an UPMC/Inserm/CNRS Research Centre, Paris, France; Professor of Ophthalmology at Pierre and Marie Curie University Medical School, and the Cumberlege Professor of Biomedical Sciences at the Institute of Ophthalmology, University College London. He chairs a department of Ophthalmology at the Quinze-Vingts National Ophthalmology Hospital and at the Rothschild Ophthalmology Foundation and coordinates the Ophthalmology Clinical Investigation Centre and the National Reference Centre for Retinal Dystrophies.

**Areas of Interest:** Vision research, focusing clinical and research activities on currently untreatable retinal diseases.

**Leadership Positions:** Founded in 1992 the Laboratory of



Retinal Cellular and Molecular Pathophysiology, Paris as a site for translational research on the mechanisms of retinal cell degeneration, with the aim of identifying therapeutic clues. Authored more than 200 papers in specialty and general audience peer-reviewed journals, he co-authored several patents. Since FP 5, He has coordinated large scale European Research programs on retinal functional genomics, neuroprotection, ageing, and now therapy, as well as a network of 40 European clinical trial centers on retinal diseases. Member or chair of several scientific boards (Inserm, University, Foundation Fighting Blindness, Paris City, Alcon Research Institute, etc.) he also advises several biotech and larger companies. He co-founded Fovea Pharmaceuticals in 2005, now the Ophthalmology Division of Sanofi-Aventis. **Special Honors:** Several awards for his team achievements (e.g. Foundation Fighting Blindness (FFB) Trustee Award, Grand Prix NRJ-Neurosciences-Institut de France, Alcon Research Institute Award for Excellence in Vision Research, Foundation Altran Innovation Award etc.). Since 2008, he is Honorary Member of the D.O.G., Knight of Ordre National de la Légion d'Honneur, Member of the Academy of Sciences, Institut de France - Human Biology and Medical Sciences section, Member of Academia Ophthalmologica Internationalis and Honoris Causa Doctorate of the University of Geneva, Switzerland.


**Hiroshi Sakai, MD, PhD**

**Affiliation:** Lecturer, Ophthalmology, University of the Ryukyus, Okinawa, Japan

**Areas of Interest:** Primary angle-closure glaucoma, glaucoma surgery, imaging of the anterior chamber, epidemiology, cell biology of the trabecular meshwork

**Leadership:** A councilor of Japanese Glaucoma Society

**Special Honors:** WGA Award (2005), Suda Glaucoma Prize (2005), Imai-Kinen Glaucoma Prize (2006).



**Lisandro Sakata, MD, PhD**

**Affiliation:** Glaucoma consultant of Universidade Federal do Parana, Brazil.

**Areas of Interest:** angle closure glaucoma, anterior segment imaging, glaucoma epidemiology.

**Leadership Positions:** Invited reviewer for several publications in high impact journals. Invited lecturer at research and educational events throughout the world. Authored or co-authored over 70 journal articles, abstracts, and book chapters in major ophthalmic publications.

**Special Honors:** Tyson ARVO Award (2006); ARVO International Travel Grant (2007), and other local prizes.



**Thomas W. Samuelson, MD**

**Affiliation:** Adjunct associate professor of Ophthalmology at the University of Minnesota, Minneapolis, MN; Faculty Member, Hennepin County Medical Center.

**Areas of Interest:** Surgical procedures involving Schlemm's Canal as well as the management of coincident cataract and glaucoma. He has also performed research on the safety of LASIK in patients with other ocular disorders, especially glaucoma.

**Leadership Positions:** Past chairman of the medical staff at the Phillips Eye Institute in Minneapolis; Treasurer for the American Glaucoma Society; Member of the Executive Committee of the AGS; Associate Secretariat of AAO Annual Meeting, chairing the skills transfer course committee. Member of the Basic Clinical Science Course Committee for the AAO. Glaucoma section editor for Ocular Surgery News.



**U. Schlötzer-Schrehardt, PhD**

**Affiliation:** Associate professor and group leader at the Department of Ophthalmology of the University of Erlangen-Nürnberg, Germany.

**Research interest:** Pseudoexfoliation syndrome, a frequent cause of glaucoma.

She is an expert on the cellular and molecular pathogenetic mechanisms causing this disorder. Other research interests include corneal epithelial stem cells as well as ultrastructural ophthalmic pathology.

**Special Honors:** Recipient of the distinguished ICO Ophthalmic Pathology Award of the International Council of Ophthalmology.



**Leopold Schmetterer**

**Affiliation:** Professor, Department of Clinical Pharmacology, Center of Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna.

**Research Interest:** Ocular blood flow, glaucoma pathogenesis, retinal imaging.

**Leadership Positions:** Member of ARVO Program committee 2011; President elect for EVER 2012; Visionary of the quarter 2/2011; Editorial Board Member of Progress in Retinal and Eye Research, Acta Ophthalmologica, Current Eye Research, The Open Physiology Journal, President of Association of Ocular Circulation (AOC), Chair of



Scientific Committee of the Austrian Ophthalmological Society.

**Joel S. Schuman, MD**

*Affiliation:* Eye and Ear Foundation Professor and Chairman of Ophthalmology, the Eye and Ear Institute, University of Pittsburgh School of Medicine and Director of the University of Pittsburgh Medical Center (UPMC) Eye Center, Pittsburgh, PA; Professor of Bioengineering at the Swanson School of Engineering, University of Pittsburgh, and Professor in the Center for the Neural Basis of Cognition, Carnegie Mellon University and University of Pittsburgh, interim co-Director of the Louis J. Fox Center for Vision Restoration of UPMC and the University of Pittsburgh and a member of the McGowan Institute for Regenerative Medicine.

*Leadership Positions:* Founding member of the ARVO Multidisciplinary Ophthalmic Imaging cross-sectional group; member of the program committee from its founding and chaired the MOI program committee (2007-2008); Founder and chair of ARVO/ISIE (The International Society for Imaging in the Eye, inaugurated 2002); Co-chair of the International Glaucoma Symposium (1998-2007), the world's largest meeting devoted to glaucoma, which merged with the World Glaucoma Congress in 2007, for which he is Program co-Chair 2007-2011. With the exception of a three year hiatus, he has chaired the Hawaiian Eye meeting glaucoma section since 1993. Dr. Schuman has published more than 200 peer-reviewed scientific journal articles, has authored or edited 8 books, and has contributed more than 50 book chapters.

*Special Honors:* Recipient of the Senior Achievement Award from the American Academy of Ophthalmology (2003). Elected into the American Society for Clinical Investigation (2004). Recipient of the Association for Research in Vision and Ophthalmology (ARVO) Translational Research Award (2006). Elected to the American Ophthalmological Society (2008). He received a 2006-2009 American Medical Association Physician's Recognition Award with Commendation. In 2010 he became a silver Fellow of ARVO. In 2011 Dr. Schuman was the Clinician-Scientist Lecturer of the American Glaucoma Society. He is named in Who's Who in America, Who's Who in Medical Sciences Education, America's Top Doctors and Best Doctors in America, and has been named a Top Doctor by Pittsburgh Magazine 2006 – 2011.

**Eric A. Sellem, MD**

*Affiliation:* Centre Ophtalmologique Kléber (Lyon, France)

*Leadership Positions:* President of the French Glaucoma Society, Member of the Board of the French Society of Ophthalmology. Numerous educational papers on glaucoma, essentially published in French, about risks factors, fundus examination, gonioscopy, visual fields, mechanisms of angle-

closure glaucoma, progression, medical and physical treatments.



**Tarek M. Shaarawy, MD**

*Affiliation:* Head of the Glaucoma unit, and the Glaucoma Surgery Research Group at the University of Geneva Hospitals.

*Areas of Interest:* Innovations in techniques of glaucoma surgery, normal pressure glaucoma, diurnal intraocular pressure monitoring and control, as well as glaucoma patterns of practice in developed and developing countries.

*Leadership Positions:* Member of editorial board of many ophthalmology journals, such as International Journal of Ophthalmology, the Journal of Glaucoma, the Canadian Journal of ophthalmology, and the Middle East African Journal of ophthalmology. Secretary General of the International Society of Glaucoma Surgery as well as the Associate Vice President of the World Glaucoma Association. Author and editor of five text books on Glaucoma, and more than 100 book chapters and publications in peer reviewed journals.



**Mark B. Sherwood, MD, PhD**

*Affiliation:* Daniels Professor of Ophthalmology and Director of the Vision Research Center at the University of Florida.

*Areas of Interest:* Modulation of wound healing following glaucoma surgery, detection of glaucoma progression, drug delivery and compliance.

*Leadership Positions:* He is Chair of the Online Education Committee for the American Academy of Ophthalmology.



**Anurag Shrivastava, MD**

*Affiliation:* Montefiore Medical Center, Dept. of Ophthalmology, Bronx, N.Y., Albert Einstein College of Medicine, Bronx, NY

*Research interest:* Cataract, Glaucoma.





**Ramanjit Sihota, MD, FRCS, FRCOphth**

*Affiliation:* Head, Glaucoma Research facility and clinical services at Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.

*Areas of Interest:* primary angle closure glaucoma, neovascular glaucoma and imaging in glaucoma.

*Leadership Positions:* Member of the international Glaucoma Research Society; Member the Glaucoma advisory group; Member of the and Project evaluation committee of the Indian Council of Medical Research; Member of the executive committee of SEAGIG and various committees of the Association of International Glaucoma Societies. She is a past president of the Glaucoma Society of India. She extensively revised 'Parson's Diseases of the Eye', and has published over 100 papers in peer reviewed indexed international journals.

*Special Honors:* Several national and international awards for research in glaucoma.



**Kuldev Singh, MD, MPH**

*Affiliation:* Professor of Ophthalmology and Director, Glaucoma Service at the Stanford University School of Medicine, Stanford, CA. *Research interest:* Glaucoma surgical trials, the epidemiology of glaucomatous disease and health care delivery in developing countries.

*Leadership Positions:* Executive Vice President of the World Glaucoma Association; Chair, Board of Directors for the Glaucoma Research Foundation; Vice President/President-Elect of the American Glaucoma Society; Served as Chair and Methodologist for the glaucoma section of the Ophthalmic Technology Assessment Panel of the American Academy of Ophthalmology (AAO). Dr. Singh served as an Academic Advising Dean at the Stanford University School of Medicine from 2002-2005 and is currently serving his second term as an elected member of the Faculty Senate.

*Special Honors:* Recipient of the Senior Achievement Award from AAO(2005); Secretariat Awards in 2006 and 2009. He was the sole recipient of the 2006 Franklin G. Ebaugh Jr. Award at the Stanford University School of Medicine.



**Arthur Sit**

*Affiliation:* Department of Ophthalmology at the Mayo Clinic, Rochester, MN.

*Areas of interest:* Aqueous humor dynamics, circadian variations of intraocular pressure, and development of novel diagnostic instruments to facilitate this research. The current

focus of our research is the development of a reliable method for non-invasive measurement of episcleral venous pressure in humans. When combined with other techniques for measurement of aqueous humor dynamics, this will allow accurate assessment of physiologic changes in glaucoma and mechanisms of action of glaucoma therapies.

*Leadership positions:* Chair, Research Committee, American Glaucoma Society; Co-Chair of the Strategic Planning Committee, World Glaucoma Association; Member, Associate Advisory Board, World Glaucoma Association; Member, Board of Directors, Minnesota Academy of Ophthalmology.

*Special Honors:* American Glaucoma Society Clinician-Scientist Award; Research to Prevent Blindness Special Scholar Award; American Health Assistance Foundation National Glaucoma Research Grant; Best Doctors in America, 2009-2011.



**Kwok-Fai So**

*Affiliation:* Chair Professor and Head of the Department of Anatomy, Jessie Ho Professor in Neuroscience at The University of Hong Kong; Co-Chairman of the Board of Director of the China Spinal Cord Injury Network, and Co-Director of the State Key Laboratory of Brain and Cognitive Sciences at HKU.

*Research Interests:* Neuroprotection and neuroregeneration of the mammalian optic nerve and brain.

His team identifies neuroprotective and regenerative factors including: peptide nanofiber scaffold, trophic factors, herbal extracts, other small molecules, immune responses and environmental manipulation.

*Leadership positions:* Member of the Chinese Academy of Sciences; He is one of the pioneers in the field of axonal regeneration in visual system. He was the first to show lengthy regeneration of retinal ganglion cells in adult mammals with peripheral nerve graft. He is currently using multiple approaches to promote axonal regeneration in the optic nerve and spinal cord. He is the author and co-author of over 250 publications.



**George L. Spaeth, MD**

*Affiliation:* Louis J. Esposito Research Professor, Research Laboratories at the Wills Eye Institute/Jefferson Medical College, Philadelphia, PA

*Research interest:* Glaucoma

*Leadership Positions:* He serves on the editorial boards of six journals, and was for many years Editor in Chief of Oph-

thalmic Surgery. Current or past president of the American Glaucoma Society, the European Glaucoma Society, the Chinese Glaucoma Society, the Pan-Arab-African Glaucoma Society, and the Christian Medical College in Lahore India. Founding member and the first President of the American Glaucoma Society. He was the founder and is current president of the Glaucoma Service Foundation to Prevent Blindness and served as the chair of the Ethics Committee of the American Academy of Ophthalmology. He has published over 360 articles in peer-reviewed journals, many hundred commentaries in various formats, over 100 book chapters, around 200 editorials, and 18 books, several of which have been translated into other languages, including Chinese. His surgical text is used in many countries around the world and a fourth edition is currently being prepared.



#### **Robert L. Stamper, MD**

**Affiliation:** Professor of Clinical Ophthalmology at the University of California, San Francisco, School of Medicine; Director of the Glaucoma Service in the Department of Ophthalmology, University of California, San Francisco, CA.

**Leadership Positions:** He has given numerous presentations at both national and international conferences and society meetings – most recently as visiting professor in Venezuela, Peru, New Zealand, Harvard, Washington University St. Louis and Yale. He is the senior author of the 7th and 8th editions of Becker-Shaffer's Diagnosis and Therapy of the Glaucomas. President, American Glaucoma Society (1999-2000). He served for over 25 years with the Joint Commission on Allied Health Personnel in Ophthalmology, was its President in 1984-5.

**Special Honors:** Recipient of many awards and honors, including being listed in the Best Doctors in America six times, Who's Who in America and Who's Who in the World. He has received the Lifetime Achievement Award of the American Academy of Ophthalmology in 2008. He has published over 85 peer-reviewed articles and has served on the editorial or review boards of the AJO, Archives, Ophthalmology, IOVS, British Journal of Ophthalmology, Eye Research, and Cataract and Refractive Surgery.



#### **James E. Standerfer, MD**

**Affiliation:** Professor of Clinical Ophthalmology, University of Minnesota.

**Areas of Interest:** He left private practice 15 years ago to teach, as a volunteer, a 2-week glaucoma workshop: 43

workshops in 36 training centers of 30 developing countries.

**Leadership Position:** Chairman of the AAO International Education Development Committee, 2001-2008.

**Special Honors:** AAO Outstanding Humanitarian Award; International Public Service Award, Foundation of the AAO; Distinguished Alumni Award and Visiting Professor Washington University Eye Alumni Association; Tani Humanitarian Award, Minnesota Academy of Ophthalmology.



#### **Kazuhisa Sugiyama, MD**

**Affiliation:** Professor and Chairman, Dept. of Ophthalmology and Visual Science, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

**Area of Interest:** Evaluation of structure and function in glaucomatous optic neuropathy; Glaucoma pharmacology and tailor-made medicine; Disc hemorrhage and retinal nerve fiber layer defect; Glaucoma surgery and lasers.

**Leadership Positions:** Executive Board Member of Japan Glaucoma Society; Board Member of Japanese Ophthalmological Society; Active Member of Glaucoma Research Society; Regional Representative of Asian-Oceanic Glaucoma Society; Executive Board Member of Japanese Society of Ophthalmic Surgeons; Board Member of Japanese Society of Ocular Pharmacology.

**Special Honors:** Special Award (Suda Award) from Japan Glaucoma Society; Young Investigator Award from Japanese Ophthalmological Society; Young Investigator Award from Gifu University.



#### **Kyung Rim Sung, MD**

**Affiliation:** Assistant Professor, Dept. of Ophthalmology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea.

**Areas of Interest:** Glaucoma, Pathophysiology, Imaging, Surgery.



**Remo Susanna Jr., MD**

*Affiliation:* Director of Glaucoma Service and chairman of the Department of Ophthalmology and Otorhinolaryngology of the University of São Paulo.

*Areas of Interest:* He developed the Early Diagnostic Program based in stereo-photographs launched in Europe and Asia, considered one of the best programs to teach physicians to diagnose glaucoma optic neuropathy.

*Leadership Positions:* Dr. Susanna is a member and has held office in numerous international ophthalmic societies. He was the founder and served as president of the Latin America Glaucoma Society from 2000 to 2008 and served as governor of the Association of International Glaucoma Societies from 2001 to 2003. He is the President of the Pan America Glaucoma Society and Past president of the World Glaucoma Association. He has authored and edited nine books, 32 book chapters and over 280 papers on glaucoma. He has served on the editorial board of three ophthalmic journals and is a reviewer for numerous journals including British Journal of Ophthalmology, Archives of Ophthalmology, and Journal of Glaucoma, American Journal. Dr. Susanna holds the patent for the Susanna implant for glaucoma, the implant most commonly used in Brazil, and has been the driving force behind the creation of programs in Brazil providing free cataract surgery, glaucoma treatment, and children's eye care for the poor.

*Special Honors:* Recipient of several Awards in his Country; He will receive the International Scholar Award. This award is given to a colleague for 'lifetime contributions to glaucoma research, education, patient care, and international collaboration'.



*Leadership Position:* Active Member of Glaucoma Research Society, Board Member of Japanese Ophthalmological Society, Executive Board Member of Japan Glaucoma Society, Executive Board Member of Japanese Society of Ophthalmic Surgeons, Board Member of Society Board Member of Japan Ocular Pharmacology, Co-Chief-in-Editor of Japanese Journal of Ophthalmology, Editorial Board Member of Investigative Ophthalmology and Visual Science.

*Special Honors:* Young Investigator Award of Japanese Ophthalmologists Society (1995), Japanese Glaucoma Society Suda Memorial Award (1999), Japanese Ophthalmologists Society Council Award (2005).



**Angelo P. Tanna, MD**

*Affiliation:* Vice Chairman of the Department of Ophthalmology and Director of the Glaucoma Service at the Northwestern University Feinberg School of Medicine in Chicago, IL.

*Research interest:* Efficacy and safety of glaucoma medications, detection of glaucoma progression, correlates of structure and function in glaucoma and tonometry.

*Leadership Positions:* Board of Directors, American Glaucoma Society; Listed in Best Doctors in American from 2005-2010.

*Special Honors:* American Academy of Ophthalmology Achievement Award in 2009.



**James C.H. Tan, MD  
FRCOphth, PhD**

*Affiliation:* Assistant Professor, Doheny Eye Institute and University of Southern California, Los Angeles, CA

*Areas of Interest:* Trabecular meshwork cell biology and physiology; ocular imaging.



**Hiddenobu Tanihara, MD**

*Affiliation:* Professor & Chairman, Department of Ophthalmology and Visual Science, Kumamoto University Graduate School of Medical Sciences, Japan.

*Areas of Interest:* Aqueous outflow system, Molecular mechanisms related to glaucomatous optic neuropathy, Neuroprotection and neuro-regeneration, Glaucoma surgery, Secondary glaucoma.

**Dr. Celso Tello, MD**

*Affiliation:* Associate Professor of Ophthalmology, Co-Director Glaucoma Service, New York Eye and Ear Infirmary, New York, NY, USA.



**Clement C.Y. Tham**

*Affiliation:* Professor, Department of Ophthalmology and Visual Sciences at The Chinese University of Hong Kong (CUHK), Honorary Chief-of-Service of Hong Kong Eye Hospital, Hong Kong.



**Research interest:** Laser and surgical management of glaucoma; argon laser peripheral iridoplasty (ALPI) in the immediate management of acute glaucoma. Applications of lens extraction in angle closure glaucoma.

**Leadership Positions:** Deputy Secretary-General of Asia-Pacific Academy of Ophthalmology (APAO); Ophthalmology Editor of Hong Kong Medical Journal; previously the Editor-in-Chief of Hong Kong Journal of Ophthalmology. Published over 80 peer-reviewed articles, delivered over 100 lectures and instruction courses at international ophthalmology conferences, and authored more than 10 book chapters on angle closure glaucoma.

**Special Honors:** Recipient of numerous awards, including the Nakajima Award and the Prevention of Blindness Award from APAO, the Achievement Awards from both APAO and the American Academy of Ophthalmology (AAO), and the Ten Outstanding Young Persons Award in Hong Kong.



#### **Ravi Thomas, MD, MBBS**

**Affiliation:** Queensland Eye Institute and University of Queensland, Brisbane.

**Leadership Positions:** Formerly Head of the Department of Ophthalmology, Schell Eye Hospital, Christian Medical College, Vellore, India; Formerly Director of the LV Prasad Eye Institute in Hyderabad; Teaching for more than twenty five years in India and overseas; More than 175 publications, a book and some book chapters.



#### **John Thygesen, MD**

**Affiliation:** Clinical associate professor at Copenhagen University Hospitals; Department of Ophthalmology, Glostrup Hospital and Rigshospitalet, Copenhagen; Director of glaucoma services at the University glaucoma clinics in Copenhagen. He serves as the educational programme director and senior consultant ophthalmologist at the same hospital.

**Areas of Interest:** Glaucoma diagnostics and therapy, paediatric glaucomas, angle closure glaucoma, automated perimetry, lasers, pharmacology, costs and quality of life related to glaucoma. Ocular traumatology.

**Leadership Position:** Member of the Executive Committee of



The European Glaucoma Society (EGS) since 2000, where he chairs the EGS Educational Committee; Chairman of the Educational Committee of The European Glaucoma Society; EGS representative at the World Glaucoma Association; Co-founder and past-president of the Danish Glaucoma Society; Member of several committees of World Glaucoma Association; Medical advisor for the Danish National Board of Health and The Danish Medicines Agency under the Ministry of the Interior and Health; Associate Editor of Acta Ophthalmologica and Editorial Advisory Board Member at Ophthalmologica, View on Glaucoma and Ophthalmology Times Europe; Reviewer for the Journal of Glaucoma, Graefes Archives of Ophthalmology, Acta Ophthalmologica, The Journal of cataract and refractive Surgery, Scandinavian Journal of Medicine and Science in Sports, Expert Opinion on Pharmacotherapy, Ophthalmologica, Archives of Ophthalmology, Eye and the British Journal Ophthalmology; Authored 72 scientific papers (47 peer-reviewed scientific, and 26 non-peer-reviewed) on glaucoma therapy, paediatric glaucomas, automated perimetry, lasers, pharmacology, ocular traumatology and analysis of costs and quality of life related to Glaucoma. He has contributed with 30 book chapters and two books.

**Special honors:** Honorary Member of the South African Glaucoma Society; Glaucoma Section Medal of the Polish Ophthalmological Society; 'Optime de Glaucomatologia Merenti'.

#### **Goji Tomita, MD, PhD**

**Affiliation:** Professor, 2nd Department of Ophthalmology, Toho University School of Medicine.

Director, Department of Ophthalmology Toho University Ohashi Medical Center.

**Areas of Interest:** Normal Pressure Glaucoma, Optic nerve head, Image Analysis, Angle Closure Glaucoma.

**Leadership Positions:** Trustee of Japanese Ophthalmological Society, Program committee of Japanese Ophthalmological Society, Trustee of Japan Glaucoma Society, General secretary of 14th Annual Meeting of Japan Glaucoma Society, Program committee of 16th, 17th and 18th Annual Meeting of Japan Glaucoma Society, Trustee of The Japanese Society of Ophthalmic Surgeons, Executive member of Asian Angle Closure Glaucoma Club. Glaucoma section chief editor of Japanese Journal of Ophthalmology, International advisory board of Korean Journal of Ophthalmology.

**Special Honor:** The Third Suda Award (Japan Glaucoma Society).



#### **Fotis Topouzis, MD, PhD**

**Affiliation:** Associate Professor of Ophthalmology and Head and Founder of the Laboratory of Research and Clinical Applications in Ophthalmology, A' Department of Ophthalmology, Aristotle University of Thessaloniki, Greece

**Areas of Interest:** Epidemiology and clinical and genetic

research in ophthalmic diseases, with a particular focus on glaucoma and age-related macular degeneration.

**Leadership Positions:** Member of the Executive Committee of the European Glaucoma Society (EGS); Secretary of GlaucoGENE, a special interest group of the EGS; Co-chair of the World Glaucoma Association Committee on Guidelines for Reporting and Publishing. Member of the Editorial Board of five medical journal; Reviewer for 18 medical journals. Principal Investigator of two large population-based studies (Thessaloniki Eye Study, EUREYE Study), and co-ordinator for the EGS GlaucoGENE project.

**Special Honors:** He has received distinguished awards for his scientific work.



#### **Carol B. Toris, PhD**

**Affiliation:** Director of Glaucoma Research and Professor in the Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE.

**Areas of Interest:** Aqueous humor dynamics in monkeys, rabbits, mice and humans. Specific studies include the effects of aging, drugs, glaucoma drainage devices, and day and night fluctuations.

**Leadership Positions:** Trustee of Association for Ocular Pharmacology and Therapeutics; Trustee of ARVO; Membership Committee of International Society for Eye Research; Director of the UNMC clinical research program.

**Special Honors:** Dr. Stan Truhlsen Research Award from Prevent Blindness Nebraska (2006); ARVO FARVO Gold Award (2009); Silver U Award University of Nebraska Medical Center (2010).



#### **Carlo E. Traverso, MD**

**Affiliation:** Director of Clinica Oculistica, Department of Neurosciences, Ophthalmology and genetics (Di.N.O.G.), University of Genova; Director, Residency program in Ophthalmology, Department of Neurosciences, Ophthalmology and genetics (Di.N.O.G.), University of Genova.

**Leadership Positions:** Department of Neurosciences, Ophthalmology and Genetics (Di.N.O.G.), Univer-



sity of Genova; Medical Director, Eye Bank of Genova – Fondazione Melvin Jones Lions; President, European Glaucoma Society (EGS) since 2010; Coordinator and founder, Clinical Research Center and laboratory for Glaucoma and Cornea, Department of Neurosciences, Ophthalmology and Genetics (Di.N.O.G.), University of Genova, since 2006; Coordinator, Regional Center for Biological Resources (Centro Ligure per le Risorse Biologiche) since 2006; Member of the Board, PhD Program in Biotechnology and Regenerative Medicine, University of Genova, since 2007.

**Special Honors:** Senior Achievement Award American Academy of Ophthalmology (2008); Silver Fellowship Association for Research in Vision and Ophthalmology (2009).

#### **Graham E. Trope, MB, BCh, PhD, FRCSC, FRCs(Ed) FRCOphth**

**Affiliation:** Professor Ophthalmology, University of Toronto, Director Glaucoma Services, Toronto Western Hospital, Toronto, Canada.

**Areas of Interest:** Research and treatment of Glaucoma.

**Leadership Positions:** Founder and Scientific Director of Glaucoma Research Society of Canada; Past Editor in Chief of the Canadian Journal of Ophthalmology; Past Ophthalmologist in chief at University Health Network; Past examiner for the Royal College of Physicians and Surgeons of Canada; Published over 160 scientific articles and two books.

**Special Honors:** The Ontario College of Physicians and Surgeons Council Award for his contributions to patient care.



#### **James C. Tsai, MD, MBA, MA (Hon)**

**Affiliation:** Robert R. Young Professor of Ophthalmology and Visual Science at Yale University; Chair of the Department of Ophthalmology and Visual Science at Yale School of Medicine and Chief of Ophthalmology at Yale-New Haven Hospital.

**Leadership Positions:** Member of the National Eye Health Education Program Planning Committee of NIH (NEHEP); Examiner for the American Board of Ophthalmology; Chairman of the Medical Advisory Board of The Glaucoma Foundation; President of the Chinese American Ophthalmological Society (CAOS); Chair of the American Academy of Ophthalmology's Global Ophthalmic News and Education Network (O.N.E.) Advisory Board; Chair of the Strategic Planning Committee of Yale Medical Group's Board of Governors; Member of the Singapore Translational Clinical Research (TCR) Scientific Advisory Board.



---

*Special Honors:* Honorary Master of Arts (privatim) degree from Yale University.

**Anja Tuulonen, MD, PhD**

*Affiliations:* Professor of Ophthalmology, Department Head, Eye Centre of Tampere University Hospital, Tampere.

*Research interests:* Health sciences research (glaucoma and eye care systems, health economics, modeling studies, prioritization); Glaucoma screening, diagnostics, treatment and follow-up; EBM.

*Leadership Positions:* Vice President and Leader of the Health Economic Special Interest Group of the European Glaucoma Society (EGS); Secretary, Glaucoma Research Society.



**Françoise Valtot, MD**

*Affiliation:* Glaucoma consultant and Glaucoma surgeon, Glaucoma Institute, Saint Joseph Hospital, Paris.

*Areas of Interest:* Histology of the glaucomatous eye; Laser treatments of Glaucoma; Ultrasound treatment of Glaucoma; Genetics of Glaucoma; Non penetrating Glaucoma Surgery.



**Rohit Varma, MD, MPH**

*Affiliation:* Professor of Ophthalmology and Preventive Medicine, Director of the Glaucoma Service, Ocular Epidemiology Center and the Clinical Trials Unit at the Department of Ophthalmology, at the USC Keck School of Medicine.

*Research interest:* Epidemiologic studies of eye disease in children and aging populations.

*Leadership Positions:* Editorial Advisory Board, Ophthalmology - the Journal of the American Academy of Ophthalmology (1999-); Board of Scientific Counselors, National Eye Institute, National Institutes of Health (2005-); NEHEP Planning Committee member, National Eye Health Education Program (2007-); Anterior Eye Disease Study Section, National Institutes of Health (2008-). Published over 156 articles in various peer reviewed ophthalmic journals, and co-authored two ophthalmic books

*Special Honors:* AAO Senior Achievement Award (2006); RPB Special Research Scholar Award (2007); RPB Scientific Career Dev. Award (2007); President's Award-GRF (2009); ARVO Fellow Silver Award (2009).



**Dr. Lingam Vijaya, MBBS, MS**

*Affiliation:* Director, Smt. Jadhavabai Nathmal Singhvee Glaucoma Services, Sankara Nethralaya, Chennai.

*Areas of Interest:* Angle closure glaucoma, genetics of glaucoma.

*Leadership Positions:* President of Glaucoma Society of India (2006-2008); Organizing Chairperson SEAGIG, Chennai (2006); Published 88 papers in peer reviewed national and international journals

and has also written several chapters in various national textbooks. She has delivered more than 120 lectures at various national and international conferences. Reviewer for various national and international ophthalmology journals.

*Special Honors:* Rustom Ranji Oration Medal for the year 2007; Dr Rustom D Ranji Rotary Award (2008); American Academy of Ophthalmology Achievement Award (2009); Dr. Samir Biswas Memorial Oration (2009); Prof. T. Gopinatha Menon Memorial Oration (2009); AIOS IJO Platinum Award (2010) for the best paper published in Indian Journal of Ophthalmology (Outcomes of cataract surgery in a rural and urban south Indian population).



**Gianmarco Vizzeri, MD**

*Affiliation:* Assistant Professor at the Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch; Medical Director of the Ophthalmology Clinical Research Center; Associate Residency Program Director.

*Research interest:* Ocular imaging, electrophysiology, ocular blood flow and glaucoma surgery.

*Leadership Positions:* Member of the Editorial Board of Journal of Clinical and Experimental Ophthalmology; Reviewer for Ophthalmology, Investigative Ophthalmology and Visual Science, Journal of Glaucoma and International Glaucoma Review, among others; Principal Investigator of a NASA funded study evaluating the effect of microgravity on ocular structures and visual function. Authored and co-authored over 80 journal articles, abstracts and book chapters in major ophthalmic publications.



**Martin Wand, MD, PhD**

*Affiliation:* Clinical Professor of Ophthalmology, University of Connecticut School of Medicine.

*Leadership Positions:* 60 peer-reviewed journal articles, 23 book chapters, 35 other medical publications, eight AAO educational videos, and 234 talks/courses world-wide; Multiple committees in New England Ophthalmological Society (NEOS), American Glaucoma Society (AGS), American Academy of Ophthalmology (AAO), and American Board of



Ophthalmology (ABO); Past NEOS President, AGS Councilor and Executive Committee member, AAO Chair of Council and Trustee, ABO Director and Chair. *Honors:* Recipient of AAO Honor, Senior Honor, Lifetime Achievement, and Secretariat Awards.



**Robert N. Weinreb, MD**

*Affiliation:* Distinguished Professor of Ophthalmology and Chairman of the Department of Ophthalmology at the University of California, San Diego; Morris Gleich Chair; Director of the Hamilton Glaucoma Center.

*Areas of Interest:* The innovative glaucoma research ranges from the front to the back of the eye and from the clinic to the laboratory.

*Leadership Positions:* Clinician, surgeon, scientist and also mentor; President of the Association for Research in Vision and Ophthalmology (ARVO), President of the World Glaucoma Association (WGA), and President of the American Glaucoma Society. Chief Editor of the International Glaucoma Review; Chair of the World Glaucoma Association Consensus Initiative; author of more than 1200 publications and 20 books. He has trained more than 130 post-doctoral Fellows in Glaucoma, many of whom hold distinguished academic positions throughout the world.

*Honors:* The recipient of numerous prizes and awards, his work has significantly impacted our understanding of the pathophysiology and biology of glaucoma, as well as its diagnosis and management.



**Lan Wang, MD PhD**

*Affiliation:* Clinical Professor of Beijing Tongren Hospital, Capital Medical University.

*Leadership Position:* Director of Ophthalmology Department of Nanjing Tongren Hospital.

*Areas of Interest:* Angle-closure glaucoma, Glaucoma Surgery.



**Ningli Wang MD, PhD**

*Affiliation:* Director of Beijing Tongren Eye Center; Vice president of Beijing Tongren Hospital.

*Areas of Interest:* Cerebrospinal Fluid Pressure in Glaucoma; Epidemiology on Handan Eye study; Genome research and gene mapping on glaucoma; Sleep Related Eye Disease.

*Leadership Position:* Chinese Ophthalmological Society, President-Elect; Chairman of Committee of the Chinese Ultrasound Technology Association; Vice Chair of the Chinese Glaucoma Society; President of the Beijing Medical Association, Ophthalmology Society; Executive Committee Member of the Asia Angle Closure Glaucoma Club; Board Member of the South-east Asia Glaucoma Interest Group. Published 83 articles in English journals and 137 articles in Chinese journals

*Honors:* APAO, Arthur Lim award 2011, APAO Achievement Awards, 2010; The 7th China Medical Doctor Association Awards, 2010; Outstanding Achievement Awards of Chinese Ophthalmological Society, 2009; The Golden Key Awards of Chinese-American Ophthalmological Association, 2008; First prize of Nature and Science Awards for Ministry of Education of Peoples Republic of China, 2008.



**Larry A. Wheeler, PhD**

*Affiliation:* Senior Vice-President of Biological Sciences Discovery Research at Allergan, Inc.

*Areas of Interest:* pharmacology and drug discovery in glaucoma, ocular inflammation, retinal disease and neurotoxins.

*Leadership Position:* Authored book chapters and over 100 papers in peer-reviewed journals and awarded over 50 patents in the areas of neuroprotection, glaucoma, retinal disease therapeutics, pharmacology of alpha-2 receptors and NMDA antagonists.



**Janey L. Wiggs, MD, PhD**

*Affiliation:* Physician scientist at the Massachusetts Eye and Ear Infirmary (MEEI) and Harvard Medical School (HMS); Associate Professor of Ophthalmology at Harvard Medical School, Associate Chief for Clinical Research in Ophthalmology at the Massachusetts Eye and Ear Infirmary.

*Areas of Interest:* Discovery and characterization of genetic factors that contribute to the blinding eye disease glaucoma.



**Leadership Positions:** co-chair of the US-INDO joint working group (NEI); member of the NEI eyeGENE consortium; Member of the editorial boards of Investigative Ophthalmology and Visual Science (IOVS), Archives of Ophthalmology (Section Editor from Molecular Genetics), Molecular Vision, and the Journal of Glaucoma. Member of the scientific advisory board for the Glaucoma Research Foundation and is a past member of the National Advisory Council of the National Eye Institute.

### **M. Roy Wilson, MD, MS**

**Affiliation:** Chancellor Emeritus of the University of Colorado Denver (UC Denver), Senior Scholar at the Association of Academic Health Centers (AAHC), and Chairman of the Board of Trustees of the Charles R. Drew University of Medicine and Science (CDU).

**Leadership Positions:** governing boards of the Charles R. Drew University of Medicine and Science (Chair), the Institute for the Advancement of Multicultural and Minority Medicine, the American International Health Alliance, and the Association of Academic Health Centers; Chair of the NIH Data Monitoring and Oversight Committee for the Los Angeles Latino Eye Study and the Advisory Board of the American Academy of Ophthalmology's Hoskins Center for Quality Eyecare.

**Honors:** Distinguished Physician Award from the Minority Health Institute, the Honored Alumnus Award from the Mass Eye and Ear Infirmary, the Senior Achievement Award from the American Academy of Ophthalmology, the Gold Citation from Allegheny College, and the Association of American Medical College's Herbert W. Nickens Award.



### **Gadi Wollstein, MD**

**Affiliation:** Adjunct Assistant Professor of ophthalmology, New England Eye Center, Tufts Medical Center, Boston, MA; Director of the Scholarly Research Program, Department of Ophthalmology, UPMC Eye Center, Pittsburgh, PA; Associate Professor of ophthalmology, Director of Ophthalmic Imaging Research Laboratories, UPMC Eye Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.

**Area of Interest:** Ocular imaging using various technologies (time-domain and spectral-domain optical coherence tomography, confocal scanning laser ophthalmoscopy, and scanning laser polarimetry), structure-function relationship and longitudinal assessment of glaucomatous changes. Clinical testing of glaucoma imaging devices, development of new



imaging devices or innovative modifications of existing technologies, development of new software for analyzing scans and improving detection ability. Investigating the ocular anatomy and the glaucomatous pathophysiological process. Development of in-vivo optical coherence tomography contrast agent enabling visualization and quantification of area of interest.

**Leadership Position:** Active reviewer for 18 peer-reviewed Ophthalmic and Bioengineering journals; Ad-hoc reviewer for national research funding institutes, funding organizations and universities; Director of Resident Scholarly Project Program, Department of Ophthalmology, UPMC Eye Center, Pittsburgh, PA, USA; Standing Committee for Non-Tenured Faculty Promotions and Appointments member, University of Pittsburgh, Pittsburgh, PA, USA; Institutional Review Board (IRB) board member, University of Pittsburgh, Pittsburgh, PA, USA.

**Honors:** American Academy of Ophthalmology Achievement Award (2007); University of Pittsburgh Innovator Award (2009, 2010); University of Pittsburgh Faculty Honor Award (2010).

### **Dr. Tina T. Wong BSc, MBBS, FRCOphth, FRCSEd, PhD**

**Affiliation:** Consultant, Glaucoma Service, Singapore National Eye Centre; Assistant Director, Translational Clinical Research, Singapore Eye Research Institute; Head, Ocular Drug Delivery Group, Singapore Eye Research Institute; Assistant Professor (Adj), School of Materials Science and Engineering, Nanyang Technological University, Singapore; Assistant Professor (Adj), Dept Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore.

**Areas of Interest:** Cellular and molecular mechanisms of inflammation and wound healing following medical and surgical management in glaucoma; Ocular drug delivery nanosystems and therapy for the glaucoma patient: anti-glaucoma medications and wound healing modulating agents; Primary angle closure glaucoma – mechanisms, pathophysiology, biomechanics; Cell based drug screening for glaucoma therapy

**Leadership Positions:** Associate Advisory Board Member, World Glaucoma Association

**Honors:** Moorfields Eye Hospital Research Gold Medal, UK, 2006; Clinician Scientist Award, NMRC, Singapore, 2010; Distinguished Service Award, APAO, 2011.



### **Tetsuya Yamamoto, MD**

**Affiliation:** Professor and Chairman, Department of Ophthalmology, Gifu University Graduate School of Medicine, Gifu-shi, Japan

**Area of Interest:** Glaucoma management, Normal-tension glaucoma, Glaucoma surgery, Prognosis of glaucoma, Primary angle closure.



**Leadership Positions:** Board member, Japan Glaucoma Society; Council member, Japanese Ophthalmological Society; Active Member, Glaucoma Research Society; President, Asian Angle-Closure Glaucoma Club; Board member, South East Asia Glaucoma Interest Group

**Special Honors:** Suda Award (Japan Glaucoma Society, 1994); Council Award (Japanese Ophthalmological Society, 2001).



**Yeni Yücel**

**Affiliation:** Professor and Director, Ophthalmic Pathology Laboratory, University of Toronto; Departments of Ophthalmology and Visual Sciences, and Laboratory Medicine and Pathobiology, St. Michael's Hospital, Toronto, Canada; Staff Scientist, The Keenan Research Center at the Li Ka Shing Knowledge Institute of St. Michael's Hospital.

**Areas of Interest:** Neural degeneration and protection of the central visual pathways in glaucoma; Lymphatic circulation in the eye as a novel therapeutic target for disease.

**Leadership Positions:** Director, Ophthalmic Pathology Laboratory, University of Toronto; Chair, Research Biosafety, The Keenan Research Center at the Li Ka Shing Knowledge Institute of St. Michael's Hospital; Editorial Board Member: Eye and Brain, Journal of Glaucoma, International Glaucoma Review, Journal of Middle East and African Ophthalmology

**Special Honors:** The New York Academy of Medicine Lewis Rudin Glaucoma Award 2010; World Glaucoma Association – Best Article Award 2006.




**Alan H. Zalta, MD**

**Affiliation:** Director of the Glaucoma Service in the Dept. of Ophthalmology at the University of Cincinnati College of Medicine.

**Areas of Interest:** Stereoscopic atlases of glaucomatous disc damage and gonioscopy; aqueous shunt surgery.

**Honors:** Honor Award from the American Academy of Ophthalmology in 1994; outstanding resident teaching at the University of Cincinnati; Best Doctors in (2001-2011).



**Linda M. Zangwill, PhD**

**Affiliation:** Professor, Director, Diagnostic Imaging Laboratory, Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, CA.

**Areas of Interest:** To improve techniques for detection and monitoring of glaucomatous structural damage; to develop improved methods to measure the rate of glaucomatous progression; to characterize the complex relationship between structural and functional change over time; to identify risk factors for the development and progression of glaucoma.

**Leadership Positions:** Journal of Glaucoma Editorial Board Member (since 1999); International Perimetric Society Board Member (2002- present); Glaucoma Research Society (elected 2002); UC San Diego The Sam and Rose Stein Institute for Research on Aging (elected 2004); Faculty Chair: UC San Diego Chancellor's Advisory Committee on the Status of Women (2004-2006); International Glaucoma Review (IGR) Editorial Board Member (2007-present); Women's Leadership Alliance Executive Committee (2009- present); Principal Investigator, National Eye Institute funded: 'Diagnostic Innovations in Glaucoma Study (DIGS): Structural Assessment' (2005-present); Principal Investigator National Eye Institute funded: African Descent and Glaucoma Evaluation Study (ADAGES) II: Glaucoma Progression (2010 – present); Principal Investigator National Eye Institute funded: 'OHTS and EGPS: Glaucoma detection using Confocal Scanning Laser Ophthalmoscopy' (2008-present).

**Honors:** One of ten 'Best papers on glaucoma published in the scientific literature', Association of International Glaucoma Societies (WGA) 2001, 2005; American Academy of Ophthalmology Achievement Award 2006; Association for Research in Vision and Ophthalmology Silver Fellow Award 2010.



**Thierry Zeyen, MD, PhD**

**Affiliation:** Professor, Catholic University of Leuven. Head Glaucoma Unit, University Hospital of Leuven

**Research Interest:** Medical and Surgical Treatment of Glaucoma, Optic Disc Imaging in Glaucoma, Psychophysical testing in Glaucoma, Adherence in Glaucoma Therapy.

**Leadership Positions:** Board member Executive Board European Glaucoma Society (EGS), Chair of EVER Glaucoma section, President Belgian Glaucoma Society, Vice-president Belgian Ophthalmological Society. Over 90 peer reviewed articles and several textbook chapters.



---

**Chun Zhang, MD, PhD**

*Affiliation:* Professor and Glaucoma Specialist, Peking University Eye Center; Director The Clinical Stem Cell Center; Chief Department of Research Administration, Peking University Third Hospital.

*Areas of Interest:* glaucoma clinical study, neuroprotection and regenerative medicine.



**Jialiang Zhao, MD**

*Affiliation:* Professor in the Department of Ophthalmology at Peking Union Medical college Hospital

*Areas of Interest:* glaucoma; ophthalmic epidemiology.

*Leadership Positions:* Vice Chairman of Asia Pacific Academy of Ophthalmology (APAO), President of Chinese Ophthalmologist Association; Vice President of Chinese Disabled Person Rehabilitation Association; Member of Academia Ophthalmologica Internationalis

*Special Honors:* Distinguished Award of Asia Pacific Cataract and Refractive Surgery Society in 2002, Beijing Science and Technology Award in 2003, Chinese Medical Science and Technology Award in 2003, Award of APAO in 2003, Distinguished Award of COS in 2005, Arthur Lim Award of APAO in 2007, Golden Apple Award of Chinese American Ophthalmologist Society (CAOS) in 2008, Doherty Scholar from Southern California University and China Physician Award in 2009.



# CME DISCLOSURES

**Speaker/Planner Disclosure Information** (\*Disclosure not available at press time, will be communicated at the time of the meeting by the faculty members during their sessions)

| Family Name      | First Name | Financial support   | Personal Financial Interest | Supported / Contracted Research | Advisory board / Consulting                            | Patent Holder / Receipt of intellectual Property | Salary / royalty / Honoraria                                |
|------------------|------------|---|-----------------------------|---------------------------------|--|--|---|
| Agulto           | Manuel     | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE  |
| Aihara           | Makoto     | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE  |
| Al Aswad*        | L.         |   |                             |                                 |  |  |   |
| Allouch*         | C.         |   |                             |                                 |  |  |   |
| Alvarado         | Jorge      | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE  |
| Ancker           | Ellen      | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE  |
| Anton            | Afonso     | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE  |
| Araie            | Makoto     | NONE  | NONE                        | NONE                            | Pfizer, Alcon, Allergan, Kowa, Senju, MSD,             | Topcon,  | Santen  |
| Asawaphureekorn* | Somkiat    |   |                             |                                 |  |  |   |
| Asrani           | Sanjay     | ICare Finland -- Research materials at no cost                    | NONE                        | NONE                            | NONE   | NONE   | Travel Reimbursement--Sensimed AG                           |
| Aung             | Tin        | Alcon, Carl Zeiss Meditec, Ellex, Clarity Medical Systems         | NONE                        | NONE                            | Alcon, Merck, Pfizer                                   | NONE   | Alcon, Carl Zeiss Meditec, Merck, Allergan, Clarity, Santen |
| Azuara-Blanco    | Augusto    | Research funding for a phase-II trial (ASTRA-ZENECA and Allergan) | NONE                        | NONE                            | NONE   | NONE   | NONE  |
| Baerveldt        | George     | NONE  | NONE                        | NONE                            | NeoMedix, AMO  | NeoMedix, AMO                                    | NeoMedix  |
| Barton           | Keith      | AMO, New World Medical, Alcon, Merck, Allergan                    | NONE                        | NONE                            | Alcon, Aquesys, Ivantis, Refocus, Glaukos, Merck, Kowa | NONE   | Allergan, Pfizer  |
| Bastelica        | Antoine    | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE  |
| Baudouin         | Christophe | Alcon, Allergan, MSD, Pfizer, Santen, Théa                        | NONE                        | NONE                            | Alcon, Allergan, MSD, Pfizer, Santen, Théa             | NONE   | NONE  |
| Beck             | Allen      | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE  |
| Bellucci*        | Roberto    |   |                             |                                 |  |  |   |
| Ben Amor         | Khaled     | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE  |

| Family Name      | First Name  | Financial support                                    | Personal Financial Interest | Supported / Contracted Research | Advisory board / Consulting   | Patent Holder / Receipt of intellectual Property / Property | Salary / royalty / Honoraria                         |
|------------------|-------------|--|-----------------------------|---------------------------------|---|---|--|
| Bengtsson        | Boel        | NONE   | NONE                        | NONE                            | Carl Zeiss Meditec Inc.   | NONE  | NONE   |
| Best             | Stephen     | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Bloom            | Philip      | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Blumenthal*      | Eytan Z.    |  |                             |                                 |   |   |  |
| Boehm            | Andreas     | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Bourne           | Rupert      | Medisoft Ltd   | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Bowd             | Christopher | Lace Elettronica                                     | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Brandt           | James       | NONE   | NONE                        | NONE                            | Abbot Medical Optics; Alcon Laboratories; EndoOptiks; Glaukos; Pfizer | NONE  | Alcon Laboratories; Merck                            |
| Bresson-Dumont   | Hélène      | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Bron             | Alain       | NONE   | NONE                        | NONE                            | Alcon, Allergan, MSD, Pfizer, Théa                                    | NONE  | NONE   |
| Brown            | Reay        | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Budenz           | Donald      | Carl Zeiss Meditec                                   | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Burgansky-ELiash | Zvia        | NONE   | NONE                        | Optical Imaging, Ltd            | NONE  | NONE  | NONE   |
| Burk             | Reinhard    | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Burr             | Jennifer    | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Buys             | Yvonne      | Alcon; IMed  | NONE                        | NONE                            | NONE  | NONE  | Alcon  |
| Carassa          | Roberto     | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Chakrabarti      | Subhabrata  | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Chang            | Robert      | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Chauhan          | Balwantray  | Allergan, Carl Zeiss Meditec, Heidelberg Engineering | NONE                        | NONE                            | Allergan  | NONE  | Allergan, Carl Zeiss Meditec, Heidelberg Engineering |
| Chen             | Teresa      | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Chew             | Paul        | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Clark            | Abbot       | Alcon Research, Ltd. (research support)              | NONE                        | NONE                            | NONE  | NONE  | NONE   |
| Congdon          | Nathan      | NONE   | NONE                        | NONE                            | NONE  | NONE  | Alcon Laboratories; Reichert Inc.                    |

| Family Name           | First Name     | Financial support  | Personal Financial Interest    | Supported / Contracted Research | Advisory board / Consulting                                       | Patent Holder / Receipt of intellectual / Property | Salary / royalty / Honoraria   |
|-----------------------|----------------|--------------------|--------------------------------|---------------------------------|---|--|--|
| Cordeiro              | Francesca      | NONE               | NONE                           | NONE                            | NONE  | UCLB   | Allergan, Heidelberg Engineering, Alcon, Merz                              |
| Costa                 | Vital          | NONE               | NONE                           | NONE                            | Alcon Laboratories, Merck Sharp & Dohme, Eyetec, Germed           | NONE   | Alcon Laboratories, Merck Sharp & Dohme, Germed, New Medical (Ahmed Valve) |
| Craig                 | Jamie          | NONE               | NONE                           | NONE                            | NONE  | NONE   | NONE   |
| Crandall              | Alan           | NONE               | NONE                           | NONE                            | Alcon Labs, Glaukos, AquSys, Asico, Mastel Surgical, Ivantis Inc. | NONE   | Alcon Labs   |
| Crowston              | Jonathan       | NONE               | NONE                           | NONE                            | NONE  | NONE   | NONE   |
| Csiszar               | Katalin        | NONE               | NONE                           | NONE                            | NONE  | NONE   | NONE   |
| Dada                  | Tanuj          | NONE               | NONE                           | NONE                            | NONE  | NONE   | NONE   |
| Dahan                 | Elie           | Alcon Laboratories | NONE                           | NONE                            | Alcon Laboratories  | NONE   | Alcon Laboratories   |
| Danias                | John           | NONE               | NONE                           | NONE                            | NONE  | NONE   | NONE   |
| De Moraes             | Carlos Gustavo | NONE               | NONE                           | NONE                            | NONE  | NONE   | NONE   |
| Denis*                | Philippe       |                    |                                |                                 |   |  |  |
| Diestelhorst          | Michael        | NONE               | proprietary interests, patents | NONE                            | NONE  | NONE   | NONE   |
| D'Mellow              | Guy            | NONE               | NONE                           | NONE                            | NONE  | NONE   | Pfizer, Allergan, Alcon  |
| Eke                   | Tom            | NONE               | NONE                           | NONE                            | NONE  | NONE   | NONE   |
| El Sayyad             | Fathi          | NONE               | NONE                           | NONE                            | NONE  | NONE   | NONE   |
| Epstein               | David          | NONE               | NONE                           | NONE                            | NONE  | NONE   | NONE   |
| Fang                  | Seng Kheong    | NONE               | NONE                           | NONE                            | NONE  | NONE   | NONE   |
| Fechtner              | Robert         | NONE               | NONE                           | NONE                            | Alcon, Allergan, Merck  | NONE   | Alcon, Allergan, Merck   |
| Feldman*              | Robert         |                    |                                |                                 |   |  |  |
| Fellman               | Ronald         | NONE               | NONE                           | NONE                            | NONE  | NONE   | NONE   |
| Fernando Stieminski * | Sandra         |                    |                                |                                 |   |  |  |
| Feuer                 | William        | NONE               | NONE                           | NONE                            | NONE  | NONE   | NONE   |



| Family Name     | First Name       | Financial support   | Personal Financial Interest | Supported / Contracted Research | Advisory board / Consulting  | Patent Holder / Receipt of intellectual / Property | Salary / royalty / Honoraria   |
|-----------------|------------------|---|-----------------------------|---------------------------------|--|--|--|
| Fingeret        | Murray           | Heidelberg Engineering, Carl Zeiss Meditec, Topcon, Reichert, Optovue | NONE                        | NONE                            | Allergan, inc., Carl Zeiss Meditec   | NONE   | Alcon, Allergan, Carl Zeiss Meditec, Pfizer  |
| Flammer         | Josef            | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Flanagan        | John             | Heidelberg Engineering  | NONE                        | NONE                            | Heidelberg Engineering   | Heidelberg Engineering                             | Heidelberg Engineering   |
| Fortune         | Brad             | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Freedman        | Jeffrey          | NONE  | NONE                        | NONE                            | NONE   | NONE   | IOpinc.  |
| Friedman        | David            | NONE  | NONE                        | NONE                            | Merck, Allergan, Pfizer, Bausch & Lomb, Alcon  | NONE   | NONE   |
| Fujimoto        | James            | NONE  | Optovue                     | NONE                            | NONE   | Carl Zeiss Meditec, Optovue                        | NONE   |
| Gandolfi        | Stefano          | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Garway-Heath    | David (Ted)      | Allergan; Carl Zeiss Meditec; Heidelberg Engineering; Pfizer; Optovue | NONE                        | NONE                            | Alcon; Allergan; Bausch and Lomb; Carl Zeiss Meditec; Glaxo Smith Kline; Merck Sharp and Dohme; Pfizer | Moorfields Motion Displacement Test                | Allergan; Carl Zeiss Meditec; Heidelberg Engineering; Merck Sharp and Dohme; Pfizer; Optovue |
| Gazzard         | Gus              | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Ge*             | Jian             |   |                             |                                 |  |  |  |
| Gedde           | Steven           | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| George          | Ronnie           | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Geyer           | Orna             | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Goldberg        | Ivan             | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Gomez Goyeneche | Hector Fernando  | NONE  | NONE                        | NONE                            | Nidek  | NONE   | Nidek  |
| Goñi            | Francisco Javier | NONE  | NONE                        | NONE                            | NONE   | NONE   | Carl Zeiss Meditec   |
| Graham          | Stuart           | NONE  | NONE                        | NONE                            | NONE   | Sydney University                                  | NONE   |
| Greenfield      | David            | NONE  | NONE                        | NONE                            | Alcon, Allergan, Topcon, Quark   | NONE   | Carl Zeiss Meditec, Heidelberg Engineering, Optovue  |
| Grehn           | Franz            | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Grigera         | Daniel           | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE   |

| Family Name   | First Name  | Financial support   | Personal Financial Interest | Supported / Contracted Research | Advisory board / Consulting   | Patent Holder / Receipt of intellectual / Property | Salary / royalty / Honoraria   |
|---------------|-------------|---|-----------------------------|---------------------------------|---|--|--|
| Gruber*       | Denis       |   |                             |                                 |   |  |  |
| Grus          | Franz       | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Gupta         | Neeru       | NONE  | NONE                        | NONE                            | Alcon Laboratories Inc., Allergan Inc., Merck & Co. Inc. Pfizer Ophthalmics | NONE   | NONE   |
| Haigis        | Wolfgang    | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Hangai        | Masanori    | NONE  | NONE                        | NONE                            | Topcon, Nidek   | NONE   | Heidelberg Engineering   |
| Harris        | Alon        | Research Grants, MSD, Allergan, Alcon, Pfizer                             | NONE                        | NONE                            | NONE  | NONE   | Lecture honorarium, MDS, Allergan, Alcon, Pfizer                       |
| Harwerth      | Ronald      | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| He            | Mingguang   | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Healey        | Paul        | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Heijj*        | Anders      |   |                             |                                 |   |  |  |
| Herndon       | Leon        | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Hitchings     | Roger       | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Ho            | Ching Lin   | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Hoffmann      | Esther      | European Commission, Brussels, Belgium (BIOMED II program) and Merck & Co | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Holló         | Gabor       | NONE  | NONE                        | NONE                            | Alcon, Allergan, MSD, Pfizer, Santen, Optovue, Zeiss                        | NONE   | Alcon, Allergan, MSD, Pfizer, Santen, Optovue, Zeiss                   |
| Hommer        | Anton       | NONE  | NONE                        | NONE                            | Allergan, Pfizer, Merck   | NONE   | Alcon, Allergan, Askin, Heidelberg Inc., Merck, Nexus, Pfizer, Santen, |
| Honjo         | Megumi      | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Howden*       | T.          |   |                             |                                 |   |  |  |
| Inatani       | Masaru      | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Ishida        | Kyoko       | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Iwase         | Aiko        | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Januleviciene | Ingrida     | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Jea           | Seung Young | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |

| Family Name | First Name | Financial support  | Personal Financial Interest   | Supported / Contracted Research | Advisory board / Consulting   | Patent Holder / Receipt of intellectual Property / Property  | Salary / royalty / Honoraria   |
|-------------|------------|--|---|---------------------------------|---|--|--|
| Johnson     | Chris      | Allergan - reading center services<br>Lundbeck - reading center services<br>Boehringer Ingelheim - reading center services | NONE  | NONE                            | Allergan Welch Allyn  | NONE   | NONE   |
| Johnston    | Rob        | NONE   | Medisoft Limited, I am the Medical Director (unpaid) and also a major shareholder | NONE                            | NONE  | NONE   | NONE   |
| Johnstone   | Murray     | NONE   | NONE  | NONE                            | NONE  | NONE   | NONE   |
| Jonas       | Jost       | NONE   | NONE  | NONE                            | NONE  | NONE   | NONE   |
| Jonasson    | Fridbert   | NONE   | NONE  | NONE                            | NONE  | NONE   | NONE   |
| Kahook      | Malik      | Alcon, Allergan, Actelion, Merck, Genentech  | ShapeTech LLC, ShapeOphthalmicsLLC  | NONE                            | Alcon, Allergan, Actelion, Merck, Genentech   | Alcon  | NONE   |
| Kashiwagi   | Kenji      | NONE   | NONE  | NONE                            | NONE  | NONE   | NONE   |
| Katz        | L. Jay     | Lumenis  | NONE  | NONE                            | NONE  | NONE   | Lumenis  |
| Kaufman     | Paul       | Inspire Lens AR, Inc Nu-Lens Santen WARF   | NONE  | NONE                            | Alcon, Allergan Altheos, Inc Bausch & Lomb Campbell Alliance Genentech/ Huntsworth Hlth Infusion Pharma Inspire Johnson & Johnson KeyQuest Health LeerickSwann Med Univ South Carolina, Pfizer QLT, Santen Univ | WARF   | Alcon, Allergan Altheos, Inc Bausch & Lomb Genentech/ Huntsworth Hlth Inspire Johnson & Johnson KeyQuest Health LeerickSwann Med Univ South Carolina, Pfizer QLT, Santen Univ of Florida Yale University |
| Kee         | Changwon   | NONE   | NONE  | NONE                            | NONE  | NONE   | NONE   |
| Khaw        | Peng Tee   | AsiraZeneca, Pfizer, GSK   | Lumemed   | NONE                            | AstraZeneca, Pfizer, Allergan, Promedior, EyeSense, Roche, AqueSys, Bausch & Lomb, Novartis, Alcon  | Inventor: Matrix Metalloproteinase inhibitor for scarring, Slow release preparations, stem cells for eyes. | Pfizer, Bausch & Lomb, Alcon   |

| Family Name       | First Name  | Financial support  | Personal Financial Interest | Supported / Contracted Research | Advisory board / Consulting                          | Patent Holder / Receipt of Intellectual Property | Salary / royalty / Honoraria                               |
|-------------------|-------------|--|-----------------------------|---------------------------------|--|--|--|
| Kim               | Dong Myung  | NONE   | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Klink             | Thomas      | NONE   | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Konstas           | Anastasios  | Alcon, Allergan, MSD, Pfizer   | NONE                        | NONE                            | Alcon, Allergan, MSD                                 | NONE   | Alcon, Allergan, MSD, Pfizer                               |
| Kook              | Michael     | NONE   | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Krupin*           | Theodore    |  |                             |                                 |  |  |  |
| Kuwayama          | Ysuaki      | NONE   | NONE                        | NONE                            | Santen, Pfizer Japan, Alcon Japan, Senjyu, Kowa, MSD | NONE   | NONE   |
| Kymes             | Steven      | Pfizer, Inc.; Allergan; Genentech, Inc.; TreeAge Software                | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Labbé             | Antoine     | NONE   | NONE                        | NONE                            | NONE   | NONE   | Heidelberg Engineering                                     |
| Lachkar           | Yves        | NONE   | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Laloum            | Jacques     | NONE   | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Lam               | Dennis      | NONE   | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Lambrou*          | George      |  |                             |                                 |  |  |  |
| Latina            | Mark        | Lumenis, Inc.  | NONE                        | NONE                            | Lumenis, Inc.  | Lumenis, Inc - SLT                               | Lumenis, Inc   |
| Lemij             | Hans        | Pfizer, Zeiss Meditec  | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Lerner            | Fabian      | NONE   | NONE                        | NONE                            | Alcon, MSD, Sidus                                    | NONE   | Alcon, MSD, Sidus  |
| Leuenberger       | Edgar       | NONE   | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Leung             | Christopher | Carl Zeiss Meditec, Optovue, Tomey, Alcon, Lumenis                       | NONE                        | NONE                            | Merck, Carl Zeiss Meditec                            | NONE   | Carl Zeiss Meditec, Heidelberg Engineering, Lumenis, Alcon |
| Leung             | Dexter      | NONE   | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Levkovitch-Verbin | Hani        | NONE   | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Liebmann          | Jeffrey     | Topcon, Inc., Heidelberg Engineering, GmBH, Optovue, Inc., Dyopsis, Inc. | NONE                        | NONE                            | Allergan, Inc., Alcon, Inc., Pfizer, Inc.            | NONE   | Allergan, Inc., Alcon, Inc.                                |
| Lin               | Shan        | Genentech; Alcon; Allergan   | NONE                        | NONE                            | NONE   | NONE   | NONE   |
| Lindsey           | James       | NONE   | NONE                        | NONE                            | NONE   | NONE   | NONE   |

| Family Name | First Name     | Financial support   | Personal Financial Interest | Supported / Contracted Research | Advisory board / Consulting                  | Patent Holder / Receipt of intellectual / Property | Salary / royalty / Honoraria |
|-------------|----------------|---|-----------------------------|---------------------------------|--|--|------------------------------|
| Liu         | John H.K.      | Aerie, Alcon, Allergan, Pfizer, Sensimed  | NONE                        | NONE                            | NONE   | NONE   | NONE                         |
| Loewen      | Nils           | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE                         |
| Lu          | Da-Wen         | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE                         |
| Lynch       | Mary           | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE                         |
| Mackey      | David          | Pfizer Australia Fellowship Alcon Research Institute  | NONE                        | NONE                            | NONE   | NONE   | NONE                         |
| Manassakorn | Anita          | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE                         |
| Mandal      | Anil Kumar     | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE                         |
| Mani        | Baskaran       | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE                         |
| Mansberger  | Steven         | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE                         |
| Mansouri    | Kaweh          | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE                         |
| Martin      | Keith          | NONE  | NONE                        | NONE                            | Allergan, Alcon, Pfizer                      | NONE   | NONE                         |
| Matsumoto   | Chota          | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE                         |
| Maul        | Eugenio        | NONE  | NONE                        | NONE                            | NONE   | NONE   | Allergan                     |
| McAllister  | James          | NONE  | NONE                        | NONE                            | NONE   | NONE   | NONE                         |
| McLaren     | Grant Drummond | Allergan has sponsored my airfare and accommodation to Glaucoma and ophthalmology congresses in the past. Alcon and Pfizer and MSD as well. The purpose is for my educational input and for me to deliver educational lectures to colleagues in the ophthalmology profession. | Not applicable              | Not applicable                  | Not applicable                               | NONE   | Allergan, Alcon and MSD      |
| Medeiros    | Felipe         | Carl-Zeiss Meditec, Alcon, Allergan, Merck, Pfizer, Reichert, Sensimed  | NONE                        | NONE                            | Alcon, Allergan, Pfizer                      | NONE   | NONE                         |
| Melamed     | Shlomo         | Lumenis, Ellex, Allergan, IOPTima, MSD, Teva, Solx  | NONE                        | NONE                            | Allergan, MSD, Lumenis, Ellex, IOPTima, Solx | NONE   | Ellex, Lumenis               |



| Family Name     | First Name    | Financial support                          | Personal Financial Interest | Supported / Contracted Research | Advisory board / Consulting   | Patent Holder / Receipt of Intellectual Property | Salary / royalty / Honoraria            |
|-----------------|---------------|--|-----------------------------|---------------------------------|---|--|---|
| Mermoud         | André         | MSD, Anteis, Pfizer, Alcon, Staar Surgical | NONE                        | NONE                            | NONE  | /  | MSD, Alcon, Pfizer                      |
| Michelson       | Georg         | NONE                                       | NONE                        | NONE                            | NONE  | NONE   | NONE                                    |
| Mills           | Richard       | NONE                                       | NONE                        | NONE                            | Bausch and Lomb   | NONE   | NONE                                    |
| Molteno         | Anthony       | NONE                                       | Molteno Ophthalmic Limited  | NONE                            | NONE  | NONE   | NONE                                    |
| Morgan*         | James         |  |                             |                                 |   |  |   |
| Morselli*       | Simonetta     |  |                             |                                 |   |  |   |
| Mosaed          | Sameh         | NONE                                       | NONE                        | NONE                            | NONE  | NONE   | NONE                                    |
| Nakazawa        | Toru          | NONE                                       | NONE                        | NONE                            | NONE  | NONE   | NONE                                    |
| Nardi           | Marco         | NONE                                       | NONE                        | NONE                            | Alcon, Transcend  | NONE   | Alcon                                   |
| Netland*        | Peter         |  |                             |                                 |   |  |   |
| Nicolela*       | Marcelo       |  |                             |                                 |   |  |   |
| Noecker*        | Robert        |  |                             |                                 |   |  |   |
| Nolan           | Winifred      | NONE                                       | NONE                        | NONE                            | NONE  | NONE   | NONE                                    |
| Nordmann        | Jean-Philippe | NONE                                       | NONE                        | NONE                            | Alcon, Allergan, Pfizer, MSD  | NONE   | NONE                                    |
| O'Brien*        | Colm          |  |                             |                                 |   |  |   |
| Palmberg        | Paul          | NONE                                       | NONE                        | NONE                            | NONE  | NONE   | NONE                                    |
| Pang            | Chi Pui       | NONE                                       | NONE                        | NONE                            | NONE  | NONE   | NONE                                    |
| Parikh          | Rajul         | NONE                                       | NONE                        | NONE                            | NONE  | NONE   | NONE                                    |
| Park            | Ki Ho         | NONE                                       | NONE                        | NONE                            | Alcon Laboratory, MSD, Pfizer, Allergan                               | NONE   | Alcon Laboratory, MSD, Pfizer, Allergan |
| Parrish II, MD  | Richard       | NONE                                       | NONE                        | NONE                            | InnFocus LLC, AqueSys, Inc., Glaukos Corporation, Bausch & Lomb, Inc. | US Patent for sustained release of fluorouracil  | NONE                                    |
| Pasquale        | Louis         | NONE                                       | NONE                        | NONE                            | NONE  | NONE   | NONE                                    |
| Pérez Grossmann | Rodolfo       | NONE                                       | NONE                        | NONE                            | NONE  | NONE   | NONE                                    |
| Pfeiffer        | Norbert       | NONE                                       | NONE                        | NONE                            | NONE  | NONE   | NONE                                    |
| Pillunat*       | Lutz E.       |  |                             |                                 |   |  |   |
| Piltz-Seymour   | Jody          | NONE                                       | NONE                        | Alcon, Allergan, Merck          | Sucampo Pharmaceuticals   | NONE   | NONE                                    |
| Prum            | Bruce         | NONE                                       | NONE                        | NONE                            | Allergan  | NONE   | NONE                                    |

| Family Name   | First Name    | Financial support                            | Personal Financial Interest | Supported / Contracted Research | Advisory board / Consulting  | Patent Holder / Receipt of intellectual Property / Property | Salary / royalty / Honoraria   |
|---------------|---------------|--|-----------------------------|---------------------------------|--|---|--|
| Quigley       | Harry         | Zeiss Meditec, Heidelberg Instruments, Alcon | NONE                        | NONE                            | Genentech, Alcon, Allergan, Ono  | NONE  | NONE   |
| Radcliffe     | Nathan        | NONE   | NONE                        | NONE                            | Ophthalmic Imaging Systems, Carl Zeiss Meditec, Allergan, Inc., Alcon Laboratories.  | NONE  | Allergan, Inc., Alcon Laboratories, Ophthalmic Imaging Systems, Carl Zeiss Meditec, Reichert, Merck Pharmaceuticals. |
| Ramakrishnan* | R.            |  |                             |                                 |  |   |  |
| Ramdas        | Wishal        | NONE   | NONE                        | NONE                            | NONE   | NONE  | NONE   |
| Ramulu        | Pradeep       | NONE   | NONE                        | NONE                            | NONE   | NONE  | NONE   |
| Realini       | Anthony       | Lumenis                                      | NONE                        | NONE                            | NONE   | NONE  | Lumenis  |
| Renard*       | Jean Paul     |  |                             |                                 |  |   |  |
| Rhee          | Douglas       | Alcon  | NONE                        | NONE                            | Alcon, Allergan, Merck, Santen   | NONE  | Alcon, Allergan, Merck, Santen   |
| Ritch         | Robert        | NONE   | NONE                        | NONE                            | NONE   | NONE  | NONE   |
| Rojanapongpun | Prin          | NONE   | NONE                        | NONE                            | NONE   | NONE  | NONE   |
| Romanet*      | Jean Paul     |  |                             |                                 |  |   |  |
| Rossetti      | Luca          | NONE   | NONE                        | NONE                            | NONE   | NONE  | NONE   |
| Rouland       | Jean François | NONE   | NONE                        | NONE                            | Allergan, Alcon Pfizer, Thea Zeiss MSD   | NONE  | NONE   |
| Sahel         | Jose-Alain    | Noveea-Sanofi                                | NONE                        | NONE                            | Noveea-Sanofi, Allergan, Alcon   | Novartis, Noveea-Sanofi                                     | Noveea-Sanofi  |
| Sakai         | Hiroshi       | NONE   | NONE                        | NONE                            | NONE   | NONE  | NONE   |
| Sakata        | Lisandro      | NONE   | NONE                        | NONE                            | NONE   | NONE  | NONE   |
| Samuelson     | Thomas        | NONE   | NONE                        | NONE                            | Alcon, AcuMEMS, Allergan, Advanced Medical Optics, AqueSys, EndOptiks, Glaukos, iScience, Ivantis, Ocular Surgery News, Optonol, Pfizer, QLT, Santen, Slack Inc. | NONE  | NONE   |

| Family Name          | First Name   | Financial support  | Personal Financial Interest | Supported / Contracted Research | Advisory board / Consulting   | Patent Holder / Receipt of intellectual / Property  | Salary / royalty / Honoraria  |
|----------------------|--------------|--|-----------------------------|---------------------------------|---|---|---|
| Sanfilippo           | Paul         | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE  |
| Schargus             | Marc         | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE  |
| Schlötzer-Schrehardt | Ursula       | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE  |
| Schmetterer          | Leopold      | Croma, Merck, Allergan, Pharmaselect, Santen, Sucampo, Ursa Pharma, Abbott, Lux, Baxter, Wyeth, Imedos | NONE                        | NONE                            | Merck, Croma, Bausch&Lomb, Alcon, Sucampo   | NONE  | Croma, Merck, Bausch&Lomb, Alcon, Pfizer, Thea, Sucampo, Imedos, Novartis, Pharmaselect |
| Schuman              | Joel         | NONE   | NONE                        | NONE                            | NONE  | Massachusetts Institute of Technology IP licensed to Carl Zeiss Meditec, Inc. and University of Pittsburgh IP licensed to Biopptgen, Inc. | NONE  |
| Schwartz             | Michal       | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE  |
| Sellem               | Eric         | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE  |
| Shaarawy*            | Tarek        |  |                             |                                 |   |   |   |
| Sherwood             | Mark         | BioVascular Inc LPath Inc  | NONE                        | NONE                            | Merck, Alcon, Allergan  | NONE  | Merck, Allergan   |
| Shrivastava          | Anurag       | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE  |
| Sihota               | Ramanjit     | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE  |
| Singh                | Kuldev       | NONE   | NONE                        | NONE                            | Alcon, Allergan, Santen, Ivantis, Transcoend, iScience                            | NONE  | NONE  |
| Sirbat*              | Daniel       |  |                             |                                 |   |   |   |
| Sit                  | Arthur       | Glaukos Corp.  | NONE                        | NONE                            | Alcon Laboratories Inc., Allergan Inc., Glaukos Corp. AcuMEMS (unpaid consultant) | NONE  | NONE  |
| So                   | Kwok-Fai     | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE  |
| Solebo               | Ameenat Lola | NONE   | NONE                        | NONE                            | NONE  | NONE  | NONE  |
| Sourdille*           | Philippe     |  |                             |                                 |   |   |   |
| Spaeth               | George       | NONE   | NONE                        | NONE                            | NONE  | NONE  | Alcon, Allergan, Merck, Pfizer  |

| Family Name  | First Name   | Financial support  | Personal Financial Interest | Supported / Contracted Research | Advisory board / Consulting                                       | Patent Holder / Receipt of intellectual / Property | Salary / royalty / Honoraria               |
|--------------|--------------|--|-----------------------------|---------------------------------|---|--|--|
| Stamper      | Robert       | NONE   | NONE                        | NONE                            | Allergan Inc.; Pfizer Inc; Alcon Inc; Glaukos Inc; Transcend Inc. | NONE   | Allergan Inc; Pfizer Inc;                  |
| Standefer    | James        | NONE   | NONE                        | NONE                            | NONE  | NONE   | NONE                                       |
| Strouthidis* | Nicholas     |  |                             |                                 |   |  |  |
| Sugiyama     | Kazuhiisa    | NONE   | NONE                        | NONE                            | NONE  | NONE   | NONE                                       |
| Sung         | Kyung Rim    | NONE   | NONE                        | NONE                            | NONE  | NONE   | NONE                                       |
| Susanna Jr   | Remo         | NONE   | NONE                        | NONE                            | Pfizer, Alcon, Merck Sharp Dohme, Allergan                        | NONE   | Pfizer, Alcon, Merck Sharp Dohme, Allergan |
| Tan          | James C. H.  | NONE   | NONE                        | NONE                            | NONE  | No firm  | NONE                                       |
| Tanihara     | Hideobu      | Santen, Pfizer, Alcon, Senju, MSD, Otsuka, Kowa                      | NONE                        | NONE                            | Senju, Santen, Alcon, Kowa  | NONE   | NONE                                       |
| Tanna        | Angelo       | NONE   | NONE                        | NONE                            | Alcon; Apotex, Inc.   | NONE   | NONE                                       |
| Teekhasaene* | Chaiwat      |  |                             |                                 |   |  |  |
| Tello        | Celso        | NONE   | NONE                        | NONE                            | SOLX  | NONE   | NONE                                       |
| Tham         | Clement      | NONE   | NONE                        | NONE                            | NONE  | NONE   | NONE                                       |
| Thieme*      | H            |  |                             |                                 |   |  |  |
| Thomas       | Ravi         | NONE   | NONE                        | NONE                            | NONE  | NONE   | NONE                                       |
| Thygesen     | John         | Alcon, Allergan, Merck, Pfizer, Santen                               | NONE                        | NONE                            | Alcon, Allergan, Merck, Pfizer, Santen                            | NONE   | Alcon, Allergan, Merck, Pfizer, Santen     |
| Tomita       | Goji         | NONE   | NONE                        | NONE                            | NONE  | NONE   | NONE                                       |
| Topouzis     | Fotis        | Alcon Laboratories Inc, Pfizer Inc, Novartis, Heidelberg Engineering | NONE                        | NONE                            | Merck & Co Inc, Pfizer Inc  | NONE   | Alcon Laboratories Inc, Pfizer Inc         |
| Toris        | Carol        | NONE   | NONE                        | NONE                            | NONE  | NONE   | NONE                                       |
| Traverso*    | Carlo Enrico |  |                             |                                 |   |  |  |
| Trope        | Graham       | NONE   | NONE                        | NONE                            | NONE  | NONE   | NONE                                       |
| Tsai         | James        | Merck  | NONE                        | NONE                            | Alcon, Allergan, Inspire, Merck, Pfizer                           | NONE   | NONE                                       |

| Family Name  | First Name | Financial support   | Personal Financial Interest | Supported / Contracted Research | Advisory board / Consulting   | Patent Holder / Receipt of intellectual Property | Salary / royalty / Honoraria   |
|--------------|------------|---|-----------------------------|---------------------------------|---|--|--|
| Tuulonen     | Anja       | NONE  | NONE                        | NONE                            | NONE  | NONE   | Direct and indirect industrial support is essential part of all meetings organized by international glaucoma societies in which the main sponsors are Alcon, Allergan, Heidelberg Engineering, Merck, Pfizer and Santen. |
| Ubaud*       | Charles    |   |                             |                                 |   |  |  |
| Uusitalo*    | Hannu      |   |                             |                                 |   |  |  |
| Valtôt       | Françoise  | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Varma        | Rohit      | Allergan, Inc., Genentech, National Eye Institute, Replenish, Inc.                              | Aquesys, Replenish, Inc.    | NONE                            | Allergan, Inc., Aquesys, Genentech, Merck & Co., Inc., Replenish, Inc.                    | NONE   | NONE   |
| Vijaya       | Lingam     | NONE  | NONE                        | NONE                            | MSD and Allergan  | NONE   | Allergan   |
| Viswanathan* | Ananth     |   |                             |                                 |   |  |  |
| Vizzeri      | Gianmarco  | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Vold         | Steven     | NONE  | NONE                        | NONE                            | iScience Interventional, Alcon  | NONE   | NONE   |
| Wand         | Martin     | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Wang         | Lan        | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Wang         | Ningli     | NONE  | NONE                        | NONE                            | NONE  | NONE   | NONE   |
| Weinreb      | Robert     | Heidelberg Engineering, National Eye Institute, Nidek, Optovue, Paradigm, Topcon, Zeiss-Meditec | NONE                        | NONE                            | Acix, Alcon, Allergan, Vital Sensors, Amira, Bausch&Lomb, Glaxo, Genentech, Implantsdata, | NONE   | Alcon, Allergan, Bausch&Lomb, Genentech, Merck, Optovue, Pfizer  |



| Family Name | First Name | Financial support  | Personal Financial Interest | Supported / Contracted Research      | Advisory board / Consulting  | Patent Holder / Receipt of intellectual / Property  | Salary / royalty / Honoraria                          |
|-------------|------------|--|-----------------------------|--------------------------------------|--|---|---|
|             |            |  |                             |                                      | Merck, Sesotec, Novartis, Optovue, Othera, Pfizer, Sensimed, Solx, Topcon, Zeiss-Meditec |   |   |
| Wells       | Tony       | Alcon, Allergan  | NONE                        | NONE                                 | Alcon, Allergan  | NONE  | NONE  |
| Wheeler     | Larry      | NONE   | NONE                        | Employee of Allergan Pharmaceuticals | NONE   | NONE  | NONE  |
| Wiggs       | Janey      | NONE   | NONE                        | NONE                                 | NONE   | NONE  | NONE  |
| Wilson      | M. Roy     | NONE   | NONE                        | NONE                                 | NONE   | NONE  | NONE  |
| Wollstein   | Gadi       | NONE   | NONE                        | NONE                                 | NONE   | NONE  | NONE  |
| Wong        | Tina       | NONE   | NONE                        | NONE                                 | NONE   | NONE  | NONE  |
| Yamamoto    | Tetsuya    | Pfizer Japan, Alcon Japan, Santen, Senju   | NONE                        | NONE                                 | Pfizer, Alcon Japan, Kowa, Senju, Otsuka, Banyu  | NONE  | Pfizer, Alcon Japan, Kowa, Senju, Otsuka, Santen, MSD |
| Yücel       | Yeni       | NONE   | NONE                        | NONE                                 | NONE   | NONE  | NONE  |
| Zalta       | Alan       | NONE   | NONE                        | NONE                                 | NONE   | I have multiple copyrights with the United States Copyright Office for the stereoscopic optic disc images that I will be projecting during my course (VA 1195-244-, January 24, 2003; Vau 536964-, October 15, 2001; Txu 989109-, October 23, 2000) | NONE  |
| Zangwill    | Linda      | Heidelberg Engineering, Topcon Medical Systems, Inc, Optovue, Carl Zeiss Meditec | NONE                        | NONE                                 | NONE   | NONE  | Heidelberg Engineering                                |
| Zeyen       | Thierry    | Investigator initiated study grant from Pfizer                                   | NONE                        | NONE                                 | Advisory board member Pfizer   | NONE  | NONE  |
| Zhang       | Chun       | NONE   | NONE                        | NONE                                 | NONE   | NONE  | NONE  |
| Zhao        | Jialiang   | NONE   | NONE                        | NONE                                 | NONE   | NONE  | NONE  |

## PRESENTERS INDEX

### (with reference to page numbers)

- Abou-el Enein A., 17; 18  
Abu-Amero K., 21  
Acosta J., 16  
Aguiar C., 21  
Agulto M.B., 54  
Aihara M., 20; 50  
Al Aswad L., 33  
Alaswad L., 18  
Aldasheva N., 19  
Aljadaan I., 21  
Allouch C., 46  
Alobeidan S., 21  
Alraji A., 21  
Alvarado J., 31; 34; 54  
Amirov A., 19  
Anastasopoulos E., 20  
Ancker E., 47; 56  
Anton Lopez A., 43  
Aptel F., 36  
Araie M., 23; 24; 29; 40; 48  
Ariga M., 16  
Asawaphureekorn S., 50  
Asrani S., 40  
Atanassov M., 18  
Aung T., 26; 28; 32; 34  
Azuara Blanco A., 22; 26; 40
- Badeeb O., 21  
Baerveldt G., 32; 56  
Barton K., 23; 31; 33; 42; 42; 51  
Bastelica A., 46  
Baudouin C., 22; 25; 33; 35; 53  
Beck A.D., 52; 54  
Beeram P.K.R., 26  
Bellucci R., 55  
Ben Amor K., 33; 47  
Bengtsson B., 27; 35  
Berlin M., 49  
Best S., 53  
Bettin P., 37  
Bhorade A., 14  
Bloom P., 48  
Blumenthal E.Z., 39; 53  
Böhm A., 43
- Botabekova T., 19  
Bourne R., 35  
Bowd C., 34  
Brandt J.D., 31; 32; 33; 52; 54; 55  
Bressont Dumont H., 47  
Bron A., 22; 24; 25; 35  
Brookes J., 25  
Brown R., 30  
Budenz D.L., 28; 34  
Burgansky-Eliash Z., 48  
Burk R., 31  
Burr J., 35; 56  
Buys Y.M., 15; 51; 54
- Carassa R., 27; 51  
Carvalho M., 21  
Chacón C., 16  
Chakrabarthi S., 42; 48; 51  
Chang R., 54  
Chauhan B., 35; 43  
Chen T.C., 52  
Chen Z., 49  
Chew P., 41  
Cillino S., 37  
Clark A., 46  
Coelho A., 21  
Congdon N., 26; 33  
Coote M., 15  
Cordeiro F., 32; 42; 50; 53  
Costa V.P., 40; 49  
Craig J., 15; 34; 42; 48  
Crandall A.S., 50; 51; 55  
Crowston J.G., 15; 28; 35  
Csiszar K., 31
- D'Mellow G., 39  
Da Luz Freitas M., 21  
Dada T., 39; 48; 54  
Dahan E., 32; 36; 37; 43; 49  
Dalidovich A., 19  
Danias J., 42  
De Jong L., 36  
De Moraes C.G., 14; 27; 34; 43  
Denis P., 22; 36; 44
- Detorakis E.T., 25  
Diagourtas A., 20  
Diestelhorst M., 40  
Downs C., 14
- Egorov E., 19  
Eke T., 33  
El Sayyad F., 17; 33; 54  
El-Beltagi T., 17  
El-Emari T., 17  
Epstein D., 25; 46  
Erichiev V., 19  
Espino García A., 25  
Estrela Silva S., 21
- Fang S.K., 48  
Fechtner R., 30; 33; 35; 36; 51  
Fedulov A., 19  
Feldman R., 42  
Fellman R.L., 30; 50; 54  
Fernando Sieminski S., 51  
Feuer W.J., 32; 34  
Figuereido A., 21  
Fingeret M., 32; 34; 40; 51  
Flammer J., 40  
Flanagan J., 48; 51  
Fortune B., 34  
Freedman J., 32; 34; 42  
Friedman D., 26; 32; 48  
Fujimoto J.C., 32; 41; 53
- Gandolfi S., 55  
Garway-Heath D., 25; 33; 35; 40; 45  
Gazzard G., 26; 33; 47; 50  
Ge J., 26  
Gedde S.J., 14; 34; 42; 51  
George R., 16; 26; 35; 49  
Geyer O., 31; 51  
Gil Carrasco F., 16  
Goldberg I., 15; 23; 24; 25; 36; 44; 48; 50; 56  
Gomez Goyeneche F., 33  
Goñi F.J., 30; 48; 51

---

Graham S., 15; 34  
 Greenfield D.S., 14; 23; 27; 30; 50  
 Grehn F., 22; 38; 41; 49; 52; 54; 56  
 Grigera D.E., 27; 48; 54  
 Gruber D., 46  
 Grus F., 51  
 Guguchkova Pr., 19  
 Gupta N., 28; 41; 46; 50  
 Gupta V., 16  
  
 Haigis W., 50  
 Hammouda L., 17  
 Hangai M., 28; 34; 53  
 Harasymowycz P., 15  
 Harris A., 40; 48  
 Hartleben C., 17  
 Harwerth, R.S., 48; 52  
 He M., 26; 32; 47; 48  
 Healey P., 15; 23; 27; 56  
 Heijl A., 27; 30; 35  
 Hergeldzhieva-Fileva T., 19  
 Herndon L.W., 33; 47  
 Hitchings R.A., 22; 24; 43  
 Ho C.L., 33  
 Hoffmann E.M., 53  
 Holló G., 31; 52  
 Hommer A., 33  
 Honjo M., 48  
 Hossain M., 18  
 Howden T., 48  
  
 Inatani M., 48  
 Ishida K., 51  
 Islam M.N., 18  
 Islamov S., 19  
 Ivanova S., 19  
 Iwase A., 51; 53  
  
 Januleviciene I., 40  
 Jazzaf A., 17  
 Jea S.Y., 49  
 Johnson A., 51  
 Johnson C.A., 48  
 Johnston R., 51  
 Johnstone M., 46  
 Jonas J., 28; 33; 35; 39  
 Jonasson F., 34; 42  
 Jordan J., 52  
  
 Kagemann L., 43  
  
 Kahook M., 29; 35; 36; 43; 44; 48; 51  
 Karim M.A., 18  
 Karim Z., 18  
 Karmiris E., 20  
 Kasahara N., 26  
 Kashiwagi K., 35; 49  
 Kasimov A., 19  
 Katz L.J., 34; 39  
 Kaufman P.L., 28; 35; 46  
 Kee C., 20; 54  
 Khan N., 18  
 Khaw P.T., 41; 51; 52  
 Kim D., 47  
 Kim T.W., 20  
 Kirilova Y., 19  
 Klink T., 44  
 Konareva M., 18; 19  
 Konstas A.G.P., 31; 52  
 Konstas A.P., 20  
 Kook M.S., 20; 26  
 Kramorenko Y., 19  
 Krupin T., 14; 39  
 Kumar H., 16  
 Kuroyedov A., 19  
 Kuwayama Y., 31  
 Kymes S., 16; 35  
  
 Labbé A., 46  
 Lachkar Y., 33; 41; 46; 50  
 Lai J., 37  
 Lai M., 37  
 Laloum J., 46; 50  
 Lam D., 24; 47; 51; 55  
 Lambrou G.N., 33; 56  
 Latina M.A., 31; 34  
 Lemij H.G., 32; 34; 40  
 Lerner S.F., 29; 41; 50  
 Leuenberger E.U., 33  
 Leung C.K.S., 20; 29; 30; 32; 34; 40; 49; 56  
 Leung Yu-Lung D., 27  
 Liang Y., 26  
 Liebmann J.M., 23; 24; 27; 29; 41; 45  
 Lin J., 37  
 Lin S., 28; 44; 48  
 Lindsey J.D., 31  
 Liu J.H.K., 33; 40  
 Loewen N., 41; 50  
  
 Lovett Joe, 33  
 Lu D., 51; 53  
 Lynch J.F., 16  
 Lynch M., 32  
  
 Mackey D., 15; 33; 34; 42; 48  
 Manassakorn A., 53  
 Mandal A.K., 32; 52; 54  
 Mani B., 28  
 Mannaf Sk.M.A., 18  
 Mansberger S.L., 14; 26  
 Mansouri K., 39  
 Marchenko L., 19  
 Martin K., 23; 30; 35; 50  
 Matin M.A., 18  
 Matsumoto C., 49  
 Maul E., 52  
 May F., 34  
 Maynar Tavares I., 16  
 McAllister J., 34  
 McLaren G.D., 34; 55  
 Medeiros F., 28; 29; 32; 34; 35; 39; 43; 49; 53; 56  
 Melamed S., 23; 24; 31; 35; 41; 44; 45; 49  
 Mermoud A., 37; 44  
 Meyer D., 52  
 Micale R., 43  
 Michelson G., 40  
 Mills R., 53  
 Mishev L., 19  
 Misheva A., 19  
 Mokbel T.H., 17  
 Molteno A., 32; 34; 42  
 Morales J., 21  
 Morgan J.E., 28; 35  
 Morselli S., 55  
 Mosaed S.S., 45  
 Mossboeck G., 49  
 Moster M., 36  
 Mura J.J., 16  
 Murthy G., 16  
 Musch D., 43  
 Myers J., 34  
  
 Nakazawa T., 50  
 Nardi M., 30; 52  
 Nassar M., 18  
 Nesher R., 49  
 Netland P.A., 32; 51

---

- Nicolela M., 15; 27; 35  
Noecker R., 31; 35; 52  
Nolan W., 32; 47  
Nordmann J.P., 22; 29; 46; 50  
Noureddin B., 17
- O'Brien C., 35  
Ouertani A., 17; 17
- Palmberg P., 55  
Pang C., 34; 48  
Parikh R.S., 43  
Park K.H., 20; 27  
Parra J.C., 16  
Parrish R.K., 30; 51  
Parthsarthi S., 16  
Pasi Pehkonen P., 51  
Pasquale L.R., 42  
Patel N., 52  
Pereira I., 43  
Pérez Grossman R., 17; 40; 51  
Peterson Faralli J., 46  
Petkova N., 18; 19  
Pfeiffer N., 25; 29; 30; 33; 39; 41;  
44; 45; 55  
Pillai M.R., 16  
Pillunat L.E., 33  
Piltz-Seymour J., 40  
Prum B.E., 35
- Quigley H., 26; 50
- Radcliffe N., 45; 51  
Ramakrishnan R., 33  
Ramdas W., 34  
Ramulu P., 45; 56  
Realini A.D., 39  
Renard J.P., 22  
Rhee D.J., 31; 49; 53  
Ritch R., 23; 31  
Rojana Pongpun P., 30; 47  
Romanet J., 32  
Rossetti L.M., 26  
Rouland J.P., 22; 32  
Roy S., 37  
Rozhko Y., 19  
Russ H., 49
- Sahel J.A., 28  
Sakai H., 50
- Sakata L., 34; 49  
Samuelson T., 25; 49; 50; 55  
Sanfilippo P., 34  
Sathyan P., 37  
Schargus M., 22  
Schlötzer-Schrehardt U., 31  
Schmetterer L., 27; 33  
Schuman J.S., 24; 32; 34; 41; 43;  
51; 53  
Schwartz M., 50; 56  
Sedky A., 17  
Sehi M., 14  
Sellem E., 24; 35; 43; 46  
Shaarawy T., 17; 23; 24; 29; 36;  
39; 48; 49; 52; 55  
Shahid Z.S., 18  
Sherwood M., 32; 35; 41  
Shrivastava A., 45; 51  
Sihota R., 16; 47  
Singh K., 23; 24; 28; 30; 42; 44; 55  
Sirbat D., 47  
Sit A., 14; 23; 33; 40; 41; 44  
So K.F., 33  
Solebo L., 32  
Sourdille P., 55  
Spaeth G., 40; 45; 56  
Spohr H., 21  
Stamper R.L., 25; 30; 48; 51; 55  
Standefor J.E., 47  
Strouthidis N., 20; 56  
Sugiyama K., 48  
Sung K., 20; 53  
Susanna R., 17; 23; 25; 42; 43;  
44; 48
- Tan A., 49  
Tan J., 46  
Tanihara H., 31; 33; 45  
Tanna A., 44  
Teekhasaene C., 47  
Tello C., 31; 45; 52; 55  
Ter Haar G., 35  
Tham C.C.Y., 26; 47; 51; 56  
Thieme H., 55  
Thomas R., 26; 32; 39  
Thygesen J., 22; 25; 33; 47  
Tomita G., 35; 49  
Topouzis F., 26; 32; 39  
Toris C.B., 14; 35
- Traverso C.E., 22; 24; 29; 30;  
41; 54  
Trobe G., 15; 32  
Tsai J.C., 27; 50; 53  
Tuulonen A., 35; 45
- Ubaud C., 46  
Uddin S., 18  
Uusitalo H., 22
- Valtort F., 22; 34; 46; 56  
Van Went C., 43  
Varma R., 14; 32; 41  
Vassileva P., 19  
Vazirani J., 25  
Viera J.C., 17  
Viestenz A., 25  
Vijaya L., 16; 47; 50  
Viswanathan A., 22; 45  
Vizzeri M., 53  
Vold S., 49; 50  
Vyas P., 16
- Wand M., 31; 34  
Wang L., 49  
Wang N., 37; 44; 47; 55  
Weinreb R.N., 23; 24; 38; 40; 42;  
44; 52  
Wells A., 15; 33; 45  
Wheeler L., 28  
Wiggs J., 26; 28; 42; 48  
Wilson R., 32; 39  
Wollstein G., 32; 34  
Wong H.T., 47  
Wong T., 29; 41; 56  
Wright D., 36
- Yamamoto T., 27; 39  
Yaqub M., 17  
Yücel Y., 32  
Yun Kim C., 20
- Zalta A.H., 49  
Zangwill L., 32; 35; 53  
Zavgorodnyaya N., 19  
Zeyen T., 27  
Zhang C., 33  
Zhao J., 31  
Ziaul Islam Md. Ali Kh., 18

---

# THE WORLD GLAUCOMA ASSOCIATION

## THE GLOBAL GLAUCOMA NETWORK

### Core Purpose

To eliminate glaucoma-related disability worldwide.

### Core Values

The leadership and member societies of WGA are committed to acting consistently with the following values:

- Responsibility (Accountability) – to each other, to member societies, to the larger global glaucoma community, to the patient and to the public
- Consensus – open communication, inclusion of diverse viewpoints, and the aspiration to achieve practical consensus before acting
- Collegiality and Mutual Respect
- Best Care and Service – advancing the best care available to glaucoma patients worldwide

### WGA MEMBER GLAUCOMA SOCIETIES

#### National Glaucoma Societies or related groups from the following countries:

Algeria, Argentina, Austria, Azerbaijan, Bangladesh, Belgium, Bolivia, Brazil, Bulgaria, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Ecuador, Egypt, Estonia,

Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Indonesia, Iran, Ireland, Israel, Italy, Korea, Latvia, Lesotho, Lithuania, Mexico, Netherlands, Nigeria, Norway, Pakistan, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, Venezuela, Zambia.

### Regional Glaucoma Societies

American Glaucoma Society  
Asian-Oceanic Glaucoma Society  
Australian and New Zealand Glaucoma Interest Group  
Canadian Glaucoma Society  
Chinese Glaucoma Society  
European Glaucoma Society  
Glaucoma Society of India  
Japan Glaucoma Society  
Latin-American Glaucoma Society  
Middle East African Glaucoma Society  
Pan American Glaucoma Society  
South-East Asian Glaucoma Interest Group

### Supranational Glaucoma Societies

Optometric Glaucoma Society and International Society for Glaucoma Surgery.



## **WGA INDUSTRY MEMBERS**

### **Glaucoma Industry Members**

Alcon, Allergan, Merck.

### **Associate Glaucoma Industry Members**

Carl Zeiss Meditec, Heidelberg Engineering, Oculus, Pfizer, Topcon.

### **Supporting Glaucoma Industry Members**

Abott Medical Optics, Aeon Astron Europe B.V., Anteis, EyeTechCare, Glaukos, Haag Streit, Iridex, Lumenis, NeoMedix, Optovue, Otsuka, Santen, Senju, Sensimed, Ziemer Ophthalmic Systems.

### **Global WGA Directory of Glaucoma Societies**

The WGA has identified 76 Glaucoma Societies and has compiled a Global WGA Directory of Glaucoma Societies, which includes basic information on the Glaucoma Society. This directory is available through the WGA website. The Directory includes information on the board members, contact details, publications, etc.

### **World Glaucoma Patient Organization**

At the initiative of the WGA, a Global Glaucoma Patient Organization was founded in October 2004, New Orleans, LA, US. The aim of the organization is a further cooperation between national and regional Glaucoma Patient Organizations. Contacts between the WGPA and the WGA are formalized through the World Glaucoma Week Committee.

## **WGA Goals**

### **Goal 1 – Education**

The WGA will be an important source of education for ophthalmologists and other healthcare providers related to glaucoma.

### **Goal 2 – WGC**

The WGC will be the best glaucoma meeting in the world.

### **Goal 3 – Public Awareness and Recognition of Glaucoma**

Public awareness and recognition of glaucoma will increase.

### **Goal 4 – Impact in Developing Countries**

The resources of the global glaucoma community – including individuals, member societies, industry, governments, NGOs and patients – will be integrated and leveraged to enhance glaucoma care, particularly in developing countries.

### **Goal 5 – Technology**

The WGA will use information/communication technologies as a key tool in achieving its goals.

### **Goal 6 – Organization**

The WGA will be financially sound and organized to lead the glaucoma community.

## **WGA Membership**

The WGA is an association of Glaucoma Societies. It has no individual members. New or undiscovered Glaucoma Societies that desire to become a member of the WGA are asked to contact the WGA Executive Office through [info@worldglaucoma.org](mailto:info@worldglaucoma.org). The involvement in the WGA of the Glaucoma Societies is planned to be through:

- 
1. Joining of forces, cooperation, coordination of efforts in order to improve quality of glaucoma science and care
  2. Meeting and communicating in the Global Assembly, WGC, Committees activities, special *ad hoc* meetings
  3. Distribution of information through International Glaucoma Review, WGC, Consensus Outcomes and Guidelines, publications
  4. Participation in the Consensus & Guidelines process
    - 4.1 Preparation
    - 4.2 Meeting
    - 4.3 Publication
    - 4.4 Promulgation
  5. Cooperation in development of Glaucoma Patient Organizations
  6. Improving glaucoma curriculum in ophthalmology training
7. Training of glaucoma sub specialists / fellowships
  8. Glaucoma Society Organization
    - 8.1 Support in developing an even more effective organization
    - 8.2 Training in:
      - 8.2.1 Organization of societies
      - 8.2.2 Organization of congresses/ meetings
      - 8.2.3 Development of educational programs
      - 8.2.4 Manual on glaucoma (Guidelines from EGS, AAO, JGS, SEAGIG and others)
    - 8.3 Advocacy; prevention of blindness, support for eye care
    - 8.4 Critical research: necessary clinical studies, access to care
    - 8.5 Availability of Project Forum for Internet discussions within member Glaucoma Societies

## WGA COMMITTEES

### Board of Governors

M. Araie, J. Ge, I. Goldberg, F. Grehn, D. Grigera, R.A. Hitchings, Y. Kitazawa, T. Krupin, D. Lam, J.M. Liebmann, K. Martin, K. Singh, R. Susanna Jr, R. Thomas, R.N. Weinreb

### Executive Committee

Makoto Araie, *President*,  
R. Susanna Jr, *Past President (2008-2009)*,  
I. Goldberg, *Past President (2006-2007)*,  
R.N. Weinreb, *Past President (2004-2005)*,  
R.A. Hitchings, *Past President (2002-2003)*,  
K. Singh, *Executive Vice President*,  
K. Martin, *Treasurer*

### Associate Executive Vice Presidents

T. Aung, J. Crowston, T. Shaarawy

### Advisory Board

A. Alm, D. Anderson, M. Aquino, G. Baerveldt, C. Baudouin, C. Camras, D. Epstein, J. Flammer, Y. Hong, P. Hung, M. Kass, P. Kaufman, D. Kim, G. Kriegelstein, L. Leske, E. Maul, D. Minckler, H. Mishima, A. Molteno, S. Obstbaum, P. Palmberg, B. Shields, G. Spaeth, R. Stamper, R. Wilson, J. Zhao, K. Singh (EVP, ex-officio)

### Associate Advisory Board

A. Boehm, R. Casson, S. Chakrabarthi (co-chair), T. Dada, P. Foster, R. George, C. Girkin, M. He, P. Healey (co-chair), E. Hoffman, M. Honjo, C. Leung, F. Medeiros, W. Nolan, R. Parikh, L. Sakata, A. Sit, C. Tham, T. Wells, T. Wong, K. Singh (EVP, ex-officio)

### Glaucoma Society Representatives Committee

M. Araie (AOGS & JGS), F. El Sayyad (MEAGS), F. Fantes (PAGS), J. Ge (ChinGS), I. Goldberg (ANZGIG), H. Kumar (GSI), J.M. Liebmann (AGS), M. Nicolela (CanGS), M. Patella (OGS), P. Rojanapongpun (SEAGIG), T. Shaarawy (ISGS), C. Traverso (EGS), K. Singh (EVP, ex-officio)

### Steering Committee

M. Aihara, M. Araie, A. Azuara Blanco, J. Cioffi, A. Coleman, R. Fechtner, D. Friedman, S. Gandolfi, T. Garway Heath, J. Ge, I. Goldberg, F. Grehn, E. Greve, C. Greve-Geijssen, D. Grigera, N. Gupta, P. Healey, A. Heijl, R.A. Hitchings, P. Khaw, Y. Kitazawa, T. Krupin, D. Lam, G. Lambrou, R. Lewis, J.M. Liebmann, K. Martin, C. Melamed, C. Migdal, J.-P. Nordman, K. Park, R. Perez-Grossman, H. Quigley, R. Ritch, P. RojanaPongpun, J.S. Schuman, G. Skuta, R. Susanna Jr, R. Thomas, C. Traverso, N. Wang, R.N. Weinreb, R. Wilson, K. Singh (EVP, ex-officio)

### Liaison Committees

### World Glaucoma Week Committee

E. Ancker, M. Carrasco, P. Chew, H. Danesh, R. Dolgoff, D. Gatton, I. Goldberg (co-chair), P. Healey (co-chair), E. Hoffman, F. Kanadini, Y. Kitazawa, Y. Lachkar, G. Lambrou (executive vice-chair), M. Miller, R. Ritch (co-chair), G. Sekhar, T. Shaarawy (co-chair), R. Susanna Jr, J. Thygesen, T. Yamamoto, K. Singh (EVP, ex-officio)

---

## **Glaucoma Industry**

D. Friedman, I. Goldberg, E. Greve, (co-chair), F. Medeiros, R. Thomas, (co-chair), R.N. Weinreb (co-chair), R. Chan, (Alcon), representative Allergan, representative MSD, K. Singh (EVP, ex-officio)

## **World Glaucoma Association Liaison Committee**

R.A. Hitchings, Y. Kitazawa, K. Singh (co-chair), R. Susanna Jr (co-chair)

## **Quality Committees**

### **Code of Practice**

T. Dada, C. Girkin, I. Goldberg, K. Kashiwagi (co-chair), H. Levkovitch-Verbin, M. Sherwood (co-chair), R.N. Weinreb, T. Yamamoto, R. Halprin (Alcon), T. Huuhtanen (Santen), M. Long (Heidelberg), M. Patella (CZM), representative Allergan, representative MSD, K. Singh (EVP, ex-officio)

### **Guidelines for Reporting and Publishing**

M. Araie, K. Barton, A. Coleman (co-chair), P. Foster, S. Gandolfi (co-chair), M. Honjo, D. Minckler, T. Shaarawy (co-chair), F. Topouzis (co-chair), A. Viswanathan, R. Wormald, J. Grunden (Pfizer), R. Halprin (Alcon), representative Allergan, representative MSD, K. Singh (EVP, ex-officio)

### **Subcommittee on Guidelines for Reporting on Glaucoma Surgery Results**

F. Grehn (co-chair), T. Shaarawy (co-chair), M. Sherwood (co-chair), K. Singh (EVP, ex-officio)

## **Guidelines on Quality and Quantity of Glaucoma Meetings**

M. Ahaira, W. Alward, T. Aung (co-chair), A. Boehm, E. Greve, D. Grigera, N. Gupta, (co-chair), C. Leung, C. Migdal (co-chair), W. Nolan, P. RojanaPongpun, R. Thomas, R. Besthof (Pfizer), R. Chan (Alcon), representative Allergan, representative MSD, K. Singh (EVP, ex-officio)

## **Consensus and Guidelines Committee**

R. Abdul Rahman, M. Agulto, M. Araie, (co-chair), R. Casson, B. Chauhan, J. Crowston (co-chair), H. Danesh Meyer, (co-chair), T. Garway Heath, C. Girkin, I. Goldberg, T. Konstas, H. Lemij, F. Lerner, J.M. Liebmann (co-chair), K.H. Park, N. Pfeiffer, P. Sample, M. Sherwood, R. Susanna, C. Tham, C. Traverso (co-chair), R.N. Weinreb (co-chair), L. Zangwill, K. Singh (EVP, ex-officio)

## **Global Research and Screening**

A. Azuaro-Blanco, L. Cantor, V. Costa, P. Foster (co-chair), D. Friedman (co-chair), D. Grigera, R. Gross, A. Heijl, M. Irkec, Y. Kuwayama, D. Lam, P. Lee, S. Melamed (co-chair), S. Miglior, K.H. Park, H. Quigley, P. RojanaPongpun, S. Seah, T. Valorie, N. Wang, R. Wilson, T. Yamamoto (co-chair), L. Zangwill, representative Allergan, K. Singh (EVP, ex-officio)

## **Clinician Scientists**

M. Aihara, J. Crowston, A. Harris, M. He, (co-chair), P. Khaw (co-chair), C. Leung (co-chair), J.S. Schuman (co-chair), A. Sit, R.N. Weinreb, K. Singh (EVP, ex-officio)

### **Glaucoma Society Organization**

G. d'Mellow, C. Girkin (co-chair), G. Holló, Y. Kitazawa, M. Kook, T. Krupin, Y. Kuwayama, C. Leung, C. Migdal, W. Nolan (co-chair), R. Parikh, G. Sekhar, G. Skuta, R. Thomas, J. Thygesen, N. Wang, T. Wells (co-chair), R. Wilson, T. Yamamota, K. Singh (EVP, ex-officio)

### **Promulgation Committee**

C. Chakrabarti, J. Crowston, R. Fechtner, D. Friedman, R. George (co-chair), P. Healey, K. Martin, P. Palmberg, A. Sit (co-chair), A. Viswanathan (co-chair), R.N. Weinreb (co-chair), K. Singh (EVP, ex-officio)

### **Advocacy Committee**

A. Boehm, J. Caprioli, D. Grigera, M. He (co-chair), R.A. Hitchings, P. Kaufman, T. Krupin, D. Lam, K. Martin (co-chair), E. Maul, F. Medeiros (co-chair), W. Nolan, R. Parrish, G. Spaeth, H. Tanihara, J. Thygesen, L. Vijaya, N. Wang, K. Singh (EVP, ex-officio)

### **Global Projects Committee**

K. Ben Amor, L. Herndon, S. Melamed (co-chair), H. Quigley (co-chair), P. RojanaPongpun, J.S. Schuman, T. Shaarawy (co-chair), R. Thomas, R. Wilson, K. Singh (EVP, ex-officio)

### **WGA Executive Office**

Mariska van der Veen  
Executive General  
Manager



Corresponding address:  
Jan van Goyenkade 11  
1075 HP Amsterdam,  
The Netherlands  
Tel: +31 20 679 34 11  
Fax: +31 20 673 73 06  
E-mail: [vanderveen@worldglaucoma.org](mailto:vanderveen@worldglaucoma.org)  
[www.worldglaucoma.org](http://www.worldglaucoma.org)

*The World Glaucoma Association is an association founded according to Swiss law. Founded January 1, 2002. Registered office Geneva, Switzerland*



---

## WGA RESEARCH AWARDS

The WGA Research Award is the only global glaucoma research award supported by all member Glaucoma Societies. The award was started in 1999 as the IGR Award, later called AIGS-Award, and now it is called the WGA Research Award. At the WGC-2011, the 11th Award ceremony will be held.

During the past year, and confirmed at meetings of the WGA Award Advisory Group and Board of Governors held at ARVO, it was decided to restructure the selection of the WGA Research Award awardees to make the process more transparent. Additionally, the Board agreed to combine the awards of 2009 and 2010.

For the selection of the WGA Award 2009/2010, all member Glaucoma Societies were asked for their input and suggestions for nominees based on the following specifications:

- A. The award aims to recognize an important body of work within glaucoma by an individual who authored a manuscript during 2009/2010. Unlike prior WGA Research Awards, the awardees will not be selected on the basis of a single published manuscript, but rather on their body of work, including the manuscript.
- B. Each member Glaucoma Society was asked to select one nominee for the following four categories:
  1. Body of work by clinician scientist
  2. Body of work by research scientist
  3. Body of work by young clinician scientist (< 42 years of age)
  4. Body of work by young research scientist (< 42 years of age)

In providing us with the four selected nominees for the WGA Research 2009/2010 Award we asked each member Glaucoma Societies to inform us about:

1. Name and email address of nominee
2. List of 10 significant publications (in case of young nominees, 5 publications are sufficient)
3. Abbreviated CV
4. Statement why the nominee should be selected (maximum of 100 words)

The award winners will be announced during the Opening of the 4<sup>th</sup> World Glaucoma Congress. Award winners will receive a complimentary registration as well as € 2500 to cover travel & hotel expenses.

WGA-Award Winners 1999-2008

**1999, London**

Peng Khaw and Francesca Cordeiro; Ronald Harwerth

**2000, Seoul**

Paul Palmberg and Douglas Gaasterland; Harry Quigley

**2001, Orlando**

Michal Schwartz; Jack Crawford, Yeni Yücel and Robert N. Weinreb

Special Recognition: Douglas Anderson, Dunbar Hoskins and Stephen Drance

**2002, Tokyo**

Michael Kass and Mae Gordon; Anders Heijl

**2003, Firenze**

Elke Lütjen-Drecoll and Paul Kaufman; Paul Mitchell

**2004, Vienna**

Aiko Iwase; Claude Burgoyne

**2005, Chennai**

Simon John; Hiroshi Sakai

**2006, Singapore**

Terete Borrás; Neeru Gupta and Yeni Yücel

**2007, Berlin**

'The Present' Award: Fridbert Jonasson and Kari Stefansson

'The Promise' Award: Gülgün Tezel

'The Promise' Award: Robert Duncan

**2008, Boston**

'The Present' Award: Abott Clark

'The Promise' Award: Hiroshi Murata, Makoto Aihara and Makoto Araie

'The Promise' Award: Harry Quigley and Mark Walsch

'The Promise' Award: Robert N. Weinreb and Christopher K.S. Leung

The 2011 WGA-Award Ceremony for the Global WGA-Award 2009/2010 will be held on Wednesday, June 29 as part of the Opening Ceremony (3.00-5.30 p.m.). The WGA Research Award is supported in part by a grant from Pfizer Ophthalmics.

---

## INTERNATIONAL GLAUCOMA REVIEW

The *International Glaucoma Review* (IGR), which has been published since 1984, became the official journal for the WGA in 2002. IGR is a journal for glaucoma specialists and general ophthalmologists with an interest in glaucoma from all over the world, and is a forum for the world's Glaucoma Societies. The IGR is distributed four times per year to all members of the member Glaucoma Societies of the WGA without charge. Subscriptions of each Glaucoma Society Member to IGR are supported by a grant from the WGA and through advertising.

IGR has the most complete collection of abstracts from the glaucoma literature, some of which is not readily available. It is the only journal that presents a three-monthly critical review of selected glaucoma literature. IGR also contains the Glaucoma Dialogue, the Glaucoma Opinion, and reports from the member Glaucoma Societies. It may also include reports of meetings, interviews, hypotheses, reviews, and anything else consid-

ered to be of interest to the members of the Glaucoma Societies.

### IGR online Database

Abstracts have been provided online only since 2007, and all abstracts published in IGR since 1999 are already available through the fully searchable IGR glaucoma literature database. But that's not all. The comments from the Editor's Selection have also been put into a database and are also fully searchable and linked to the abstracts. This makes it possible to read what experts have to say about important abstracts.

### Registration for IGR online

Access to IGR Online remains complimentary for all members of glaucoma societies associated with the WGA. However, you are required to register before you can access the abstracts and make use of other features of the IGR website.

**Web address: [www.e-igr.com](http://www.e-igr.com)**

**Chief Editor**  
Robert N. Weinreb

**Founding Editor**  
Erik L. Greve

**Associate Editors**

Makoto Araie (JP), Jack Cioffi (US), Jonathan Crowston (AU), Roger Hitchings (UK),  
Jeffrey Liebmann (US), Remo Susanna (BR)

**Society Editors**

Ellen Ancker (ASG), Makoto Araie (JGS en AOGS), Anne M. Brooks (A&NZGC),  
Javier Casiraghi (PAGS), Seng Kheong Fang (SEAGIG), Christopher Girkin (AGS),  
Francesco Goñi (EGS), Rodolfo Perez Grossman (LAGS), Harsh Kumar (GSI),  
Marcello Nicoletta (CanGS), Mike Patella (OGS), Tarek Shaarawy (ISGS), Fotis Topouzis (EGS),  
Moustafa Yaqub (PARGS), Ningli Wang (ChinGS)

**Board of Editors**

Rand Allingham (US), Makoto Aihara (JP), Lee Alward (US), Alfonso Anton (SP), Tin Aung (SG),  
Keith Barton (UK), Augusto Azuara Blanco (UK), Christoph Baudouin (FR), Eytan Blumenthal (IS),  
Andreas Boehm (DE), Terete Borrás (US), Chris Bowd (US), James Brandt (US),  
Don Budenz (US), Claude Burgoyne (US), Subho Chakrabarthi (IN), Anne Coleman (US),  
Robert Fechtner (US), Robert Feldman (US), Murray Fingeret (US), Josef Flammer (CH),  
Paul Foster (UK), David Friedman (US), Jiang Ge (CN), Chris Girkin (US), Ivan Goldberg (AU),  
David Greenfield (US), Franz Grehn (DE), Daniel Grigera (AR), Neeru Gupta (CA), Alon Harris (US),  
Ron Harwerth (US), Mingguang He (CN), Paul Healey (AU), Esther Hoffman (DE), Gabor Holló (HU),  
Henry Jampel (US), Chris Johnson (US), Jost Jonas (DE), Malik Kahook (US),  
Kenji Kashiwagi (JP), Paul Kaufman (US), Peng Khaw (UK), Dong Myung Kim (KR),  
Tae Woo Kim (KR), Tasos Konstas (GR), Ted Krupin (US), Dennis Lam (HK), George Lambrou (GR),  
Fabian Lerner (AR), Christopher Leung (HK), Shan Lin (US), James Lindsey (US), John Liu (US),  
Nils Loewen (US), Steve Mansberger (US), Keith Martin (UK), Eugenio Maul (CL),  
G.D. McLaren (ZA), Felipe Medeiros (US), James Morgan (UK), Sameh Mosaed (US),  
Paul Palmberg (US), Norbert Pfeiffer (DE), Harsha Rao (IN), Tony Realini (US), Doug Rhee (US),  
Prin RojanaPongpun (TH), Luca Rossetti (IT), Joel Schuman (US), Tarek Shaarawy (CH),  
Kuldev Singh (US), Arthur Sit (US), George Spaeth (US), Ernst Tamm (DE), Hidenobu Tanihara (JP),  
Ravi Thomas (IN), Fotis Topouzis (GR), Rohit Varma (US), Ananth Viswanathan (UK),  
Ningli Wang (CN), Tsing-Hong Wang (TW), Tony Wells (NZ), Tina Wong (SG), Yeni Yücel (CA),  
Linda Zangwill (US)

H. Caroline Greve-Geijssen (NL) – Managing Editor

# SPONSORS AND EXHIBITORS OF THE 4<sup>th</sup> WORLD GLAUCOMA CONGRESS 2011

## Platinum



**MSD Ophthalmics**

## Silver



## Other Sponsors and Exhibitors



## TECHNICAL EXHIBITION

### List of Sponsors and Exhibitors

#### *Platinum*

|                               |                |                              |                 |
|-------------------------------|----------------|------------------------------|-----------------|
| Alcon Laboratories, Inc ..... | <b>Booth 5</b> | Glaukos Corporation .....    | <b>Booth 32</b> |
| Allergan Ltd .....            | <b>Booth 1</b> | Haag-Streit .....            | <b>Booth 4</b>  |
| Merck Sharp & Dohme .....     | <b>Booth 2</b> | Heidelberg Engineering ..... | <b>Booth 8</b>  |

#### *Silver*

|   |                |                           |                 |
|---|----------------|---------------------------|-----------------|
| Pfizer, Inc .....                       | <b>Booth 9</b> | Kowa Company Ltd .....    | <b>Booth 20</b> |
| Santen Pharmaceutical Co.,<br>Ltd ..... | <b>Booth 6</b> | Life Spring Biotech ..... | <b>Booth 25</b> |
|   |                | Lumenis .....             | <b>Booth 3</b>  |

#### *Exhibitors*

|  |                 |  |                 |
|--|-----------------|--|-----------------|
| Aeon Astron Europe BV .....              | <b>Booth 38</b> | IOPTima Ltd .....                        | <b>Booth 13</b> |
| Anteis SA .....                          | <b>Booth 22</b> | Iridex .....                             | <b>Booth 16</b> |
| Carl Zeiss Meditec AG .....              | <b>Booth 10</b> | Kowa Company Ltd .....                   | <b>Booth 20</b> |
| D.O.R.C. International BV ...            | <b>Booth 18</b> | Life Spring Biotech .....                | <b>Booth 25</b> |
| EGS - European Glaucoma<br>Society ..... | <b>Booth 30</b> | Lumenis .....                            | <b>Booth 3</b>  |
| Ellex .....                              | <b>Booth 15</b> | MédiThèque Bookshop .....                | <b>Booth 34</b> |
| Endo Optiks, Inc .....                   | <b>Booth 33</b> | NeoMedix Corporation .....               | <b>Booth 14</b> |
| EyeTechCare .....                        | <b>Booth 11</b> | Oculus Optikgeräte GmbH ...              | <b>Booth 27</b> |
|  |                 | Optovue, Inc .....                       | <b>Booth 7</b>  |
|  |                 | Quantel Medical .....                    | <b>Booth 12</b> |
|  |                 | Sensimed AG .....                        | <b>Booth 21</b> |
|  |                 | Wisepress Online Bookshop                | <b>Booth 35</b> |
|  |                 | World Glaucoma Association/<br>IGR ..... | <b>Booth 29</b> |
|  |                 | Ziemer Ophthalmic Systems<br>AG .....    | <b>Booth 23</b> |


### Opening Hours

|                    |                        |
|--------------------|------------------------|
| Wednesday, June 29 | 8.00 a.m. – 7.00 p.m.  |
| Thursday, June 30  | 8.00 a.m. – 6.00 p.m.  |
| Friday, July 1     | 8.00 a.m. – 6.30 p.m.  |
| Saturday, July 2   | 8.00 a.m. – 12.00 p.m. |



# EXHIBITION FLOOR PLAN

## LEVEL 3






**Please stop by  
Santen booth #6  
at WGC Paris 2011!**

*A Clear Vision For Life™*



**Santen**



Santen specializes in the research, development, manufacturing and marketing of ophthalmic and anti-rheumatic pharmaceuticals to protect and improve people's eyesight and health. We have created innovative pharmaceuticals for all types of ophthalmic disorders and provide information tailored to clinical needs. As a result, we lead Japan's market for prescription ophthalmics. With marketing and development bases in Japan and other Asian countries, the United States and Europe, backed by first-rate R&D capabilities, we aim to increase our corporate value as a world-class company that delivers unique products worldwide.

**SANTEN PHARMACEUTICAL COMPANY**

<http://www.santen.com>

# AZARGA®

(brinzolamide 10mg/ml+timolol 5mg/ml) eyedrops, suspension

**PRESCRIBING INFORMATION:** Consult the Summary of Product Characteristics before prescribing, particularly in relation to side-effects, precautions and contraindications. AZARGA® 10 mg/ml + 5 mg/ml eye drops, suspension. **Presentation** Plastic bottle containing 5ml eye drops. Each 1 ml contains 10 mg brinzolamide, 5 mg timolol (as maleate), benzalkonium chloride 0.1 mg. **Indication** Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction. **Dosage/Administration** Adults, including the elderly One drop twice daily. **Paediatric patients** Not recommended. **Use in hepatic and renal impairment** No studies conducted. **Contraindications** Hypersensitivity to any component. Presence or history of bronchial asthma, severe chronic obstructive pulmonary disease. Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock. Severe allergic rhinitis and bronchial hyperreactivity. Hyperchloraemic acidosis. Severe renal impairment. Hypersensitivity to other beta-blockers and/or sulphonamides. **Warnings and precautions** **Systemic effects** Cardiovascular and pulmonary adverse reactions as seen with systemic beta-blockers may occur (death due to bronchospasm in patients with asthma and to cardiac failure, have been reported following use of timolol). Cardiac failure should be adequately controlled before beginning therapy with timolol. Patients with history of severe cardiac disease should be watched for signs of cardiac failure and have pulse rates checked. Beta-blockers may mask the signs and symptoms of acute hypoglycaemia and hyperthyroidism, and cause worsening of Prinzmetal angina, severe peripheral and central circulatory disorders and hypotension. Give with caution in patients subject to spontaneous hypoglycaemia or labile insulin-dependent diabetes. Adverse effects attributable to sulphonamides and acid-base disturbances may occur and there is a potential for additive systemic effects in patients receiving oral carbonic anhydrase inhibitors. Concomitant administration with oral carbonic anhydrase inhibitors is not recommended. **Anaphylactic reactions** While taking beta-blockers, patients with a history of atopy or severe anaphylactic reaction may be unresponsive to usual doses of adrenaline used in treatment. **Concomitant Therapy** Effect on IOP or known effects of systemic beta blockade may be potentiated when AZARGA® is given to patients already taking oral beta-blockers. Use of two local beta-blockers or local carbonic anhydrase inhibitors is not recommended. **Ocular effects** There is limited or no experience in patients with narrow-angle, pseudoexfoliative or pigmentary glaucoma. Carbonic anhydrase inhibitors may affect corneal hydration. Careful monitoring of patients with compromised corneas (such as in diabetes mellitus and corneal dystrophies) and contact lens wearers is recommended. Benzalkonium chloride may cause eye irritation, discolour soft contact lenses and has been reported to cause keratopathy. Soft contact lens wearers should remove contact lenses prior to use and wait 15 minutes after instillation before reinsertion. **Interactions** No studies performed. Potential exists for additive effects resulting in hypotension and/or marked bradycardia when eye drops with timolol are administered concomitantly with oral calcium channel blockers, guanethidine, beta-blockers, antiarrhythmics, digitalis glycosides, parasympathomimetics or CYP2D6 inhibitors (e.g. quinidine, cimetidine). Beta-blockers may potentiate hypoglycaemic effect of antidiabetic agents and hypertensive reaction to sudden withdrawal of clonidine. **Pregnancy** Do not use unless clearly necessary. **Lactation** May be used. **Driving/use of machines** May blur vision and has potential to impair mental alertness or physical coordination in the elderly. **Undesirable effects** **Ocular:** Common blurred vision, pain, irritation, foreign body sensation. **Uncommon:** corneal erosion, punctate keratitis, dry eye, discharge, pruritus, hyperaemia, blepharitis, allergic conjunctivitis, corneal disorder, anterior chamber flare, conjunctival hyperaemia, eyelid - margin crusting/pruritus/erythema, asthenopia, abnormal sensation, allergic blepharitis. **Systemic:** Common dysgeusia. **Uncommon** insomnia, decreased blood pressure, chronic obstructive pulmonary disease, pharyngolaryngeal pain, rhinorrhoea, cough, hair disorder, lichen planus. \* Refer to SPC for additional information and before prescribing\*. **Overdose** Symptomatic and supportive treatment. Timolol does not dialyse readily. **Incompatibilities** Not applicable. **Shelf life** 2 years, discard 4 weeks after first opening. **Special precautions for storage/disposal** None. **MAH Holder/Further Information** : Alcon Laboratories (UK) Ltd., Pentagon Park, Boundary Way, Hemel Hempstead, Herts HP2 7UD, United Kingdom. **MAH Number** EU/1/08/482/001 **Date of Preparation of Prescribing Information** August 2010 (V3).

DECREASE OF INTRAOCULAR PRESSURE (IOP) IN ADULT PATIENTS  
WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION  
FOR WHOM MONOTHERAPY PROVIDES INSUFFICIENT IOP REDUCTION

**Alcon®**

1105P21B



Decrease of elevated intraocular pressure in patients  
with ocular hypertension or open-angle glaucoma

# TRAVATAN®

40 micrograms/ml eye drops, solution  
travoprost



## NEW FORMULA

FIRST AND ONLY MULTIDOSE  
PROSTAGLANDIN WITHOUT BAK\*,  
NOW WITH POLYQUAD® PRESERVATIVE

**TRAVATAN 40 micrograms/ml eye drops, solution (travoprost).** (Refer to full Summary of Product Characteristics (SmPC) before prescribing). **Presentation:** Plastic bottle containing 2.5 ml eye drop solution; 1 ml of solution contains 40 micrograms travoprost. **Indication(s):** Decrease of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. **Posology and method of administration:** *Adults, including the elderly:* One drop in the affected eye(s) once daily, optimally in the evening. *Children and adolescents:* Not recommended. **Hepatic and renal impairment:** No dosage adjustment necessary. **Contra-indications:** Hypersensitivity to travoprost or any of the excipients. **Warnings and precautions:** TRAVATAN® may gradually change eye colour. This occurs slowly and may not be noticeable for months to years. Before treatment is instituted, patients must be informed of the possibility of a permanent change in eye colour. Unilateral treatment can result in permanent heterochromia. Long term effects on melanocytes and any consequences are currently unknown. After discontinuation of therapy, no further increase in brown iris pigment has been observed. Periorbital and/or eyelid skin darkening has been reported. TRAVATAN® may gradually increase the length, thickness, pigmentation, and/or number of eyelashes in the treated eye(s). Exercise caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule or anterior chamber lenses, and in patients with known risk factors for cystoid macular oedema or iritis/uveitis. Skin contact with TRAVATAN® must be avoided. Patients must remove contact lenses prior to application of TRAVATAN® and wait 15 minutes after instillation before reinsertion. TRAVATAN® contains polyoxyethylene hydrogenated castor oil 40 and propylene glycol which may cause skin reactions or irritations. **Interactions:** None known. **Fertility, pregnancy and lactation:** *Women of child-bearing potential:* Do not use unless adequate contraceptive measures are in place. *Pregnancy:* Do not use unless clearly necessary. *Breast-feeding women:* Not recommended. **Effects on ability to drive and use machines:** If blurred vision occurs, wait until vision clears before driving or using machinery. **Undesirable effects:** *Very common:* ocular hyperaemia, iris hyperpigmentation. *Common:* headache, punctate keratitis, anterior chamber inflammation, eye pain, photophobia, eye discharge, ocular discomfort, visual acuity reduced, vision blurred, dry eye, eye pruritus, lacrimation increased, erythema of eyelid, eyelid oedema, growth of eyelashes, eyelash discolouration, skin hyperpigmentation (periocular), skin discolouration. *Serious:* Herpes simplex, keratitis herpetic, uveitis, peptic ulcer reactivated, macular oedema. Prescribers should consult the SmPC in relation to other side effects. **Overdose:** A topical overdose may be flushed from the eye(s) with lukewarm water. Treatment of a suspected oral ingestion is symptomatic and supportive. **Special Precautions for Storage:** None. **MA Number(s):** EU/1/01/199/001-002. **MA Holder /Further information:** Alcon Laboratories (UK) Limited, Pentagon Park, Boundary Way, Hemel Hempstead, Hertfordshire, HP2 7UD. **Date of preparation:** April 2011 (V5). 1105P21C

\* Benzalkonium chloride



## ***Advances in Glaucoma Surgery: New Evidence in Filtration Surgery***

*Hear from your colleagues about newly published data demonstrating the effectiveness and safety of the EX-PRESS® Glaucoma Filtration Device over trabeculectomy.*

### **Faculty**

**Moderator:**

Ivan Goldberg, MD - *Australia*

Elie Dahan, MD - *Israel*

Leo DeJong, MD - *Netherlands*

Robert Fechtner, MD - *USA*

Malik Kahook, MD - *USA*

Marlene Moster, MD - *USA*

This program is intended for healthcare professionals only. Please present your congress badge for admission.

**Thursday, 30 June 2011**

**Paris, France**

**Hotel Concorde Lafayette, Paris Monceau Salon**

*Held during the 4th Annual World Glaucoma Congress*

**17:30-18:00    Registration and Reception**

Please join us for light refreshments and hors d'oeuvres.

**18:00-19:15    Symposium**

**Alcon®**

## Company Profiles (in alphabetical order)

### Aeon Astron Europe BV (Booth 38)

|                |                                     |
|----------------|-------------------------------------|
| Address        | Niels Bohrweg 11-13                 |
| Zip Code       | 2333 CA                             |
| City (& State) | Leiden                              |
| Country        | The Netherlands                     |
| Phone Number   | + 31 71 33 22 280                   |
| Fax Number     | + 31 71 33 22 281                   |
| E-mail         | info@aeonastron.net                 |
| Website        | www.aeonastron.com & www.ologen.com |
| Contact        | Mr. Michael H.J. Lai (CEO)          |



Aeon Astron Europe B.V. (AAE) is a company specialized in ophthalmology. Being a company working with the world's prominent opinion leaders in tissue engineering and regenerative medicine, our aim is to bring patients the best technological products for better vision.

AAE has the product "ologen® Collagen Matrix" for eye tissue repair which has been used in more than 10,000 operations with glaucoma, strabismus, pterygium, subconjunctival scar revision, corneal ulcer, and other ophthalmic interventions in the past two years. Its safety and efficacy have been proven by many doctors in the United States, Europe, India, Middle East, and Korea, among others. With its core technology in manufacturing bioscaffolding materials, a new product "Biocontact lens" as contact lens for ocular surface repair will be in the market in 2012.

Focusing on our aim to help millions of blind people regain vision, the first in-house paper for artificial "Biocornea" development was published in 2010. (<http://www.ecmjournal.org/journal/papers/vol019/vol019a06>).

---

### Alcon Laboratories, Inc.(Booth 5)

|                |                    |
|----------------|--------------------|
| Address        | 6201 South Freeway |
| Zip Code       | 76134              |
| City (& State) | Fort Worth, TX     |
| Country        | USA                |
| Phone Number   | +1 800 451 39 73   |
| Website        | www.alcon.com      |



Built on its 65-year legacy, Alcon is dedicated to discovering, developing and producing high-quality eye care products that preserve, restore and enhance sight globally. With products available in over 180 countries, Alcon is committed to serving the world's eye care needs with a broad portfolio of market-leading surgical, pharmaceutical and vision care products that treat diseases and conditions of the eye.



---

## Allergan Ltd (Booth 1)

|                |  |
|----------------|--|
| Address        | 2525 Dupont Dr.  |
| Zip Code       | 92612  |
| City (& State) | Irvine, CA   |
| Country        | USA  |
| Phone Number   | +1 714 246 45 00                                       |
| Fax Number     | +1 714 246 4971  |
| Website        | <a href="http://www.allergan.com">www.allergan.com</a> |



Allergan, helping people to see more clearly, move more freely, express themselves more fully for more than 60 years. Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential. The Company employs more than 9,000 people worldwide and operates state-of-the-art R&D facilities and world-class manufacturing plants. In addition to its discovery-to-development research organization, Allergan has global marketing and sales capabilities with a presence in more than 100 countries.

---

## Anteis S.A. (Booth 22)

|                |  |
|----------------|--|
| Address        | Chemin des Aulx 18   |
| Zip Code       | CH-1228  |
| City (& State) | Plan les Ouates, Geneva  |
| Country        | Switzerland  |
| Phone Number   | + 41 22 308 93 42  |
| Fax Number     | + 41 22 308 93 71  |
| E-mail         | <a href="mailto:c.thebaud@anteis.com">c.thebaud@anteis.com</a> |
| Website        | <a href="http://www.anteis.com">www.anteis.com</a>             |
| Contact        | Mrs. Catherine Thebaud   |



Anteis S.A. is a Swiss company specialised in modifying and functionalizing injectable hyaluronic acid for a range of medical applications in the fields of aesthetic dermatology, ophthalmology and orthopedics. Based in Geneva, with around 150 employees and manufacturing facilities in two Swiss locations, Anteis distributes products to over 90 countries worldwide.

In ophthalmology, Anteis introduced in 2007 its first ophthalmic viscoelastic devices (OVD) and launched in 2008, HealaFlow, a slow resorbable drainage implant for glaucoma surgery. The R&D is developing second generation and innovative products (OVD / posterior segment surgery /extra-ocular surgery / drug delivery system ...) to be launched in the coming years.

Anteis vision is to offer life-changing solutions to meet the needs of doctors and their patients worldwide. It is committed to investing in constant improvement and innovation. These values are embodied in the Anteis promise "change starts here".

## **Carl Zeiss Meditec A.G. (Booth 10)**

|                |                          |
|----------------|--------------------------|
| Address        | Göschwitzer Straße 51-52 |
| Zip Code       | D-07745                  |
| City (& State) | Jena                     |
| Country        | Germany                  |
| Phone Number   | +49 3641 220 331         |
| Fax Number     | +49 3641 220 112         |
| E-mail         | info@meditec.zeiss.com   |
| Website        | www.meditec.zeiss.com    |
| Contact        | Petra Rettenmaier        |



Good health is an important requirement for enjoying life and performing successfully at work. Therefore, patients and doctors are now expecting more and more from diagnostic and treatment outcomes.

Medical systems from Carl Zeiss allow doctors to further improve the efficiency, safety and reliability of diagnosis and treatment: with innovative solutions for ophthalmology and ophthalmic surgery and visualization systems – in particular for neurosurgery, ENT surgery and dental treatment. The offering is rounded off with systems used for intraoperative radiotherapy in the treatment of breast cancer.

In the field of ophthalmology, Carl Zeiss Meditec's Glaucoma Workplace uniquely offers superior solutions within a complete diagnostic suite, to increase the quality of clinical decision making in routine glaucoma care, helping doctors focus on the patient and make more informed treatment decisions.

---

## **D.O.R.C. International BV (Booth 18)**

|                |                  |
|----------------|------------------|
| Address        | Scheijdelveweg 2 |
| Zip Code       | 3214 VN          |
| City (& State) | Zuidland         |
| Country        | The Netherlands  |
| Phone Number   | +31 181 45 80 80 |
| Fax Number     | +31 181 45 80 90 |
| E-mail         | sales@dorc.nl    |
| Website        | www.dorc.nl      |
| Contact        | Frank Ruseler    |



D.O.R.C. continues to develop leading edge products, from unique design & specifications: Associate-2500®; Xenon BrightStar Illumination System; LaserStar 532nm Diode Laser; CryoStar; 20G/23G/25G/27G Transconjunctival Trocar Systems; Forceps/Scissors, Backflush instruments; Vitrectomy Lenses; Innovative Liquids: VisionBlue®; MembraneBlue®; MembraneBlue-Dual®; ILM-Blue®; EFTIAR® / SIL-1000/5000®.

---

## EGS – European Glaucoma Society (Booth 30)

|                |                    |
|----------------|--------------------|
| Address        | Baarerstrasse, 2   |
| Zip Code       | CH-6300            |
| City (& State) | Zug                |
| Country        | Switzerland        |
| Phone Number   | +39 010 353 38 289 |
| Skype          | egs.alexia.piaggio |
| E-mail         | ap@eugs.org        |
| Website        | www.eugs.org       |
| Contact        | Alexia Piaggio     |



The European Glaucoma Society is a non-profit organization. Built on the success of its policies on education (which include the publication of the 3rd edition of the EGS Guidelines, the bi-annual Congress and the Residents™ course), innovation (promoting international research cooperation including the GlaucoGene project) and communication (improving relationships between the National Glaucoma Societies and the EGS and promoting contacts with the political leaders of the EC), the EGS is committed to continue in its leading role in education and research throughout Europe. The main aim of the society is to improve glaucoma care for all patients. The EGS undertakes projects to raise the awareness of glaucoma and to secure funding and approval for improved management of this disease and to promote the diffusion of specific knowledge to the general ophthalmologists in Europe. More details are available on the EGS website: [www.eugs.org](http://www.eugs.org).

---

## Ellex (Booth 15)

|                |                   |
|----------------|-------------------|
| Address        | 82 Gilbert Street |
| Zip code       | 5000              |
| City (& State) | Adelaide, SA      |
| Country        | Australia         |
| Phone Number   | +61 8 8104 5200   |
| Fax Number     | +61 8 8104 5231   |
| Email          | info@ellex.com    |
| Website        | www.ellex.com     |



Focused solely on ophthalmologists, Ellex is dedicated to advancing the role of ophthalmic technology through a line of premium laser and diagnostic ultrasound systems. With more than 15,000 systems delivered to hospitals, clinics and ophthalmic practices worldwide, Ellex is known for its superior quality and commitment to customer care.

### Endo Optiks, Inc. (Booth 33)

|                |                     |
|----------------|---------------------|
| Address        | 39 Sycamore Ave.    |
| Zip Code       | 07739               |
| City (& State) | Little Silver, NJ   |
| Country        | USA                 |
| Phone Number   | +1 732 530 6762     |
| Fax Number     | +1 732 530 5344     |
| E-mail         | info@endooptiks.com |
| Website        | www.endooptiks.com  |
| Contact        | Paula Ender         |



Endo Optiks, Inc., world leader in microendoscopy for over 15 years, is the sole manufacturer of the E2 combined laser and endoscopy system allowing simultaneous illumination, video imaging and laser delivery through a patented, 20-gauge, autoclavable microendoscope. The E4 endoscopy system can be utilized with an external laser for combined endoscopy and laser treatment capability. Endoscopic Cyclophotocoagulation (ECP) is an elegant technique allowing the ciliary process to be easily viewed and titrated for long-term IOP reduction in the treatment of medically controlled glaucoma. New, high resolution, wide field microendoscopes with a panoramic 140-degree field of view will be presented.

---

### EyeTechCare (Booth 11)

|                |                         |
|----------------|-------------------------|
| Address        | 2871 Avenue de l'Europe |
| Zip Code       | 69140                   |
| City (& State) | Rillieux la Pape        |
| Country        | France                  |
| Phone Number   | +33 (0)4 78 88 09 00    |
| Fax Number     | +33 (0)4 78 97 45 11    |
| E-mail         | contact@eyetechcare.com |
| Website        | www.eyetechcare.com     |
| Contact        | Sophie Picq             |



EyeTechCare develops non-invasive therapeutic medical devices for the ophthalmologist making use of state-of-the art high-intensity focused ultrasound (HIFU). HIFU technology allows for rapid and outpatient treatment, thereby minimizing the risk for the patient and curbing operating costs. EyeOP1®, the first device developed by the company, was conceived for the treatment of glaucoma. The EyeOP1® system has been undergoing clinical trials in Lyon since the beginning of 2010 and is due to be launched onto the market this year. The device utilizes the UC<sup>3</sup> (Ultrasound Circular Cyclo-Coagulation) technique which makes it possible to reduce intraocular pressure by neutralizing with pinpoint accuracy targeted sections of the ciliary body that produce aqueous humor.

---

---

## Glaukos Corporation (Booth 32)

|                |   |
|----------------|---|
| Address        | 26051 Merit Circle, Suite 103               |
| Zip Code       | 92653                                       |
| City (& State) | Laguna Hills, CA                            |
| Country        | USA   |
| Phone Number   | +1 949 367 96 00                            |
| Fax Number     | +1 949 367 99 84                            |
| E-mail         | avaughan@glaukos.com / shalseth@glaukos.com |
| Website        | www.glaukos.com                             |
| Contact        | Aimee Vaughan / Shelli Halseth              |



Glaukos® Corporation is a privately-held, ophthalmic company located in Laguna Hills, California, that is dedicated to researching and developing micro-technologies to improve glaucoma therapy and has developed the iStent® Trabecular Micro-Bypass Stent. The iStent is intended to reduce IOP in patients with mild-to-moderate open-angle glaucoma undergoing concurrent cataract surgery. The iStent is CE marked with limited availability throughout Europe, has a Medical Device License in Canada, and is in FDA clinical trials for market approval in the USA.

---

## Haag-Streit (Booth 4)

|                |                       |
|----------------|-----------------------|
| Address        | Gartenstadtstrasse 10 |
| Zip Code       | CH-3098               |
| City (& State) | Koeniz (Berne)        |
| Country        | Switzerland           |
| Phone Number   | +41 31 978 01 11      |
| Fax Number     | +41 31 978 02 82      |
| E-mail         | info@haag-streit.com  |
| Website        | www.haag-streit.com   |
| Contact        | Martina Schumacher    |



Haag-Streit and our sister companies – Reliance, Moeller-Wedel, Clement Clarke and John Weiss – are leading players in ophthalmology today. Visit our booth for the latest developments in EyeSuite progression analysis, Octopus 900 static and Goldmann kinetic perimetry, world's first LED powered slit lamp family with imaging systems, contact lenses and more.



## Heidelberg Engineering (Booth 8)

|                |                                 |
|----------------|---------------------------------|
| Address        | Tiergartenstr. 15               |
| Zip Code       | D-69121                         |
| City (& State) | Heidelberg                      |
| Country        | Germany                         |
| Phone Number   | +49 6221 64 63 0                |
| Fax Number     | +49 6221 64 63 62               |
| E-mail         | Sales@HeidelbergEngineering.com |
| Website        | www.HeidelbergEngineering.com   |
| Contact        | Philip Staehler                 |



Heidelberg Engineering is a high-tech medical device company which designs, manufactures, and distributes diagnostic instruments for eye care professionals. The company's products are used around the world by ophthalmologists and optometrists to exam patients' eyes for signs of disease and to assist in disease management. Early diagnosis can help delay and often prevent the most common causes of blindness.

Typical diseases which can be recognized and tracked with Heidelberg Engineering devices include glaucoma, age-related macular degeneration, diabetic retinopathy and macular edema.

Heidelberg Engineering's core technologies include confocal microscopy, scanning lasers and optics, optical coherence tomography and software image analysis. The list of products includes: SPEC-TRALIS Product Family; Heidelberg Retina Tomograph (HRT); Heidelberg Retina Tomograph with Rostock Cornea Module (RCM); Heidelberg Edge Perimeter (HEP); Slit Lamp OCT (SL-OCT)

Heidelberg Engineering is a privately held company, headquartered in Heidelberg, Germany. The company distributes its products through a network of subsidiaries and distribution partners in most countries of the world.

---

## IOptima Ltd. (Booth 13)

|                |  |
|----------------|--|
| Address        | 5-7 Shoham st                          |
| Zip Code       | 52521                                  |
| City (& State) | Ramat Gan                              |
| Country        | Israel                                 |
| Phone Number   | +972 3 75 34 100                       |
| Fax Number     | +972 3 75 15 134                       |
| E-mail         | allon@ioptima.co.il; dan@ioptima.co.il |
| Website        | www.ioptima.co.il                      |
| Contact        | Allon Bogin / Dan Peres                |



Founded in 2005, IOptima Ltd. develops, produces and distributes novel surgical treatments for glaucoma.

The company's flagship IOptiMate™ is a breakthrough surgical system for CO<sub>2</sub> Laser-Assisted Sclerectomy Surgery (CLASS) designed and produced to provide long-term relief from intraocular pressure and reduced reliance on anti-glaucoma pharmaceutical drugs.

---

The IOPTiMate™ CLASS surgical system is based on the self-regulating properties of CO<sub>2</sub> laser that safely limits and controls sclera tissue ablation to successfully regenerate aqueous outwards flow – with no need to insert shunts or other foreign implantable devices. This unique method halts sclera ablation when adequate percolation is achieved, thus minimizing the chance of penetrating the eye. Keeping the eyeball intact significantly reduces the risk of intra-operative and post-operative complications as well as the follow-up interventions that are commonly associated with penetrating surgical alternatives.

The CE-approved system is currently commercially available in major medical centers.

---

## Iridex (Booth 16)

|                |                         |
|----------------|-------------------------|
| Address        | 1212 Terra Bella Avenue |
| Zip Code       | 94043                   |
| City (& State) | Mountain View, CA       |
| Country        | USA                     |
| Phone Number   | +1 650 940 47 00        |
| Fax Number     | +1 650 940 47 10        |
| E-mail         | info@iridex.com         |
| Website        | www.iridex.com          |
| Contact        | Sue McDonald            |



IRIDEX is a leading worldwide provider of therapeutic based laser systems used in ophthalmology, ENT and dermatology. IRIDEX's new generation of lasers include the IQ 810 (810nm), designed to perform traditional and transscleral photocoagulation procedures and is available with a MicroPulse option; the IQ 577 (577nm) which is the first visible wavelength laser to incorporate MicroPulse technology; and the IQ 532 (532nm) which encompasses the latest in solid-state technology. The IQ 810™ is a state-of-the-art system designed to perform traditional and MicroPulse Laser Trabeculoplasty (MLT) procedures including next-generation therapy for the treatment of glaucoma. The settings available on the IQ 810, along with a variety of delivery devices, provide a multi-functional solution. Some of the many treatment options include standard photocoagulation, transscleral photocoagulation and suture lysis. The IQ 532 is a premiere green laser offering dual-port outputs and intuitive controls including a touchscreen user interface, voice confirmation and a full-featured remote control.

## Kowa Company Ltd. (Booth 20)

|                |   |
|----------------|---|
| Address        | 4-14, 3-chome, Nihonbashi-honcho, Chuo-ku |
| Zip Code       | 103-8433                                  |
| City (& State) | Tokyo                                     |
| Country        | Japan                                     |
| Phone Number   | +81 3 32 797 639                          |
| Fax Number     | +81 3 32 797 541                          |
| E-mail         | y-hiroki@kowa.co.jp                       |
| Website        | www.kowa.co.jp/e-life/                    |
| Contact        | Mr. Yasuhiko Hiroki                       |



We are one of the world-leading retinal imaging companies having very unique instrument. The first Kowa retinal camera was released in 1962, so we have been offering many types of retinal cameras for approx. 50 years!

Our current mission is to offer the nice instrument for "Glaucoma screening". Now, the unique instrument, "nonmydWX", is coming! It is the only non-mydratic 3D retinal camera in the world. The latest technology "1-shot 3D imaging" gives the 3D optic disc image with 3D viewers (3D glasses), so the detailed Cup & Disc analysis result is given by the special analysis application.

---

## Life Spring Biotech (Booth 25)

|                |   |
|----------------|---|
| Address        | 3F, No. 19, Gongye 23rd Road, Nantun District |
| Zip Code       | 408   |
| City (& State) | Taichung                                      |
| Country        | Taiwan  |
| Phone Number   | +886 919 323 501                              |
| Fax Number     | +886 235 019 920                              |
| E-mail         | ckh3333@yahoo.com                             |
| Website        | www.lsbioetek.com                             |
| Contact        | Mr. Laurent Cheng                             |



Life Spring Biotech uses a unique development approach to inspire a host of new applications in the medical arena for our pharmaceutical-grade collagen biomaterials.

Leveraging years of medical expertise and clinical experience, we have developed a range of all-new medical applications for our innovative biomaterials. With applications ranging from dental to ophthalmic, orthopedic to gynecology, our tissue engineering products fulfill previously unmet needs in today's challenging clinical and pharmacological treatment environment.

The mission of Life Spring Biotech Co., Ltd. is devoting the company resources in the field of pharmaceutical grade collagen biomaterials and tissue re-engineering for developing products for medical applications.

The vision of Life Spring is being a global biotech company focusing in R&D of tissue engineering medical devices to serve the needs of niche markets. Principles of the company are Professional, Innovative, Outstanding, and Persisting.

---

---

## Lumenis (Booth 3)

|                |  |
|----------------|--|
| Address        | Heinrich-Hertz-Strasse 3                               |
| Zip Code       | D-63303  |
| City (& State) | Dreieich   |
| Country        | Germany  |
| Phone Number   | +49 162 44 207 90                                      |
| Fax Number     | +49 610 38 335 307                                     |
| E-mail         | silvijo.kunic@lumenis.com                              |
| Website        | www.lumenis.de   |
| Contact        | Silvijo Kunic (Sales & Marketing Director Vision EMEA) |



Lumenis is the global leader in laser technologies for ophthalmic applications. Since introducing the first laser in 1970, Lumenis has focused on providing ophthalmologists with innovative laser therapies to preserve and improve the eyesight of patients worldwide.

Lumenis has developed, commercialized and introduced SLT for open-angle glaucoma and is currently developing selective retina therapy (SRT) for treating diabetic macular edema. Today, Lumenis offers the industry's most extensive and highly regarded line of ophthalmic lasers along with an unparalleled product service support. As the industry leader, Lumenis has more than 75,000 medical systems installed worldwide and +250 registered patents.

---

## MédiThèque Bookshop (Booth 34)

|                |                    |
|----------------|--------------------|
| Address        | 88, rue des Moines |
| Zip Code       | F-75017            |
| City (& State) | Paris              |
| Country        | France             |
| Phone Number   | +33 1 42 28 17 35  |
| Fax Number     | +33 1 42 28 21 17  |
| E-mail         | meditheque@noos.fr |
| Website        | www.meditheque.fr  |
| Contact        | Philippe Bon       |



International Medical Bookseller in several languages.

## **Merck Sharp & Dohme (Booth 2)**

|                |  |
|----------------|--|
| Address        | One Merck Drive                                  |
| Zip Code       | 08889  |
| City (& State) | Whitehouse Station, NJ                           |
| Country        | USA  |
| Phone Number   | +1 908 423 1000                                  |
| Website        | <a href="http://www.merck.com">www.merck.com</a> |

## **MSD Ophthalmics**

Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with our customers and operate in more than 140 countries to deliver innovative health solutions. Merck. Be Well. For more information, visit [www.merck.com](http://www.merck.com).

---

## **NeoMedix Corporation (Booth 14)**

|              |  |
|--------------|--|
| Address      | 15042 Parkway Loop, Suite A                                      |
| Zip Code     | 92780-6528   |
| City & State | Tustin, California   |
| Country      | USA  |
| Phone Number | + 1 714 258 8355   |
| Fax Number   | + 1 714 258 8356   |
| E-mail       | <a href="mailto:Neomedix@neomedix.net">Neomedix@neomedix.net</a> |
| Website      | <a href="http://www.NeoMedix.net">www.NeoMedix.net</a>           |
| Contact      | <a href="mailto:info@neomedix.net">info@neomedix.net</a>         |

**NeoMedix**  
*Precision Medical Products by Design*

NeoMedix is focused on manufacturing and distribution of advance medical products such as the Trabectome. Trabectome is an FDA-cleared device for minimally invasive surgical treatment of glaucoma ideally suited for combination surgeries with phaco.

Using the same clear corneal incision, the needle sized electrosurgical Trabectome probe safely ablates and removes a 60°-120° strip of Trabecular meshwork and inner wall of Schlemm's canal reestablishing aqueous access to the eye's natural drainage pathways.

Clinical data up to 72 months of over 4000 patients has shown to safely and effectively lower IOP on average 30% with minimal complications.

---

## Oculus Optikgeräte GmbH (Booth 27)

|                |                         |
|----------------|-------------------------|
| Address        | Münchholzhäuser Str. 29 |
| Zip Code       | D-35582                 |
| City (& State) | Wetzlar                 |
| Country        | Germany                 |
| Phone Number   | +49 641 20 050          |
| Fax Number     | +49 64 20 05 295        |
| E-mail         | sales@oculus.de         |
| Website        | www.oculus.de           |
| Contact        | Angela Schmidt          |



For more than 115 years, OCULUS from Germany has been a partner for eyecare professionals around the world. OCULUS' support for the challenging daily tasks includes sophisticated Scheimpflug-technology, perimeters and the exciting new Corvis® ST. OCULUS proudly presents new software features on the famous Pentacam® and will display three Perimeters with visual fields from 30° to 90°. OCULUS was the builder of the first static perimeters in the 1950s, tradition and German precision are the basis in the latest perimeter technique. New features such as the unique Glaucoma Staging Program (GSP) and SPARK progression-software will support the doctor's diagnostic steps. OCULUS will also show a prototype of the Corvis® ST. Its high-speed Scheimpflug-camera records the movements of the cornea in ultra-slow-mo. So far unseen pictures allow exciting new ways in the assessment of corneal properties for various applications from keratoconus screening to glaucoma.

---

## Optovue, Inc. (Booth 7)

|                |                        |
|----------------|------------------------|
| Address        | 45531 Northport Loop W |
| Zip Code       | 94538                  |
| City (& State) | Fremont, CA            |
| Country        | USA                    |
| Phone Number   | +1 510 623 88 68       |
| Fax Number     | +1 510 623 86 68       |
| E-mail         | info@optovue.com       |
| Website        | www.optovue.com        |
| Contact        | Shalini Swamy          |



Optovue, Inc. is continually changing the boundaries of glaucoma and retinal imaging with uncompromising clinical integrity to improve the lives of patients around the world. As the first FDA approved Spectral-Domain OCT (SD-OCT) on the market, Optovue has led the industry in OCT innovation with, the largest Normative Database, C/D ratio and patented Ganglion cell complex that aids early detection of glaucoma and other ocular disorders. The RTVue is the most comprehensive SD-OCT available in the market offering both Posterior and Anterior scanning with 3D, retina Maps, RNFL, GCC as well as pachymetry mapping and angle measurement. Optovue furthered OCT innovation with iVue, the most versatile, compact SD-OCT in the world providing eye-care professionals with high resolution scans delivering Posterior/Anterior Segment imaging in a portable platform. Optovue is a trusted partner committed to making SD-OCT accessible to eye-care professionals and meeting patients' needs.



## **Pfizer Inc. (Booth 9)**

|                |                                 |
|----------------|---------------------------------|
| Address        | 235 East 42nd St                |
| Zip Code       | 10017                           |
| City (& State) | New York, NY                    |
| Country        | USA                             |
| Phone Number   | +1 212 733 66 64                |
| Fax Number     | +1 646 441 46 57                |
| E-mail         | Christine.a.derienzo@pfizer.com |
| Website        | www.pfizer.com                  |
| Contact        | Christine De Rienzo             |



At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

## **Quantel Medical (Booth 12)**

|                |                               |
|----------------|-------------------------------|
| Address        | 21 rue Newton, Z.I. Le Brezet |
| Zip Code       | F-63039                       |
| City (& State) | Clermont-Ferrand              |
| Country        | France                        |
| Phone Number   | +33 473 745 745               |
| Fax Number     | +33 473 745 700               |
| E-mail         | contact@quantel-medical.fr    |
| Website        | www.quantel-medical.com       |



Founded in 1993, Quantel Medical offers innovative ophthalmology solutions. The company develops and markets a complete range of diagnostic ocular Ultrasound systems and surgical lasers. This range offers global therapeutic solutions that meet the needs of both patients and doctors. Today, Quantel Medical has built up a worldwide leadership position in the fields of ocular Ultrasound and laser photocoagulation.

---

## Santen Pharmaceutical Co., Ltd. (Booth 6)

|                |  |
|----------------|--|
| Address        | 3-9-19 Shimoshinjo, Higashiyodogawa-ku,                |
| Zip Code       | 533-8651   |
| City (& State) | Osaka  |
| Country        | Japan  |
| Phone Number:  | +81 (0)6 6321 7172                                     |
| Fax Number:    | +81 (0)6 6321 8400                                     |
| E-mail         | tuomas.huuhtanen@santen.fi; mayumi.fujino@santen.co.jp |
| Website        | www.santen.com   |
| Contact        | Tuomas Huuhtanen; Mayumi Fujino                        |



Santen, one of the oldest ophthalmic pharmaceutical companies in the world, is Japan's pioneer and leader in ophthalmic pharmaceuticals. Today, we at Santen are focusing our research and development efforts on glaucoma, retinal, and corneal disorders. We are also accelerating our efforts towards globalization to deliver our products and our message of "A clear vision for life TM" to people around the world.

---

## Sensimed AG (Booth 21)

|                |                       |
|----------------|-----------------------|
| Address        | Route de Chavannes 37 |
| Zip Code       | CH-1007               |
| City (& State) | Lausanne              |
| Country        | Switzerland           |
| Phone Number   | +41 21 621 91 91      |
| Fax Number     | +41 21 621 91 93      |
| E-mail         | info@sensimed.ch      |
| Website        | www.sensimed.ch       |



SENSIMED AG is a Swiss medical device company that has developed a breakthrough solution to continuously and non-invasively monitor up to 24hours fluctuations in intraocular pressure. The SENSIMED Triggerfish® provides specialists with precise and unseen clinical data, facilitating the choice of customized therapy for patients diagnosed with a glaucoma condition.

## Wisepress Online Bookshop (Booth 35)

|                |                        |
|----------------|------------------------|
| Address        | 25 High Path           |
| Zip Code       | SW19 2JL               |
| City (& State) | London                 |
| Country        | UK                     |
| Phone Number   | +44 208 715 1812       |
| Fax Number     | +44 208 715 1722       |
| E-mail         | bookshop@wisepress.com |
| Website        | www.wisepress.com      |
| Contact        | Michelle Coogan        |

**WISEPRESS**

Wisepress.com, Europe's leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting including copies of the brand new: *Clinical Ophthalmology: A Systematic Approach* by Kanski and Bowling. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.

---

## Zieler Ophthalmic Systems AG (Booth 23)

|                |                           |
|----------------|---------------------------|
| Address        | Allmendstrasse 11         |
| Zip Code       | CH-2562                   |
| City (& State) | Port                      |
| Country        | Switzerland               |
| Phone Number   | +41 32 332 7152           |
| Fax Number     | +41 32 332 7071           |
| E-mail         | marketing@ziemergroup.com |
| Website        | www.ziemerophthalmics.com |
| Contact        | Sandro Palumbo            |

**ziemer**   
OPHTHALMOLOGY

After only ten years the Ziemer Group is already globally-renowned for its contributions to high-tech ophthalmology.

Amongst these is the PASCAL DCT (Dynamic Contour Tonometer) which, through the use of new technologies and innovative materials, has taken a fresh look at the Goldmann Applanation principles and combined these with the improved understanding of corneal biomechanics that has been reached since Goldmann's days.

The result is a device which, totally independently of corneal thickness and other factors, offers an unsurpassable accuracy and reproducibility, proven in several manometric comparisons, in IOP measurement.

We welcome your visit on our booth so that we can prove our claims to you and, at the same time, enter you into our draw for a free Pascal.

---

# PROGRAM AT A GLANCE

## WEDNESDAY June 29, 2011

|            | Grand Amphitheatre   | Room 364            | Room Havane         | Room 341           | Room 342A                      | Room 342B        | Room 343                | Room 353  | Room 352B          | Room 352A          | Room 351        | Room 361                   | Room 362 + 363                   | Room 322M+323M | Room 326M+327M       |
|------------|--|---------------------|---------------------|--------------------|--------------------------------|------------------|-------------------------|---|--------------------|--------------------|-----------------|----------------------------|----------------------------------|----------------|----------------------|
| 8.00 a.m.  |  | Bulgarian GS - Symp | Symposium of CIS GS | Canadian GS - Symp | Latin American GS - Joint Symp | Korean GS - Symp | MEAGS/ ESG - Joint Symp | Australian and New Zealand Glaucoma Interest Group - Symp | GS of India - Symp | American GS - Symp | Greek GS - Symp | Saudi Glaucoma Group- Symp | Portuguese Glaucoma Group - Symp |                | Bangladesh GS - Symp |
| 8.30 a.m.  |  |                     |                     |                    |                                |                  |                         |   |                    |                    |                 |                            |                                  |                |                      |
| 9.30 a.m.  |  |                     |                     |                    |                                |                  |                         |   |                    |                    |                 |                            |                                  |                |                      |
| 9.45 a.m.  |  |                     |                     |                    |                                |                  |                         |   |                    |                    |                 |                            |                                  |                |                      |
| 10.00 a.m. | French Glaucoma Society Symp                                       |                     |                     |                    |                                |                  |                         |   |                    |                    |                 |                            | WGC FILM FESTIVAL                |                |                      |
| 10.50 a.m. |  |                     |                     |                    |                                |                  |                         |   |                    |                    |                 |                            |                                  |                |                      |
| 10.55 a.m. | European Glaucoma Society Symp                                     |                     |                     |                    |                                |                  |                         |   |                    |                    |                 |                            | WGC FILM FESTIVAL                |                |                      |
| 11.50 a.m. |  |                     |                     |                    |                                |                  |                         |   |                    |                    |                 |                            |                                  |                |                      |
| 12.00 a.m. | Plenary Lunch Symposium  |                     |                     |                    |                                |                  |                         |   |                    |                    |                 |                            | WGC FILM FESTIVAL                |                |                      |
| 1.00 p.m.  |  |                     |                     |                    |                                |                  |                         |   |                    |                    |                 |                            |                                  |                |                      |
| 1.45 p.m.  |  |                     |                     |                    |                                |                  |                         |   |                    |                    |                 |                            |                                  |                |                      |
| 2.00 p.m.  |  |                     |                     |                    | Global Assembly                |                  |                         |   |                    |                    |                 |                            |                                  |                |                      |
| 3.00 p.m.  |  |                     |                     |                    |                                |                  |                         |   |                    |                    |                 |                            |                                  |                |                      |
| 3.30 p.m.  | Opening Session  |                     |                     |                    |                                |                  |                         |   |                    |                    |                 |                            |                                  |                |                      |
| 5.30 p.m.  |  |                     |                     |                    |                                |                  |                         |   |                    |                    |                 |                            |                                  |                |                      |
|            | 5.30 - 7.00 p.m. WELCOME RECEPTION - EXHIBITION AREA (THIRD FLOOR) |                     |                     |                    |                                |                  |                         |   |                    |                    |                 |                            |                                  |                |                      |

5.30 - 7.00 p.m. WELCOME RECEPTION - EXHIBITION AREA (THIRD FLOOR)

**THURSDAY June 30, 2011**

| Grand Amphitheatre | Room Bordeaux                                     | Room Havane   | Room 341                                     | Room 342A | Room 342B | Room 343         | Room 353 | Room 352B | Room 352A | Room 351 | Room 361 | Room 362+363      | Room 364 |
|--------------------|---|---|--|-----------|-----------|------------------|----------|-----------|-----------|----------|----------|-------------------|----------|
| 7.00 a.m.          |   | Symposium Pfizer  |  |           |           | Symposium Ziemer |          |           |           |          |          |                   |          |
| 7.55 a.m.          |   |   |  |           |           |                  |          |           |           |          |          |                   |          |
| 8.00 a.m.          | S21 Grand Rounds                                  | S1 Angle-closure Glaucoma   | S4 Epidemiology and screening of POAG        |           |           |                  |          |           |           |          |          |                   |          |
| 8.45 a.m.          |   |   | S5 Risk factors for GL onset and progression |           |           |                  |          |           |           |          |          |                   |          |
| 9.00 a.m.          |   |   |  |           |           |                  |          |           |           |          |          | WGC FILM FESTIVAL |          |
| 9.30 a.m.          | BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION |   |  |           |           |                  |          |           |           |          |          |                   |          |
| 10.15 a.m.         | S3 Glaucoma Progression                           | S28 Innovative approaches for protecting the retinal ganglion cells | S23 Glaucoma and myopia                      |           |           |                  |          |           |           |          |          | WGC FILM FESTIVAL |          |
| 11.00 a.m.         |   |   | S25 Update on Consensus rep                  |           |           |                  |          |           |           |          |          |                   |          |
| 11.45 a.m.         | BREAK   |   |  |           |           |                  |          |           |           |          |          |                   |          |
| 12.00 a.m.         | Plenary Lunch Symp MSD & Santen                   |   |  |           |           |                  |          |           |           |          |          | WGC FILM FESTIVAL |          |
| 1.00 p.m.          | BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION |   |  |           |           |                  |          |           |           |          |          |                   |          |

## THURSDAY June 30, 2011 - continued

[illegible]



**FRIDAY July 1, 2011**

|            |  |               |             |   |           |           |                  |           |           |          |                   |
|------------|--|---------------|-------------|---|-----------|-----------|------------------|-----------|-----------|----------|-------------------|
| 7.00 a.m.  | Grand Amphitheatre   | Room Bordeaux | Room Havane | Room 341  | Room 342A | Room 342B | Room 343         | Room 352A | Room 351  | Room 361 | Room 362+363      |
|            |  |               |             | Symposium AEON Astron Europe B.V.                     |           |           | Symposium Anteis |           |           |          |                   |
| 7.55 a.m.  |  |               |             |   |           |           |                  |           |           |          |                   |
| 8.00 a.m.  | WGA SUR-GERY DAY<br>Decision-making and laser trabeculectomy | S26           | S7          | Normal-tension GL: Diag and treatment                 | Room 342A | Room 342B | Room 343         | Room 352B | Room 352A | Room 351 | Room 361          |
| 8.45 a.m.  |  | S10           |             |   |           |           |                  |           |           |          |                   |
| 9.00 a.m.  | WGA SUR-GERY DAY<br>Trabeculectomy                           | S10           | S12         | Ocular blood flow (perfusion and Consensus)           |           |           |                  |           |           |          | WGC FILM FESTIVAL |
| 9.30 a.m.  | BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION            |               |             |   |           |           |                  |           |           |          |                   |
| 10.15 a.m. |  | S30           | S14         | The most exciting contrib to GL in the last 5 yrs     |           |           |                  |           |           |          | WGC FILM FESTIVAL |
| 10.30 a.m. |  | S6            | S15         | Myths and misconceptions in glaucoma drainage devices |           |           |                  |           |           |          |                   |
| 11.00 a.m. | WGA SUR-GERY DAY<br>Tubes - glaucoma drainage devices        | S6            | S15         | Myths and misconceptions in glaucoma drainage devices |           |           |                  |           |           |          |                   |
| 11.45 a.m. |  |               |             |   |           |           |                  |           |           |          |                   |
| 12.00 a.m. | Plenary Lunch Symp Alcon                                     |               |             |   |           |           |                  |           |           |          | WGC FILM FESTIVAL |
| 1.00 p.m.  | BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION            |               |             |   |           |           |                  |           |           |          |                   |

## FRIDAY July 1, 2011 - continued


|           | Grand Amphitheatre  | Room Bordeaux  | Room Havane   | Room 341   | Room 342A   | Room 342B   | Room 343   | Room 353                               | Room 352B   | Room 352A          | Room 351                                    | Room 361   | Room 362+363      |  |
|-----------|---|--|---|--|---|---|--|--|---|--------------------|---|--|-------------------|--|
| 2.00 p.m. | WGA SUR-GERY DAY<br>Surgery for open-angle glaucoma                 | S20<br>Decision-making, improving patient outcomes in glaucoma | French GS Session<br>Glaucoma surgical treatments       |  | S16<br>Conventional & unconventional outflow                        |   |  |  |   |                    |   |  | WGC FILM FESTIVAL |  |
| 2.45 p.m. |   |  |   | S27<br>Glaucoma management in the developing world                         |   |   |  |  |   |                    |   |  |                   |  |
| 3.30 p.m. | WGA SUR-GERY DAY<br>Angle-closure glaucoma                          |  |   | BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION                          |   |   |  |  |   |                    |   |  |                   |  |
| 4.00 p.m. |   | C10<br>Primary angle closure: Diagnosis & treatment            | French GS Courses<br>Structural progression in glaucoma | C26<br>Blood flow and aqueous flow in glaucoma                             | C25<br>Gonioscopy & imaging for anterior chamber & angle evaluation | C29<br>Cyclophotocoagulation: Why, when and how?    | C31<br>Understanding the genetic basis of GL                             | C37<br>Management of complex glaucomas | C32<br>Interpretation of visual fields: Detection (diagnosis & selective tests) | C38<br>Free Papers | C21<br>Emerging GL surgery-1 (ab interno)   | C34<br>Stereoscopic optic disc viewing               |                   |  |
| 4.30 p.m. | WGA SUR-GERY DAY<br>Cataract and refractive surgery in eyes with GL |  |   |  |   |   |  |  |   |                    |   |  |                   |  |
| 5.00 p.m. | WGA SUR-GERY DAY<br>Childhood glaucoma                              | C19<br>Secondary angle closure: Diag & management              | French GS Courses<br>Gonioscopy                         | C27<br>Neuroprotection & apoptosis of retinal ganglion cells related to GL | C28<br>Decision making after failed trab                            | C30<br>Modulating wound healing in glaucoma surgery | C36<br>Managing cataract and GL: Surg manag of co-existing cataract & GL | C40<br>Alternative glaucoma therapies  | C33<br>Interpretation of visual fields: progression (rates, event vs. trend)    | C39<br>Free Papers | C22<br>Emerging GL surgery - 2 (ab externo) | C35<br>Exfoliation syndrome and exfoliation glaucoma |                   |  |
| 5.30 p.m. |   |  |   |  |   |   |  |  |   |                    |   |  |                   |  |
| 6.00 p.m. |   |  |   | 8.00 p.m. WGC GALA DINNER AT THE PAVILLON D'ARMENONVILLE                   |   |   |  |  |   |                    |   |  |                   |  |
| 6.30 p.m. |   |  |   |  |   |   |  |  |   |                    |   |  |                   |  |

SATURDAY July 2, 2011


|           | Grand Amphitheatre   | Room Bordeaux   | Room Havane  | Room 362+363      |
|-----------|--|---|--|-------------------|
| 8.00 a.m. | S2<br>Advances in imaging technology and application (detection, progression, technology, risk assessment) | S35<br>Glaucoma and coexisting diseases (cornea-DSEK, PKP, keratoprosthesis, retina, ocular surface & inflammation) | S40<br>Pediatric glaucoma  | WGC FILM FESTIVAL |
| 8.45 a.m. |  |   | S19<br>Managing the failing glaucoma surgery (trabeculectomy, tubes) |                   |
| 9.30 a.m. | BREAK AND VISIT TO THE POSTER AREA AND EXHIBITION  |   |  |                   |
| 0.15 a.m. | S13<br>Cataract and glaucoma surgeries   | S08<br>Initial treatment for glaucoma: Medical vs. laser vs. surgery  | S11<br>Clinician Scientist Symposium                                 | WGC FILM FESTIVAL |
| 1.00 a.m. |  | S33<br>Glaucoma: The patient's angle (WGPA, patient perspective)  |  |                   |
| 1.45 a.m. |  |   |  |                   |

# CONGRESS VENUE MAP


## Level 3



## Level 1



## Level 0



# NEW FORMULA

# DUOTRAV®

40 micrograms/ml + 5mg/ml eye drop solution (travoprost/timolol)



## FIRST & ONLY MULTIDOSE Prostaglandin/Beta-Blocker Fixed Combination without BAK\*, Now with POLYQUAD® Preservative

Decrease of intraocular pressure (IOP)  
in adult patients with open-angle glaucoma  
or ocular hypertension who are insufficiently  
responsive to topical beta-blockers  
or prostaglandin analogues

**DUOTRAV®**  
40 micrograms/ml + 5mg/ml eye drop solution (travoprost/timolol)

# Alcon®

\* Benzalkonium chloride

**DuoTrav® 40 micrograms/ml + 5 mg/ml eye drops solution (travoprost and timolol maleate).** **Prescribing Information.** (Refer to full Summary of Product Characteristics (SmPC) before prescribing). **Presentation:** Plastic bottle containing 2.5ml eye drops. Each 1 ml contains 40 micrograms of travoprost, 5 mg of timolol (as maleate). **Indication(s):** Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. **Posology and method of administration: Adults:** *including the elderly population:* One drop once daily, morning or evening. Administer at same time each day. **Children and adolescents:** Not recommended. **Use in hepatic and renal impairment:** No dose adjustment necessary. Nasolacrimal occlusion after administration is recommended. If more than one ophthalmic medicinal product is being used administer at least 5 minutes apart. Instruct patients to remove contact lenses prior to use and wait 15 minutes after instillation before reinsertion. **Contra-indications:** Hypersensitivity to the active substances or any of the excipients. Bronchial asthma or severe chronic obstructive pulmonary disease. Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure or cardiogenic shock. Severe allergic rhinitis, bronchial hyper reactivity; corneal dystrophies, hypersensitivity to other beta-blockers. **Warnings and precautions:** **Systemic effects:** Cardiovascular and pulmonary adverse reactions as seen with systemic beta-blockers may occur. Cardiac failure should be adequately controlled before beginning therapy with timolol. Patients with a history of severe cardiac disease should be watched for signs of cardiac failure and have pulse rates checked. Respiratory and cardiac reactions, including death due to bronchospasm in patients with asthma and, rarely, death in association with cardiac failure, have been reported with timolol maleate. Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to diabetic (especially labile diabetes) patients as Beta-blockers may mask the signs and symptoms of acute hypoglycaemia. They may also mask signs of hyperthyroidism, and cause worsening of Prinzmetal angina, severe peripheral and central circulatory disorders and hypotension. Women who are pregnant or attempting to become pregnant should avoid direct exposure to the product. **Anaphylactic reactions:** While taking beta-blockers, patients with a history of atopy or severe anaphylactic reaction to a variety of allergens may be unresponsive to usual doses of adrenaline used in treatment. **Concomitant Therapy:** Effect on IOP or known effects of systemic beta-blockade may be potentiated when DuoTrav® is given to patients already taking oral beta-blockers. Use of two local beta-blockers or local prostaglandins is not recommended. **Ocular effects:** Travoprost may gradually change the eye colour. Unilateral treatment can result in permanent heterochromia. Change in eye colour occurs slowly. Predominantly seen in patients with mixed coloured irides and may increase brown iris pigmentation. Travoprost may cause periorbital and/or eyelid skin darkening. Travoprost may gradually change eyelashes (length, thickness, pigmentation and/or number of lashes). Use with caution in aphakic and pseudophakic patients with a torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for cystoid macular oedema, or predisposing risk factors for iritis/uveitis. Contains Propylene Glycol may cause skin irritation. Contains polyoxyethylene hydrogenated castor oil 40 which may cause skin reactions. **Interactions:** No interaction studies performed. Potential for additive effects resulting in hypotension and/or marked bradycardia when eye drops with timolol are administered concomitantly with oral calcium channel blockers, guanethidine or beta-blockers, antiarrhythmics, digitalis glycosides or parasympathomimetics. The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta-blockers. Beta-blockers may increase the hypoglycaemic effect of antidiabetic products and can mask the signs and symptoms of hypoglycaemia. **Women of Childbearing Potential:** Do not use unless adequate contraceptive measures are in place. **Fertility:** No data are available. **Pregnancy:** Do not use unless clearly necessary. **Lactation:** Not recommended. **Effects on ability to drive and use machines:** May blur vision. The patient should wait until vision is clear before driving or using machines. **Undesirable effects:** *Very common:* ocular discomfort, ocular hyperaemia. *Common:* nervousness, dizziness, headache, punctate keratitis, anterior chamber inflammation, eye pain, photophobia, eye swelling, conjunctival haemorrhage, visual acuity reduced, visual disturbance, vision blurred, dry eye, eye pruritus, conjunctivitis, lacrimation increased, erythema of eyelid, blepharitis, asthenopia, growth of eyelashes, heart rate irregular, heart rate decreased, blood pressure increased, blood pressure decreased, bronchospasm, urticaria, skin hyperpigmentation (periocular), pain in extremity. *Serious:* cerebrovascular accident, macular oedema, cardiac failure, uveitis, cerebral ischaemia, myasthenia gravis, cardiac arrest, respiratory failure. Prescribers should consult the SmPC in relation to other side effects. **Overdose:** Topical overdose with travoprost not likely to occur or be associated with toxicity. Most common symptoms of systemic timolol overdose are bradycardia, hypotension, bronchospasm and heart failure. Symptomatic and supportive treatment. Timolol does not dialyse readily. **MA Number(s):** EU/1/06/338/001-003. **MA Holder / Further information:** Alcon Laboratories (UK) Limited, Pentagon Park, Boundary Way, Hemel Hempstead, Hertfordshire. HP2 7UD. **Date of preparation:** March 2011 (V6).

1105P21A